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Oxidative stress is represented as an imbalance between reactive oxygen species (ROS) production
and the response of antioxidant proteins. Oxidative stress is implicated in the pathogenesis of a
variety of conditions, including cardiovascular diseases, neurodegenerative diseases, and cancer.
Unfortunately, antioxidant therapies have not been proven to be effective in most clinical studies [1].
One of the reasons for this disappointing failure was testing antioxidant potential of compounds only
through their capacity to reduce the number of free radicals directly by their free radical scavenging
and metal chelating activities. It took some time to realize that some small molecules can achieve a
more significant antioxidant effect by targeted modulation of activities of proteins included in the
antioxidant system [2]. Relatively recently modulation of oxidative stress through regulation of gene
transcription has been discovered to be a promising strategy for the development of new drugs
for cardiovascular diseases and cancer types that are resistant to other treatments [3]. This Special
Issue of the “Antioxidants” collects seven original research manuscripts and six reviews addressing
different pharmacological aspects of the modulation of oxidative stress by natural and synthetic small
molecular weight compounds in regard to various therapeutic approaches in cardiovascular and
neurodegenerative diseases, cancer and diabetes. Understanding the relationship between oxidative
stress and underlying anti- and pro-oxidant mechanisms is crucial to understand mechanisms of
diseases and also for the discovery and development of innovative, targeted therapeutic strategies.
The two research articles present the results of cellular studies on contribution of antioxidants
in alleviating ischemia–reperfusion (IR) injuries in myocardial cells and cardiac fibroblasts (CF).
IR injury is a common clinical problem that occurs in the heart (in myocardial infarction) as well
as other organ systems (e.g., in the brain in stroke and in limb ischemia) and may also be a result
of reperfusion strategy or occur during surgeries [4]. IR occurs when blood supply to an organ
is diminished and then re-established. Although blood flow is necessary for survival, reperfusion
induces necrotic and apoptotic cell death. One of the key mediators of reperfusion injury is an
oxidative stress. A huge generation of ROS at the beginning of reperfusion initiates lipid peroxidation
and protein/nucleic acid oxidation, consequently activating pro-apoptotic pathways associated with
p38-MAPK and JNK proteins [5]. In their manuscript, Parra-Flores et al. [6] showed for the first time
synergistic cytoprotective effect of ascorbic acid, deferoxamine, and N-acetylcysteine in simulated
IR in CF. When added at low concentrations (10 μM) each at the onset of simulated reperfusion,
the three antioxidants synergistically reduced intracellular ROS production and increased cell viability,
induced phosphorylation of pro-survival kinases ERK1/2 (extracellular-signal-regulated kinases 1/2)
and PKB (protein kinase B)/Akt, and decreased phosphorylation of the pro-apoptotic kinases p38-MAPK
(proteins p38-mitogen-activated protein kinase) and JNK (c-Jun-N-terminal kinase). The mixture
also recovered the CF function associated with wound repair by restoring serum-induced migration,
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TGF-1-mediated differentiation of CF into CMF and angiotensin II-induced pro-collagen I synthesis.
The three compounds have different mechanism of antioxidant activity and act at concentrations
higher than 10 μM. However, in the mix, the oxidized form of ascorbate—dehydroascorbate, can be
transformed back in the reduced form by intracellular glutathione (GSH) [7] and the decreased
intracellular concentration of GSH may be replenished by N-acetylcysteine which is a GSH precursor.
Deferoxamine can chelate an excess of catalytic free iron which increases during ischemia and cardiac
reperfusion from cell lysis, and in this way the production of OH radicals through the Fenton reaction
is lowered, thus preventing the pro-oxidant interaction of iron with ascorbate [8]. In another study,
Peserico et al. [9] pointed to the repurposing of ezetimibe from a lipid-lowering compound to the
antioxidant with diminishing effects of the oxidative stress induced by the simulated IR in the human
monocyte-like cells THP-1 and cardiomyocytes [10]. Overnight pre-incubation of the cells with
ezetimibe (50 μM) reduced ROS formation, NF-kB activation and apoptosis, induced by simulated IR.
Ezetimibe induced up-regulation of NRF2 (Nuclear factor erythroid 2-related factor 2)/ARE (antioxidant
response element) signalling and the pro-survival UPR (unfolded protein response) pathway by
up-regulation of the pro-survival activating transcription factor 6 (ATF6) and down-regulation of
the pro-apoptotic CCAAT-enhancer-binding protein homologous protein (CHOP). In such a way,
misfolded protein mass may be reduced and cells convert to a pro-survival state. The NRF2 activation
was found to be dependent on AMPK phosphorylation.
Oxidative stress and depletion of intracellular antioxidants, together with a systemic inflammatory
response and ultimately organ failure are characteristics of the sepsis [11]. Since organ dysfunction
associated with sepsis is due, at least in part, to mitochondrial dysfunction and mitochondrial
dysfunction is considered as main cause of oxidative stress in sepsis, antioxidants targeted to
mitochondria have been considered as an efficient antioxidant protection in sepsis [12]. Minter et al. [13]
compared the positively charged antioxidant MitoVitE, which accumulates within mitochondria,
with the membrane-bound α-tocopherol and water-soluble cytosolic Trolox with regard to their effects
on oxidative stress, mitochondrial function and expression of key genes and proteins involved in the
toll-like receptor (TLR)-2 and -4 inflammatory signalling pathways in the umbilical vein endothelial
cell line HUVEC-C under conditions mimicking acute bacterial sepsis. Each of these three forms of
vitamin E (5 μM each) was found to have similar reducing effects against induced oxidative stress and
NFκB activation caused by exposure to lipopolysaccharide/peptidoglycan G. However, in difference to
α-tocopherol and Trolox, MitoVitE had also widespread downregulatory effects on gene expression
involved in TLR pathways, resulting in anti-inflammatory profile. Many of these downregulated genes
have been shown to be upregulated in mononuclear cells from patients with sepsis.
Mitochondrial dysfunction and consequential oxidative stress are also connected with organ
injuries caused by exposure to ionizing radiation in cancer therapy [14]. A serious limitation to
radiation therapy for some cancers is the possibility of irradiating the liver and induced liver injury.
When cells are exposed to radiation, the redox system begins producing free radicals a few hours after
exposure, but with the potential to last for years and cause pathological long-term persistent liver
responses to ionizing radiation, such as radiation-induced liver disease (RILD) [15]. It has been known
that major mitochondrial deacetylase sirtuin 3 (SIRT3) contributes to the development of ionizing
radiation-induced acute liver injury [16]. The results of the in vivo study conducted by LoBianco et
al. [17] show that loss of or decrease in SIRT3 levels could be an important factor contributing to a
damage-permissive phenotype in murine liver long after exposure to ionising radiation. Their study
on the two groups of Sirt3−/− and Sirt3+/+male mice six months after their liver was exposed to 24 Gy
radiation additionally suggested that superoxide radical anion-driven acute liver injury following
radiation exposure appears to shift towards a peroxide-mediated long-term injury and is no longer
limited to the mitochondria. On the other hand, there is a possibility to use radiation to stimulate
cellular mechanisms and facilitate the removal of oxidative stress through the modulation of various
signalling pathways in the presence of nonionizing light at a specific wavelength. In their review
article, Rajendran et al. [18] described and discussed the effects of photobiomodulation on the progress
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of cancer, diabetes and wound healing through the crosstalk between ROS and the first discovered
redox-regulated transcription factor, NF-кB (nuclear factor kappa-light-chain-enhancer of activated
B cells).
A master regulator of cellular redox homeostasis is the transcription factor NRF2 [1,3]. NRF2 is a
regulator of the transactivation of over 500 cytoprotective genes, many of which are included in the
antioxidant defence against intracellular ROS increase. The major signalling pathway that regulates
oxidative stress is NRF2–KEAP1 (Kelch-like ECH-associated protein 1). Panieri et al. [19] reviewed
the activation mechanisms and the therapeutic modulation of NRF2 within the specific biological
context. In the early stages of carcinogenesis, pharmacological induction of the NRF2 pathway might
be chemopreventive. The NRF2 inducers protect normal cells from carcinogen effects by reducing
the risk of cancer initiation and development in normal cells by ROS scavenging, decreasing DNA
damage and preventing genomic instability. However, in advanced stages of cancer, the adverse effects
of the NRF2 induction might occur due to the development of therapy resistance [20]. Over-activation
of the NRF2–KEAP1 pathway in many tumours has been found to promote cancer growth and
survival, metastasis formation and therapy resistance. Sustained NRF2 activation in cancer cells lead to
metabolic changes that frequently develop “NRF2 addiction” [21]. Panieri et al. pointed to disruption
of NRF2 signalling in cancer cells by using NRF2 inhibitors as a promising therapeutic approach
against NRF2-addicted cancers.
NRF2 activators have also been proposed as antioxidants in neurodegenerative and
neuropsychiatric disorders (Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, autism,
schizophrenia, and depression) to counteract the increase in oxidative stress and inflammation.
Alvarez-Arellano et al. [22] made an overview of the role of inflammation and oxidative stress in
attention-deficit/hyperactivity disorder (ADHD). The amelioration of inflammation and oxidative stress
by natural antioxidants sulforaphane, N-acetylcysteine and omega-3 fatty acids (docosahexaenoic acid
(DHA) and eicosapentaenoic acid (EPA)) in potential adjuvant therapy of ADHD is described, and the
observed effects of these antioxidants on the activation of the NRF2 pathway in neurodegenerative
and neuropsychiatric disorders are summarized.
García-Guede et al. [23] reviewed the effects of oxidative stress on the epigenetic machinery of
DNA methylation, histone modifications and non-coding RNA, particularly microRNAs (miRNAs)
and long non-coding RNAs (lncRNAs). The influence of these epigenetic modifications is extensively
described in the case of the specific mechanisms for developing cisplatin resistance.
In the four studies reported in this Special Issue, the effects of food components on human health
through modulation of oxidative status of the body cells are investigated. One of the irreplaceable
food component necessary for maintaining health and preventing diseases for humans is ascorbic
acid/vitamin C [24]. By employing untargeted mass spectrometry and metabolomics analysis of
the C2C12 myoblast cells pre-treated with ascorbic acid (100 μM), Magaña et al. [25] suggested
that co-supplementation of ascorbate with folic acid may activate the folate-mediated one-carbon
cycle, thereby promoting the conversion of homocysteine into methionine while reducing cellular
oxidative stress. The pre-treatment of the C2C12 myoblast causes a change in the concentration
of tetrahydrofolate (THF) metabolites. Ascorbate appears to spare NAD(P)H and thus increases
availability of reducing equivalents for the reductive steps from 10-formyl-THF to 5-methyl-THF via
5,10-methylene-THF. In agreement, an increase in the levels of methionine, whose formation from
homocysteine is 5-methyl-THF dependent, and an increase in thymidine, whose formation from
deoxyuridine monophosphate (dUMP) is dependent on 5,10-methylene-THF, were observed.
Castejón et al. [26] made a comprehensive review of secoiridoid compounds of the olive
tree (Olea europaea L. (Oleaceae)) in regard to the chemical, biosynthetic and pharmacological
(including pharmacokinetic) aspects. They have tabulated and discussed the effects of the main
olive phenolics, namely, oleuropein and its aglycon, oleocanthal and oleacein, which were observed
recently in in vitro and in vivo studies in relation to the control and progression of different types of
3
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cancer, cardiovascular diseases and neurodegeneration processes in autoimmune diseases, as well as
their potential roles in anti-aging.
Overconsumption of some type of food has been associated with the induction of oxidative stress
and consequentially the development of pathological transformations. In the review conducted
by Cherkas et al. [27], current epidemiological evidence and redox biology advancements are
discussed with the purpose of defining the linkage between the observed disruptive metabolic effects,
detrimental health consequences of chronic nutritional carbohydrate overload and the metabolic role of
glucose in maintaining redox homeostasis. Glucose is the most important energy source and glycolysis
is a main pathway for obtaining energy when glucose is abundant and redox conditions are favourable.
The authors hypothesized that under extreme oxidative and toxic challenges, glucose provides stress
resistance by the reduction of nicotinamide adenine dinucleotide phosphate NADP+ to NADPH
through its metabolism in the pentose phosphate pathway (PPP). The reduced form NADPH is needed
for the reduction of oxidized glutathione and protein thiols, the synthesis of lipids and DNA as well as
for xenobiotic detoxification, regulatory redox signalling and counteracting infections. In regard to this
aspect, they discussed the role of glycogen stores in resistance to oxidative challenges.
The important approach to study ageing and age-linked pathologies is to investigate sex
dimorphism in the defence against metabolic stressors. In most mammals, females show lower
incidence of some age-related pathologies linked with oxidative stress conditions, and this sex
difference disappears after menopause, which led to the conclusion that this protection is attributed
to the effect of sex hormones [28]. By conducting in vivo experiments on Sirt3 wild-type (WT)
and knockout (KO) mice of both sexes fed with a standard or high-fat diet (HFD) for ten weeks,
Pinterić et al. [29] found significant sex differences in male and female mice responses at the metabolic
level, oxidant/antioxidant status, and liver mitochondrial parameters. Their study points towards a
different role of SIRT3 in males and females under the conditions of nutritive stress. For example,
the male-specific effects of an HFD include reduced SIRT3 expression in WT and alleviated lipid
accumulation and reduced glucose uptake in KO mice.
The research articles and reviews collected in this Special Issue clearly contribute to further
appreciation and enlightening of the underlying complexity of the investigation of chemical and
pharmacological aspects of modulators of oxidative stress and the importance of studying the
modulation of NRF2–KEAP1 and other relevant signalling pathways in order to develop effective
drugs for diseases in which oxidative stress plays a significant etiopathogenetic role.
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Conflicts of Interest: The authors declare no conflict of interest.
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Abstract: Acute myocardial infarction is one of the leading causes of death worldwide and thus,
an extensively studied disease. Nonetheless, the effects of ischemia/reperfusion injury elicited
by oxidative stress on cardiac fibroblast function associated with tissue repair are not completely
understood. Ascorbic acid, deferoxamine, and N-acetylcysteine (A/D/N) are antioxidants with known
cardioprotective effects, but the potential beneficial effects of combining these antioxidants in the
tissue repair properties of cardiac fibroblasts remain unknown. Thus, the aim of this study was to
evaluate whether the pharmacological association of these antioxidants, at low concentrations, could
confer protection to cardiac fibroblasts against simulated ischemia/reperfusion injury. To test this,
neonatal rat cardiac fibroblasts were subjected to simulated ischemia/reperfusion in the presence
or absence of A/D/N treatment added at the beginning of simulated reperfusion. Cell viability was
assessed using trypan blue staining, and intracellular reactive oxygen species (ROS) production
was assessed using a 2′,7′-dichlorofluorescin diacetate probe. Cell death was measured by flow
cytometry using propidium iodide. Cell signaling mechanisms, differentiation into myofibroblasts
and pro-collagen I production were determined by Western blot, whereas migration was evaluated
using the wound healing assay. Our results show that A/D/N association using a low concentration of
each antioxidant increased cardiac fibroblast viability, but that their separate administration did not
provide protection. In addition, A/D/N association attenuated oxidative stress triggered by simulated
ischemia/reperfusion, induced phosphorylation of pro-survival extracellular-signal-regulated kinases
1/2 (ERK1/2) and PKB (protein kinase B)/Akt, and decreased phosphorylation of the pro-apoptotic
proteins p38- mitogen-activated protein kinase (p38-MAPK) and c-Jun-N-terminal kinase (JNK).
Moreover, treatment with A/D/N also reduced reperfusion-induced apoptosis, evidenced by a decrease
Antioxidants 2019, 8, 614; doi:10.3390/antiox8120614 www.mdpi.com/journal/antioxidants7
Antioxidants 2019, 8, 614
in the sub-G1 population, lower fragmentation of pro-caspases 9 and 3, as well as increased B-cell
lymphoma-extra large protein (Bcl-xL)/Bcl-2-associated X protein (Bax) ratio. Furthermore, simulated
ischemia/reperfusion abolished serum-induced migration, TGF-β1 (transforming growth factor beta
1)-mediated cardiac fibroblast-to-cardiac myofibroblast differentiation, and angiotensin II-induced
pro-collagen I synthesis, but these effects were prevented by treatment with A/D/N. In conclusion, this
is the first study where a pharmacological combination of A/D/N, at low concentrations, protected
cardiac fibroblast viability and function after simulated ischemia/reperfusion, and thereby represents
a novel therapeutic approach for cardioprotection.
Keywords: ascorbic acid; deferoxamine; N-acetylcysteine; ischemia/reperfusion; cardiac fibroblasts;
reactive oxygen species
1. Introduction
Ischemic heart disease is still one of the leading causes of mortality in the world [1]. Prolonged
myocardial ischemia due to partial or complete coronary artery occlusion generates an imbalance
between the supply and demand of O2, which subsequently leads to cardiac cell death and thus,
to development of acute myocardial infarction (MI) [2,3]. Restoration of blood flow is of utmost
importance for myocardial salvage. Nevertheless, this procedure itself induces necrotic and apoptotic
cell death. This paradoxical effect is known as lethal reperfusion injury and can contribute up to
50% of final infarct size [4,5]. One of the key mediators of reperfusion injury is oxidative stress,
characterized by a massive release of reactive oxygen species (ROS) at the beginning of reperfusion,
which triggers cellular lipid peroxidation, as well as protein/nucleic acid oxidation, and consequently,
activates pro-apoptotic pathways associated with p38-MAPK and JNK proteins [6,7]. In addition, ROS
of enzymatic origin can be produced by xanthine oxidase, reduced nicotinamide adenine dinucleotide
phosphate hydrogen (NADPH) oxidase, and uncoupled endothelial nitric oxide synthase (eNOS),
whereas non-enzymatic generation of ROS may arise from uncoupled mitochondrial electron transport
chain and Fenton and Haber-Weiss reactions mediated by free iron from cell lysis [6,8].
After myocardial damage caused by ischemia/reperfusion (I/R), the tissue repair processes are
mainly coordinated by cardiac fibroblasts (CF) [9], which are the second most numerous non-myocyte
population in the mouse heart [10]. Under physiological conditions, these cells can synthesize
and degrade collagen to provide a constant replacement of the myocardial extracellular matrix
(ECM). Moreover, CF secrete a variety of paracrine factors that may regulate cellular function in
cardiomyocytes, the endothelium, vascular smooth muscle cells, and immune system cells [11].
In addition, upon pathophysiological stimuli, CF migrate, proliferate, secrete pro-inflammatory
mediators, metalloproteases, and differentiate into cardiac myofibroblasts (CMF) to promote scar tissue
formation [9].
Although previous studies have evaluated the effect of simulated I/R (sI/R) on CF death [12–15],
the impact of oxidative stress triggered by reperfusion injury on the functional capacity associated with
fibroblast-mediated tissue repair, remains to be fully elucidated. In this context, the use of antioxidants
to confer cardioprotection in patients with MI subjected to percutaneous coronary angioplasty has
been previously reviewed [6,8,16]. Ascorbic acid (A), deferoxamine (D), and N-acetylcysteine (N) are
antioxidants that can separately act as a free radical scavenger, a free iron chelator and a reduced
glutathione (GSH) precursor, respectively. In ex vivo and in vivo models of MI these three antioxidants
can protect against myocardial reperfusion injury and prevent the death of cardiomyocytes exposed
to sI/R [17–22]. However, the effects of these antioxidants, either separate or combined, on the
viability of CF after sI/R and the potential mechanisms associated with this protection have not been
thoroughly explored.
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The aim of this study was to determine whether the pharmacological association of A/D/N, at low
concentrations, protects CF from death and recovers cellular function associated with tissue repair
processes after damage by sI/R; along with elucidating the signaling pathways that mediate this effect.
2. Material and Methods
2.1. Reagents
Dulbecco’s Modified Eagle’s medium F12 (DMEM-F12; No 12500062), alamarBlue™ Cell Viability
Reagent (Resazurin; No DAL1100), and Collagenase, Type II, powder (No 17101015) were obtained
from Thermo Fisher Scientific (Waltham, MA, USA). Fetal Bovine Serum (FBS; No 04-001-1A),
Trypsin ethylenediaminetetraacetic acid (EDTA; 0.5%), EDTA 0.2% (10X Solution (No 03-051-5B),
penicillin-streptomycin-amphotericin B Solution (No 03-033-1B), and Trypan Blue (0.5%) Solution
(No 03-102-1B) were obtained from Biological Industries (Cromwell, CT, USA). Recombinant human
TGF-beta 1 protein (TGF-β1; No 240-B) was obtained from R & D Systems, Inc. (Minneapolis, MN, USA).
Pascorbin (vitamin C infusion bottle) was obtained from Pascoe Naturmedizin (Giessen, Germany).
M199 medium (No M2520), pancreatin from porcine pancreas (No P3292), RNAse A (No 10109142001),
propidium iodide (No P4170), Bradford reagent (No B6916), RIPA lysis and extraction buffer (No
89900), Halt™ Protease Inhibitor Cocktail (100X, No 78438), Halt™ Phosphatase Inhibitor Cocktail (No
78427), enhanced chemiluminescence (ECL) western blotting detection reagents (No GERPN2209),
deferoxamine mesylate salt (No D9533), N-Acetyl-L-cysteine (No A7250), 2′,7′-Dichlorofluorescin
diacetate (DCFH-DA; No D6883), 5-Bromo-2′-deoxyuridine (BrdU; No B5002), angiotensin II human
(No A9525), and crystal violet (No C0775) were obtained from Sigma-Aldrich Corp. (St. Louis, MI,
USA). All inorganic salt products and methanol (No 106035) were obtained from Merck (Darmstadt,
Germany). Prestained Protein Ladder-Broad molecular weight (10–245 kDa; No ab116028) was obtained
from Abcam (Cambridge, MA, USA). Nitrogen gas (N2) cylinders were obtained from Linde Group
(Santiago, Chile). Primary antibodies for phospho-ERK 1/2 (p-ERK1/2, No 9101), ERK1/2 (No 9102),
phospho-Akt (p-Akt, No 9271), Akt (No. 9272), phospho-p38-MAPK (p-p38-MAPK, No 9211), p38 (No
9212), phospho-JNK (p-JNK, No 9251), JNK (No 9252), Pro-caspase 3 (No 9662), Pro-caspase 9 (No
9508), Bax (No 2772), Bcl-xl (No 2764), alpha-smooth muscle actin (α-SMA; No 19245), alpha-1 type 1
collagen (COL1A1; No 84336), glyceraldehyde 3-phosphate dehydrogenase (GAPDH; No 5174), and
secondary antibodies for anti-rabbit IgG (No 7074) and anti-mouse IgG (No 7076) conjugated with
horseradish peroxidase (HRP) were obtained from Cell Signaling Technology (Danvers, MA, USA). All
plastic material was obtained from Corning Incorporated (Corning, NY, USA).
2.2. Animals
Sprague-Dawley neonatal rats (1 to 3-days-old) were obtained from Animal Breeding Facilities
of the Facultad de Ciencias Químicas y Farmacéuticas (Universidad de Chile, Santiago, Chile). All
studies followed the Guide for the Care and Use of Laboratory Animals (8th edition, 2011) [23], and
International Guiding Principles for Biomedical Research Involving Animals, as issued by the Council
for the International Organizations of Medical Sciences [24]. Experimental protocols were approved by
the Bioethics Committee for Animal Research from the Facultad de Ciencias Químicas y Farmacéuticas,
Universidad de Chile (CBE2017-08).
2.3. Isolation and Culture of Cardiac Fibroblasts
Neonatal rat CF were isolated as previously described [12]. In a sterile zone, rats were swiftly
decapitated and their hearts rapidly excised. After removing the atrium, ventricles were minced
and digested with collagenase (0.05% w/v) and pancreatin (0.05% w/v). Cells were pre-cultured on
plastic dishes of 100 mm diameter, with DMEM-F12/M199 (4:1) medium containing FBS (10%) and
penicillin-streptomycin-amphotericin B and kept in an incubator with O2 (95%) and CO2 (5%) at
37 ◦C. CF differentially adhered on plastic dishes, which separated them from cardiomyocytes. After
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3 h, CF were washed three times with sterile phosphate buffer saline (PBS) and culture medium was
replenished. Next, CF were incubated during 3–5 days, until confluence was reached. Afterwards,
medium was replaced by DMEM-F12 containing FBS (3%) and penicillin-streptomycin-amphotericin B.
Cells underwent up to a maximum of two passages and detachment was performed using trypsin
EDTA (0.5%), EDTA 0.2% (1X), followed by protease inhibition with DMEM-F12 containing FBS (10%).
CF were then collected and seeded on plastic plates in DMEM-F12 medium without FBS for 24 h
before experiments.
2.4. Isolation and Culture of Cardiomyocytes
Isolation of neonatal rat ventricular cardiomyocytes was performed using one- to three-day-old
Sprague-Dawley rats, as described previously [25]. After enzymatic digestion of the myocardium with
collagenase 0.02% and pancreatin 0.06%, cells were pre-plated to discard non-myocyte cells and the
myocyte-enriched fraction was plated on gelatin-precoated 35 mm dishes and grown in DMEM/M199
(4:1) medium with 10% (w/v) fetal bovine serum (FBS) and 100 mM bromodeoxyuridine for 24 h before
the experiments.
2.5. Simulated Ischemia/Reperfusion (sI/R) and Antioxidant Treatment
We used a modified protocol from Vivar et al. [13]. Following 24 h serum deprivation,
cells were washed two times with PBS before sI/R. Cell medium was replaced with ischemic
buffer, which contained: NaCl (115 mM), KCl (12 mM), MgCl2 (1.2 mM), CaCl2 (2 mM),
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (25 mM), and lactic acid (20 mM),
pH 6.2. For simulated ischemia, hypoxia was achieved by placing the cells in a customized chamber
(STEMCELL Technologies Inc., Vancouver, Canada) with < 1% O2 and 99% N2 environment at 37 ◦C for
6 h. Simulated reperfusion was performed replacing the ischemic medium with DMEM-F12 medium
and placing cells with O2 (95%) and CO2 (5%) at 37 ◦C for 16 h. At the onset of simulated reperfusion
CF, were treated separately with A, D, and N using 10,000, 1000, 100, 10, and 1 μM each for preliminary
cell viability studies. Antioxidants were then, administered in different combinations at 10 or 1 μM
each. In later experiments, the A/D/N association was added using 10 μM of each antioxidant and
simulated reperfusion time was variable, depending on the experiment. Control cells were incubated
under normoxic conditions in DMEM-F12 medium and kept in an incubator with O2 (95%) and CO2
(5%) at 37 ◦C for the exact duration of simulated ischemia and sI/R experiments.
2.6. Cell Viability with Trypan Blue
CF at a 156 cells/mm2 density on 35 mm plastic dishes were used to assess viability using trypan
blue (0.5%) staining. After 16 h simulated reperfusion, cells were washed two times with PBS and
treated with trypsin EDTA (0.5%), EDTA 0.2% (1×) to detach cells, followed by administration of FBS
(10%) to induce inactivation. After collecting the cells, aliquots of 20 μL of sample, plus 20 μL of
trypan blue (0.5%) reagent were homogenized, and then 8 μL were transferred to a Neubauer chamber
(Paul Marienfeld GmbH & Co. KG, Lauda-Königshofen, Germany) to count viable cells (unstained)
using optic microscopy. Cell viability was quantified as a percentage (%) of number of cells after 6 h
normoxia (100%). A minimum of 1000 cells/mL was counted in each sample.
2.7. Cell Viability with the Resazurin Reduction Assay
Cells were seeded in clear bottom 24-well plates with a density of 263 cells/mm2. After 16 h
simulated reperfusion, culture medium was replaced by DMEM-F12, followed by incubation with
resazurin (10%) for 4 h. Viable cells with active metabolism can reduce the non-fluorescent resazurin to
fluorescent resorufin. Fluorescence was measured at 585 nm (λ excitation) and 570 nm (λ emission) in
a BioTek™ Synergy™ 2 Multi-Mode Microplate Reader (BioTek Instruments, Inc., Winooski, VT, USA).
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2.8. Determination of Intracellular ROS
Cells were seeded in clear bottom 24-well plates with a density of 421 cells/mm2. DCFH-DA
is a non-fluorescent cell membrane permeable probe which is de-esterified intracellularly and then
oxidized to the fluorescent 2′,7′-dichlorofluorescein. At the end of 6 h simulated ischemia, cells were
incubated with DCFH-DA (20 μM) dissolved in fresh ischemic medium for 45 min at 37 ◦C. Rapidly,
cells were washed two times with PBS, and then DMEM-F12, with or without antioxidants, was added.
Fluorescence intensity was measured during the first 30 min of simulated reperfusion at 485 nm (λ
excitation) and 535 nm (λ emission) in a BioTek™ Synergy™ 2 Multi-Mode Microplate Reader (BioTek
Instruments, Inc., Winooski, VT, USA).
2.9. Necrosis Assessment by Flow Cytometer
CF were seeded with a 106 cells/mm2 density on 60 mm plastic dishes. After 16 h of simulated
reperfusion, dead cells were collected from medium, centrifuged at 252× g for 5 min, and kept at 4 ◦C.
Live cells were detached from plates using trypsin EDTA (0.5%), EDTA 0.2% (1X), and mixed with the
pellet of dead cells. Subsequently, propidium iodide (1 mg/mL) was added and necrotic cell death was
evaluated by flow cytometry in a BD FACSCantoA (Becton Dickinson & Company, Franklin Lakes, NJ,
USA). A total of 5000 cells/sample were analyzed.
2.10. Sub-G1 Population Determination by Flow Cytometry
Cells were seeded at 106 cells/mm2 density on 60 mm plastic dishes. After 16 h of simulated
reperfusion, dead and live cells were collected according to the same protocol used in Section 2.8. Next,
to permeabilize cell membranes, cold methanol was added to the live and dead cell mixture for 24 h,
at −20 ◦C. RNAse (0.1 mg/mL) was then added to the samples for 1 h at room temperature. Finally,
propidium iodide (1 mg/mL) was added to cells and apoptosis was determined by flow cytometry
using a BD FACSCanto (Becton Dickinson & Company, Franklin Lakes, NJ, USA). Propidium iodide
marks condensed chromatin and/or fragmented DNA in apoptotic bodies giving a low intensity signal
(sub-G1 population), under the prominent G1 signal of living cells with integral DNA. A total of
5000 cells/sample were analyzed.
2.11. Western Blot Analysis
For protein content analysis, CF were seeded at a 106 cells/mm2 density on 60 mm plastic dishes.
At the end of simulated reperfusion, cells were washed three times with cold PBS, followed by
addition of RIPA lysis buffer with protease and phosphatase inhibitors. Samples were centrifuged at
252× g for 10 min at 4 ◦C, and supernatants were collected. Total protein concentration of samples
was determined using the Bradford reagent, and absorbance was measured to 595 nm in an Epoch
UV-Vis Spectrophotometer (BioTek Instruments, Inc., Winooski, VT, USA). We used 25 μg of total
protein sample, which was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) using 10–20% acrylamide/bis-acrylamide gels run for 1.5–2 h. at constant 70–100 V.
Proteins were then electro-transferred to a nitrocellulose membrane for 1–1.5 h with a 0.35 A constant
current. Membrane was blocked with non-fat milk (5% w/v) for 1 h. Primary antibodies against
p-ERK1/2, ERK1/2, p-Akt, Akt, p-p38, p38, p-JNK, JNK, pro-caspase 3, pro-caspase 9, Bax, Bcl-xl,
α-SMA, COL1A1 (dilution 1:1000), or GAPDH (dilution 1:2000) were incubated overnight at 4 ◦C.
Secondary antibodies for anti-rabbit IgG or anti-mouse IgG conjugated with HRP (dilution 1:5000) were
incubated for 1.5 h at room temperature. Membrane was exposed to the ECL reagent and revealed in
the C-DiGit Chemiluminescent Western Blot Scanner (LI-COR Biosciences, Lincoln, NE, USA). Images
and blots were analyzed and quantified using the Image Studio™ software (LI-COR Biosciences,
Lincoln, NE, USA).
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2.12. Evaluation of Cell Migration by Wound Healing Assay
CF were seeded 156 cells/mm2 density on 35 mm plastic dishes in DMEM-F12 containing FBS
(10%) and penicillin-streptomycin-amphotericin B and incubated during 24 h to allow proliferation
until confluence was reached. Subsequently, cells were washed two times with PBS and incubated
with DMEM-F12 for 24 h. Next, simulated ischemia was performed for 6 h, followed by a scratch made
using a 200 μL tip in fibroblast monolayers at the beginning of simulated reperfusion. BrdU (100 μM)
was used as a proliferation inhibitor, allowing CF to migrate without proliferating in the presence of
FBS (10%). After 24 h, cells were stained with crystal violet (0.3% w/v) for 20 min at room temperature.
After washing and drying plates, images were obtained from four fields per plate using an optic
microscope. Scratched areas per image were analyzed with ImageJ software (LI-COR Biosciences,
Lincoln, NE, USA). and the mean of four fields of scratched areas per plate was used for data analysis.
All values of mean scratched area were normalized with respect to the value of mean scratched area of
control groups with cells incubated in DMEM-F12.
2.13. Statistical Analysis
All data are presented as mean ± standard error of the mean (S.E.M.), of at least three independent
experiments, and were analyzed using GraphPad Prism (GraphPad, San Diego, CA, USA) version 5.01
software. The differences between two experimental groups were evaluated by paired Student’s t-test.
The differences between three or more experimental groups were evaluated by a one-way analysis of
variance (ANOVA) followed by a Tukey post-test. The differences between two experimental groups
at each time were evaluated by two-way ANOVA, followed by a Bonferroni post-test. Statistical
significance was accepted at p < 0.05.
3. Results
3.1. Individual Effects of Ascorbic Acid, Deferoxamine, and N-Acetylcysteine on Viability of Cardiac Fibroblasts
after Simulated Ischemia/Reperfusion
In order to study the cytoprotective effects of antioxidants, we first validated our model by
subjecting neonatal rat CF to 6 h of simulated ischemia, followed by 16 h of simulated reperfusion
and we measured cell viability using trypan blue. The results show that after sI/R, cell viability was
significantly reduced compared to normoxic controls (p < 0.001; Figure 1A), which was corroborated
using the resazurin reduction assay (p < 0.01; Figure 1B). We then tested administration ascorbic acid
(A), deferoxamine (D), and N-acetylcysteine (N) at 10,000; 1000; 100; 10; and 1 μM at the beginning of
reperfusion and evaluated cell viability using trypan blue. None of the three antioxidants had any
effect on CF viability at 10 and 1 μM after sI/R. (Figure 1C–E). However, treatment with D increased cell
viability at 10,000; 1000; and 100 μM, while addition of N increased cell viability at 1000 and 100 μM,
but not at 10,000 μM (Figure 1D,E, respectively). Administration of A increased cell viability only
at 100 μM (non-significant), whereas 10,000 μM further reduced CF viability after sI/R, compared to
untreated cells (p < 0.001; Figure 1C).
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Figure 1. Effects of ascorbic acid, deferoxamine and N-acetylcysteine, at different concentrations, on
viability of cardiac fibroblasts exposed to simulated ischemia/reperfusion. Cardiac fibroblasts were
exposed to 6 h simulated ischemia, followed by 16 h simulated reperfusion (sI/R). (A) Cell viability
was quantified as a percentage (%) of number of cells after 6 h normoxia (C6, 100%) by cell count
after trypan blue staining (n = 3). (B) Cell viability was quantified as fluorescence intensity using
the resazurin reduction assay (n = 3). At the beginning of simulated reperfusion, ascorbic acid (C),
deferoxamine (D) and N-acetylcysteine (E) were added using 10,000; 1000; 100; 10; and 1 μM. Cell
viability was quantified as the percentage (%) of number of cells after 6 h normoxia (100%) by cell count
after trypan blue staining (n = 3). The results are expressed as mean ± S.E.M. &&& p < 0.001 vs. C6;
$$$ p < 0.001 vs. I (cells after 6 h simulated ischemia); *** p < 0.001 and ** p < 0.01 vs. C22 (control cells
after 22 h normoxia); ### p < 0.001, ## p < 0.01, and # p < 0.05 vs. sI/R.
3.2. Ascorbic Acid, Deferoxamine, and N-Acetylcysteine Association Increased Cell Viability and Reduced
Intracellular ROS Production in Cardiac Fibroblasts Subjected to Simulated Ischemia/Reperfusion
Next, we sought to evaluate whether the pharmacological association of A, D, and N could
provide synergistic protection by using a low concentration of each antioxidant that had no effect
on cell viability when administered separately. To achieve this, CF were exposed to sI/R and we
simultaneously administered combinations of the three antioxidants at the onset of reperfusion at 1
and 10 μM, and then measured cell viability using trypan blue. Our results show that treatments with
the associations of A/D, A/N, and A/D/N, but not D/N, increased cell viability after sI/R at 10 μM each,
when compared to untreated conditions (Figure 2A). However, only the A/D association protected at
1 μM (Supplementary Figure S1). Based on these findings, we decided to study the cytoprotective effect
of the A/D/N association at 10 μM given its potential to provide more robust protection by reducing
oxidative stress by three different mechanisms, unlike double associations of these antioxidants. In
addition, we observed that the A/D/N association at 10 μM each significantly reduced intracellular ROS
production after sI/R, compared to untreated cells, as measured with a DCFH-DA probe (Figure 2B).
Therefore, we used the joint administration of 10 μM of A/D/N for the rest of the experiments.
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Figure 2. The association of ascorbic acid, deferoxamine, and N-acetylcysteine, at 10 μM each, increased
cell viability and decreased intracellular reactive oxygen species (ROS) generation in cardiac fibroblasts
exposed to simulated ischemia/reperfusion. (A) Cardiac fibroblasts were exposed to 6 h simulated
ischemia followed by 16 h simulated reperfusion (sI/R). Associations between ascorbic acid (A),
deferoxamine (D), and N-acetylcysteine (N), using 10 μM of each antioxidant, were added at the
beginning of simulated reperfusion. Cell viability was quantified as a percentage (%) of number of
cells after 6 h normoxia (100%) by cell count after trypan blue staining (n = 5). (B) Cardiac fibroblasts
were exposed to 6 h simulated ischemia followed by 30 min simulated reperfusion (sI/R). At the end of
ischemia, cells were incubated with 2′,7′-dichlorofluorescin diacetate and then treated with A/D/N
using 10 μM of each antioxidant at the onset of simulated reperfusion. Intracellular ROS generation
was measured as the fluorescence intensity in a time course during the first 30 min of simulated
reperfusion (n = 3). The results are expressed as mean ± S.E.M. *** p < 0.001 vs. C22 (control cells after
22 h normoxia); ### p < 0.001, ## p < 0.01 and # p < 0.05 vs. sI/R. Symbol “+” represents presence of
condition and symbol “-” represents absence of condition.
3.3. Association of Ascorbic Acid, Deferoxamine, and N-Acetylcysteine Reduced Apoptosis of CF Exposed to
Simulated Ischemia/Reperfusion
To confirm our findings of cell death types, we measured necrosis and apoptosis after sI/R
using flow cytometry analysis with propidium iodide staining. The results indicate that antioxidant
association had no effect on necrosis induced by sI/R (Figure 3A). However, treatment with A/D/N
induced a decrease in the sub-G1 population of CF exposed to sI/R, compared to untreated conditions
(p < 0.05; Figure 3B). To further corroborate that the A/D/N association can inhibit apoptosis induced
by sI/R in CF, we determined the protein levels of pro-caspase 9 and pro-caspase 3, as well as the
Bcl-xl/Bax ratio after treatment with A/D/N. Our data shows that cells exposed to sI/R presented lower
levels of pro-caspases 9 and 3, as compared with normoxic cells (both p < 0.001). This result suggests
an induction of apoptosis (Figure 3C,D), but administration of the A/D/N association prevented this
effect and increased the Bcl-xl/Bax ratio (p < 0.05), compared to untreated CF after sI/R (Figure 3C–E).
In addition, to test whether these findings were reproduced in a different cell type, we subjected
primary neonatal rat cardiomyocytes to sI/R and then treated them with A/D/N. Our results show that
A/D/N increased viability of cardiomyocytes (Supplementary Figure S2A) and increased the levels of
pro-caspases 9 and 3 (Supplementary Figure S2B,C).
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Figure 3. The association of ascorbic acid, deferoxamine and N-acetylcysteine reduced apoptosis
induced by simulated ischemia/reperfusion in CF. Cells were exposed to 6 h simulated ischemia,
followed by 16 h simulated reperfusion (sI/R). Cells were treated with the association of ascorbic acid,
deferoxamine, and n-acetylcysteine (A/D/N) using 10 μM of each antioxidant at the onset of simulated
reperfusion. (A) The percentage (%) of necrotic cells was quantified by flow cytometry using propidium
iodide (right panel), with representative histograms of each experimental group (left panel; n = 4).
(B) The percentage (%) of the sub-G1 population was quantified by flow cytometry using propidium
iodide (right panel), with representative histograms of each experimental group (left panel; n = 5).
(C–E) show representative Western blots (upper panel) and densitometric analysis (lower panel) of
pro-caspase 9 (n = 4), pro-caspase-3 (n = 5), and Bcl-xl/Bax ratio (n = 3), respectively. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was used as a loading control. The results are expressed as
mean ± S.E.M. *** p < 0.001 and * p < 0.05 vs. C22 (control cells after 22 h normoxia); ### p < 0.001 and
# p < 0.05 vs. sI/R.
3.4. Association of Ascorbic Acid, Deferoxamine and N-Acetylcysteine Activated the Pro-Survival Kinases
ERK1/2 and Akt and Reduced the Phosphorylation of the Pro-Apoptotic Proteins p38.MAPK and JNK Induced
by Simulated Ischemia/Reperfusion in CFs
In order to pursue the mechanism by which the association of antioxidants conferred its protective
effect, we sought to evaluate the signaling pathways associated with cell survival. To test this, we
determined by Western blot the early activation of ERK1/2 and Akt in response to administration of
A/D/N in CF exposed to sI/R. The results show that sI/R significantly increased phosphorylation of
ERK1/2 and Akt after 10 min of simulated reperfusion, compared to normoxic conditions, but this effect
was further potentiated by the treatment with the antioxidant association (Figure 4A,B). In addition,
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sI/R also elicited early phosphorylation of the pro-apoptotic proteins p38 and JNK in comparison with
normoxic conditions, but this effect was diminished by administration of A/D/N (p < 0.05; Figure 4C,D).
Figure 4. The association of ascorbic acid, deferoxamine, and N-acetylcysteine increased the activation
of the pro-survival kinases ERK1/2 and Akt, and reduced activation of the pro-apoptotic proteins p38
and JNK in cardiac fibroblasts exposed to simulated ischemia/reperfusion. Cardiac fibroblasts were
exposed to 6 h simulated ischemia, followed by 10 min of simulated reperfusion (sI/R). Cells were
treated with the association of ascorbic acid, deferoxamine and N-acetylcysteine (A/D/N) using 10 μM
of each antioxidant at the onset of simulated reperfusion. (A–D) show representative Western blots
(upper panel) and densitometric analysis (lower panel) of p-ERK1/2 and ERK1/2 (n = 3), p-Akt and Akt
(n = 3), p-p38 and p38 (n = 4), and p-JNK and JNK (n = 3), respectively. GAPDH was used as a loading
control. The results are expressed as mean ± S.E.M. *** p < 0.001 and ** p < 0.01 vs. C (control cells after
70 min normoxia); ### p < 0.001 and # p < 0.05 vs. sI/R.
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3.5. Association of Ascorbic Acid, Deferoxamine, and N-Acetylcysteine Prevented the Loss of Function
Associated with Tissue Repair Induced by Simulated Ischemia/Reperfusion in CF
Finally, we studied whether the A/D/N association can protect CF function associated with
detriments in migration, differentiation and collagen secretion, after sI/R. To assess cell migration,
we performed the wound healing assay using FBS (10%) to induce migration of CF to the scratched
area during simulated reperfusion, and we applied BrdU to inhibit the proliferation induced by FBS.
Figure 5A shows that, in normoxic conditions, CF migrated in the presence of FBS (10%), with or
without BrdU, reducing the scratched area over 50%, compared with control cells (p < 0.001). However,
cells did not migrate in the presence of the A/D/N association. Then, we tested whether CF exposed
to sI/R can migrate in the presence of FBS (10%) + BrdU. Figure 5A shows that, after 6 h simulated
ischemia followed by 24 h simulated reperfusion, CF did not migrate in the presence of FBS (10%) +
BrdU. In addition, the A/D/N association by itself did not modify the migration of CF exposed to sI/R.
However, when the cells were exposed to sI/R and treated with A/D/N in the presence of FBS (10%) +
BrdU, migration was significantly increased compared to normoxic control cells without FBS (10%;
p < 0.01), and compared to cells under sI/R and in presence of FBS (10%) + BrdU (p < 0.01; Figure 5A).
In addition, we induced CF-to-CMF differentiation by incubating CF in the presence or absence
of TGF-β1 (10 ng/mL) during simulated reperfusion, and measured α-SMA (alpha smooth muscle
actin)—a differentiation protein level marker—by Western blot after 48 h. Figure 5B shows that α-SMA
protein content is increased after 6 h simulated ischemia, followed by 48 h simulated reperfusion with
or without TGF-β1 administration, compared to control conditions (p < 0.001), but these effects were
inhibited after sI/R. Addition of A/D/N alone did not increase α-SMA protein levels in CF after sI/R, but
co-administration of antioxidants with TGF-β1 restored the cytokine’s differentiating effect, compared
to control conditions (p < 0.001; Figure 5B).
Furthermore, pro-collagen I synthesis was assessed by stimulation of CF with angiotensin II
(100 nM) during simulated reperfusion for 48 h. Western blot analysis revealed increased angiotensin
II induced-pro-collagen I protein levels with respect to control conditions (p < 0.05), which were
significantly inhibited after 6 h simulated ischemia followed by 48 h simulated reperfusion (p < 0.001;
Figure 5C). A/D/N alone also had no effect in pro-collagen I protein levels in CF after sI/R, but joint
administration with angiotensin II restored the production of pro-collagen I induced by this peptide,
in comparison to normoxic conditions (p < 0.05), and to cells under sI/R treated with angiotensin II
(p < 0.01; Figure 5C).
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Figure 5. The association of ascorbic acid, deferoxamine, and N-acetylcysteine prevents the loss of
serum-induced migration, TGF-β1-mediated differentiation and angiotensin II-induced pro-collagen I
synthesis induced by simulated ischemia/reperfusion in CF. (A) Cells were exposed to 6 h simulated
ischemia, followed by 24 h simulated reperfusion (sI/R). Cells were treated with the association of
ascorbic acid, deferoxamine, and n-acetylcysteine (A/D/N) using 10 μM of each antioxidant at the onset
of simulated reperfusion. A scratch was made on a cell monolayer prior to simulated reperfusion with
DMEM-F12, FBS (10%), or FBS (10%) + BrdU (100 μM). Representative images of each experimental
group (left panel) and quantification of area (right panel) are shown (n = 3). (B) Cardiac fibroblasts
were exposed to 6 h simulated ischemia, followed by 48 h simulated reperfusion (sI/R). At the onset of
simulated reperfusion, cells were treated with the association of A/D/N using 10 μM of each antioxidant
and stimulated with or without TGF-β1 (10 ng/mL). Representative Western blots (upper panel) and
densitometric analysis (lower panel) of α-SMA and GAPDH as loading control are shown (n = 5).
(C) Cardiac fibroblasts were exposed to 6 h simulated ischemia, followed by 48 h simulated reperfusion
(sI/R). At the beginning of simulated reperfusion, cells were treated with the association of A/D/N using
10 μM of each antioxidant and stimulated with or without angiotensin II (100 nM). Ascorbic acid (100
nM) was added to all experimental groups as a co-factor in pro-collagen type I synthesis. Representative
Western blots (upper panel) and densitometric analysis (lower panel) of COL1A1 and GAPDH as
loading control are shown. The results are expressed as mean ± S.E.M. *** p < 0.001, ** p < 0.01 and
* p < 0.05 vs. Normoxia (30 h) + DMEM-F12; $$ p < 0.01 and $ p < 0.05 vs. Normoxia (30 h) + FBS
(10%) + BrdU; ## p < 0.01 vs. sI/R + FBS (10%) + BrdU; §§§ p < 0.001 vs. Normoxia (0 h); % p < 0.05 vs.
Normoxia (56 h); && p < 0.01 vs. Normoxia (56 h) + TGF-β1; ††† p < 0.001, †† p < 0.01 and † p < 0.05
vs. Normoxia (56 h) + angiotensin II; ¢¢ p < 0.01 vs. sI/R + angiotensin II. COL1A1 = alpha-1 type 1
collagen; TGF-β1 = transforming growth factor beta 1; α-SMA = alpha smooth muscle actin; FBS = fetal
bovine serum; BrdU = 5-bromo-2′-deoxyuridine. Symbol “+” represents presence of condition and
symbol “-” represents absence of condition.
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4. Discussion
The main findings of the present study showed that the pharmacological association of A, D,
and N: (a) increased cell viability in CF exposed to sI/R using a lower concentration than those of
each antioxidant which, separately, did not show cell viability protection, (b) reduced intracellular
ROS production and decreased apoptotic cell death induced by sI/R, (c) activated the pro-survival
kinases ERK1/2 and Akt, but inhibited the pro-apoptotic p38 and JNK kinases, and (d) recovered
CF function associated with wound repair induced by sI/R by restoring serum-induced migration,
TGF-β1-mediated differentiation of CF into CMF and angiotensin II-induced pro-collagen I synthesis.
The deleterious effects of reperfusion injury and oxidative stress on the functional capacity of
CF could negatively affect the optimal development of myocardial repairing after tissue damage [26];
therefore, cytoprotection of fibroblasts is of the utmost importance. Currently, there are multiple
strategies to protect the myocardium from I/R injury, but the translation of these therapies from bench
to bedside has proved challenging. Combinations of therapies with synergistic effects, as well as
protection of all cardiac cell types and not just cardiomyocytes, are believed to be essential to achieve
cardioprotection in the clinical arena [27,28].
Our preliminary studies revealed that A, D, and N separately increase the viability of CF exposed
to sI/R in a concentration-dependent manner, at high concentrations (≥100 μM). However, 10 mM of A
was cytotoxic due to its pro-oxidant activity at higher concentrations, which has been demonstrated in
murine tumors [29]. Moreover, these antioxidants, separately, did not protect against sI/R injury at
1 and 10 μM, but when they were associated (dual or triple combinations) at 10 μM each, showed a
synergistic cytoprotective effect. Previous studies have thoroughly established that A, D, and N -alone
or in dual combination- yield cardioprotective effects [17–22,30–33]. Nonetheless, this is the first study
that shows protection elicited by A/D/N administration in CF after sI/R. In addition, in vivo assays of
MI will also be necessary to clarify whether the A/D/N association could prevent cardiac cell death,
in order to reduce infarct size and finally, improve wound healing. Conversely, a study reported by
Nikas et al., [34] showed that combined intravenous administration of A, D, and N, 15 min before and
5 min after reperfusion, with the same dose, was unable to reduce infarct size, the deleterious effects
on ventricular function parameters, or oxidative stress markers in an in vivo model of myocardial
reperfusion injury in pigs. Although the authors use a reliable I/R model tested in large animals, they
only tested a single dose of each antioxidant (3–3.5 g A, 1.8–2.1 g D, and 3–3.5 g N) and did not measure
the plasma levels reached by A, N, and D to compare with the results of the present study.
We speculated that the synergistic cytoprotective effects of the associations between A/D, A/N,
and A/D/N, but not D/N (using each antioxidant at 10 μM) on the viability of CF exposed to sI/R, could
be intrinsically related to a favorable pharmacological interaction between A, N and D, in the context
of myocardial reperfusion injury elicited by oxidative stress [6,8]. Intracellular GSH -an endogenous
antioxidant molecule- can reduce oxidized dehydroascorbate to ascorbate (an ionized form of A),
which increases the bioavailability of ascorbate to interact against ROS [35]. Moreover, the decrease
in intracellular GSH levels may be replenished by N, and D can chelate an excess of catalytic free
iron (which increases during ischemia and cardiac reperfusion from cell lysis), thereby decreasing the
production of hydroxyl radicals through the Fenton reaction, and preventing the pro-oxidant interaction
of iron with A [36]. Thus, the A/D/N association has the advantage of improving the antioxidant
response against the increase of intracellular ROS during simulated reperfusion, by providing three
different mechanisms of antioxidant action. Finally, the use of lower concentrations of each antioxidant,
compared to those used in independent administration to achieve a pharmacological effect in CF,
ensured us that possible toxic effects could be low or absent.
Moreover, the A/D/N combination also activated ERK1/2 and Akt, which are key components of
the reperfusion injury salvage kinases (RISK) pathway and therefore, essential to protect cardiac cells
exposed to sI/R from reperfusion-induced cell death [37,38]. Currently, there are a few studies linking
the activation of the RISK pathway to A and N [18,31,39], and therefore, our findings further support a
nexus between this well-known survival signaling pathway and the cytoprotective effect of antioxidant
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association. However, additional studies are necessary to establish cause-effect mechanisms in order to
evaluate whether inhibition of the RISK pathway results in the loss of protection conferred by the A/D/N
triad. Additionally, treatment with A/D/N triggered anti-apoptotic effects in CF exposed to sI/R by
reducing the phosphorylation of p38 and JNK, which are important players in apoptosis in the context
of cardiac I/R [7,40]. This signaling pathway may be triggered by the apoptosis signal-regulating kinase
1 (ASK1), which can be activated by ROS, and consequently, induce apoptosis [41]. Further research
is also required to thoroughly assess the molecular mechanisms by which the A/D/N antioxidant
association activates the RISK pathway and also inactivates p38 and JNK.
The A/D/N association reduced the activation of caspases 9, 3 and increased the Bcl-xl/Bax ratio.
Moreover, using the same sI/R protocol, protection was also observed in cardiomyocytes treated with
A/D/N. These effects were further confirmed by the assessment of pro-apoptotic proteins, suggesting
that our pharmacological approach may protect the whole myocardium and not only fibroblasts.
These results are consistent with the previously reported anti-apoptotic effects conferred by A, D,
and N [18,19,31,42], and contribute to a better characterization of the role of oxidative stress as a
pharmacological target in apoptosis induced by I/R. Furthermore, we did not observe a protective effect
of A/D/N against necrosis, which could initially suggest that there are factors other than oxidative stress
(e.g., decreased energy metabolism) that might contribute most importantly to this type of cell death
during simulated reperfusion. However, the RISK pathway protects against cell death by apoptosis
and necrosis, and in our in vitro model this survival pathway is activated by the A/D/N association in
cardiac fibroblasts; therefore, future studies will be required to understand this differential protection
against these two types of cell death. Moreover, given the normal limitations of the cell death assays
we used, future research should thoroughly assess the exact type of cell death prevented by the
A/D/N association.
CF migration is a key step in the wound repair process, allowing CF located in close areas to the
infarction zone to migrate and repopulate the necrotic area. Chemokines (Fractalkine/CX3CL1), growth
factors (TGF-β and fibroblast growth factor), and cytokines (interleukin-1β, tumor necrosis factor α
and cardiotrophin-1) secreted from other cells types further secrete ECM, cytokines and chemokines
(as MCP-1) to induce immune cell migration and ensure fast tissue repair [9,43]. Due to its high
content of embryonic growth-promoting factors, FBS is used to induce in vitro migration in CF and
other cell types [44,45]. In our study, cellular injury caused by sI/R triggered the impairment of the
FBS-induced migratory capacity of CF. Similar results were found in adult rat CF, where stimulation
with hydrogen peroxide 10 and 100 μM showed that migration induced by a fibronectin gradient
was delayed, compared to untreated control cells [46]; these results highlight the deleterious effect of
oxidative stress on migration of these cells and suggest the protective molecular mechanism of the
A/D/N association.
One of the main characteristics of CF is their ability to differentiate into CMF, which are
characterized by a pro-fibrotic phenotype [47]. These cellular changes are induced by several
stimuli, such as TGF-β1, interleukin-10, thrombospondin-1, angiotensin II, stimulation of injury-site
cardiomyocytes, and vascular cells, among others [26]. CMF are the main secretory source of ECM
proteins, as well as matrix metalloproteases, in cardiac fibrotic remodeling [26]. In our study, we
induced spontaneous CF-to-CMF differentiation, which is due probably to the autocrine effects of
TGF-β1 secreted by CF in culture, as well as treatment with TGF-β1. Both methods induced an increase
in α-SMA levels in CF after 48 h of simulated reperfusion. Although TGF-β1 stimulation was not
significantly greater than spontaneous differentiation, we and others have shown that TGF-β1 increases
α-SMA levels in CF in a time-dependent manner [45,48]. Interestingly, this inhibitory effect of sI/R
on the increase of α-SMA levels induced by TGF-β1 or spontaneous differentiation in CF has not
been previously described. A similar effect has been observed in H9c2 cardiomyocytes and in corneal
keratocytes, where hypoxia prevented the transformation to myofibroblasts induced by, an effect which
was associated with changes in TGF-β1 signaling pathways [49,50]. Further studies are necessary
20
Antioxidants 2019, 8, 614
to elucidate the effects of the A/D/N association on signaling pathways implicated in the effects of
differentiation of CF to MCF induced by TGF-β1 after sI/R.
CF and CMF secrete and degrade various types of collagen to maintain ECM homeostasis. Among
these, type I collagen is widely expressed in cardiac tissue of mammals and forms thick and stiff
fibers [26]. Angiotensin II is a peptide known to elicit cardiac fibrosis [51,52] by stimulating CF collagen
production and secretion [53,54]. In our CF in vitro model, sI/R prevented the increase of pro-collagen
I synthesis triggered by angiotensin II and did not induce pro-collagen I production by itself. These
results were corroborated by Siwik et al., [55] who demonstrated that oxidative stress decreases fibrillar
collagen synthesis in CF. Interestingly, previous reports have shown that 72 h of hypoxia induce an
increase in pro-collagen type I α mRNA and protein levels in human CF [56], while 6 h of hypoxia also
increased collagen I levels in adult rat CF [57]. Additionally, another study found that 1 h of hypoxia
followed by 12 h reoxygenation increases the secretion of soluble collagen from neonatal rat CF [58].
These differences can be attributed to various factors, such as duration of hypoxia/reoxygenation, age,
and species from which these cells originate.
Our observations that the A/D/N association prevents cell death, reduces oxidative stress and
recovers cellular functions associated with tissue repair induced by sI/R in CF certainly supports
the previously described cardioprotective effects of A, D, and N; either separately or combined, on
ventricular function in animal models of myocardial I/R [17–19,30,32,33].
5. Conclusions
Overall, our findings indicate, for the first time, that the association of A, D, and N protects CF from
cell death and recovers pro-wound healing function damaged by sI/R. We used a low concentration
of each antioxidant, which did not increase cell viability when administered separately. Moreover,
this effect may be mediated by activation of the RISK pathway and inhibition of the pro-apoptotic
proteins p38 and JNK, suggesting that pharmacological association of these antioxidants may be a novel
therapeutic strategy to protect the myocardium from reperfusion injury elicited by oxidative stress.
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Figure S1: Effects of the association between ascorbic acid, deferoxamine and N-acetylcysteine, at 1 μM each,
on viability of cardiac fibroblasts exposed to simulated ischemia/reperfusion. Cardiac fibroblasts were exposed
to 6 h simulated ischemia, followed by 16 h simulated reperfusion (sI/R). Associations between ascorbic acid
(A), deferoxamine (D) and N-acetylcysteine (N), using 1 μM of each antioxidant, were added at the beginning of
simulated reperfusion. Cell viability was quantified as a percentage (%) of the number of cells after 6 h normoxia
(100%) by cell count after trypan blue staining (n = 3). The results are expressed as mean ± S.E.M. *** p < 0.001
and * p < 0.05 vs. C22 (control cells after 22 h normoxia); ## p < 0.01 vs. sI/R. Figure S2: Effects of associations
between ascorbic acid, deferoxamine and N-acetylcysteine, at 10 μM each, on viability and pro-caspases 9 and
3 protein levels of cardiomyocytes exposed to simulated ischemia/reperfusion. Cardiomyocytes were exposed
to 6 h simulated ischemia, followed by 16 h simulated reperfusion (sI/R). Associations between ascorbic acid
(A), deferoxamine (D) and N-acetylcysteine (N), using 10 μM of each antioxidant, were added at the beginning
of simulated reperfusion. (A) Cell viability was quantified as a percentage (%) of the number of cells after 6
h normoxia (100%) by cell count after trypan blue staining (n = 3). (B) and (C) show representative Western
blots (upper panel) and densitometric analysis (lower panel) of pro-caspase 9 (n = 4) and pro-caspase-3 (n = 4),
respectively. GAPDH was used as a loading control. The results are expressed as mean ± S.E.M. *** p < 0.001 and
** p < 0.01 vs. C22 (control cells after 22 h normoxia). ### p < 0.001, ## p < 0.01 and # p < 0.05 vs. sI/R.
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Abstract: Background: While reperfusion is crucial for survival after an episode of ischemia, it also
causes oxidative stress. Nuclear factor-E2-related factor 2 (Nrf2) and unfolded protein response
(UPR) are protective against oxidative stress and endoplasmic reticulum (ER) stress. Ezetimibe,
a cholesterol absorption inhibitor, has been shown to activate the AMP-activated protein kinase
(AMPK)/Nrf2 pathway. In this study we evaluated whether Ezetimibe affects oxidative stress and Nrf2
and UPR gene expression in cellular models of ischemia-reperfusion (IR). Methods: Cultured cells
were subjected to simulated IR with or without Ezetimibe. Results: IR significantly increased reactive
oxygen species (ROS) production and the percentage of apoptotic cells without the up-regulation of
Nrf2, of the related antioxidant response element (ARE) gene expression or of the pro-survival UPR
activating transcription factor 6 (ATF6) gene, whereas it significantly increased the pro-apoptotic
CCAAT-enhancer-binding protein homologous protein (CHOP). Ezetimibe significantly decreased the
cellular ROS formation and apoptosis induced by IR. These effects were paralleled by the up-regulation
of Nrf2/ARE and ATF6 gene expression and by a down-regulation of CHOP. We also found that Nrf2
activation was dependent on AMPK, since Compound C, a pan inhibitor of p-AMPK, blunted the
activation of Nrf2. Conclusions: Ezetimibe counteracts IR-induced oxidative stress and induces Nrf2
and UPR pathway activation.
Keywords: oxidative stress; Nrf2; ER stress; Ezetimibe; ischemia-reperfusion
1. Introduction
Ischemia-reperfusion (IR) injury takes place when blood provision to an organ is diminished or
interrupted and then reestablished, and underlies many pathological situations such as heart attacks,
strokes and peripheral artery disease (PAD). While reperfusion is crucial for survival, it also causes
oxidative stress and cell damage through the production of reactive oxygen species (ROS) [1–3].
Nuclear factor-E2-related factor 2 (Nrf2) is a master transcription factor that target genes coding for
antioxidant proteins and detoxification enzymes [4–6]. Nrf2 controls the basal and induced expression
of an array of antioxidant response element (ARE)-dependent genes, such as heme-oxygenase
(HO)-1 and glutamate-cysteine ligase catalytic (GCLC) subunit, to regulate the physiological and
pathophysiological outcomes of oxidant exposure [4–6]. Under basal conditions, Nrf2-dependent
transcription is repressed by its negative regulator Kelch-like enoyl-CoA hydratase- associated protein
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1 (Keap-1); when cells are exposed to oxidative stress or electrophiles, Nrf2 accumulates in the nucleus
and drives the expression of its target genes [4–6].
The canonical nuclear factor (NF)-kB complex is composed of a dimer of p65 and p50 that
is involved in various processes such as inflammation, apoptosis and the immune response [7].
In unstimulated cells, NF-kB is retained in the cytoplasm and bound to IkB-α; during oxidative stress,
IkB kinase is activated and causes the phosphorylation of IkB-α, resulting in the nuclear translocation
of p65 with the subsequent transcription of pro-inflammatory mediators [7]. Interestingly, activation of
the Nrf2 and NF-kB pathways has been recently reported in different models of IR [8–10].
Stresses like ischemia and oxidative stress that perturb the folding of nascent endoplasmic
reticulum (ER) proteins activate ER stress, which, in turn, triggers the unfolded protein response (UPR)
that deals with unfolded and misfolded proteins [11–13]. In this context, it has been shown that the
activating transcription factor 6 (ATF6) branch of the UPR may induce the expression of proteins that
can reduce IR injury in the hearts of transgenic mice [12] and in cardiac myocytes [13]. Moreover,
we have recently demonstrated in cultured cells that IR promoted a considerable increment in ROS,
which was not followed by Nrf2 and UPR signaling pathway activation [14].
There is evidence showing that oxidative stress, ER stress and inflammation are inseparably
linked, as each causes and amplifies the others: in particular, it has been shown that direct or indirect
activation and inhibition occur between members of the Nrf2 and NF-kB pathways [15] and that the
UPR-induced Nrf2 activation participates in maintaining redox homeostasis and cell survival [16].
Furthermore, we have previously shown, in the circulating cells of smokers [17] and of patients
with type 2 diabetes [18] and coronary artery disease [19], that the degree of oxidative stress greatly
influences the Nrf2, NF-κB and UPR signaling pathways.
Ezetimibe regulates exogenous dietary cholesterol absorption in the small intestine, blocking the
transmembrane protein Niemann Pick C1-like 1 (NPC1L1) [20,21]. Beyond its powerful cholesterol
lowering effects, the latest evidence shows that Ezetimibe has additional pleiotropic effects. In fact,
Ezetimibe has been demonstrated to reduce oxidative stress through the activation of the AMP-activated
protein kinase (AMPK)/Nrf2 pathway in animal models of nonalcoholic steatohepatitis [22] and ischemic
stroke [23,24]. Furthermore, there are data showing that Ezetimibe can reduce the expression of ER
stress markers in liver extracts of Zucker obese fatty rats [25] and that Ezetimibe may increase the
glutathione content in rat livers subjected to IR [26].
Therefore, in cellular models of IR (using monocyte-like THP-1 cells and human cardiomyocytes),
we aimed to investigate: (1) whether Ezetimibe reduces oxidative stress, NF-kB activation and apoptosis;
(2) the effect of Ezetimibe on the adaptive response to oxidant injuries through Nrf2/ARE and UPR
pathway up-regulation; and (3) the involvement of AMPK phosphorylation in Nrf2 activation.
2. Materials and Methods
2.1. Cell Cultures
Monocyte-like THP-1 cells were cultured in RPMI 1640 (Invitrogen Carlsbad, CA, USA),
as previously described [19]. Human cardiomyocyte ventricular primary cells (Celprogen, Torrance,
CA, USA) were cultured following the recommended manufacturer’s protocols in extracellular matrix
pre-coated flasks and/or well plates with ready-to-use complete growth medium (Celprogen, Torrance,
CA, USA ). The choice of such human cell lines was guided by previous evidence showing their high
reliability for evaluating oxidative stress, antioxidant signaling pathways and IR injuries [19,27,28].
Human hepatocarcinoma HepG2 cells (Sigma-Aldrich, St. Louis, MI, USA) were cultured in EMEM
medium (Invitrogen, Carlsbad, CA, USA) and used as control cells to test the presence of NPC1L1
receptor. All cell cultures were maintained in a humidified incubator with 95% air and 5% CO2 at
37 ◦C. The endotoxin contamination of cells was routinely excluded with the chromogenic Limulus
amoebocyte lysate assay.
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2.2. Dose-Response Effect of Ezetimibe on Cell Viability and Toxicity
We performed preliminary dose-dependent tests with Ezetimibe (Cayman Chemical Company,
Ann Arbor, MI, USA) in order to identify the appropriate experimental conditions. THP-1 cells and
human cardiomyocytes were incubated overnight with increasing amounts of Ezetimibe (from 5 to
50 μM). Cellular viability was evaluated with the Annexin V staining assay (BD Bioscience, Franklin
Lakes, NJ, USA) as previously reported [19] and analyzed by flow cytometry on FACSCantoII (Becton
Dickinson). The number of each type of cell was expressed as a percentage of the number of total
stained cells.
2.3. Oxidative Stress Assessment
To evaluate intracellular ROS formation, THP-1 cells and human cardiomyocytes were pretreated
overnight with increasing amounts of Ezetimibe (from 5 to 50 μM), then incubated for 45 min at
37 ◦C with 100 μM of tert-butyl hydroperoxide solution (TBHP), followed by incubation with the
fluorogenic CellROX™Deep Red Reagent (Life Technologies, Eugene, CA, USA) (1 μM) for 45 min [29].
The cells were immediately analyzed by flow cytometry on FACSCantoII (Becton Dickinson). After IR
experiments, CellROX™ Deep Red reagent (1 μM) was added to the cells, which were then incubated
for 45 min at 37 ◦C and immediately analyzed by flow cytometry.
Then, 8-iso Prostaglandin F2α (8-iso) was measured in the medium of cell cultures using
the 8-isoprostane ELISA kit (Cayman Chemical Company, Ann Arbor, MI, USA) following the
manufacturer’s instructions.
2.4. Quantification of Ezetimibe and of Its Derivative Ezetimibe-Glucuronide in Cells
The quantification of ezetimibe (EZE) and its derivative glucuronate (ezetimibe glucuronide,
EZE-G) was performed with a liquid chromatography–tandem mass spectrometry-based method
(LC-MS/MS). The sample preparation was carried by protein precipitation extraction. Briefly, 100 μL
of lysate cell sample were spiked with 10 μL of IS-mixture (containing EZE-D4 and EZE-G-D4 at a
final concentration of 400 nmol/L), mixed with 150 μL of acetonitrile and then vortexed for 1 min.
After 15 min of centrifugation at 13,000× g, 300 μL of the supernatant were transferred to autosampler
vials for LC-MS/MS analysis. The injection volume was 10 μL. A mixed stock solution of each standard
was prepared in methanol and then diluted with methanol/water (50:50, v/v) to prepare an 8-point
calibration curve (range: 0.25–200 nM). Standard solutions of EZE and EZE-G were purchased from
Cayman Chemical Company (Ann Arbor, MI, USA), while their labeled internal standards were
purchased from Santa Cruz Biotecnology (Santa Cruz, CA, USA). Chromatographic separation was
performed on a Nexera X2 series UHPLC (Shimadzu, Kyoto, Japan), followed by detection on a
4500 MD triple quadrupole Mass Spectrometer (AB Sciex, Darmstadt, Germany). The electrospray
ionization was completed in negative mode. Data were recorded in multiple reaction monitoring mode
(MRM). System operation, data acquisition and quantification were performed using the Analyst 1.6.2.
software and Multiquant 3.0.2. (AB Sciex, Darmstadt, Germany). The limit of quantitation (LOQ),
determined as where the signal-to-noise ratio is ten, was below 0.20 nmol/L for both compounds.
The intra-assay imprecision was between 3% and 3.5%, whereas the inter-assay imprecision was
between 4.6% and 6.7%. The cellular concentrations of Ezetimibe were expressed as pmol/μg protein.
2.5. Induction of IR in THP-1 Cells and Cardiomyocytes
For IR experiments, the EVOS FL Auto Imaging System (Thermo Fisher, Waltham, MA, USA),
equipped with the EVOS Onstage Incubator, was used, according to the manufacturer’s instructions
and as previously reported [14]. The EVOS FL system provides an environmental chamber, allowing for
the precise control of temperature, humidity and gases (N2, CO2 and O2), and hypoxia can be monitored
by long-term fluorescence live-cell imaging, using Invitrogen™ Image-iT™ Hypoxia Reagent (Thermo
Fisher, Waltham, MA, USA). THP-1 cells were cultured in RPMI 1640 with L-glutamine at 37 ◦C in
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an incubator set at normoxic conditions (20% O2). Then, THP-1 cells were placed on the EVOS FL
Auto Imaging System and incubated for 60 min to allow the system to reach the required temperature
(37 ◦C), humidity (>80%) and CO2 level (5%) under normoxic conditions (20% O2). Under normoxic
conditions, there was no signal from the Image-iT™ Hypoxia Reagent (Thermo Fisher, Waltham,
MA, USA) but in response to the decrease in oxygen levels, the signal from the Image-iT™Hypoxia
Reagent increased, with nearly all the cells being hypoxic after 60 min at 5% O2 levels. The increase
in signal from the Image-iT™Hypoxia Reagent was reversible, and when oxygen levels returned to
normal, the signal decreased back to baseline. After reaching hypoxic conditions, THP-1 cells and
cardiomyocytes were subjected to a single period (2 h at 0% O2 and 24 h at 1% O2, respectively) of
ischemia followed by reperfusion (1 h and 24 h at 20% O2, respectively), as previously described [14,30],
in the presence or absence of Ezetimibe. Oxidative stress markers, apoptosis, Nrf2/ARE and UPR gene
expression, as well AMPKα, phosphorylated (p)-AMPKα, p65 and p-p65, were evaluated. Moreover,
in some experiments, THP-1 cells were pre-treated with Compound C (CC, 10 μM, Abcam, Cambridge,
UK), a pan inhibitor of AMPK phosphorylation, for 30 min, then incubated overnight with or without
Ezetimibe and subjected to IR. Control cells were maintained at 37 ◦C in an incubator set at normoxic
conditions for the same period of time. The endotoxin contamination of cells was routinely excluded
with the chromogenic Limulus amoebocyte lysate assay.
2.6. RNA Isolation and Quantitative Real-Time PCR
Total RNA was isolated with the RNEasy Mini Kit (Qiagen, Hilden, Germany). The concentration
and quality of RNA were evaluated using the RNA 6000 Nano LabChip Kit (Agilent 2100 Bioanalyzer,
Agilent Technologies Inc., Santa Clara, CA, USA). Reverse transcription of total RNA was carried out
using the IScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) according to the manufacturer’s
recommendations. The relative mRNA expression levels of ACTB (β-actin), NFE2L2 (Nrf2), HMOX1
(HO-1), GCLC, ATF6 and DDIT3 (CHOP) were measured in triplicate using the PrimePCR Probe
Assay (ACTB 5′ HEX, NFE2L2 5′ 6-FAM, HMOX1 5′ TEX615, GCLC 5′ Cy5, ATF6 5′ 6-FAM, DDIT3
5′ Cy5 and MAPLC3B 5′ TEX615) and SsoAdvanced Universal Supermix, with the CFX96 RealTime
System C1000 Touch Thermal Cycler instrument (Bio-Rad). Data were analyzed using the CFX Maestro
software (Bio-Rad). Normalized gene expression levels are given as the ratio between the mean value
for the target gene and that for β-actin in each sample.
2.7. Western Blot Analysis
Western blots were performed as previously described [31] with some modifications. Cytoplasmic
and nuclear extracts were prepared using the Nuclear Extraction Kit (Cayman Chemical Company,
Ann Arbor, MI, USA), and the protein concentration was determined using the Pierce™ BCA Protein
Assay Kit (Thermo Fisher, Waltham, MA, USA). Western blots were performed using the XCell
SureLock™Mini-Cell and XCell II™ Blot Module (Thermo Fisher) devices, following the recommended
manufacturer’s protocols. iBright Prestained Protein Ladder and MagicMark™ XP Western Protein
Standard (Thermo Fisher) markers were included in at least two lanes on all gels. Samples (8 μg)
were loaded into NuPAGE™ Bis-Tris protein gels (4–12% and 10% gel) (Thermo Fisher) and resolved
by SDS-PAGE using NuPAGE™MES SDS Running Buffer (Thermo Fisher), then transferred onto a
polyvinylidene difluoride (PVDF) Transfer Membrane (0.45 μm, Thermo Fisher) using NuPAGE™
Transfer Buffer (Thermo Fisher). Blots were blocked in BSA prepared in Tris-buffered saline with 1%
Tween 20 (TBS-T) for 1 h at room temperature. The following primary antibodies were used overnight
at 4 ◦C: anti-AMPKα (#5831) (1:1000), anti-AMPKα (phospho Thr172) (#2535) (1:1000), anti-NF-кB
p65 (#8242) (1:1000), anti-NF-кB p65 (phospho Ser536) (#3033) (1:1000) and anti-β-tubulin (#2128)
(1:1000) from Cell Signaling Technology (Danvers, MA, USA); anti-Nrf2 (ab62352) (1:500), anti-HO-1
(ab52947) (1:2000), anti-GCLC (ab190685) (1:1000) from Abcam; anti-β-actin (sc-47778) (1:200) and
anti-NPC1L1 (sc-166802)(1:100) from Santa Cruz Biotecnology; anti-ATF6 (NBP1-40256) (1:500) from
Novus Biologicals (Centennial, CO, USA); anti-CHOP (MA1-250) (1:500) from Thermo Fisher. After 1 h
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incubation at room temperature with goat anti-rabbit IgG H&L (HRP) (ab6721) (1:3000) (Abcam) or
anti-mouse IgG HRP-linked (#7076) (1:2000) (Cell Signaling Technology) antibodies, probed blots
were treated with SuperSignal™WestPico PLUS Chemiluminescent Substrate (Thermo Fisher) and
visualized using ImageQuant™ LAS 4000 (GE Healthcare). Bands were quantified with ImageJ [32].
2.8. Nuclear and Cytoplasmic Assays of Nrf2
Nuclear and cytoplasmic Nrf2 were quantified using sandwich enzyme-linked immunosorbent
assay (ELISA) kits (LifeSpan BioScience, Seattle, WA, USA), following the manufacturer’s instructions.
2.9. Statistical Analysis
Data are expressed as mean ± SD values. Differences between groups were analyzed by a
two-tailed Student’s t-test or by ANOVA followed by post hoc analysis. A probability value (p) of 0.05
was considered to be statistically significant. All data were analyzed with SPSS Statistic Version 20
(IBM Corp., New York, NY, USA).
3. Results
3.1. Effects of Ezetimibe on NPC1L1 Protein Expression, Intracellular ROS Formation and Cell Viability
Preliminarily, we assessed the presence of NPC1L1 receptor on THP-1, HepG2 cells and
cardiomyocytes and excluded any effect of Ezetimibe and IR on NPCL1 expression (Figure 1a,b).
Ezetimibe dose-dependently reduced ROS formation (p < 0.01), without affecting cell viability, in THP-1
cells and cardiomyocytes exposed to TBHP (Figure 1c–e). Based on these results, all subsequent
experiments were performed by incubating cells overnight with Ezetimibe 50 μmol, determining a
cellular concentration of 0.34 ± 0.02 nmol/μg protein as assessed by LC-MS/MS. Although it is always
difficult to compare the drug concentrations used in in vitro studies with those found in vivo [33],
the cellular concentrations found in our study are of the same order of magnitude as those found in
patients treated with Ezetimibe.
3.2. Effect of Ezetimibe on the Oxidative Stress, Apoptosis and NF-kB Activation Induced by IR
Our results show that IR induced a significant rise in intracellular ROS formation (p < 0.01),
(Figure 2a) and 8-iso in the culture medium (p < 0.01) of THP-1 cells (Figure 2b). Interestingly, both ROS
and 8-iso were significantly reduced (p < 0.01) in the cells pre-incubated with Ezetimibe (Figure 2a,b).
Our results also show that the percentage increase of apoptotic THP-1 cells (p < 0.01) induced by
IR was almost abolished when the cells were pre-incubated with Ezetimibe (Figure 2c).
We next evaluated the expression of p65 and p-p65 in the cytoplasmic and nuclear extracts of
THP-1 cells in the presence or absence of Ezetimibe. As shown in Figure 2d,f, IR induced a significant
nuclear translocation of p-p65 (p < 0.01) that was reduced (p < 0.01) in THP-1 cells pre-incubated with
Ezetimibe. To the contrary, no p65 nuclear translocation was observed (Figure 2e,f). Taken together
these results indicate the ability of Ezetimibe to counteract oxidative stress, apoptosis and the activation
of the NF-kB pathway induced by IR.
3.3. Ezetimibe Up-Regulates Nrf2/ARE and Pro-Survival UPR Gene Expression in THP-1 Cells Subjected to IR
In our cellular models of IR, we also assessed whether Ezetimibe affects Nrf2/ARE and UPR
gene expression. After IR, there were no significant changes in Nrf2 (mRNA and protein) expression
(Figure 3a,c,d) and in that of the ARE-correlated genes HO-1 and GCLC (Figure 3b,e,f). To the contrary,
when THP-1 cells were preincubated with Ezetimibe, we found a significant up-regulation of the Nrf2
mRNA and nuclear protein (p < 0.01) under basal conditions that was even more evident in THP-1 cells
subjected to IR (Figure 3a,c,d). Accordingly, the mRNA and protein expression of HO-1 and GCLC
was significantly up-regulated by Ezetimibe (Figure 3b,e,f).
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Figure 1. The effects of Ezetimibe (EZE) on Niemann Pick C1-like 1 (NPC1L1) protein expression,
intracellular reactive oxygen species (ROS) formation and cell viability. (a) Representative Western blot
analyses for NPC1L1 protein expression in THP-1 cells, cardiomyocytes (Cardiomyo.) and HepG2 cells
and the average quantification of NPC1L1 obtained by the densitometric analysis of three independent
experiments. (b) Representative Western blot analyses for NPC1L1 protein expression in THP-1 cells
under basal conditions, pre-treated with EZE or subjected to ischemia-reperfusion (IR) and the average
quantification of NPC1L1 obtained by the densitometric analysis of three independent experiments.
(c) The dose-response effect of EZE on tert-butyl hydroperoxide (TBHP)-induced ROS formation in
THP-1 cells and cardiomyocytes. (d) The dose-response effect of EZE on cell viability in THP-1 cells and
cardiomyocytes. (e) Representative Fluorescence-activated cell sorter (FACS) analysis on cell viability.
Data represent the mean ± SD of measurements performed in triplicate in three different experiments;
* p < 0.01 vs. control; ¶ p < 0.01 vs. TBHP.
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Cytoplasmic extract
(a)                                                              (b) 
(c)                                                              (d)                                                         
(e) (f)
Nuclear extract
Figure 2. The effect of Ezetimibe on markers of oxidative stress, apoptosis and p65 and p-p65 protein
expression in THP-1 cells subjected to ischemia-reperfusion (IR). (a) IR-induced ROS formation in
THP-1 cells. (b) 8-iso concentrations in the culture medium of THP-1 cells. (c) The percentages
apoptotic THP-1 cells upon exposure to IR. (d) The average quantification of nuclear and cytoplasmic
p-p65 obtained by the densitometric analysis of three independent experiments. (e) The average
quantification of nuclear and cytoplasmic p65 obtained by the densitometric analysis of three
independent experiments. (f) Representative cytoplasmic and nuclear Western blot analyses for
the indicated proteins. Data represent the mean ± SD of measurements performed in triplicate in three
different experiments; * p < 0.01 vs. control; ** p < 0.01 vs. IR.
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(a) (b)
(c)                                                               (d)
(e)                                                               (f)                                                        
Figure 3. Ezetimibe induces nuclear factor-E2-related factor 2 (Nrf2)/antioxidant response element
(ARE) gene expression in THP-1 cells subjected to ischemia-reperfusion (IR). (a) The mRNA expression of
Nrf2. (b) The mRNA expression of HMOX1 (HO-1) and GCLC. (c) Representative Western blot analysis
for Nrf2 nuclear protein. (d) The Nrf2 average quantification obtained by the densitometric analysis
of three independent experiments. (e) Representative Western blot analyses for the indicated proteins.
(f) The average quantification of the HO-1 and GCLC proteins obtained by the densitometric analysis of
three independent experiments. mRNA was analyzed by quantitative real-time PCR; normalized gene
expression levels are given as the ratio between the mean value for the target gene and that for β-actin in
each sample. Data are expressed as mean ± SD; * p < 0.01 vs. control; ** p < 0.01 vs. IR.
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Concerning UPR gene expression, IR did not modify ATF6 mRNA and protein expression
(Figure 4a–c), whereas it significantly up-regulated (p < 0.01) the mRNA and nuclear protein of the
pro-apoptotic CHOP (Figure 4a,b,d). IR did not modify the expression of the IRE1-XBP1 pathway
(data not shown). Intriguingly, Ezetimibe was able to significantly increase ATF6 gene expression
(p < 0.01) and to significantly down-regulate (p < 0.01) CHOP gene expression (Figure 4a–d) in THP-1
cells subjected to IR.
(a)                                                     (b)
(c)                                                              (d) 
Figure 4. The effect of Ezetimibe on unfolded protein response (UPR) gene expression in THP-1 cells
exposed to ischemia-reperfusion (IR). (a) The mRNA expression of activating transcription factor 6
(ATF6) and CCAAT-enhancer-binding protein homologous protein (CHOP). (b) Representative Western
blot analyses for the indicated proteins. (c,d) The average quantification of ATF6 and CHOP obtained
by the densitometric analysis of three independent experiments. mRNA was analyzed by quantitative
real-time PCR; normalized gene expression levels are given as the ratio between the mean value for the
target gene and that for β-actin in each sample. Data are expressed as mean ± SD. * p < 0.01 vs. control
(up-regulation); ** p < 0.01 vs. IR; § p < 0.01 vs. control (down-regulation).
3.4. Effect of Ezetimibe on AMPK Activation in Our Model of IR
To assess whether AMPK activation has a role in the Nrf2 activation induced by Ezetimibe, we first
evaluated the effect of Ezetimibe on phosphorylated and non-phosphorylated AMPK expression.
We found that Ezetimibe was able to induce a significant increase in the p-AMPK/AMPK ratio, both in
control and in THP-1 cells subjected to IR (Figure 5a,c). Then, we performed further experiments
using Compound C, a pan inhibitor of AMPK phosphorylation. Our results show that Compound C
significantly decreased the Ezetimibe- and Ezetimibe plus IR-mediated increases in the p-AMPK/AMPK
ratio (Figure 5a,c). Moreover, the pre-incubation of THP-1 cells with Compound C almost abolished
the nuclear Nrf2 translocation induced by Ezetimibe (p < 0.001), both in THP-1 cells subjected to IR
and in control cells (Figure 5b,c).
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Figure 5. The effect of the AMP-activated protein kinase (AMPK) inhibitor Compound C (CC) on
Ezetimibe-induced Nrf2 activation in THP-1 cells exposed to ischemia-reperfusion (IR). (a) The average
quantification of the p-AMPK/AMPK ratio obtained by the densitometric analysis of three independent
experiments. (b) The average quantification of nuclear Nrf2 obtained by the densitometric analysis
of three independent experiments. (c) Representative cytoplasmic and nuclear Western blot analyses
for the indicated proteins. Data represent the mean ± SD of measurements performed in triplicate in
three different experiments; * p < 0.01 vs. control; ** p < 0.001 vs. EZE; § p < 0.01 vs. IR; §§ p < 0.01 vs.
EZE + IR; # p < 0.001 vs. EZE; ¶ p < 0.001 vs. EZE + IR.
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Furthermore, the pre-incubation with Compound C induced a significant increment in ROS
generation (Figure 6a) and an increase in the percentage of apoptotic THP-1 cells (Figure 6b,c).
(a) 
CONTROL                          CC                                   IR
(b)
(c)
EZE + IR                      CC + EZE + IR 
Figure 6. The effect of Compound C (CC) on ROS formation and apoptosis in THP-1 cells pretreated
with Ezetimibe (EZE) and subjected to IR. (a) ROS formation. (b) The percentages of apoptotic cells.
(c) Representative FACS analyses of the percentages of apoptotic cells. Data are represented as the
mean ± SD of measurements performed in triplicate in three different experiments; * p < 0.01 vs control;
** p < 0.01 vs. IR and EZE + IR.
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3.5. Effect of Ezetimibe on IR-Induced Oxidative Stress, Apoptosis and Nrf2/ARE Activation in
Human Cardiomyocytes
Finally, in order to additionally confirm our data in primary cells directly subjected to IR,
we performed further experiments using cardiomyocytes. IR induced a significant rise in intracellular
ROS formation (p< 0.01), which was reduced (p< 0.01) in cardiomyocytes pre-incubated with Ezetimibe
(Figure 7a). Moreover, we found a significant increment in the percentage of apoptotic cells (p < 0.01)
induced by IR that was completely abolished when human cardiomyocytes were pre-incubated with
Ezetimibe (Figure 7b,c).
CONTROL                EZE                                IR        EZE + IR
(a)                                                        (b)
(c)                                                          
(f)
(d)                                                        (e)
(f) 
Figure 7. The effect of Ezetimibe on markers of oxidative stress, apoptosis and Nrf2/ARE gene
expression in cardiomyocytes subjected to ischemia-reperfusion (IR). (a) IR-induced ROS formation.
(b) The percentages of apoptotic cardiomyocytes upon exposure to IR. (c) Representative FACS analyses
of cell viability. (d) Cytoplasmic and nuclear assays of Nrf2. (e) The average quantification of the
HO-1 and GCLC proteins obtained by the densitometric analysis of three independent experiments.
(f) Representative Western blot analyses for the indicated proteins. mRNA was analyzed by quantitative
real-time PCR; normalized gene expression levels are given as the ratio between the mean value for the
target gene and that for β-actin in each sample. Data are expressed as mean ± SD; * p < 0.01 vs. control;
** p < 0.01 vs. IR.
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Regarding Nrf2 signaling pathway activation, IR did not modify cytoplasmic or nuclear
protein concentrations and was not associated with variations of BACH1 gene expression (data
not shown), whereas when cardiomyocytes were pre-incubated with Ezetimibe, Nrf2 nuclear protein
was significantly increased (p < 0.01), both in control cells and under IR conditions (Figure 7d).
Accordingly, the protein expression of the Nrf2-correlated genes HO-1 and GCLC was significantly
increased (p < 0.01) by Ezetimibe (Figure 7e,f).
Finally, we tested whether Ezetimibe was also able to phosphorylate AMPK in cardiomyocytes.
Similarly to THP-1, we found that Ezetimibe significantly increased the p-AMPK/AMPK ratio, both in
controls and in cardiomyocytes subjected to IR (Figure 8a,b).
(a)                                                          
(b)
Figure 8. The Ezetimibe (EZE)-induced phosphorylation of AMPK in cardiomyocytes subjected to
ischemia-reperfusion (IR). (a) The average quantification of the p-AMPK/AMPK ratio obtained by the
densitometric analysis of three independent experiments. (b) Representative Western blot analyses for
the indicated proteins. Data represent the mean ± SD of measurements performed in triplicate in three
different experiments; * p < 0.01 vs. control; ** p < 0.01 vs. IR.
4. Discussion
IR injury is a common and important clinical problem that occurs in many different organ systems,
including the brain (in stroke) and heart (in myocardial infarction), and in limb ischemia, and it
occurs with the respective reperfusion strategies (thrombolytic therapy, angioplasty and operative
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revascularization) but also in routine surgical procedures (organ transplantation, free tissue-transfer,
cardiopulmonary bypass, vascular surgery and the treatment of major trauma/shock) [3]. Over the past
three decades, many ischemic and pharmacological cardioprotective tools, derived from experimental
studies, have been examined in the clinical setting of acute pathological situations characterized by
IR [34]. The results of these studies have been disappointing, and no effective cardioprotective therapy
is currently used in clinical practice [34].
In this study, we found that after IR, there was a significant increase in intracellular ROS formation
and in 8-iso in the culture media, together with an increased percentage of apoptotic cells. As recently
reviewed by Cadenas S., the mitochondrial electron transport chain, as well as some NOX isoforms,
contribute to ROS generation during IR injury [35]. This augmented oxidative stress induced by IR was
not associated with an up-regulation of Nrf2/ARE gene expression. This apparently paradoxical result
may be related to the fact that oxidative stress activates I-κB kinase, which phosphorylates NF-kB,
leading to its translocation into the nucleus and the activation of pro-inflammatory cytokines [7].
Furthermore, when NF-kB binds to cAMP-response-element binding protein (CBP) in a competitive
manner, it inhibits the binding of CBP to Nrf2, which leads to the inhibition of Nrf2 transactivation [7].
In addition, NF-kB increases the recruitment of histone deacetylase to the ARE region, and hence,
Nrf2 transcriptional activation is prevented [7]. The fact that in this study, IR caused a significant
increment in nuclear p-p65—an indicator of NF-kB activation—supports this conclusion.
The lack of Nrf2/ARE gene up-regulation in our model of IR is in line with the data recently
published by our group showing that in peripheral blood mononuclear cells derived from patients
with peripheral artery disease subjected to one cycle of IR, there was no up-regulation of Nrf2/ARE
gene expression [14]. At variance with our results, previous studies have shown a protective role of
the Nrf2/ARE pathway in animal models of myocardial ischemia and reperfusion injury [36,37]. It is
likely that these differences are related to the different experimental conditions.
Concerning UPR, the results of this study also show that IR did not modify the expression of the
pro-survival genes ATF6 and IRE1, but it increased the expression of CHOP, i.e., the pro-apoptotic gene.
As a matter of fact, CHOP has been shown to play an important role in the induction of apoptosis [11]
and therefore in causing the cellular injuries caused by IR.
Ezetimibe was able to counteract both the effect on oxidative stress and apoptosis caused by IR.
In particular, Ezetimibe was associated with a substantial decline in intracellular ROS and 8-iso in the
culture media and also led to a substantial reduction in apoptotic cells.
In our study, the positive effect of Ezetimibe on oxidative stress and apoptosis was paralleled
by an up-regulation of Nrf2, HO-1 and GCLC expression. Although Ezetimibe did not affect nuclear
p-p65 translocation in control cells, it strongly reduced nuclear p-p65 and the p-p65/p65 ratio in THP-1
cells subjected to IR, confirming the inverse relationship between Nrf2 and NF-kB activation [7].
Previous reports have shown that Nrf2 activation attenuates the injuries caused by IR [8,9]; since the
generation of ROS has been implicated in the cell injury caused by IR [1–3], reducing oxidative stress
may be a potential therapeutic approach to the prevention of IR injuries. Here, for the first time,
we show that Ezetimibe protects cells subjected to IR by up-regulating Nrf2 and the related ARE
gene expression. The mechanism involved in Ezetimibe-induced Nrf2 gene activation in our cellular
model of IR is unclear. However, Ezetimibe has recently been found to protect the mouse liver from
oxidative injury caused by diet-induced nonalcoholic fatty liver disease [22]. In particular, it has been
shown that Ezetimibe induced Nrf2 activation in a p62-dependent manner and that this induction
can be attributed to Nrf2 activation [22], since p62 has been shown to be an Nrf2 target gene [38].
As previously reported, the increment in p62 phosphorylation induced by Ezetimibe was demonstrated
to be dependent on p-AMPK activation [22]. The N-terminus PB1 domain of p62 was shown to
specifically bind AMPKα1 and AMPKα2 [22]. In agreement with these data, our study shows that
Ezetimibe, but not IR, increased the phosphorylation of AMPK and that Compound C, a specific
inhibitor of AMPK phosphorylation, inhibited this phosphorylation. Moreover, our evidence that
Compound C was also able to inhibit Nrf2 nuclear translocation suggests that Ezetimibe activates
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AMPK, leading to Nrf2 activation. This indirect effect of Compound C on Nrf2 nuclear translocation
was associated with an increment in ROS generation and a decline in the percentage of apoptotic cells.
A likely mechanism for Ezetimibe-induced AMPK phosphorylation was elucidated in a recent report
suggesting that Ezetimibe increases the oxygen consumption rate (OCR) and reduces the amount of
adenosine triphosphate (ATP) in subjects with hypercholesterolemia [39]. AMPK activity is governed
by adenosine diphosphate (ADP) and adenosine monophosphate (AMP) levels by phosphorylation
when the ratio of intracellular AMP or ADP to ATP increases [40]. Therefore, an Ezetimibe-induced
rise in OCR may cause an elevated ADP/ATP ratio followed by the activation of AMPK.
Furthermore, the results we obtained using human cardiomyocytes (primary cell line directly
subjected to IR) are in line with those found in THP-1 cells. Concerning oxidative stress, we showed
that Ezetimibe dose-dependently decreased TBHP-induced intracellular ROS formation. Moreover,
IR induced a significant rise in ROS accompanied by a significant increment in apoptosis that were
almost abolished when cardiomyocytes were pre-incubated with Ezetimibe. Interestingly, Nrf2/ARE
gene expression was also significantly up-regulated by Ezetimibe both in the control cells and in the
cardiomyocytes exposed to IR.
Finally, the results of this study also show that Ezetimibe affected UPR gene expression.
In particular, Ezetimibe was shown to increase the pro-survival ATF6 gene’s expression both after IR
and in control cells; to the contrary, the increased up-regulation of the pro-apoptotic CHOP induced by
IR was almost abolished by Ezetimibe. The mechanism underlying this effect of Ezetimibe is presently
unclear. However, recent studies showed that oxidative stress can elicit a reduction–oxidation imbalance
and worsen ER stress through reducing the efficiency of protein folding pathways and increasing the
production of misfolded proteins [41]. The abnormal amount of misfolded proteins may drive the
UPR towards cellular apoptosis through the activity of CHOP. Ezetimibe, by reducing oxidative stress,
may reduce misfolded protein mass and therefore convert the cells to a pro-survival state.
5. Conclusions
In these cellular models of IR, we describe new pleiotropic effects of Ezetimibe and the molecular
mechanism that cause a series of adaptations that may contribute to the modification of the cells towards
a “resistant phenotype”. In particular, we show that Ezetimibe prevents IR-induced oxidative stress
and apoptosis and up-regulates the Nrf2 and UPR signaling pathways. Nevertheless, the well-known
difficulties in comparing the drug concentrations used in in vitro studies with those found in vivo must
be considered a limitation of the study. Hence, although these preliminary results need to be confirmed
in patients, we suggest that Ezetimibe, beyond its cholesterol absorption inhibitor effect, may be
beneficial in IR injury, a common important clinical problem that affects many different organ systems.
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Abstract: Sepsis is a life-threatening response to infection associated with inflammation, oxidative
stress and mitochondrial dysfunction. We investigated differential effects of three forms of vitamin E,
which accumulate in different cellular compartments, on oxidative stress, mitochondrial function,
mRNA and protein expression profiles associated with the human Toll-like receptor (TLR) -2 and
-4 pathways. Human endothelial cells were exposed to lipopolysaccharide (LPS)/peptidoglycan G
(PepG) to mimic sepsis, MitoVitE, α-tocopherol, or Trolox. Oxidative stress, mitochondrial function,
mitochondrial membrane potential and metabolic activity were measured. NFκB-P65, total and
phosphorylated inhibitor of NFκB alpha (NFκBIA), and STAT-3 in nuclear extracts, interleukin (IL)-6
and IL-8 production in culture supernatants and cellular mRNA expression of 32 genes involved
in Toll-like receptor-2 and -4 pathways were measured. Exposure to LPS/PepG caused increased
total radical production (p = 0.022), decreased glutathione ratio (p = 0.016), reduced membrane
potential and metabolic activity (both p < 0.0001), increased nuclear NFκB-P65 expression (p = 0.016)
and increased IL-6/8 secretion (both p < 0.0001). MitoVitE, α- tocopherol and Trolox were similar
in reducing oxidative stress, NFκB activation and interleukin secretion. MitoVitE had widespread
downregulatory effects on gene expression. Despite differences in site of actions, all forms of vitamin
E were protective under conditions mimicking sepsis. These results challenge the concept that
protection inside mitochondria provides better protection.
Keywords: sepsis; MitoVitE; antioxidant; mitochondria; gene expression; cytokines; mRNA
1. Introduction
Sepsis is a complex syndrome and is a leading cause of morbidity and mortality worldwide. It is
characterized by a dysregulated immune response to infection, usually bacterial, leading to a systemic
inflammatory response, oxidative stress, depletion of intracellular antioxidants, and ultimately organ
failure [1,2]. Development of organ dysfunction associated with sepsis is now accepted to be due,
at least in part, to mitochondrial dysfunction [3,4].
Vitamin E belongs to a group of compounds that includes both tocopherols and tocotrienols [5].
Vitamin E sequesters into the hydrophobic interior of membranes and α-tocopherol is the most
biologically active form. Tocopherol is able to protect cell membranes from oxidation, reacting with
lipid radicals produced during lipid peroxidation [5]. MitoVitE is essentially the chromanol moiety of
vitamin E bound to a triphenyl phosphonium (TPP) cation and accumulates within mitochondria as a
result of the large negative charge inside the mitochondrial inner membrane, with the vitamin moiety
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directed towards the matrix. MitoVitE has been shown to accumulate in all major organs of mice and
rats after oral, intraperitoneal or intravenous administration and has potent antioxidant activity [6].
Trolox (6-hydroxy-2,5,7,8-tetra-methylchroman-2-carboxylic acid) is a synthetic, water soluble and
cell-permeable derivative of vitamin E which accumulates in the cell cytosol. It is a potent antioxidant
in several model systems [6–9].
Since mitochondria are both a major source of production and a target for damage of reactive
oxygen species that contribute to oxidative stress in sepsis, antioxidants targeted to mitochondria have
been proposed as a better approach than non-targeted forms for antioxidant protection in sepsis [10,11].
In this study, we investigated the relative effects of MitoVitE, α-tocopherol and Trolox on oxidative
stress, mitochondrial function and expression of key genes and proteins involved in the toll-like
receptor (TLR)-2 and -4 signalling pathways in human endothelial cells cultured in an environment
mimicking acute bacterial sepsis. Despite differences in site of actions, we found that all three forms of
vitamin E had protective effects in human endothelial cells under conditions mimicking sepsis.
2. Materials and Methods
2.1. Chemicals
Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich (Poole, Dorset, UK)
2.2. Cell Culture
The human umbilical vein endothelial cell line (HUVEC-C, obtained from ATCC, Teddington,
Middlesex, UK) was used from passages 7 to 10 as described previously in detail [12–14]. Microscopy
images of the cells are shown in Supplementary Figure S1. For experimentation, cells were cultured in
96- or 6-well plates in the presence of 0.2 μg/mL lipopolysaccharide (LPS) plus 20 μg/mL peptidoglycan
G (PepG) plus 5 μM MitoVitE, α-tocopherol acetate or Trolox or molecular grade ethanol as vehicle
control. The duration of treatment was either 4 h, 24 h or 7 d based on expected expression profiles as
detailed below. Cell viability was assessed using acid phosphatase activity [15].
2.3. Oxidative Stress
Total radical production was measured in intact cells as follows: following treatment for
24 h, cells were washed with PBS before being loaded with 50 μM of the oxidation sensitive dye
5-(-6)-carboxy-2’,7′-dichlorofluorescein diacetate (carboxy-DCFDA, molecular probes, Invitrogen,
Paisley, UK) in Hank’s balanced salt solution (HBSS) supplemented with 1g/L glucose, and incubated
for 1 h in the dark at 37 ◦C. Following incubation, cells were washed with phosphate buffered
saline (PBS, pH 7.4) and fluorescence was determined immediately over 3 h at 37 ◦C at an excitation
wavelength of 485 nm/emission wavelength 530 nm.
For measurement of reduced glutathione (GSH), buffer containing 0.1% (v/v) Triton X-100 and 0.1 M
potassium phosphate, pH 6.5, plus 20 μM monochlorobimane was added to cells after 24 h treatment,
for 37 ◦C in the dark for 30 min. To measure oxidised glutathione (GSSG), buffer containing 0.1% (v/v)
Triton X-100 and 0.1 M potassium phosphate, pH 6.5 and 2.2 mM diethylenetriamine-penta-acetic acid
and 2 mM dithiothreitol were added to additional cells for 30 min at 37 ◦C followed by the addition of
an equal volume of 40 μM monochlorobimane for 30 min at 37 ◦C. Fluorescence was determined at
ambient room temperature (excitation 355 nm, emission 520 nm) and data were normalised to total
cellular protein level, determined using the Bradford method [16].
2.4. Mitochondrial Function
Mitochondrial membrane potential was determined in intact cells using the fluorescent probe JC-1
(5,5,6,6-tetrachloro-1,1,3,3-tetraethylbenzimidazolcarbocyanine iodide (Invitrogen, Paisley, UK) [12–14].
Following treatments for 7 d, with a medium change after 3–4 days, cells were washed with PBS,
incubated for 30 min with 10 μg/mL JC-1 in PBS at 37 ◦C in the dark, then washed with PBS and the
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red/green fluorescence ratio measured. A decrease in the ratio of red/green fluorescence indicates loss
of mitochondrial membrane potential [12–14]. As a positive control, some cells were treated with 1 μM
rotenone without LPS/PepG for 5 h prior to the addition of JC-1. Metabolic activity was analyzed by
measuring the rate of reduction of Alamar Blue™ (Invitrogen, Paisley, UK) in intact cells after 7 d
treatment as described above. Alamar Blue™ is a novel redox indicator that exhibits both fluorescent
and colourimetric changes in response to changes in metabolic activity via oxidative metabolism [17].
Briefly, Alamar BlueTM was added to each well and fluorescence was measured every 15 min for 2 h at
37 ◦C at excitation 530 nm/emission 620 nm. Metabolic activity was determined as the rate of change
in fluorescence over time [13,14].
2.5. Differential Gene Expression
The genes were selected based on their roles in the TLR2 and TLR4 pathways which ultimately
result in activation of nuclear factor kappa B (NFκB). This transcription factor is known to be redox
sensitive and has a crucial role in propagation of the inflammatory response to sepsis. The TLR2 and
TLR4 signalling pathways are illustrated in Supplementary Figure S2 and the genes investigated are
listed in Supplementary Table S1. Expression of 32 key genes was measured using pre-coated custom
RT-PCR plates (Applied Biosystems, Warrington, UK).
Total RNA was isolated from treated cells after 4 h treatments using Trizol and further purified
using the Qiagen RNeasy Mini Kit with on-column genomic DNA digestion. Total RNA (100ng)
was used for cDNA synthesis using the Applied Biosystems high capacity RNA-to-cDNA TaqMan®
Kit. For qPCR, cDNA was mixed with TaqMan® gene expression master mix (Applied Biosystems,
Warrington, UK) and added to the pre-coated well plate. Targets were amplified and detected using the
7500 HT Fast Real-Time PCR System. Hypoxanthine-guanine phosphoribosyltransferase-1 (HPRT-1)
was used as housekeeping gene. The PCR system run cycle: activation (95 ◦C, 10 min), melt (95 ◦C,
15 s), annealing and extension (60 ◦C, 1 min) for 40 cycles. Gene expression (as fold change) was
determined using the Delta-Delta Ct (2−ΔΔCT) method using the SA Biosciences (Qiagen, Manchester,
UK) web-based PCR array system from raw threshold cycle data (Ct). The ΔΔCt algorithm is an
approximation method to determine relative gene expression with quantitative real-time PCR (qPCR)
experiments. Six independent experiments were performed and a minimum fold change of at least 2
compared to LPS/PepG treatment alone was pre-defined. p values were calculated using Student’s
T-tests of the replicate 2−ΔΔCT values for each gene and a p value of ≤0.05 was taken as significant.
2.6. Protein Expression
To determine NFκB activation, nuclear extracts from treated cells were prepared following 4 h
treatments using the Novagens NucbusterTM protein extraction kit (Merck Chemicals Ltd., Nottingham,
UK). NFκB activation was measured as the amount of the p65 subunit present in the nucleus using
the Novagen NoShiftTM transcription factor assay kit (Merck, Nottingham, UK) [12,13]. To determine
phosphorylated inhibitor of NFκB alpha (NFκBIA, also known as IκBα), and signal transducer and
activator of transcription-3 (STAT-3) activation, after 4 h exposure to LPS/PepG, cells were lysed in
TRIS Base buffer containing protease/ phosphatases inhibitors and adjusted to a protein concentration
of 0.25 mg/mL. Commercially available enzyme immunoassay kits were used to quantify the total and
phosphorylated proteins (InstantOneTM eBioscience Ltd., Hatfield, UK) according to the manufacturer’s
protocols. Commercially available enzyme immunoassay kits were used to quantify interleukin (IL)-6
and IL-8 secretion (R&D Systems, Oxford, UK) in culture supernatants of cells treated with LPS/PepG
with and without the three forms of vitamin E for 24 h, as described in the manufacturer’s protocol.
2.7. Statistical Analysis
For oxidative stress and mitochondrial function assays, six independent experiments were
performed (n = 6). For protein expression, 3–6 independent experiments were performed.
No assumptions were made about data distribution. Data were analysed using non-parametric
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Kruskal Wallis testing with Mann Whitney post hoc testing where appropriate and are presented as
median, interquartile and full range, or individual raw data points when n ≤ 6. A p value of ≤ 0.05 was
taken to be significant.
3. Results
3.1. Cell Viability
Acid phosphatase activity was similar regardless of cell treatment at both 24 h and 7 d, showing
no detrimental effect on cell viability (Supplementary Figure S3).
3.1.1. Oxidative Stress
Exposure of endothelial cells to LPS/PepG resulted in a significant increase in total radical
production compared to vehicle control (p = 0.022, Figure 1A). Co-treatment of cells with any of the
forms of vitamin E plus LPS/PepG abrogated the increase in radical production (Figure 1A). The ratio
of GSH:GSSG was significantly lower in LPS/PepG treated cells compared to vehicle control treated
cells (p = 0.016, Figure 1B). Co-exposure to LPS/PepG in the presence of all of the forms of vitamin E
prevented the LPS-PepG mediated decrease in the glutathione ratio (Figure 1B).
Figure 1. Oxidative stress. Endothelial cells were treated with vehicle control, lipopolysaccharide plus
peptidoglycan (LPS/PepG) alone, or LPS/PepG plus 5 μM MitoVitE (MitoE), tocopherol (Toc) or Trolox
for 24 h. (A) Total radical production, (B) reduced/oxidised glutathione. Box and whisker plots show
median, interquartile and full range (n = 6). p value in italics refers to Kruskal–Wallis across LPS/PepG
treated groups. # = significantly lower and * = significantly higher, than LPS/PepG alone (p < 0.05).
3.1.2. Mitochondrial Function
Cells exposed to LPS/PepG for 7 d had significantly lower mitochondrial membrane potential
compared to vehicle control treated cells (p < 0.0001, Figure 2A). Membrane potential was significantly
higher in cells exposed to LPS/PepG plus MitoVitE compared to LPS/PepG alone (p = 0.003) but not in
those cells treated with Trolox or α-tocopherol; indeed, tocopherol worsened the loss of membrane
potential (Figure 2A). Pre-treatment with rotenone resulted in around 50% loss of membrane potential
in vehicle control treated cells (Figure 2A).
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Metabolic activity was also significantly lower in cells exposed to LPS/PepG compared to vehicle
control cells (p < 0.0001) and co-treatment with MitoVitE (p = 0.03), Trolox (p = 0.002) or α-tocopherol
(p = 0.002) ameliorated the loss of metabolic activity (Figure 2B).
Figure 2. Oxidative stress. Endothelial cells were treated with vehicle control, lipopolysaccharide
plus peptidoglycan (LPS/PepG) alone, or LPS/PepG plus 5 μM MitoVitE (MitoE), tocopherol (Toc)
or Trolox for 7 d, or 1μM rotenone. (A) Mitochondrial membrane potential, (B) metabolic activity.
Box and whisker plots show median, interquartile and full range (n = 6). p-value in italics refers to
Kruskal–Wallis across LPS/PepG treated groups. # = significantly lower and * = significantly higher,
than LPS/PepG alone (p < 0.05).
3.1.3. Gene Expression
Identities of the 32 genes analysed and their associated proteins and functions are summarized
in Supplementary Table S1 and Supplementary Figure S2. Differential gene expression following
LPS/PepG exposure for 4 h compared to vehicle control showed that expression of 7 genes were
upregulated by at least 2–fold but only two of these were statistically significant: NFκBIA (p = 0.02)
and NFκB1 (p = 0.04, Table 1, Figure 3A). Two genes were downregulated by >2 fold (XPO1 and
IRAK4, both p = 0.02, Table 1, Figure 3A). In cells exposed to LPS/PepG plus MitoVitE, no genes
were upregulated, but 12 genes were downregulated compared to LPS/PepG alone (p < 0.05, Table 1,
Figure 3B). In contrast, only one gene, NFκB1, was downregulated in cells exposed to LPS/PepG
plus α-tocopherol (p = 0.002, Table 1, Figure 3C) but none were downregulated by Trolox. PTGS2
was upregulated by α-tocopherol and Trolox (p = 0.02 and p = 0.006 respectively), a gene which was
downregulated by MitoVitE (p = 0.02, Table 1, Figure 3D).
49
Antioxidants 2020, 9, 195
Table 1. Differential gene expression.
Gene Name. LPS/PepG a
LPS/PepG LPS/PepG LPS/PepG



















(0.06, 0.40) (0.17, 0.28) (0.18, 0.51)
p = 0.01 p = 0.0003 p = 0.002
NFkBIA
+11.7 -2.7
(0.00001, 0.18) 0.18) (0.18, 0.56)







(0.12, 0.45) (1.29, 4.62) (1.30, 4.50)

























a Mean fold change (red), 95% confidence interval (CI) and p-value compared to vehicle control or b to LPS/PepG
alone. CI = indicateS 95% certainty that the mean value is the true mean of the population. For full gene names and
functions see Supplementary Table S1.
50
Antioxidants 2020, 9, 195
Figure 3. Gene expression. Differential gene expression as mean fold change in endothelial cells
showing the effect of (A) Lipopolysaccharide plus peptidoglycan (LPS/PepG) compared to vehicle
control (B) LPS/PepG plus 5 μM MitoVitE compared to LPS/PepG alone (C) LPS/PepG plus 5 μM
tocopherol compared to LPS/PepG alone or (D) LPS/PepG plus 5 μM Trolox compared to LPS/PepG
alone. Bars show mean fold changes where p < 0.05. Red = upregulation, blue = downregulation, n = 6.
95% confidence intervals and p values are given in Table 1.
3.1.4. Protein Expression
Nuclear NFκB-p65 protein was maximally expressed following 4 h LPS/PepG exposure
(Supplementary Figure S4) and was higher than vehicle control treated cells (p = 0.016, Figure 4A).
Co-treatment of cells with either of the three forms of vitamin E plus LPS/PepG resulted in decreased
nuclear NFκB-p65 protein expression similar to that seen in vehicle control treated cells (Figure 4A).
Significant increases in both IL-6 and IL-8 protein levels were seen in culture supernatants from cells
exposed to LPS/PepG for 24 h compared to vehicle control treated cells (both p < 0.0001, Figure 4B,C).
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All forms of vitamin E appeared to suppress IL-6 and IL-8 secretion when compared to LPS/PepG
exposed cells. However, IL-6 levels were statistically significantly lower only in cells exposed to
LPS/PepG plus α-tocopherol or Trolox compared to LPS/PepG alone (Figure 4B) and IL-8 levels were
significantly lower only in Trolox treated cells (Figure 4C).
Figure 4. NFκB activation and cytokine expression. Endothelial cells treated with vehicle control,
lipopolysaccharide plus peptidoglycan (LPS/PepG) alone, or LPS/PepG plus 5 μM MitoVitE (MitoE),
tocopherol (Toc) or Trolox for 4 or 24 h. (A) Nuclear NFkB p65, (B) interleukin-6 (IL-6) and (C)
interleukin-8. Box and whisker plots show median, interquartile and full range (n = 6). p value in italics
refers to Kruskal–Wallis across LPS/PepG treated groups, # = significantly lower than LPS/PepG alone
(p < 0.05).
Total and phosphorylated NFκBIA and STAT3 proteins were markedly increased in cells co-treated
with LPS/PepG and α-tocopherol, whilst MitoVitE and Trolox had no effect (Figure 5).
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Figure 5. Total and phosphorylated IκBα and STAT3 expression. Endothelial cells were treated with
vehicle control, lipopolysaccharide plus peptidoglycan (LPS/PepG) alone, or LPS/PepG plus 5 μM
MitoVitE (MitoE), tocopherol (Toc) or Trolox for 4 h. (A) Total IκBα, (B) phosphorylated IκBα, (C) total
STAT3 and (D) phosphorylated STAT3. Individual data points shown (n = 3–6). p value in italics refers
to Kruskal–Wallis across LPS/PepG treated groups, * = significantly higher than LPS/PepG alone (p <
0.05).
4. Discussion
We found that exposure of human endothelial cells to LPS/PepG resulted in mitochondrial
dysfunction and oxidative stress, associated with changes in expression of genes and selected proteins
involved in TLR2 and TLR4 signalling and the inflammatory response to conditions of sepsis.
Surprisingly, we found that although the effects of the three forms of vitamin E act in different
cellular compartments, we found largely similar effects on mitochondrial function and oxidative stress.
However, only the mitochondria targeted form of vitamin E, MitoVitE, had widespread downregulatory
effects on genes involved in TLR pathways, resulting in a clear anti-inflammatory profile.
Oxidative stress and mitochondrial damage/dysfunction are consistent findings in sepsis and
drive the dysregulated and prolonged inflammation seen in these patients [3,4]. TLRs are pattern
recognition receptors which detect pathogen associated molecular patterns (PAMPs) that include LPS
and PepG, and initiate signal transduction, culminating in the activation of NFκB and transcription of
cytokines [18,19]. Exposure of endothelial cells to LPS/PepG resulted in maximal nuclear translocation
of NFκB at 4 h. Since antioxidants acting in mitochondria have been advocated as a better protective
strategy in sepsis than those that do not [10,11], and as NFκB has a fundamental and wide ranging role
in propagation of immune responses in sepsis [20], we determined the effects of compartmentalized
antioxidants on expression of genes involved in relevant pathways (see Supplementary Figure S2) at
maximal NFκB protein expression and subsequent downstream effects on inflammatory mediator
expression and mitochondrial function. Many studies report on the expression of genes known to
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be regulated by NFκB following PAMP-induced activation [18–21]. NFκB comprises DNA-binding
subunits, principally NFκB1 and NFκB2, in heterodimers with transcriptional activators including
P65, also known as RelA [18]. Inactivated NFκB complexes are retained in the cellular cytoplasm
by inhibitors including NFκBIA. The process of NFκB activation involves translocation of NFκB
heterodimers into the nucleus and activation of the transcriptional subunit, which is initiated by
phosphorylation, resulting upregulation of a large number of genes required for host immune and
inflammatory mediators, including chemokines, cytokines, enzymes and adhesion molecules. It is
known that complete activation of NFκB requires a redox sensitive step and so antioxidants may have
a role in its regulation [18,19]. However, effects on the signalling cascades leading to NFκB activation
are less clear.
We and others have consistently reported low serum tocopherol levels and elevated oxidative stress
biomarkers in patients with sepsis [22–25]. Although all tocopherols and tocotrienols have pronounced
antioxidant activity in model systems in vitro, there are variable reports of the effect of administration
of vitamin E on biomarkers of oxidative stress and there is little evidence of measurable metabolites of
vitamin E after antioxidant reactions in vivo [26,27]. It has been shown that α-tocopherol, the most
biologically relevant tocopherol, inhibits the signalling cascades initiated by LPS in neutrophils and
microglial cells in vitro [28] and inhibits LPS- induced inflammatory responses in murine macrophages
in vitro [29]. MitoVitE contains a 2-carbon chain which links the functional chromanol moiety of vitamin
E to a TPP cation and is able to cross the outer mitochondrial membrane due to the positive charge of
the TPP conjugate [6,30]. In Trolox, the chromanol is connected to a short-chain carboxylic acid making
Trolox hydrophilic and cell-permeable such that it accumulates in the cell cytosol [6–9]. MitoVitE is
more effective than Trolox both in vitro and in vivo [6,31]. Antioxidants which specifically accumulate
within the mitochondrial matrix are suggested to offer better protection during sepsis-induced oxidative
stress than non-targeted antioxidants, since mitochondria are the main site of radical production during
inflammation [10,11]. We have shown that antioxidants which accumulate inside mitochondria are
protective against mitochondrial dysfunction in human endothelial cells exposed to conditions which
mimic those seen in sepsis [13,32] and have beneficial effects in an animal model of acute sepsis [32,33].
The present study was undertaken to determine the differential effects of compartmentalization of
antioxidants using α-tocopherol, MitoVitE and Trolox, on mitochondrial function, oxidative stress and
gene expression of proteins which are involved in the TLR2/4 signalling pathways, in an in vitro model
relevant to sepsis. We have reported previously on this model [12–14,22,32].
Exposure of endothelial cells to LPS/PepG in vitro results in consumption of glutathione and
initiation of inflammatory responses associated with activation of NFκB and mitochondrial oxidative
stress [12–14,22,32]. We also found that following exposure of endothelial cells to LPS/PepG there was
increased production of intracellular radicals, which was abrogated when the cells were cultured with
all three forms of vitamin E tested. Alpha-tocopherol has been reported to reduce intracellular radical
production in several other oxidative stress models [28,29] and Trolox is an effective intracellular
radical scavenger in human cells [7,8]. We also showed that the three vitamin E derivatives ameliorated
the reduction in the glutathione ratio caused by exposure to LPS/PepG. Only MitoVitE was able to
prevent the loss of mitochondrial membrane potential, although all three compounds were able to
maintain mitochondrial metabolic activity after LPS/PepG exposure of cells. This suggests that loss of
membrane potential is an adaptive response to prevent an increase in radical formation by increasing
uncoupling protein-2 to uncouple the electron transport chain [34]. Our results suggest that the loss of
metabolic activity is either caused by damage to components of the tricarboxylic acid cycle and/or
mitochondrial oxidative phosphorylation complexes with no substantial reduction of ATP synthesis
since the resultant increase in AMP production would either drive an increase in metabolic activity,
or again is an adaptive response in this model to limit damage. We have reported previously that
other mitochondria targeted antioxidants are protective in this model [32,34]. We have also shown
mitochondrial protective effects of MitoVitE in dorsal root ganglion cells exposed to the chemotherapy
drug, paclitaxel, where MitoVitE but not Trolox was able to protect against mitochondrial dysfunction
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and loss of GSH [31]. Only MitoVitE is able to scavenge radicals at source and ameliorate mitochondrial
uncoupling, as shown by maintenance of membrane potential.
NFκB-P65 subunit expression was maximal at 4 h following LPS/PepG exposure. We found
significant upregulation, consistent with other studies, of NFκB-P50 mRNA in LPS/PepG exposed
cells, whose protein is known to modulate NFκB activity, and NFκBIA, which encodes for an inhibitor
subunit of NFκB; this may be a negative regulatory process to dampen the inflammatory response.
Following phosphorylation, NFκBIA is ubiquinitated and degraded, which results in an increase in
NFκB activity. However, the increase in NFκBIA phosphorylation was not reflected by p65, IL-6 or,
IL-8 levels. Two genes were differentially downregulated by LPS/PepG exposure: XPO1 and IL-1
receptor-associated kinase 4 (IRAK4). XPO1 encodes for exportin-1 which is involved in trafficking of
proteins including NFκBIA [35,36] whereas IRAK4 is a key mediator in TLR2 and -4 signalling [37].
Overexpression of XPO1 results in increased translocation of active NFκB [35].
The increase in LPS/PepG-induced NFκB-p65 translocation was abrogated by all forms of vitamin E
tested, concomitant with lower IL-6 and IL-8 secretion. NFκB1 gene expression was also downregulated
by MitoVitE and tocopherol, but not Trolox. Tocopherols and tocotrienols and a synthetic chroman
carboxamide with a chemical structure similar to Trolox were previously shown to reduce LPS-induced
NFκB activation and cytokine secretion [28,29,38,39]. In vitro, MitoVitE reduced NFκB nuclear
translocation [40] and in vivo dampened cytokine responses and improved sepsis-induced organ
dysfunction [33,41]. We also found higher total and phosphorylated STAT3 protein expression in cells
treated with LPS/PepG plus tocopherol but not MitoVitE or Trolox. STAT3 is a transcription factor
activated in response to cytokines by receptor associated Janus kinases and MAPK [42] which can
localize within the mitochondria and is a regulator of the electron transport chain [43]. Suppression of
STAT3 by tocopherols and tocotrienols has been reported (reviewed by Jiang in [5]) but the mechanism of
changes in NFkBIA and STAT3 protein seen here with tocopherol are unclear. However, gene expression
of STAT3 following tocopherol treatment remained similar to LPS/PepG and suggests modulation by
tocopherol at the post-translational level.
Analysis of gene expression showed that endothelial cells exposed to either α-tocopherol or Trolox
plus LPS/PepG resulted in upregulation of inducible prostaglandin endoperoxide synthase 2 (PTGS2,
also known as COX-2). This protein is involved in prostanoid biosynthesis and is a mediator of the
inflammatory response. In contrast, this gene was downregulated by MitoVitE compared along with
several other crucial components of the TLR signalling cascade which. These include IκBKB, NFκB1,
MyD88 and TRAF6 (see Supplementary Table S1 for functional roles). These genes encode for proteins
that interact to initiate downstream signalling to NFκB (see Supplementary Figure S2). Downregulation
of these genes indicate a clear anti-inflammatory profile for MitoVitE. In addition, STAT1 and STAT3
mRNA were also downregulated by MitoVitE. STAT1 has been shown to be involved in interferon
signalling and cell survival. Many of these genes downregulated by MitoVitE have been shown to be
upregulated in mononuclear cells from patients with sepsis [20]. It is intriguing that the functional
effects of all three antioxidants on LPS/PepG-induced transcriptional activation, cytokine expression
and mitochondrial function were broadly similar, yet the effects at the mRNA level were very different.
It has been suggested that some of the anti-inflammatory effects of tocopherol are independent of its
antioxidant activity [44]. Plasma membrane lipid rafts containing tocopherol can interact with TLRs
and may be important in the response to LPS exposure and sepsis [45,46].
5. Conclusions
This was an in vitro study using human endothelial cells under conditions designed to mimic the
changes seen in sepsis. As such is one of several tools for translational experimental approaches to
investigate potential therapeutic strategies in patients with sepsis. Since the primary site of free radical
production in sepsis is inside mitochondria, we expected that antioxidants that acting elsewhere in
the cell may be less effective than those acting inside mitochondria. We did not expect to find that
tocopherol and Trolox would be as functionally effective as MitoVitE at blunting the inflammatory
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consequences of key mediators involved in the response to LPS/PepG exposure, despite more marked
anti-inflammatory effects of MitoVitE at the gene expression level. These results challenge current
thinking and warrant further investigation.
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Abstract: In patients with abdominal region cancers, ionizing radiation (IR)-induced long-term liver
injury is a major limiting factor in the use of radiotherapy. Previously, the major mitochondrial
deacetylase, sirtuin 3 (SIRT3), has been implicated to play an important role in the development
of acute liver injury after total body irradiation but no studies to date have examined the role of
SIRT3 in liver’s chronic response to radiation. In the current study, ten-month-old Sirt3−/− and
Sirt3+/+ male mice received 24 Gy radiation targeted to liver. Six months after exposure, irradiated
Sirt3−/− mice livers demonstrated histopathological elevations in inflammatory infiltration, the loss of
mature bile ducts and higher DNA damage (TUNEL) as well as protein oxidation (3-nitrotyrosine).
In addition, increased expression of inflammatory chemokines (IL-6, IL-1β, TGF-β) and fibrotic factors
(Procollagen 1, α-SMA) were also measured in Sirt3−/− mice following 24 Gy IR. The alterations
measured in enzymatic activities of catalase, glutathione peroxidase, and glutathione reductase in the
livers of irradiated Sirt3−/− mice also implied that hydrogen peroxide and hydroperoxide sensitive
signaling cascades in the absence of SIRT3 might contribute to the IR-induced long-term liver injury.
Keywords: ionizing radiation; liver; sirtuin 3; hydroperoxide; inflammation
1. Introduction
The lifetime probability of males developing an invasive cancer is 42% and for females, 38%.
Approximately 50% of all cancer cases benefit from radiation therapy [1]. More than 333,000 new cases of
abdominal-region cancers are expected in the U.S. alone in 2020 [1], and a serious limitation to radiation
therapy for these cancers is the possibility of irradiating the liver [2–4]. Ionizing radiation (IR)-induced
liver toxicity remains a major challenge, especially for patients with underlying liver dysfunction,
which is common with hepatic malignancies [3–9]. Clinical studies showed that IR-induced liver
pathologies could be observed within 3 months of IR, even with IR doses as low as 30 Gy [10].
Previous clinical studies have shown patients can develop radiation damage within three months
post-irradiation, which is caused by a veno-occlusive process. Fibrin accumulation of central veins
and sinusoids followed by collagen deposition increases, resulting in increased portal pressure. These
clinical manifestations have been termed “radiation-induced liver disease (RILD)”, which could
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progress to late-term radiation-induced fibrotic injury and eventual liver failure [4,11]. Received dose
and volume of the liver that has been irradiated are two major parameters correlated with increased
risk of developing RILD as well as its severity [12–14].
Stereotactic body radiation therapy (SBRT) could deliver high doses of IR to smaller volumes
and provide survival benefits to those with liver and hepatobiliary cancers. However, conventional
or SBRT IR doses delivered to the abdominal area, especially in patients with underlying liver
dysfunction, are still constrained by concerns about RILD and hepatobiliary track toxicities [12–16].
The confounding factors that contribute to these pathologies are poorly understood, so determining
the foremost molecular mechanisms is crucial for developing strategies to prevent and/or mitigate the
side effects of radiotherapy [3,17,18].
Ionizing radiation can lead to oxidative events and biological activity changes in cells by directly
interacting with target molecules, such as DNA, or through radiolysis of water. The biological activity
alterations throughout the liver following radiation exposure are paramount because of the high
mitochondrial content and oxidative metabolism [19–21]. Oxidative injury can arise from days to
months after the initial exposure from the indirect generation of reactive oxygen species (ROS) and
reactive nitrogen species (RNS), which are associated with chronic inflammatory responses [22–24].
Increased DNA damage, apoptosis and inflammation have been shown to play significant roles in
RILD [4,13,25]. Several studies have also reported IR-induced mitochondrial dysfunction and oxidative
stress in liver tissue that are thought to contribute to RILD [26–28]. Tao et al. (2010) and Coleman et al.
(2014) demonstrated a causal link between ROS-mediated acute liver injury and decreased activity of
manganese superoxide dismutase (MnSOD) in mice lacking sirtuin 3 (SIRT3) [29,30].
SIRT3 is the major mitochondrial nicotinamide adenine dinucleotide (NAD+)-dependent
deacetylase. Mitochondrial deacetylation targets of SIRT3, such as peroxisome proliferator-activated
receptor-gamma co-activator-1α, mitochondrial electron transport chain Complex I subunit NDUFA9,
or Complex II subunit A, mitochondrial ribosomal protein L10 or TCA cycle enzyme isocitrate
dehydrogenase 2, have been demonstrated to control a wide range of biological processes including
but not limited to gene expression, metabolism, cancer and aging [30–37]. SIRT3 also plays a significant
function as a stress response protein in regulation of ROS levels via posttranslational modification of
antioxidant enzymes such as MnSOD and increasing their enzymatic activity. Therefore, it is logical to
hypothesize that SIRT3, which is a pivotal mitochondrial stress-response protein, could also play a
critical role in the long-term progression of liver toxicity seen in radiotherapy patients [38–46].
In an effort to best represent the age demographic most impacted in humans for developing
liver and intrahepatic bile duct cancers, in the current study we used 10-month-old male mice for our
liver only irradiation design. We followed the irradiated homozygous wild-type or Sirt3−/− mice for
an additional 6-month period for the development of long-term liver injury. Our results indicated
significant increases in expression of inflammatory and profibrotic markers as well as decreased
numbers of bile ducts in the irradiated areas of Sirt3−/− livers compared to their sham treated controls.
These mice also have more inflammatory cell infiltration in the portal and perivenular space. The DNA
double strand breaks indicated by TUNEL staining and levels of protein oxidation in liver tissue
were still elevated at the end of 6 months in Sirt3−/− irradiated mice. Interestingly, there were no
significant changes in MnSOD activity in sham versus irradiated groups in either Sirt3−/− or Sirt3+/+
mice. However, activity peroxide-removing enzymes were significantly altered only in irradiated
Sirt3−/− livers, suggesting a shift in the types of reactive species contributing to the progression of
long-term liver pathology following radiation exposure.
2. Materials and Methods
2.1. Image Guided Irradiation of Liver Tissue of Sirt3+/+ and Sirt3−/− Male Mice
Littermates of Sirt3+/+ and Sirt3−/− male mice on B6/Sv129 background were housed in a
temperature and humidity controlled environment in filter top cages with ad libitum access to food
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and water at the University of Arkansas for Medical Sciences Animal Care facility until 10 months
of age. Irradiation of the liver tissue was performed using the Small Animal Radiation Research
Platform (SARRP, Xstrahl Inc., Suwanee, GA, USA) (Figure 1A). The mice were anaesthetized with 1%
isoflurane inhalation for the duration of the radiation treatment. Each mouse was place supine on
the horizontal mouse bed in the SARRP. A cone beam computed tomography (CBCT) image of each
mouse was obtained to provide image guided radiation targeted to the liver at 60 kVp and 0.8 mA
and reconstruction using 720 projections. From the image, precision targeting of the upper right lobe
was determined. The liver was irradiated with 2 fractions of 12 Gy from a 90◦ and 0◦ gantry angle
with a 7 mm and 5 mm tissue depth respectively. The liver treatments were performed utilizing a
0.5 mm copper filter with a 5 × 5 mm collimator using 220 kVp and 13 mA (Figure 1B). After 6 months,
mice were euthanized and blood was collected through cardiac puncture. Additionally, irradiated
liver tissue sections were flash-frozen in liquid nitrogen and stored at −80 ◦C or were fixed in formalin
and paraffin embedded for further analysis. All radiation sham mice were anaesthetized and placed in
the SARRP for an equivalent time as the irradiated treated mice. All animal protocols and procedures
used in this study were approved (AUP# 3750) by the Institutional Animal Care and Use Committees
of the University of Arkansas for Medical Sciences.
 
Figure 1. (A) Experimental timeline for the irradiation and tissue harvest from Sirt3+/+ and Sirt3−/−
male mice. (B) Image guided irradiation of the liver using Small Animal Radiation Research
Platform (SARRP).
2.2. Immunohistochemistry and Histopathology Analysis
Sections were deparaffinized and rehydrated using decreasing concentrations of ethanol. One set
of slides was stained with hematoxylin and eosin. These slides were then scored by a clinical pathologist
to determine the level of liver injury in a double-blinded manner. Differences to the sham mice groups,
when present, were noted in several categories including possible micro/macrovesicular steatosis,
lymphoplasmacytic inflammation (i.e., portal, perivenular, and lobular regions), necrosis, fibrosis,
angiectasis, and the presence of any regeneration nodules. Each liver section in each group was
given a verbal score of “none”, “mild” and “moderate” that was translated into the table as “−, +,
and ++”; the table also includes how many animals out of the group presented the liver injury marker
in the group.
Another set of slides was stained for DNA damage using a fluorescent Terminal deoxynucleotidyl
transferase (TdT) dUTP Nick-End Labeling (TUNEL) assay. Analysis of DNA damage was determined
by a double-blinded imaging and scoring of 10 random 40X fields per section for positive (green)
compared to total hepatocyte nuclei (blue).
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For the immunohistochemical staining for 3-nitrotyrosine and Cytokeratin-19, the tissue slides
were deparaffinized and endogenous peroxidase was quenched followed by incubation in Dako
protein-block to block nonspecific binding. Anti-3-nitrotyrosine rabbit polyclonal antibody (Millipore;
#06284, 1:1000) was applied for 1 h in Dako antibody diluent buffer. Rat Anti-Cytokeratin-19 antibody
(DSHB Hybridoma Product TROMA-III; #ab2133570, 1:300) was incubated for two hours in Dako
diluent. All sets were then incubated in Vector Biotinylated Goat Anti–Rabbit–1:400 prepared in TBS-T
for 30 min. Then slides were incubated in Vector ABC Elite for 30 min. Slides were developed with Dako
diaminobenzidine (DAB). Slides were counterstained with hematoxylin and mounted. The negative
control slides followed the same protocol but did not use the primary antibody. 3-Nitrotyrosine
immunohistochemical staining was quantified by counting positive cells near similar sized central
veins (cytoplasmic or nuclear staining) per 400× field with the following scoring system: 0 (0 positive
cells), 1 (1–20 positive cells), 2 (21–30 positive cells), 3 (31–40 positive cells) and 4 (>41 positive cells).
A total of 15 × 400 × fields were scored, and means of these scores were calculated. Bile ducts were
scored and counted in Cytokeratin-19 stained slides by examining 8-10 regions containing at least one
portal area per liver section.
2.3. Real Time Quantitative Reverse Transcription PCR (qRT-PCR)
Total RNA was extracted from flash-frozen liver using the DNA/RNA/Protein extraction kit
(IBI Scientific IB47702, Peosta, IA, USA) according to the manufacturer’s protocol. After extraction,
the total RNA concentration was determined. cDNA was synthesized from 1000 ng RNA using the
High-Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific, Waltham, MA, USA) as we
previously described [47].
Fibrosis and inflammation marker levels of gene transcription were determined by single gene
quantitative reverse transcription polymerase chain reaction (qRT-PCR) using Fast TaqMan Gene
Expression Assays (Life Technologies, Carlsbad, CA, USA) and the Applied Biosystems 7500 Real Time
PCR system. The genes of interest included: TGF-β, α-SMA, Procoll1, IL-6, and IL-1β; see Supplemental
Table S1. The relative fold change of mRNA for each gene of interest was determined using the
Comparative CT (2−ΔΔCt) method. These results were normalized to house-keeping gene GAPDH
values [47].
2.4. Antioxidant Enzyme Activity Measurements
Whole flash-frozen liver tissue was homogenized in 50 mM potassium phosphate buffer containing
1.34 mM diethylenetriaminepentaacetic acid (pH: 7.4) on ice. Protein concentrations were determined
using a Lowry’s Protein Assay as previously described in [48].
Catalase activity for liver homogenates was determined using a 1:10 dilution from the homogenate.
Absorbance was read using the spectrophotometer at 240 nm for both the reference blank and the
sample. 50 μL of the diluted sample was placed in a total of 4 mL of 50 mM (pH 7.0) phosphate
buffer. Then 2 mL of this total solution was placed into a sample cuvette and a reference blank cuvette.
The addition of 1 mL of 30 mM H2O2 into the sample cuvette began the reaction and absorbance
change vs. time was measured for 2 min. The absorbance of the reference blank was subtracted from
the sample cuvette to determine the level of activity per mg of protein as previously described [49].
Glutathione Peroxidase activity was calculated using an established protocol [50]. A 1:50 dilution
of liver homogenate was added into a mixture of “working buffer” (containing 1.33 mM reduced
glutathione (GSH), 1.33 U/mL glutathione reductase (GR) and 55.6 mM potassium phosphate buffer
(pH: 7)) and 4 mM NADPH. This is incubated for 5 min at 30 ◦C, then the reaction is initiated when
15 mM cumene hydroperoxide is added. Absorption changes were measured at 340 nm for 3 min that
was then compared to the blank absorbance for each sample cuvette. The activity is calculated in units
per mg protein.
Glutathione Reductase activity was measured in a similar fashion to the Glutathione Peroxidase
protocol. To initiate the reaction, a 1:10 dilution of liver homogenate was added to ddH2O, PB/EDTA
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(100 mM potassium phosphate buffer/3.4 mM EDTA), 30 mM oxidized glutathione (GSSG), 0.8 mM
NADPH, and 1% bovine serum albumin (BSA). The decrease in absorbance at 340 nm was measured
for 3 min and subtracted from the blank absorbance. The absorbance was used to calculate activity in
units per mg protein as we previously described [51].
MnSOD activity was measured based on the protocol established by Spitz and Oberley [52]. It is
determined by recording the rate of reduction of nitroblue tetrazolium (NBT) from the superoxide
generated by xanthine oxidase. The superoxide dismutase (SOD) present in the samples will scavenge
the superoxide generated. This is a competitive inhibition of the reduction of NBT. A unit of SOD is
considered the amount of SOD required to inhibit 50% of the NBT reduction. This is determined using
varying concentrations of sample to find the percent inhibition curve and determine the concentration
at 50% inhibition. The MnSOD activity is determined by adding 0.33 M sodium cyanide buffer to
inhibit the CuZnSOD enzyme activity.
2.5. Bilirubin Assay
Plasma bilirubin levels were measured following Bilirubin Assay Kit protocol (Sigma-Aldrich,
St. Louis, MO, USA) using 50 μL of blood plasma in each well of 96 well plates to determine the total
bilirubin, direct bilirubin and blank absorbance. Absorbance was measured at 530 nm. The indirect
bilirubin levels were determined by subtracting the total bilirubin numbers from the direct bilirubin,
which is also known as conjugated bilirubin.
2.6. Statistical Analysis
Statistical analysis was performed using GraphPad Prism 8.0 (GraphPad Software, San Diego, CA,
USA). Data are expressed as mean ± 1SD, unless otherwise specified. One-way ANOVA analysis with
Tukey’s post-analysis was used to study the differences among the study group’s means. Significance
was determined at p < 0.05 and the 95% confidence interval. Statistical significance is expressed as
* p < 0.05, ** p < 0.01, and *** p < 0.005.
3. Results
3.1. Exposure to 24 Gy IR Increased the Expression of Inflammatory Markers as Well as Lymphoplasmacytic
Inflammation in the Livers of Sirt3−/− Mice
The histology of the liver sections was scored in a double-blinded manner to determine the level
of injury after irradiation. The scoring demonstrated considerably increased inflammatory cells in
the Sirt3−/− mice 6 months after 24 Gy IR, and while there were no severe cases yet, several animals
displayed moderate inflammation in the portal and perivenular space of the murine livers (Figure 2).
We also measured the gene expression of inflammatory chemokines, IL-6, IL-1β, and TGF-β,
in the livers of sham or 24 Gy treated mice from both Sirt3+/+ and Sirt3−/− mice. Previous studies have
demonstrated increased expression levels of these chemokines six months after liver-targeted irradiation.
Additionally, IL-1β is an important chemokine in the formation of the liver’s inflammasome that leads
to increased liver inflammation and tissue damage. These increases in inflammatory chemokines and
profibrotic factors could contribute to the removal of necrotic tissue after irradiation and stimulate
extracellular matrix deposits that assist in regeneration. However, the chronic release of IL-6, IL-1β,
and TGF-β would result in increased liver damage and fibrosis. Expression of IL-6, IL-1β, and TGF-β
were measured in triplicates for each animal in a group. The values were averaged and normalized to
GAPDH as the housekeeping gene. Fold change was determined by comparing each group to its own
sham. Only Sirt3−/− mice, which received 24 Gy IR, showed a significant increased expression of these
chemokines (Figure 3).
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Figure 2. Increased numbers of inflammatory cells were seen in irradiated Sirt3−/− mice. H&E scoring:
− (none), + (mild/focal), and ++ (moderate). All sections were normalized to the Sham Sirt3+/+ group
and presented as number of animals with marker per animals in each group (n = 4–6). Sham groups
underwent the same procedures without receiving 24 Gy IR (irradiation).
β
Figure 3. Expression of inflammatory markers determined by quantitative real-time PCR. IL6 and
TGFβ were significantly increased in Sirt3−/−mice after irradiation compared to sham irradiated Sirt3+/+
or Sirt3−/− as well as Sirt3+/+ irradiated groups. IL1β was significantly increased in irradiated Sirt3−/−
mice compared to irradiated Sirt3+/+ livers (n = 4–6; * p < 0.05, *** p < 0.001).
3.2. The Number of Bile Ducts Was Decreased in Irradiated Livers of Sirt3−/− Mice
Liver tissue sections were stained with cytokeratin-19 to visualize and score the bile duct presence.
Double-blind scoring showed a significant reduction of number of bile ducts per portal area in
the Sirt3−/− irradiated mice (Figure 4), which could contribute to the development of cholestasis
and eventually chronic fibrosis. Interestingly there were no changes in the plasma bilirubin levels
(conjugated or unconjugated; Supplemental Figure S1) probably due to the small irradiation field that
was used in the study.
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Figure 4. Sirt3−/− irradiated mice showed decreased number of bile ducts. Liver sections were stained
and counted with anti-cytokeratin 19 to determine the presence of bile ducts. Scale bars: 200 μm. (8–10
fields were scored per mouse, n = 6; * p < 0.01).
3.3. Exposure to 24 Gy IR Increased the Expression of Profibrotic Markers in the Livers of Sirt3−/− Mice but Did
Not Cause Fibrosis at 6 Months after IR Exposure
Because TGF-β is a cytokine growth factor that signals the release of additional inflammatory
chemokines and fibrotic growth factors, next we measured gene expression of procollagen-1 and
α-SMA in the sham and 24 Gy irradiated livers of both Sirt3+/+ and Sirt3−/− mice. Expression of these
two profibrotic marker proteins was measured in triplicates for each animal in a group. The values
were averaged and normalized to GAPDH as the housekeeping gene. Only Sirt3−/− mice, which
received 24 Gy IR, showed a significant increased expression of procollagen-1 and α-SMA (Figure 5).
However, this increase did not translate into a bridging fibrosis (data not shown), which may develop
in severe RILD patients.
α
Figure 5. Expression of profibrotic markers were increased in all Sirt3−/− mice after irradiation
compared to sham irradiated Sirt3+/+ or Sirt3−/− as well as Sirt3+/+ irradiated groups (n = 4–6;
** p < 0.01, *** p < 0.001).
3.4. Persistent Significant Increases in DNA Damage and Oxidative Stress in Liver Tissue of Sirt3−/− Mice
Following 24 Gy IR
DNA damage is an early event during exposure to IR. However, chronic inflammation and
oxidative/nitrosative stress have been suggested to contribute long-term detrimental effects of radiation
exposures by creating a feed-forward mechanism for persistent injuries to macromolecules, such as
DNA. Since we have seen increased expression of inflammatory markers 6 months post IR in
liver tissue of Sirt3−/− mice, we determined the levels of protein oxidation using 3-nitrotyrosine
immunohistochemistry. Blind scoring of liver sections were performed at 15 randomly selected central
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veins, and then given a score of 0 (0 positive cells), 1 (1–20 positive cells), 2 (21–30 positive cells),
3 (31–40 positive cells), or 4 (41 positive cells or greater). Our results showed that 24 Gy IR increased
levels of protein oxidation in mouse livers, which were persistent months after the exposure (Figure 6).
Figure 6. Protein oxidation, determined by 3-nitrotyrosine staining (indicated by the arrows),
was increased in irradiated Sirt3−/− mice compared to sham irradiated Sirt3+/+ or Sirt3−/− as well as
Sirt3+/+ irradiated groups. Scale bar: 200 μm (15 fields scored per mouse, n = 4–6; *** p < 0.001).
Therefore, it was not completely surprising when Sirt3−/− livers in irradiated group also exhibited
a significant increase of TUNEL positive cells compared to sham irradiated mice, suggesting DNA
fragmentation and possible apoptosis still exists in liver cells lacking SIRT3 as a stress response protein
against IR-induced oxidative injury (Figure 7).
Figure 7. The number of TUNEL positive cells were significantly increased in Sirt3−/− mice after
irradiation compared to sham irradiated Sirt3+/+ or Sirt3−/− as well as Sirt3+/+ irradiated groups.
Scale bar: 100 μm (n = 4–6; * p < 0.05 ** p < 0.01, *** p < 0.001).
3.5. Mice Lacking SIRT3 Demonstrated Altered Activity of Antioxidant Enzymes, Which Are Responsible for
Peroxide Removal in Liver Tissue Following 24 Gy IR
As a major deacetylation target of SIRT3, increased activity MnSOD has been shown to respond
to exogenous cellular stressors including acute IR injury in liver tissue [29] and loss of SIRT3 has
been associated with increased levels of superoxide [29,30,42]. Therefore, we first examined whether
MnSOD activity has not been altered in irradiated Sirt3−/− mice but it was increased in Sirt3+/+ mice,
via deacetlyation of critical lysine residues at its active site. No significant changes were noted in liver
MnSOD activity between the sham and irradiated groups in either genotype (Figure 8).
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Figure 8. Exposure to 24 Gy liver only irradiation did not significantly alter enzymatic activity of
MnSOD in Sirt3+/+ or Sirt3−/− mice (n = 4–6).
Interestingly, the activity of antioxidant enzymes CAT and GPx were significantly higher in
irradiated Sirt3−/− mice, while GR activity was significantly lower in this group compared to its sham
irradiated counterparts (Figure 9).
 
Figure 9. Glutathione Peroxidase (GPx) and catalase (CAT) activity were significantly increased while
Glutathione Reductase (GR) enzymatic activity was decreased in irradiated Sirt3−/− mice compared to
sham irradiated Sirt3+/+ or Sirt3−/− as well as Sirt3+/+ irradiated groups (n = 4–6; * p < 0.05, ** p < 0.01,
*** p < 0.001).
This result suggested that peroxide mediated oxidative injury is more relevant in radiation-induced
long-term liver toxicity.
4. Discussion
Almost half of all men and women have a lifetime probability of developing a new invasive
cancer; therefore, radiation therapy and chemotherapy are being used more frequently [1]. The liver,
located in the abdominal region, is a large organ that plays a critical role in metabolic homeostasis
and detoxification. Because of this metabolic role, the liver contains about 25% of mitochondria in its
cytosolic space [20]. This high mitochondrial content and oxygen requirement makes the liver especially
susceptible to radiation-induced ROS that can lead to hepatic radiation-induced damage, even with
doses as low as 30 Gy [10,19]. The typical clinical presentation of RILD develops 3 months after
irradiation and is associated with increased abdominal girth, ascites, hepatomegaly, and veno-occlusive
disease that can eventually progress to liver failure [4].
Although clinical observations are established and patient-oriented morphological characteristics
of IR-induced pathologies are well described, we have limited understanding of molecular mechanisms
that would explain dose-limiting toxicities in patients treated with high-dose IR [3,4,7,13,17,18,53–56].
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In addition, no pharmacological interventions have been shown to be consistently efficacious [9,54].
Therefore, understanding the confounding factors and mechanisms involved in IR-induced long-term
liver pathologies will particularly benefit the high-risk populations with underlying liver dysfunction.
The lack of prevention and therapy post RILD diagnosis exacerbate the need for pre-clinical models
that will allow the accurate study of radiation-induced liver damage development [2].
IR induces not only immediate production of free-radical mediated effects but also persistent
increases in metabolic production of reactive species, which contribute to the long-term tissue effects of
radiation [57]. The damage response cascades (i.e., inflammation, necrosis and fibrosis) are further
stimulated from the consistent formation of reactive species in days or even months after initial
irradiation exposure [19,24,58]. Similar damage response cascades were seen in our Sirt3−/− model
(Figures 2–7) 6-months after 24 Gy radiation was delivered to a small (5 × 5 mm) field of the liver
indicating persistent oxidative injury via the indirect generation of ROS and RNS. Superoxide anion,
hydrogen peroxide, hydroxyl radical, and peroxynitrite are a few examples of the radiation-induced
reactive species which can cause mitochondrial alterations that lead to oxidative and nitrosative stress
signaling and genomic instability; all adding to the long-term injury and dysregulation of normal liver
parenchymal function [59,60]. ROS and RNS can be removed through several different antioxidant
mechanisms, including SODs, CAT, and the glutathione, thioredoxin, and peroxiredoxin systems,
most of which are regulated via transcriptional and/or post-translational modifications [29–34]. SIRT3,
a member of NAD+ dependent enzymes family, has been shown to increase the activity of antioxidant
enzymes, including MnSOD [30–48,61]. In agreement with these studies, Coleman et al. demonstrated
SIRT3’s stress response function in an acute radiation-induced liver injury model, in which the authors
provided evidence for O2•− mediated liver injury in the absence of SIRT3, 48 h after 4 Gy total body
irradiation exposure [29]. Interestingly, in our current study of IR-induced long-term liver injury,
the model suggested that O2•− may no longer be the major participant in the chronic liver damage,
as we did not see any changes in enzymatic activity of MnSOD in the presence or absence of SIRT3
6-months following targeted irradiation (Figure 8).
After examination by a clinical pathologist, liver histology of the irradiated fields exhibited a
moderate increase in lymphoplasmacytic inflammation in the perivenular space, implying an increased
inflammation that can further signal of tissue necrosis or fibrosis. In an acute response to irradiation or
other types of liver injury, increased inflammation is necessary for tissue regeneration. Inflammation
facilitates a fibrotic network for regrowth and remodeling of liver tissue as well as vascular network
using chemokines like TGF-β, IL-1β, and IL-6. However, continual elevations of inflammatory cells
releasing, secreting and recruiting more cells using cytokines like TGF-β, can be associated with the
development of chronic liver disease [62]. While IL-1β and IL-6 are initially released to protect the
surrounding tissue from further damage in an acute response, its persistent and continued exposure
causes recruitment of additional Kupffer cells within the liver that triggers a feed-forward cycle of
continuous inflammation, damaging the hepatocytes [63]. In our targeted irradiation model, we found
that there was a significant increase in TGF-β, IL-1β, and IL-6 mRNA expression, suggesting a
persistent inflammatory response and continuous liver injury progression 6 months after treatment
in the absence of SIRT3. This fold increase in the Sirt3−/− mice was significantly higher than in the
Sirt3+/+ irradiated group, suggesting that the release of IL-6 and IL-1β are no longer a beneficial injury
response due to its new sustained nature. The elevation in inflammation cytokines and histochemistry
corroborate the idea that the inflammation is chronic in our model and will eventually lead to further
liver toxicity, demonstrating that functional SIRT3 is important for liver healing and the balance
between inflammation and regeneration even 6 months after irradiation. Adding to this finding,
the increased TUNEL staining confirms DNA degradation in the irradiated Sirt3−/− mice, further
signifying the development of long-term hepatocyte injury from persistent inflammatory cascades.
These results confirm the protective role of SIRT3, which was previously demonstrated in a sepsis
model by describing its molecular links to DNA damage, apoptosis and inflammatory responses via
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NLRP3 inflammasome upregulation as well as apoptosis-associated speck-like protein in the absence
of functional SIRT3 [64].
Sinusoidal obstruction and hepatic fibrosis are classical features of radiation-induced liver injury
in patients. Histology of the samples in the current study did not show any veno-occlusive events or an
increase in fibrotic collagen staining. However, hepatobiliary tract toxicities including vanishment of
bile ducts and elevated alkaline phosphatase are also common developments after radiation exposures,
thus we used cytokeratin 19 staining for the visualization of bile ducts. The results demonstrate
an interesting finding of possible bile ductopenia in the Sirt3−/− mice 6 months after IR exposure,
which was not observed in wild-type irradiated mice. Although to date no direct mechanistic link has
been established between SIRT3 function and bile duct injury, literature evidence suggests a strong
correlation between increased oxidative stress and increased levels of apoptosis in biliary epithelial
cells, which was mediated by glutathione in primary biliary cirrhosis [65]. Furthermore, increased
inflammatory cytokine-induced oxidative stress has been shown to decrease the expression of biliary
markers through miRNA506 regulation of DNA damage and apoptosis [66]. Corroborating with the
findings of these studies, our results also revealed increased levels of 3-nitrotyrosine on irradiated
Sirt3−/−- livers (Figure 6), which evidenced the existence of sustained oxidative injury in irradiated
Sirt3−/− livers. While the irradiated liver sections obtained from both genotypes did not demonstrate an
increase in fibrotic collagen staining (data not shown), based on our findings with decreased number of
functioning bile ducts in Sirt3−/− mice and elevated mRNA of fibrotic factors (α-SMA and procollagen
1), we believe these results indicate that these mice will eventually develop persistent fibrosis in the
irradiated field [67].
The morphological evidence we presented in our current study strongly suggests a noteworthy
role SIRT3 plays in the long-term radiation-induced liver toxicity. As an NAD+ dependent deacetylase,
which resides primarily in mitochondria, SIRT3 functions to maintain redox homeostasis under stress.
A total body irradiation study by Coleman et al., demonstrated that 48 h after exposure, there is an
early increase in O2•− generation in Sirt3−/− mice livers, which mediated the increased acute liver
injury in these animals [29]. We initially expected to see a similar response in MnSOD activity in
the long-term progression of radiation-induced injury. However, there was no significant change
in MnSOD activity between sham and irradiated groups at six months after irradiation (Figure 8).
Because MnSOD, and thus O2•− were not likely to be involved in the IR-induced chronic liver injury at
6 months time point, we shifted our focus to other antioxidant networks that may now be attempting
to overcome the oxidative stress from radiation.
As a number of SIRT3 deacetylation targets occur in mitochondria, which could indirectly
contribute to the redox homeostasis by providing the necessary coenzyme NADPH (e.g., isocitrate
dehydrogenase 2) [31,32], we examined alternate antioxidant enzymes. Our data indicate a possible
switch from O2•− to hydroperoxide metabolism that contributes to the injury endpoints found in
this study. In the absence of SIRT3, 6 months after radiation there was a significant decrease in GR.
This is an important enzyme that requires NADPH for its enzymatic activity for glutathione recycling.
Without SIRT3 there may have been a decrease in availability of the necessary coenzyme NADPH for
the continued recycling of glutathione in response to the persistent elevated oxidative stress generated
from radiation exposure.
Considering that peroxiredoxin 3, the principal peroxidase responsible for mitochondrial hydrogen
peroxide, is also a SIRT3 deacetylation target [68], accumulation of hydroperoxides and hydrogen
peroxide in irradiated livers resulted in the significant increases in GPx and CAT activities we measured
in Sirt3−/− mice. However, with long-term elevations clearly still seen after 6 months, this antioxidant
system also appears to be overwhelmed in the absence of SIRT3, leading to the liver toxicity seen in
our study.
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5. Conclusions
In conclusion, our results exhibited a vital function of SIRT3, a major mitochondrial deacetylase,
in IR-induced long-term liver injury. Loss or decrease in SIRT3 levels could be an underlying factor
and contributor to a damage-permissive phenotype in murine liver long after exposure to IR. Although
our model did not fully represent the clinical indications of human RILD, we believe this was due to
the small volume of irradiation chosen in the design. There were important signs that this murine
model may relate to the clinical presentation of human RILD including ductopenia, lymphoplasmacytic
inflammation, continued hepatocyte toxicity from DNA damage and elevations in the expression of
fibrotic factors.
The data presented in the current study also strongly suggested that O2•− driven acute liver
injury following IR exposure appears to shift towards a peroxide-mediated long-term injury and
clearly is no longer limited to the mitochondria. Thus, specific SIRT3 target proteins and the reactive
species contributing to the progression of RILD, merit investigation to establish causal mechanisms for
IR-induced chronic liver toxicity and develop strategies to prevent RILD in cancer survivors.
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Abstract: Reactive oxygen species (ROS) are important secondary metabolites that play major roles
in signaling pathways, with their levels often used as analytical tools to investigate various cellular
scenarios. They potentially damage genetic material and facilitate tumorigenesis by inhibiting
certain tumor suppressors. In diabetic conditions, substantial levels of ROS stimulate oxidative
stress through specialized precursors and enzymatic activity, while minimum levels are required
for proper wound healing. Photobiomodulation (PBM) uses light to stimulate cellular mechanisms
and facilitate the removal of oxidative stress. Photodynamic therapy (PDT) generates ROS to induce
selective tumor destruction. The regulatory roles of PBM via crosstalk between ROS and nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-кB) are substantial for the appropriate
management of various conditions.
Keywords: photobiomodulation; reactive oxygen species (ROS); nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-кB); cancer; diabetes; wound healing
1. Introduction
Reactive oxygen species (ROS) are formed by the fractional reduction of molecular oxygen
and include, but are not limited to, superoxide anions, hydrogen peroxide, and hydroxyl
radicals, all obtained from sequential oxidation–reduction processes involving nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase, lipoxygenases, or cyclooxygenases [1]. Unusually high
levels of ROS can allegedly be used for cancer diagnoses, varying according to tumor type, and are potent
signaling molecules in cancer, leading to nuclear damage, genetic instability, and tumorigenesis [2–4].
However, at non-cytotoxic levels, ROS act as secondary messengers with signaling roles in many
physiological systems to activate programmed cell death, gene expression, and other cell signaling
cascades [5]. Increased ROS production was observed in diabetes and diabetic complications,
leading to oxidative stress. As a result, a series of cell death mechanisms were observed within the cell,
finally leading to tissue and organ damage. Elevated levels of blood glucose appear to be the prime
source of free radicals, unbalancing the pool of antioxidants and ROS. Therefore, the down-regulation
of ROS production and targeting factors resulting in their increased generation may have a significant
role in controlling diabetic complications [6,7].
ROS plays a pivotal role in the initial stages of wound healing by killing invading bacteria and
other microorganisms. However, under chronic conditions, increased production of free radicals was
observed, thereby inhibiting the proliferation and migration of key cell types and leading to delayed
wound healing [8,9]. The regulation of certain redox transcription factors is dependent on the level of
ROS. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-кB) was the first discovered
redox-regulated transcription factor. NF-кB is a protein complex with multiple functions in immune,
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inflammation, cell growth, and survival responses. ROS are able to both activate and suppress NF-кB
signaling pathways [10,11]. Photobiomodulation (PBM) is a modern therapeutic approach which
results in beneficial outcomes and the modulation of various signaling pathways in the presence of
light at a specific wavelength. Photodynamic therapy (PDT) uses a specific wavelength light to activate
the photosensitizer to induce cell death in conjunction with molecular oxygen.
Even though PBM is well-known for its cell-stimulating properties both in vitro and in vivo,
clinical studies have been very mixed, and some contradicted non-clinical studies [12–15]; as a result,
some clinicians consider PBM a very controversial therapy [16–18]. It is important to realize that the
underlying cellular mechanisms of PBM are not fully understood [19,20]. Additionally, PBM treatment
parameters vary, such as the wavelength, fluence, power density, pulse structure, and irradiation time.
These are factors that preclude efficient clinical transition of PBM [21–24]. However, some studies
reported the role of cytochrome c oxidase as an important chromophore in the cellular response to
PBM [25]. A similar problem exists with PDT, in that it is not clinically accepted by many clinicians.
Although photodynamic therapy (PDT) has a long history, there is a minimal amount of proven clinical
research, making it difficult for it to be recognized as a first-line treatment approach in modern medicine.
This review focuses on the effect of ROS on NF-кB activity, how ROS are affected by PBM/PDT, and its
role in diabetes, wound healing, and cancer, respectively.
2. Sources and Stimuli of ROS
ROS are oxygen intermediates with unpaired electrons; both superoxide and hydroxyl radicals
are highly unstable oxygen radicals [26]. Experimentally, hydrogen peroxide is a simple peroxide
radical involved in various signaling functions and is frequently used as a source of all oxygen-related
free radicals [27]. Elevated levels of hydrogen peroxide effectively oxidize cysteine residues (Cys-SH)
to cysteine sulfenic acid (Cys-SOH) or cysteine disulphide (Cys-S-S-Cys) in various proteins, such as
kinases, phosphatases, and transcription factors. A well-established mechanism by which ROS regulate
cellular functions is through the redox balance of cysteine residues [28].
Mitochondria and NADPH promote endogenous ROS formation in cancer and reports have shown
crosstalk between these two producers [29]. The mitochondrial oxidative generation of adenosine
triphosphate (ATP) is a major source of free radicals. During the Krebs’s cycle, unpaired electrons are
transferred to the electron transport chain (ETC), resulting in the production of superoxide anions [30].
About ten mitochondrial sites generate numerous superoxide anions through different mechanisms [31].
The reactions of the five complexes of the ETC (complex I to V) are involved in the production of
ATP and free radicals as byproducts. The radicals produced from complexes I and III have various
cellular signaling roles [32]. Both superoxide anions and hydrogen peroxides are constantly produced
by complex III, with 80% released into the intermembrane space and the rest into the mitochondrial
matrix. These ROS intermediate radicals are necessary for cell differentiation, proliferation, survival,
and adaptive immunity responses [33]. In complex IV and during oxidative phosphorylation reactions,
the movement of electrons results in the reduction of oxygen to water. Almost all of the generated
superoxide anions are effectively quenched by manganese superoxide dismutase (MnSOD) to form
hydrogen peroxide, which serves as an important precursor for other free radicals and acts as a
secondary messenger with the ability to diffuse across the mitochondrial membrane, mediated by a
specialized protein from the aquaporin family [33,34]. Other than the positive functions, mitochondrial
ROS also have some deleterious ones, including the formation and progression of various cancer types
like chronic lymphocytic leukemia, acute myelogenous leukemia, and breast cancer [35]. Figure 1
depicts the generation of free radicals and their fate in the ETC. Free radicals formed by the ETC are
immediately removed and converted to water by a series of enzymatic reactions.
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Figure 1. Free radical generation. Free radicals formed by the electron transport chain are immediately
removed and converted to water through a series of enzymatic reactions. ETC: electron transport
chain; SOD: superoxide dismutase; CAT: catalase; GPX: glutathione peroxidase; GR: glutathione
reductase; PRX: peroxiredoxins; GSH: glutathione; GSSG: glutathione disulfide; Trx: thioredoxin; O2•−:
superoxide; NO•: nitric oxide; ONOO−: peroxynitrite; H2O2−: hydrogen peroxide.
2.1. Oxidative Stress and Cancer
Oxidative damage is linked to all phases of cancer, during which ROS act throughout its
progression. Radicals generated in the mitochondria damage genetic material and produce mutations
that initiate tumor progression due to the imbalance between ROS generation and antioxidant defence
mechanisms [36]. Redox homeostasis is important to sustain normal and survival functions. Increased
aerobic glycolysis and high levels of free radicals in cancer cells are linked to modifications in cell
signaling pathways, which can be counteracted by antioxidant defence mechanisms [37]. ROS facilitate
carcinogenesis by reversibly inhibiting certain tumor suppressors, such as phosphatase and tensin
homolog (PTEN) and protein tyrosine phosphatases (PTPs), which enhance antioxidant expression
and thus decrease ROS levels. However, high levels of ROS are beneficial during the developmental
stages of tumors, promoting cancer vulnerability and death [38].
2.2. Oxidative Stress and Diabetes
Glucose metabolism is the mechanism behind the generation of oxidative stress. In a transition
metal-dependent reaction, the enediol form of glucose is oxidized to enediol anion radicals,
then converted to more reactive superoxide anions and ketoaldehydes. Through a dismutation
reaction, superoxide anions are converted into hydrogen peroxides, which are precursors of highly
reactive hydroxyl radicals. Under diabetic conditions, if these hydrogen peroxides are not degraded
by glutathione peroxidase (GPx) or catalase (CAT), then the production of reactive hydroxyl radicals
occurs in the presence of transition metals [39]. Superoxide radical formation during hyperglycaemia
may also promote additional ROS formation through the oxidation of low-density lipoproteins [40].
Amadori products and advanced glycation end-products (AGEs) are emerging as major precursors
of free radicals in diabetes. AGEs may fluoresce, produce ROS, and bind to specific cell surface
receptors [41]. These generated AGEs bind to their receptors via the receptor for AGEs (RAGE) and
deactivate enzymes, followed by the discharge of free radicals [42]. These enzymatic alterations may
also quench and inhibit the anti-proliferative effect of nitric oxide (NO), which acts as a vital vasodilator
in diabetic patients [43]. Altogether, the increased free radical production stimulates intracellular
oxidative stress by AGEs, which upregulate NF-кB-controlled target genes [44]. In endothelial cells,
ROS stimulates the hexosamine pathway and induces vascular complications in patients with high
blood glucose levels [45]. The overexpression of the enzyme xanthine oxidase may contribute to the
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pathological condition, leading to type 2 diabetes. One of the mechanisms underlying this is the ability
of xanthine oxidase to produce free radicals and oxidative stress [46].
2.3. Oxidative Stress and Wound Healing
The main processes involved in regulated wound healing are migration, adhesion, proliferation,
neovascularization, remodeling, and apoptosis. Imbalance between antioxidants and free radicals with
elevated ROS formation is often observed, followed by the induction of apoptosis. In chronic wounds,
elevated free radicals coupled with reduced antioxidants results in the stimulation of pro-apoptotic
transcription factors, caspase-3, and oxidative stress, leading to cell death and further delays in the
healing process. The development of chronic impaired wound healing involves certain cell signaling
reactions [47]. Fibroblast/keratinocyte cells with mutated mitochondrial DNA result in increased ROS
generation, which affects nuclear transcriptional events by stimulating various signal transduction
pathways and inducing cell cycle arrest, death, and oxidative stress processes [48,49]. In fibroblasts,
mitochondria-generated ROS damages mitochondrial DNA and induces a persistent oxidative stress
condition. Keratinocyte differentiation depends on the ETC for the accumulation of superoxide
anions [50]. In contrast, in normal wound healing, minimal ROS levels mediate intracellular signaling
for cell proliferation and collagen deposition. Low ROS levels and high antioxidant levels are essential
for normal tissue repair [51].
2.4. Influence of Light on Oxidative Stress
Under two different conditions, light is used to either attenuate oxidative stress (as in the case
of PBM) or generate excessive amounts of ROS (as in the case of PDT). PBM involves the use of
non-ionizing radiation or light specifically in the visible and near-infrared regions of the electromagnetic
spectrum for therapeutic applications and stimulation of various cellular mechanisms. When there is
an imbalance between antioxidants and free radicals, PBM facilitates the displacement of free radicals
and the reduction of the oxidative stress load on the organism [52]. The successful action of PBM
depends on the activation of cytochrome c oxidase, which catalyzes the reduction of oxygen to water
by increasing the mitochondrial membrane potential (MMP), ATP, cyclic adenosine monophosphate
(cAMP), and NO [53,54]. NO is an essential signaling agent for the activation of certain cellular
pathways. PBM increases the generation of NO by upregulating cytochrome c levels and/or by cleaving
the metal complexes in cytochrome c [55]. The basic concepts and principles behind PBM are clearly
described in the literature. It is understood that PBM acts on impaired or dysfunctional tissue through
light and leads to mitochondria-mediated cellular processes, thereby inciting various mechanisms that
result in a wide range of therapeutic functions [56]. Some studies proposed that light at wavelengths
between 400 and 500 nm may generate free radicals through photosensitization, while ROS production
by mitochondria was directly evident at longer wavelengths. PBM activates several transcription
factors in the cytosol such as NF-kB, which trigger the transcription of genes and protect cells from
oxidative stress [57].
PDT is a minimally invasive treatment that is becoming commonly accepted as a potential
therapeutic option for localized cancers [58]. PDT depends on the successful accumulation of
photosensitizers (PSs) in tumor cells to initiate the process of irradiation of targeted areas for activation
of the PSs (Figure 2) [59,60]. The wavelength of light should match the absorption properties of
the PSs for effective ROS generation, either through direct electron abstraction (type I) or transfer
from a substrate to oxygen in a highly reactive state (type II), killing targeted tumors and leaving the
neighboring healthy cells unaffected [61]. Due to light inaccessibility to all areas of the body, PDT was
previously limited to superficial conditions, leaving deeper diseased organs less affected. Due to
the advancement in science and the medical use of fiber optics, PDT now has the potential to treat
both superficial lesions and deeper-seated tumors, which were previously inaccessible. The recent
development of wireless photonic and contracted implantable devices for light delivery into deep
regions, such as the brain and liver, rendered PDT treatment even more effective [62].
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Figure 2. During photodynamic therapy (PDT), generated reactive oxygen species (ROS) kill the
targeted tumor cells. PDT depends on the successful accumulation of photosensitizers (PSs) in tumor
cells to initiate the process of irradiation of targeted areas for activation of the PSs. When irradiated with
light of a specific wavelength, a photochemical reaction leads to the production of ROS in the presence
of oxygen. When the PS absorbs the photon energy it is excited and jumps from the ground state to
the excited singlet state and the energy is emitted back as fluorescence or heat via internal conversion.
Should intersystem-crossing occur, the PS is converted to an excited triplet state, which can transfer
electrons with cellular biomolecules, ultimately leading to the generation of ROS in a Type I reaction.
Alternatively, the excited triplet state PS transfers its electrons to ground triplet state molecular oxygen
(3O2), leading to the generation of an excited singlet oxygen (1O2) in a Type II reaction.
2.5. Effect of Light on NF-кB Activation and ROS Regulation
Activation of NF-кB depends on various parameters, like the cell compartment and dimer
confinement. Cytoplasmic NF-кB dimers are maintained in a stationary and inactive state through their
association with IкB (inhibitor of κB) proteins. When unconfined, NF-кB dimers translocate to nuclear
regions and bind to targeted DNA sequences, promoting gene expression [63]. Other determinant factors
include the synthesis of IкB proteins, activities of IKK (IκB kinase) complexes, and displacement of
NF-кB family members, both transcriptional co-activators and DNA [64]. The N-terminal Rel homology
domain (RHD) has affinities to кB sites and characterizes members of the NF-кB family, consisting of
RelB, RelA/p65, c-Rel, p50 (NF-кB1), and p52 (NF-кB2) in mammals [65]. The binding affinities of
their кB sites are of critical merit to exert positive and negative effects on transcription processes,
dimerization formation, and maintenance [60]. Only p65, RelB, and c-Rel mediate transcription through
their C-terminal transactivation domains (TADs). Though they have no TADs, through interactions
with non-Rel proteins with transactivation ability and hetero-dimerization with TAD-containing
NF-кB subunits, NF-кB1 and NF-кB2 upregulate transcription on the one hand and downregulate
transcription on the other hand via competitive inhibition with TAD-containing dimers [66].
Activation of NF-κB can be observed by direct and indirect glutathionylation of NF-κB and I-κB,
respectively. The p50 of cysteine-62 is sensitive to oxidation, which inhibits the translocation of NF-κB
into the nucleus and prevents DNA binding [67]. However, as S-glutathionylation events occur, p50 is
selectively reduced and DNA binding is restored [68,69]. ROS modification and glutathionylation
of IκBα at cysteine 189 prevents phosphorylation events and degradation, thereby leading to NF-кB
activation and targeted gene transcription (Figure 3) [70]. The IкB-mediated regulation characterizes
the NF-кB pathway and IкB proteins (IкBα, IкBβ, IкBε, IкBz, B-cell lymphoma 3 (BCL-3), and IкBns),
together with the precursor proteins NF-кB1 and NF-кB2, are well defined by the presence of
multiple ankyrin repeat domains. NF-кB activation, via phosphorylation of IкBs on conserved
serine residues, facilitates recognition by bTrCP proteins and K48-linked polyubiquitination by the
Skp1–Culin–Roc1/Rbx1/Hrt-1–F-box family of E3 ligases acting alongside the E2 enzyme UbcH5 in a
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precise manner [63]. The NF-кB signaling pathways are classified into canonical and non-canonical
routes. The canonical route is a classical representation of the generalized regulation of the NF-кB
pathway. Upon ligand recognition, cytokine receptors, such as the antigen receptors, interleukin
(IL)-1 receptor (IL-1R), tumor necrosis factor receptor (TNFR), and pattern recognition receptors
(PRRs), stimulate and activate signaling cascades that culminate in the activation of IKKβ (IKK2). IкB
proteins are phosphorylated by activated IKKβ, which exists in a complex with the closely related
kinase IKKα (IKK1) and NF-кB essential modulator (NEMO, IKKγ). Many membrane-bound ligands,
such as TNFR, TLR, and IL-1R, are involved in activation of the NF-кB pathway and act as upstream
regulators. When activated, the IKK complex becomes the principal upstream part of all NF-кB
pathways, thereby regulating the transcription of proinflammatory genes [71].
Figure 3. Mechanism of photobiomodulation (PBM). When low-powered light (LILI) enters the cell,
it is immediately absorbed by cytochrome c oxidase, which is present in mitochondria. This results in
an increased respiratory chain reaction and the overall redox reaction is altered. The increase in reactive
oxygen species (ROS) stimulates the oxidation of cysteine molecules. The glutathionylation of IkB and
S-glutathionylation of p50 activates NF-kB and transcription of specific genes. This further stimulates
the activation of the IkB kinase complex, leading to phosphorylation, ubiquitination, and degradation of
IkB proteins. Released NF-kB dimers then translocate into the nucleus, bind to specific DNA sequences,
and promote the transcription of target genes such as interleukin (IL)-2, IL-6, IL-8, inducible nitric
oxide synthase (iNOS), COX-2, and matrix metallopeptidases (MMP)-9.
The archetypical IкBα protein promptly degrades during the canonical activation route, causing
the release of multiple NF-кB dimers. IкBα principally targets the p65:p50 heterodimer to form a
IкBα: p65:p50 complex, which has translocating capabilities and masks the p65 nuclear localization
signal. DNA binding is prevented by the IкBa nuclear export signal, which results in steady-state
cytoplasmic localization of NF-кB dimers [72]. The degradation of IкBα leads to localization of NF-кB
in the nucleus and removal of IkB from the NF-кB complex. Then, NF-кB dimers bind to specific
DNA кB sites in the promoters and enhancers of target genes, leading to the formation of homodimers
and heterodimers, and heterotypic interactions with other transcription factors, finally leading to
regulation of transcriptional activity via post-translational modifications of targeted NF-кB subunits [66].
The termination of transcription depends on the synthesis of typical IкB proteins and the elimination
of active NF-кB dimers from DNA. The difference between canonical and non-canonical routes
remains whether they are NEMO-dependent or NEMO-independent. The non-canonical pathway
is NEMO-independent and is determined by IKKα activation to induce the NF-kB/RelB activation
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complex, thereby leading to the generation of a p52/RelB complex and phosphorylation of p100
(Figure 4). IKKα proteins can activate the canonical route and expand to the non-canonical route
through the induction of p100 expression [73].
Figure 4. Activation of NF-кB by the canonical and/or the noncanonical pathway. The canonical NF-
кB-activating pathway depends on the phosphorylation of IкB-kinase (IKK) β. The phosphorylation
and ubiquitination of IкBα translocate NF-кB into the nucleus. where it helps in the transcription of
target genes. Many membrane-bound ligands involved in activating the NF-кB pathway act as effective
upstream regulators and the IKK complex is the common upstream component of all NF-кB pathways.
In contrast, the non-canonical pathway is NF-kB essential modulator (NEMO)-independent and depends
on IKKα activation to induce the NF-kB/RelB activation complex, leading to the phosphorylation of
p100 and the generation of p52/RelB complexes.
2.6. Reciprocal Influence of ROS and NF-кB Activation
Hydrogen peroxide inhibits IKK activation by directly affecting IKKβ through its cysteine
inhibitory ability in catalytic domains of tyrosine phosphatases. The interactions of ROS with cysteine
residues are essential in order to affect the NF-кB pathways [74,75]. They facilitate the phosphorylation
of serine residues in the activation loops of IKK in cells [75], and IKK triggers the ubiquitination
and degradation of IkBα, which is usually phosphorylated on serine 32 and 36 [76]. The kinase
upstream of IKK or mitogen-activated protein kinase 1 (MEKK1) is inactive when glutathionylated at
C1238. ROS also target IKK and affect the NF-кB pathway, S-glutathionylation and IKKB functions via
phosphorylation and degradation of IкBα on tyrosine residues and activation of the NF-кB pathway,
as this may inhibit IкBα phosphorylation. They have the potential to influence the ubiquitination
and degradation of IkB and activate NF-кB by inactivating Ubcl2 [77]. In the non-canonical route,
NF-кB-inducing kinases (NIK), i.e., the upstream kinases, are activated by ROS through inhibition of
phosphatase and oxidation of cysteine residues [78].
Moreover, ROS appear as vital bridging factors that mediate the crosstalk between JNK and NF-кB
signaling pathways and interconnect ROS-mediated NF-кB and cell death, with the ability to inhibit
JNK activation [79]. Furthermore, NF-кB downregulates JNK activation by suppressing TNFα-induced
ROS accumulation. Due to their exerted oxidative stress, ROS directly participate in upregulation or
downregulation of NF-кB through their interactions with cytoplasmic components. ROS are noxious
at certain cellular levels and their inhibition results in the blockage of TNFα-induced programmed cell
death facilitated by the NF-кB signaling pathway [80]. However, nuclear ROS might solely lead to a
reduction of the binding ability of NF-кB to DNA [81]. The respective ROS accumulation and resulting
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oxidative stress generated in a specific subcellular localization becomes significant, as oxidative damage
could be avoided and cell survival could be maintained [82]. Cell survival is the most probable outcome
of the increased expression of NF-кB target genes, and only in a few exceptional cases does a cell death
response prevail. Therefore, it is expected that, on one hand, ROS would modulate NF-кB responses,
and on the other hand, NF-кB target genes would promote survival by ROS attenuation [83].
2.7. NF-кB in Cancer Progression
NF-кB is involved in various stages of oncogenesis and controls the expression of certain
tumor-related genes. During initiation in pre-malignant cells, stimulated NF-кB promotes the expression
of cytokines and chemokines, leading to the recruitment and activation of immune cells, which produce
more chemokines and growth factors [71]. They act on both malignant and inflammatory cells in an
autocrine or paracrine way, creating a complex inflammatory and pro-tumorigenic microenvironment.
NF-кB mediated inflammation contributes to nuclear damage, oncogenic mutation, and tumor
initiation and progression in pre-malignant cells [84]. Epidemiological studies revealed that over
20% of all cancer types are associated with chronic inflammation, which triggers carcinogenic events,
leading to the malignant transformation of normal cells [85]. Abnormal NF-кB activity may promote
the induction of tumors and apoptosis-resistant genes; this is one of the mechanisms by which
resistance to radiotherapy and chemotherapy is acquired. Through cytidine deaminase enzymatic
activity, activation-induced cytidine deaminases (AID) cause genetic alterations in DNA sequences,
and their intrinsic mutagenic-enzyme forms can be induced in response to infectious agents and
pro-inflammatory cytokines that facilitate NF-кB activation in epithelial cells [86]. While the major
role of NF-кB in the regulation of AID expression is evident, NF-кB-mediated AID expression is
accomplished via inflammatory mechanisms for the malignant transformation of epithelial cells during
carcinogenesis. In normal cells, NF-кB is transiently activated, while in cancer cells, it exhibits sustained
activation [87].
NF-кB is involved in tumorigenesis by upregulating the anti-apoptotic pathway and tumor
cell survival. The canonical pathway of NF-кB is known to activate the transcription of a group of
anti-apoptotic proteins, which is further subdivided into two categories, namely, inhibitors of apoptotic
proteins and the Bcl-2 family members [88]. In addition to transcription, inhibition of NF-кB activity
promotes JNK activity and apoptosis, suggesting that NF-кB inhibits apoptosis via inhibition of JNK
activity [89]. Pro-survival functions of NF-кB are related to the expression of phosphoinositide 3-kinase
(PI3K/Akt cascade), one of the key elements in promoting cell proliferation and growth [90] (Figure 5).
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Figure 5. NF-κB activation in the progression of cancer by regulating genes involved in tumor cell
proliferation, cell growth, survival, angiogenesis, tumor promotion, and metastasis. BCL2: B-cell
lymphoma protein 2; BCL-XL, also known as BCL2-like 1; BFL1, also known as BCL2A1; CDK2:
cyclin-dependent kinase 2; COX2: cyclooxygenase 2; CXCL: chemokine (C-X-C motif) ligand; DR: death
receptor; ELAM1: endothelial adhesion molecule 1; FLIP, also known as CASP8; GADD45beta: growth
arrest and DNA-damage-inducible protein beta; HIF1alpha: hypoxia-inducible factor 1 alpha; ICAM1:
intracellular adhesion molecule 1; IEX-1L: radiation-inducible immediate early gene (also known as
IER3); IL: interleukin; iNOS: inducible nitric oxide synthase; KAL1: Kallmann syndrome 1 sequence;
MCP1: monocyte chemoattractant protein 1 (also known as CCL2); MIP2: macrophage inflammatory
protein 2; MMP: matrix metalloproteinase; MnSOD: manganese superoxide dismutase (also known as
SOD2); TNF: tumor necrosis factor; TRAF: TNF receptor-associated factor; uPA: urokinase plasminogen
activator; VCAM1: vascular cell adhesion molecule 1; VEGF: vascular endothelial growth factor; XIAP:
X-linked inhibitor of apoptosis protein.
2.8. NF-кB in the Pathogenesis of Diabetes
Insulin-dependent (type 1) and insulin-independent (type 2) diabetes are the two major variations
of diabetes seen among humans. In type 1 diabetes, beta pancreatic cells are prone to autoimmune
attack by cytokines, such as interferon and IL-1, and NF-кB is mostly inactive in resting cells. However,
IL-1 can activate the translocation of NF-кB to the nucleus [91]. NF-кB regulates the expression
of cytokine-induced genes, which play very significant roles in pro- or anti-apoptotic cascades
(Figure 6). Cytokine-induced NF-кB activation can be reverted by a non-degradable mutant form
of inhibitory кB (IкB) (S32A, S36A) in recombinant adenovirus (AdIB (SA) 2) in human pancreatic
islet cells or by transfection with a stable inhibitor of NF-кB in purified rat cells [92,93]. Moreover,
intravenous administration of a “dummy” NF-кB and mice deficient in NF-кB (p50) showed resistance
to alloxan- and streptozotocin-induced islet cell death [94]. This could be considered a strategy to
protect cytokine-induced in vitro and in vivo apoptosis, whereby inhibition of NF-кB is achieved.
This highlighted the pro-apoptotic effect of NF-кB activation in β-cells of the pancreas. Blocking NF-кB
for a prolonged period displayed impaired development of endocrine cells and expression of important
genes involved in the insulin-secretion pathway [95]. Interestingly, resistance to NF-кB activation
could decrease the time course of the development of diabetes. Hence, it is more important to consider
the mechanisms that regulate NF-кB in cells and genes in diabetic conditions before building up
inhibition strategies.
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Figure 6. Role and activation of NF-кB in diabetes mellitus. NF-кB regulates the expression of
cytokine-induced genes that affect pro- or anti-apoptotic cascades. NF-кB is one of the major causes in
the development of insulin resistance. Tumor necrosis factor (TNF) predominantly induces insulin
resistance by the serine phosphorylation of insulin receptor substrate-1 (IRS1), and NF-кB is a major
cause of insulin resistance.
Type 2 diabetes is mainly characterized by insulin resistance. NF-кB is one of the chief components
in the insulin resistance observed in type 2 diabetes. The anti-inflammatory agent aspirin prevents
the degradation of NF-кB inhibitor (IB), whose expression in the liver attenuates the expression of
NF-кB dependent genes, but also reduced the likelihood of type 2 diabetes development. Similarly,
inflammation-induced hyperglycemia can be inhibited using specific inhibitors of interleukin-1
signaling [96]. Hence, it is obvious that the target genes of NF-кB, such as IL-1, TNF, and IL-6, and NF-кB
itself, play vital roles in insulin resistance. NF-кB also antagonizes peroxisome proliferator-activated
receptor (PPAR), which maintains glucose homeostasis in bone marrow-derived mesenchymal cells [97].
TNF predominantly induces insulin resistance by serine phosphorylation of insulin receptor substrate-1,
which is also a potent activator of NF-кB (Figure 6). Evidence suggests that TNF is involved in insulin
resistance in humans and animal adipose tissue and blocks reversion of the diabetic condition by
masking the activity of NF-кB [98]. Hence, NF-кB is one of the major causes in the development of
insulin resistance. Given the role of NF-кB in insulin regulation, it is important to understand its
beneficial effects in insulin sensitivity and GLUT2 monitoring, a protein that controls glucose-stimulated
insulin secretion by cells [95]. In certain cases, inhibition of the transcription factor NF-кB may inflict
deleterious effects on GLUT 2, leading to diabetes progression. Although there are a lot of studies
highlighting the role of NF-кB in type 1 and 2 diabetes, its specific trail in the pathogenesis of diabetes
requires further investigation.
2.9. NF-кB in Wound Healing
NF-кB is essential for inflammatory and phagocytic cell migration as it strictly regulates
genes involved in cell proliferation (granulocyte colony-stimulating factor and macrophage
colony-stimulating factor), transformation, and survival. In wound healing, the classical NF-кB
pathway is activated as an innate immune reaction and, as a result, activation of NF-кB is more
important in the protection of cells from infections or microbes [63]. The effects of NF-кB on cell
survival mainly depends on the type and number of stimulatory molecules [99]. In normal wound
healing responses, NF-кB functions as a positive signaling molecule to enhance the proliferation phase,
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and both increase and regulate the migration of keratinocytes toward re-epithelization sites [100,101].
Under normal physiological conditions, NF-кB protein levels are standard, hence there is no defined
physiological level to clear dead cells and microbes during responses to infections or wounds. Any
defect in NF-кB activation inhibits the innate immune reaction, whereas the elevated production of
NF-кB increases inflammatory cytokine levels and leads to tumor formation [102]. Every wound is
different and requires integrated defence and repair mechanisms. In clinical settings, wound evaluation
cannot solely depend upon Nrf2 and NF-кB but can indicate an inadequate defence against oxidative
stress or innate immune reactions at large in non-healing wounds. For wounds with prolonged
inflammation, compounds that decrease NF-кB levels or activate the Nrf2 pathway can be useful, and
Nrf2 and NF-кB as markers are mainly utilized to assess healing processes. In immunosuppressed
patients, NF-кB induction can help to initiate the correct immune reaction, but the multifaceted
network of active molecules in the whole body can cause a different cell response than that observed
in vivo [103].
3. Conclusions
Unusually high levels of ROS can allegedly be used for cancer diagnosis, varying according
to tumor type, and are potent signaling molecules in cancer scenarios, thereby leading to nuclear
damage, genetic instability, and tumorigenesis. The regulation of redox transcription factors is
dependent on the generation of ROS levels. NF-кB was the first redox-regulated transcription factor
to be discovered. It is a protein complex with multiple functions in immune, inflammation, cell
growth, and survival responses. ROS have NF-кB stimulatory effects in the cytoplasm and inhibitory
effects in the nucleus. Therefore, ROS have the ability to both activate and suppress NF-кB signaling
pathways. PBM promotes photon availability and absorption by chromophores in the catalytic center
of mitochondrial cytochrome c oxidase the and subsequent reduction of molecular oxygen. This
disturbs the mitochondrial membrane potential and changes the fission–fusion homeostasis in the
mitochondrial network, leading to increased levels of intermediates such as ATP, cAMP, and ROS.
PBM-mediated ROS interact with certain family proteins that enclose highly reactive cysteine (Cys)
residues and after the oxidation of Cys residues. The activity of NF-кB is regulated by direct activation
or after disassembling from IkB, an inhibitor, then the released NF-кB translocate to the nucleus and
promotes gene transcription. The regulation of crosstalk between ROS and NF-кB appears to be a
key factor for better management of many conditions. PBM facilitates the reduction of oxidative
stress and activation of mechanisms that upregulate or downregulate NF-кB, which are critical for the
promotion of anti-apoptotic responses and tumor progression, insulin dependence or resistance in
diabetes, cell proliferation and migration in wounded sites, or cell survival by ROS attenuation.
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Abstract: The nuclear factor erythroid 2-related factor 2 (NRF2)–Kelch-like ECH-associated protein 1
(KEAP1) regulatory pathway plays an essential role in protecting cells and tissues from oxidative,
electrophilic, and xenobiotic stress. By controlling the transactivation of over 500 cytoprotective
genes, the NRF2 transcription factor has been implicated in the physiopathology of several human
diseases, including cancer. In this respect, accumulating evidence indicates that NRF2 can act
as a double-edged sword, being able to mediate tumor suppressive or pro-oncogenic functions,
depending on the specific biological context of its activation. Thus, a better understanding of the
mechanisms that control NRF2 functions and the most appropriate context of its activation is a
prerequisite for the development of effective therapeutic strategies based on NRF2 modulation.
In line of principle, the controlled activation of NRF2 might reduce the risk of cancer initiation
and development in normal cells by scavenging reactive-oxygen species (ROS) and by preventing
genomic instability through decreased DNA damage. In contrast however, already transformed
cells with constitutive or prolonged activation of NRF2 signaling might represent a major clinical
hurdle and exhibit an aggressive phenotype characterized by therapy resistance and unfavorable
prognosis, requiring the use of NRF2 inhibitors. In this review, we will focus on the dual roles
of the NRF2-KEAP1 pathway in cancer promotion and inhibition, describing the mechanisms of
its activation and potential therapeutic strategies based on the use of context-specific modulation
of NRF2.
Keywords: NRF2-KEAP1; ROS; cancer metabolism; antioxidant; oxidative stress; cancer therapy;
chemoresistance; radioresistance
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1. Introduction
Nuclear factor erythroid 2-related factor 2 (NRF2) is a key transcription factor and a key modulator
of cellular antioxidant responses that regulates the expression of genes encoding antioxidant enzymes
with a protective role against different types of oxidative changes. NRF2 in combination with its
own negative regulator, Kelch-like ECH-associated protein 1 (KEAP1), has become the center of a
debate regarding whether NRF2 suppresses the tumor promotion or, conversely, exerts pro-oncogenic
functions. Based on this, the present review will describe the role of NRF2 in cancer prevention
and promotion, discussing potential advantages and disadvantages derived from its therapeutic
modulation in cancer prevention and treatment. As it is known, under non-stressed conditions, NRF2 is
constitutively poly-ubiquitinated by the CUL3-KEAP1 E3 ubiquitin ligase complex and subjected to
degradation through the proteasome pathway [1]. After exposure to several redox altering stimuli,
highly reactive thiols of KEAP1 are subjected to instant modification, leading to NRF2 stabilization
caused by its decreased affinity for the CUL3-KEAP1 complex. Subsequently, NRF2 translocates into
the nucleus and binds to the antioxidant response element (ARE) located within the promoter region
of specific target genes, inducing the expression of a large number of cytoprotective proteins with
antioxidant and detoxifying roles [2–5]. The importance of NRF2 function has been demonstrated by
several studies using NRF2-deficient mice showing an increased susceptibility to redox disturbances
and xenobiotic stress [6–8]. It has also been shown that tissue oxidative damage after ischemia and
reperfusion is efficiently counteracted by NRF2 induction [9]. In line with the protective roles of
the KEAP1-NRF2 pathway, its activation seems to effectively prevent carcinogenesis by promoting
a number of antioxidant mechanisms [10,11]. Thus, NRF2 activation may have beneficial role as
a result of its suppressive effect on carcinogenesis. On the other hand, increasing evidence show
that constitutive NRF2 activation contributes to the progression of various cancer types. Specifically,
many studies have shown that the increased activation of NRF2 in cancer cells leads to its augmented
transcriptional activity and promotes tumor progression [12–14], metastasis formation [15], resistance to
chemo-radiotherapy [16–19], and is clinically associated with poor prognosis [20]. During the last
decade, several mechanisms through which NRF2 signaling pathway is persistently activated in
different types of cancers have been discussed. Regarding NRF2, its oncogenic activity promotes
cancer cell growth and proliferation, suppression of cancer cell apoptosis, self-renewal of cancer
stem cells, therapy resistance, increased angiogenesis and anti-inflammatory activities [21]. As the
pro-tumorigenic role of this factor has gained interest, pharmacological modulation of the NRF2
pathway offers pioneering therapeutic opportunities against several diseases. Recent studies have
brought to light a few small molecules displaying promising properties in NRF2 inhibition, but their
applicability still needs to be further investigated [22–25]. Most of these molecules lack specificity
and have off-target toxic effects since they easily react with cysteine residues of different molecules.
Metabolic instability, low bioavailability, and poor membrane permeability are some of the basic
drawbacks in the administration of many NRF2 inhibitors [26]. To date, dimethyl fumarate is the
only NRF2 activator approved by the Food and Drug Administration (FDA) but its function in cancer
prevention has not been examined yet.
Structure and Function of NRF2 and KEAP1
Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcriptional factor encoded by the NFE2L2
gene that belongs to “Cap’N’Collar” type of basic region leucine zipper factor family (CNC-bZIP) [27].
Human NRF2 protein is 605 amino acids long and contains seven conserved NRF2-ECH homology
domains known as Neh1-Neh7 [27,28]. Neh2 is a major regulatory domain located to N-terminus of
NRF2 and it has two binding sites known as DLG and ETGE. These sites help to regulate NRF2 stability
by interacting with the Kelch domains of E3 ubiquitin ligase Kelch-like ECH-associated protein 1
(KEAP1), a substrate of Cullin 3-based ubiquitin E3 ligase complex that ubiquitinates and targets NRF2
for proteasomal degradation [29–32]. The Neh1 and Neh6 domains have also been shown to control
NRF2 stability. The Neh1 contains a basic leucine zipper motif that is also known as DNA binding
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domain and it enhances NRF2 transcriptional activation [27,33]. The Neh6 domain is a serine-rich
domain containing two motifs (DSGIS and DSAPGS) that negatively modulate NRF2 stability through
beta-TrCP dependent but KEAP1 independent regulation [34]. The Neh3, Neh4, and Neh5 domains
are known as trans-activation domains of NRF2. The carboxy-terminal Neh3 domain binds to CHD6
(a chromo-ATPase/helicase DNA-binding protein) that is the transcriptional co-activator of NRF2 [35].
The Neh4 and Neh5 domains interact with the CH3 domains of CBP (CREB-binding protein) that
facilitates transactivation of NRF2 target genes [36,37]. In addition, a seventh domain of NRF2 known
as Neh7 has been shown to interact with a nuclear receptor retinoic X receptor alpha (RXRa) that
inhibits NRF2 target genes transcription [38]. A schematic representation of NRF2 structure is shown
in Figure 1A.
 
Figure 1. Domain architectures of Kelch-like ECH-associated protein 1 (KEAP1) and nuclear factor
erythroid 2-related factor 2 (NRF2). (A) Human NRF2 protein is 605 amino acids long and contains
seven Neh domains. The Neh1 contains a basic leucine zipper motif that is responsible for dimerization
with sMaf protein and ARE sequence binding in DNA. Neh2 has two binding sites known as DLG
and ETGE that control KEAP1 interaction. The Neh6 domain is a serine-rich domain containing two
motifs (DSGIS and DSAPGS) that negatively regulate NRF2 stability. The Neh7 domain interacts with a
nuclear receptor RXRα. The Neh3, Neh4, and Neh5 domains are known as trans-activation domains of
NRF2. (B) KEAP1 is a 69-kDa protein and contains five domains. The BTB domain is critical for KEAP1
dimerization and recruitment of Cul3-based E3-ligase. The IVR domain has hypercritical cysteine
residues, Cys273 and Cys288 that are essential for controlling NRF2 activity. Kelch/DGR domain
negatively regulates NRF2 activation by interacting with conserved carboxyl terminus of Neh2 domain.
BTB, broad complex, tram-track and bric-a-brac; CTR, C-terminal region; Cul3, Cullin3; IVR, intervening
region; KEAP1, kelch-like ECH-associated protein 1; sMaf, musculoaponeurotic fibrosarcoma oncogene;
Neh, NRF2-ECH homologous structure; NRF2, nuclear factor erythroid-2-related factor-2; NTR,
N-terminal region; RXRα,.
KEAP1 is a 69-kDa protein, which belongs to the BTB-Kelch family of proteins [39]. All the members
of this family assemble with Cullin-RING ligases that catalyze general protein ubiquitylation [39].
KEAP1 contains five domains including N-terminal region, the Cullin3 binding broad complex,
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tramtrack and broad complex/tramtrack/bric-a-brac (BTB) homodimerisation domain, the intervening
region (IVR), the Kelch/double glycine repeat (DGR) domain and C-terminal domain [40,41]. The BTB
domain is critical for KEAP1 dimerization and CUL3 assembly requires a BTB protein motif for
ubiquitination and proteasomal degradation of NRF2 [41]. In addition, the BTB domain also contains a
critical cysteine residue (Cys151) that has an important role in the activation of NRF2 [42]. The IVR/BACK
domain contains highly reactive cysteines, namely Cys273 and Cys288 that function as a sensor for NRF2
inducers and are essential for controlling NRF2 activity [43]. Kelch/DGR domain negatively regulates
NRF2 activation by interacting with conserved carboxyl terminus of Neh2 domain [44]. NRF2 controls
antioxidant and cytoprotective genes expression and regulates cellular defense [23]. Under physiological
conditions, NRF2 is kept at low levels in normal tissues by KEAP1-dependent ubiquitination and
proteasomal degradation [29,30]. NRF2 localizes in the cytosol where ETGE and DLG motifs on its
Neh2 domain associate with KEAP1 Kelch domain [45]. A schematic representation of KEAP1 structure
is shown in Figure 1B. KEAP1 acts as an adaptor for NRF2 binding to the KEAP1-CUL3-E3 ubiquitin
ligase complex, an event followed by rapid NRF2 proteasomal degradation [28]. Under oxidative
stress (OS) conditions or in the presence of other stressors including reactive-oxygen species (ROS) or
electrophiles, the activity of KEAP1 is decreased by direct modification of reactive cysteine residues
in the IVR domain. These redox changes induced on KEAP1 thiols alter its structure and prevent
KEAP1-mediated NRF2 ubiquitination [46,47]. Subsequently, NRF2 accumulates in the nucleus where
it induces the expression of its target genes. In the nucleus, NRF2 heterodimerizes with small Maf
proteins through Neh1 domain and promotes the antioxidant responsive elements (AREs)-dependent
expression of cytoprotective genes [46] (see Figure 2). In this regard, over 500 NRF2 target genes
have been so far identified and this number is expected to increase in the next coming future [48,49].
The genetic products of NRF2 activation can be categorized in functional categories covering multiple
cellular processes including phase I, II, III drug/xenobiotic metabolism and detoxification, antioxidant
response and redox homeostasis regulation, iron homeostasis, cellular metabolism, DNA repair,
transcriptional activation, cell proliferation, and apoptosis [46,50]. A selected list of NRF2 target genes
is presented in Table 1.
 
Figure 2. NRF2 regulation by KEAP1. Under basal conditions, NRF2 is constantly ubiquitinated
through KEAP1 and degraded in the proteasome in cytosol. Under stress conditions, KEAP1-NRF2
interaction is stopped and free NRF2 translocates into nucleus. Then, NRF2 forms heterodimers with
sMaf and binds to ARE sites within regulatory sites of antioxidant and detoxification genes. ARE,
antioxidant response element; KEAP1, Kelch-like ECH-associated protein1; NRF2, nuclear erythroid-2
like factor-2; Retinoic X receptor alpha sMafs, small musculoaponeurotic fibrosarcoma oncogene family.
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Table 1. Selected list of NRF2 target genes.
Gene Coded Protein Functional Category Biological Role Ref.
GCLC Glutamate-Cysteine LigaseCatalytic Subunit GSH Synthesis & Regeneration GSH Synthesis [51]
GCLM Glutamate-Cysteine LigaseModulatory Subunit GSH Synthesis & Regeneration GSH Synthesis [51]
GSR1 Glutathione Reductase 1 GSH Synthesis & Regeneration GSH Regeneration [51]
SLC7A11 xCT, Light Subunit of Xc-Antiporter GSH Synthesis & Regeneration Cystine Uptake [51]
PHGDH Phosphoglycerate Dehydrogenase GSH Synthesis & Regeneration Serine/Glycine Synthesis [21]
PSAT1 Phosphoserine Aminotransferase 1 GSH Synthesis & Regeneration Serine/Glycine Synthesis [21]
PSPH Phosphoserine Phosphatase GSH Synthesis & Regeneration Serine/Glycine Synthesis [21]
SHMT 1,2 Serine Hydroxymethyltransferase 1,2 GSH Synthesis & Regeneration Serine/Glycine Synthesis [21]
GPX1,2,4 Glutathione Peroxidase 1,2,4 ROS & Phase-IIXenobiotic Detoxification ROS Scavenging [21,51]
PRDX1,6 Peroxiredoxin 1,6 ROS & Phase-IIXenobiotic Detoxification ROS Scavenging [52]
TXN1 Thioredoxin 1 Thioredoxin-linked Antioxidant Role Reduction of Sulfenylated-Proteins [51]
TXNRD1 Thioredoxin Reductase-1 Thioredoxin-linked Antioxidant Role Reduction of Thioredoxin [51]
NQO1 NAD(P)H dehydrogenase Quinone 1 ROS & Phase-IXenobiotic Detoxification Reduction of quinones [51,53]
AKR1B1 Aldo-Keto Reductase Family 1Member B1 Phase-I Xenobiotic Detoxification Reduction of aldehydes and ketones [52]
AKR1B10 Aldo-Keto Reductase Family 1Member B10 Phase-I Xenobiotic Detoxification Reduction of aldehydes and ketones [52]
AKR1C1 Aldo-Keto Reductase Family 1Member C1 Phase-I Xenobiotic Detoxification Reduction of aldehydes and ketones [52]
ALDH1A1 Aldehyde Dehydrogenase 1 FamilyMember A1 Phase-I Xenobiotic Detoxification Conversion of aldehydes to carboxylic acids [54,55]
ALDH3A1 Aldehyde Dehydrogenase 3 FamilyMember A1 Phase-I Xenobiotic Detoxification Conversion of aldehydes to carboxylic acids [52]
GSTA 1,2,3,5 Glutathione-S Transferase A1,2,3,5 ROS & Phase-II XenobioticDetoxification Conjugation of Glutathione to electrophiles [51]
GSTM 1,2,3 Glutathione-S Transferase M1,2,3 ROS & Phase-II XenobioticDetoxification Conjugation of Glutathione to electrophiles [51]
UGT1A1,5 UDP Glucuronosyltransferase 1 A1,5 Phase-II Xenobiotic Detoxification Conjugation of Glucuronic acidto electrophiles [52]
ABCC1
ATP Binding Cassette Subfamily C
Member 1/Multidrug resistance
associated protein 1 (MRP1)
Phase-III Xenobiotic Detoxification Transmembrane translocationof xenobiotics [56]
ABCG2 ATP Binding Cassette Subfamily GMember 2 Phase-III Xenobiotic Detoxification Transmembrane xenobiotic transporter [57]
ABCB6 ATP Binding Cassette Subfamily BMember 6
Phase-III Xenobiotic
Detoxification/Heme Synthesis
Transmembrane transport of xenobiotics
and porphyrins [52]
ABCC2 ATP Binding Cassette Subfamily CMember 2 Phase-III Xenobiotic Detoxification Transmembrane transport of xenobiotics [52]
SRXN1 Sulfiredoxin-1 Thioredoxin-linked Antioxidant Role Reduction of Sulfinylated-Peroxiredoxins [51]
G6PD Glucose-6-Phosphate Dehydrogenase NADPH Generation Pentose Phosphate Pathway/Glucose toGlucose 6-Phosphate Conversion [53]





ME1 Malic Enzyme 1 NADPH Generation Malate to Pyruvate Conversion [53]
IDH1 Isocitrate Dehydrogenase 1 NADPH Generation Isocitrate to α-KetoglutarateConversion/TCA Cycle [53]
TKT Transketolase NADPH Generation
Pentose Phosphate Pathway/Conversion of





TALDO1 TransAldolase 1 NADPH Generation
Pentose Phosphate Pathway/Conversion of
Glyceraldehyde 3-Phosphate and
Sedoheptulose 7-Phosphate into Erythrose
4-Phosphate and Fructose 4-Phosphate
[53]
MTHFD2 MethylenetetrahydrofolateDehydrogenase 2 NADPH Generation Serine/Glycine Metabolism [53]
MTHFDL1 MethylenetetrahydrofolateDehydrogenase 1-like NADPH Generation Mitochondrial Tetrahydrofolate Synthesis [58]
HMOX1 Heme Oxygenase 1 Heme & Iron Metabolism Heme to Biliverdin Conversion [51]
FTL Ferritin Light Chain Heme & Iron Metabolism Iron Storage [51]
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2. NRF2 in Cancer Prevention and Therapeutic Implications
2.1. Therapeutic Modulation of NRF2-KEAP1 Pathway for Cancer Prevention
Historically, the NRF2-KEAP1 pathway has been the focus of extensive research aimed at assessing
its potential role in human chronic diseases characterized by alterations of the redox homeostasis such
as diabetes, cardiovascular diseases, neurodegenerative diseases and cancer. Among them, effort have
been made to explore the chemopreventive properties of naturally occurring as well as synthetic
compounds functioning as NRF2 activators or KEAP1 inhibitors in vitro and in vivo. The identification
of the molecular mechanisms underlying NRF2 modulation has driven a renovated interest in the
field of basic and clinical cancer research, fostering a growing number of studies. However, it is now
increasingly recognized that NRF2 can exert oncogenic as well as oncosuppressive functions, so that
the development of effective therapeutic approaches based on NRF2 modulation requires a careful
evaluation of the specific context of its activation including not only the histotype, stage, and genetic
background of a specific tumor but also the therapeutic scheme of administration and the target
population that might benefit from treatment. In the following section, we will describe some of the
most relevant NRF2 activators and their use in cancer treatment.
2.2. Activators of NRF2
Activation of the NRF2 system is complex and can follow canonical and non-canonical pathways.
A difficulty in identifying activators and inhibitors of NRF2 or KEAP1 as modulators of inflammation
and potential protectors against oxidative stress and carcinogenesis, is the dual nature of the
NRF2-KEAP1 protein-protein interaction [26,59–62]. Generally, activation of NRF2 has been viewed as
therapeutic, but recent evidence has suggested that this event can be pro-oncogenic as well, depending
on the context of NRF2 activation [62]. For example, an increased NRF2 activity under “normal”
conditions will lead to improved cell defense against carcinogenesis. By contrast, unrestrained NRF2
activation in a tumorigenic condition, can be protective against stressful conditions and promote
therapy resistance [62]. In cases where NRF2 activation exerts pro-tumoral effects, the therapeutic
applicability of NRF2 inhibitors has been explored. Since the NRF2-KEAP1 pathway can sense
electrophiles as potential stressors, the use of electrophilic drugs to induce its activation would be a
reasonable starting point [41,63]. There is however a substantial concern over potential side effects
associated with the use of electrophilic compounds. This concern has stimulated the development
of other “modulators” of NRF2 activity, considering that the optimal compound would not be a
strong NRF2 activator since the strength of its activation is proportional to the electrophilic effects [64].
More work is needed to determine the potential of NRF2 activators as therapeutic drugs, but first,
the pathways involved must be better elucidated [65].
2.2.1. Electrophilic and Non-Electrophilic NRF2 Activators
Collectively, NRF2-inducers fall into two classes—electrophilic and non-electrophilic [66]—with
the majority of the currently identified inducers belonging to the former class. The mechanism of
action for electrophilic NRF2 activators involves the interaction with the cysteine residues on KEAP1,
resulting in a conformational change that releases NRF2 to its active conformational state. In the
following subsections we will describe both types of molecules, but emphasizing that electrophilic
activators are inherently toxic and when used at sufficiently high doses, will cause electrophilic cellular
damage beyond NRF2 activation [66]. Despite the high risk for side effects, the quest for additional
electrophilic covalent NRF2 activators remains [67] since the advantage of these molecules is due in
part to the extremely high binding energy elicited by covalent binding compared to non-covalent and
the discovery of a low-molecular weight compound able to maintain a high binding affinity is more
likely to occur with covalent activators.
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Electrophilic/Covalent NRF2 Activators
The largest class of chemicals so far identified with the ability to activate NRF2 through
KEAP1 inhibition is represented by triterpenoids [68]. These molecules can bind to KEAP1 and
induce a conformational change that prevents its association with NRF2, promoting its target genes
transactivation. Among the others, 2-cyano-3,12-dioxooleana-1,9(11)-diene-28-oic acid (CDDO) is a
synthetic derivative of the natural triterpenoid oleanolic acid with a very potent (low nanomolar doses)
activating capacity on various NRF2-regulated proteins [66]. CDDO has received much attention due
to its ability to hamper the development of certain tumors [66,69]. Despite KEAP1 contains 15 cysteine
residues susceptible of modification by electrophilic compounds, each electrophile targets its unique
series of residues, a phenomenon referred to as the “cysteine code” [70]. A key cysteine in the binding
of triterpenoids to KEAP1 is C151 [70–72]. However, in order to improve potency, specificity and
reduce potential side effects of CDDO, Methyl ester (CDDO-Me) and imidazole (CDDO-Im) derivatives
have been subsequently developed. Both compounds have shown promising results, as they are
able to activate NRF2 and stimulate ARE-expression at low doses [73,74]. Of note, the ability of the
triterpenoids electrophilic region to react with thiol groups of many proteins and other thiol-containing
molecules underscores the potential side effects associated with their use. For example CCDDO-Im
has been shown to bind to mitochondrial glutathione (GSH), resulting in GSH depletion, increased
oxidative stress, and increased NRF2 activation [75]. Although triterpenoids have therapeutic action at
relatively low concentrations, the risk of serious side effects cannot be excluded.
The compound D3T (3H-1,2-dithiole-3-thione) has been shown to increase the nuclear accumulation
of NRF2, an effect mediated in part by the activation of the ERK 1/2 pathway [76]. ERK 1/2 inhibition
blocked the activation of NRF2 and the effects observed on other ARE-induced gene expression were
similar for oltipraz, another dithiolethione, as well as the natural NRF2-activator, sulforaphane [76].
NRF2 also controls the expression of several isoforms of the multidrug resistance-associated protein
(MDR), a molecular pump that extrudes chemicals outside the cells. Indeed, it has been show that the
administration of oltipraz or butylated hydroxyanisole resulted in a clear upregulation in the MDRs
expression as a consequence of NRF2 activation [77].
Non-Electrophilic/Non-Covalent NRF2 Activators
Recent studies have examined the therapeutic benefits provided by non-covalently bound
non-electrophiles as NRF2 activators, since electrophilic compounds can have side effects and reduce
the activity of certain proteins [78]. Binding studies revealed that cysteine 151 (C151) was an important
target since non-covalent binding to this site promoted cell protection, while in contrast covalent binding
to this residue enhanced cell toxicity [78]. Zhang et al., recently undertook a comprehensive analysis of
nearly 200 chemicals to isolate potential non-electrophilic activators of NRF2. The list was initially
shortened to 86 candidates and subsequently further reduced to only 22 molecules, after the exclusion
of compounds having an electrophilic reactive site. Based on their structures, the chemicals were
placed into one of seven groups consisting of: I—phenothiazine; II—tricyclics; III—trihexyphenidyl;
IV—phenyl pyridine; V—quinolin-8-substituted; VI—tamoxifen substituted; and VII—hexetidine.
The results indicated that each class was able to induce some level of NRF2-mediated increase in
ARE-dependent protein expression [79]. These changes varied between class and protein, but the
systematic approach used to identify biologically active non-electrophilic NRF2 activators opened many
prospects for future development. Another non-covalent small molecule activator of NRF2, RA839,
was shown to activate several pathways related to NRF2 signaling in bone marrow macrophages [80].
Investigations aimed to identify, develop, and then marketing a new non-covalent NRF2 activator
have been hindered by the low affinity and low potency of existing compounds compared to the
covalent agents. However, one potential activator with low toxicity, but still therapeutic utility is
monomethylfumerate (MMF) [59]. Another fumarate-based compound that has demonstrated promise
is dimethyl fumarate (DMF) [81,82]. In addition to screening strategies of existing chemicals based
on their structure and their potential use as non-electrophilic NRF2 activators, other studies are
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underway to find novel compounds. Chemicals that have a naphthalene moiety have shown promise
as non-electrophilic NRF2 activators. Exposure of lung epithelial cells to various naphthalene-based
chemicals led to a marked increase in the expression of several antioxidant enzymes, such as quinone
oxidoreductase (NQO1) and heme oxygenase 1 (HO-1), elicited by NRF2 activation [83]. Few of
these new compounds were of similar potency to sulforaphane, an electrophilic NRF2 activator,
in stimulating the expression of these antioxidant proteins.
2.2.2. Natural Compounds
A 2016 review systematically examined the activation of NRF2 by dietary factors, but also extended
these findings to discuss how diet changes may restrict the nutritional utility of some activators [84].
A natural marine-based compound, honaucin A, obtained from cyanobacteria, has been reported to
have anti-inflammatory properties both in vivo and in vitro. Only recently have investigators begun
to focus on the pathways activated by this compound. Honaucin A forms a covalent bond with
the sulfhydryl groups on KEAP1, resulting in the activation of NRF2 [85]. Many food-based NRF2
activators have been shown to work in multiple organs such as liver [86], lung [87], kidney [88],
brain [89] and gastrointestinal tract [90]. Most of these NRF2 activating compounds are phenol,
polyphenol, or triterpenoid. The use of compounds found in ordinary foods and spices has been an
area of great interest in the last 20–25 years. For example, the spice curcumin, from turmeric and
ginger family, has been reportedly used to treat a variety of disorders. Yet, little work has been done to
fully understand the pathways associated with the therapeutic benefits induced by these chemicals.
Recently, an entire book was dedicated to the beneficial actions of curcumin (The Molecular Targets and
Therapeutic uses of Curcumin in Health and Disease, 2007). Several investigators focused on the molecular
targets of curcumin, including NRF2, on curcumin action, and its uses as a neuroprotective agent
against toxicants inducing oxidative stress but also as an antitumor agent [91–93]. The molecular
action is non-specific with multiple systems and pathways being affected, including the involvement
of NRF2 [94]. Other compounds have been examined with mixed results including silibinin, the active
chemical from the milk thistle, and resveratrol, a biologically active compound from the skins of
various grapes and berries. Both of these molecules have been limited in their usefulness in humans,
due to mostly equivocal findings. Resveratrol has been reported to attenuate oxidative damage in the
liver by increasing the expression and activity of antioxidant enzymes [95,96]. Silibinin has been shown
to decrease metastasis by decreasing the activation of the PI3K-Akt and MAPK (mitogen-activated
protein kinase) pathways in the lung [97], and to enhance apoptosis in colon cancer [98]. From previous
reports, the effects of resveratrol and silibinin on the NRF2 pathway appear to be debatable and might
depend on direct as well as indirect effects.
Foods containing compounds with positive effects on human health are sometimes referred
to as “nutraceuticals.” One chemical class found in cruciferous vegetables is represented by the
isothiocyanates, that include compounds such as sulforaphane, isolated from broccoli, cauliflower,
cabbage, and Brussel sprouts. The role of sulforaphane in ameliorating various health-related disorders
has received a lot of attention, and some of its biological effects were described in 1992 [99]. The utility
of a given compound in a clinical setting is dictated by several properties such as its bioavailability,
potency, and interactions with other drugs. Some aspects of the sulforaphane effects within the body
suggest that there could be some level of clinical utility under certain circumstances [100]. A recent
review describes the multiple pathways affected by sulforaphane administration in reducing tumor
growth, indicating that the NRF2-KEAP1 pathway was a critical targeted [101]. Sulforaphane is
highly electrophilic due to a reactive carbon in the isothiocyanate group that readily reacts with
many nucleophiles containing a sulfur, nitrogen, or oxygen center. By targeting the sulfhydryl
groups of KEAP1, sulforaphane can non-covalently bind to these reactive groups, resulting in NRF2
activation [101]. Sulforaphane can also activate antioxidant response elements (AREs) associated
with NRF2 [102]. Some of the activated redox regulators include glutathione S-transferase, catalase,
glutathione peroxidase, and peroxiredoxins. To improve the functionality of food-based chemicals, it is
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common to use the parent compound as the “backbone” and then to develop modified versions of the
parent endowed with greater efficacy, potency, and possibly also reduced side effects. An example is a
modified sulforaphane, 6-methylsulfinylhexyl isothiocyanate (6-HITC), which was more potent than
sulforaphane in increasing the expression and activity of various AREs in lung epithelial cells [103].
Curiously, not all the effects of sulforaphane are mediated by the NRF2-KEAP1-ARE pathway. Indeed,
sulforaphane can inhibit multiple inflammasomes, sensor systems that activate pro-inflammatory
mediators, as it was recently shown in macrophages and fibroblasts [104]. The mechanisms of action
for sulforaphane and isothiocyanate is complex and may involve multiple mediators. A critical
consideration is also the cell/organ type taken into consideration. Additional research is needed to
help to clarify some of the nutraceutical pathways to better assess their in vivo benefits.
2.3. Potential Use of NRF2 Activators in Cancer Therapy
Whereas new findings indicate that NRF2 plays a dual role in cancer ([26,105,106], the potential
use of NRF2 activators in cancer prevention and therapy needs to be further elucidated. It is widely
accepted that effective chemoprevention should encompass induction of cytoprotective and detoxifying
enzymes. Therefore, the use of compounds able to activate NRF2-KEAP1 pathway and induce
genes involved in antioxidant defense appears to be a possible strategy in both cancer prevention and
therapy [64]. As explained above, NRF2 activators fall into the class of electrophilic and non-electrophilic
compounds [66] and can be of natural origin or semisynthetic/synthetic analogs [64]. As reviewed by
Sanders et al. [107], phenolic and sulfur-containing compounds are the most promising agents in cancer
prevention. Phenolic compounds such as curcumin and resveratrol exert their chemopreventive effect
via activation of NRF2-KEAP1 signaling that induces phase-II detoxifying and antioxidant enzymes
(20638930). Curcumin, a common spice obtained from the rhizomes of Curcuma longa (turmeric),
was shown to induce the expression of antioxidant enzymes such as glutathione S-transferase,
aldose reductase, and HO-1 through NRF2-KEAP1 signaling [108]. Apart from covalent modification
of KEAP1 [109], activation of upstream kinases such as MAPK seems to be an additional mechanism of
NRF2 activation [110,111]. However, the therapeutic success of this compound has been hampered by
its limited bioavailability and rapid metabolism, the poor pharmacokinetic properties [112] and the
lack of conclusive toxicity data [113]. Some studies reporting therapeutic uses of curcumin in various
diseases including cancer are illustrated in Table 2. Resveratrol is a natural compound contained in
edible plants and fruits such as grapes, peanuts, berries, and soy with the reported capacity to increase
the NRF2 levels and promote its nuclear translocation. Resveratrol monomer has been shown to induce
phase-II detoxifying enzymes by activating NRF2 signaling in several human cancer cell lines [114,115]
and to protect from carcinogenicity derived from bioactivated carcinogens [116]. In contrast, the effects
induced by its dimers are poorly understood although the monomer and the dimers have been reported
to act differently in terms of NRF2/ARE induction [117]. Table 2 illustrates some recent in vitro and
in vivo studies reporting the chemotherapeutic use of resveratrol. However, similarly to curcumin,
its poor bioavailability and rapid clearance, made it necessary to develop analogs with improved
pharmacokinetic properties and higher potency [64]. On the other hand, green tea polyphenols such as
(-)-epigallocatechin-3-gallate (EGCG) and (-)-epicatechin-3-gallate (ECG) are known NRF2 activators
showing potent induction of ARE-mediated luciferase activity [118]. EGCG potentiates cellular
defense capacity against chemical carcinogens, UV, and oxidative stress via NRF2-mediated induction
of genes codying for antioxidant or phase-II detoxifying enzymes, modulators of inflammation,
cell growth, apoptosis, cell adhesion etc. [119]. However, it has been shown that EGCG has dual effects
on NRF2-mediated ARE activation depending on its concentration, with higher doses producing
down-regulation and lower doses enhancing HO-1 expression [118,120]. Table 2 summarizes the
results of some studies exploring the potential role of EGCG in the treatment of different pathological
conditions. Other potential chemopreventive agents that exert their properties through NRF2/ARE
pathway are sulfur-containing compounds, such as sulforaphane, contained in cruciferous vegetables
and diallyl sulfide derived from garlic [121,122]. In comparison with curcumin and resveratrol,
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sulforaphane exhibits more potent activation of NRF2 and significantly better bioavailability due
to its lipophilic nature and low molecular weight [123–125]. Preclinical and clinical evaluation of
sulforaphane in breast chemoprevention revealed the presence of its metabolites in the rat mammary
gland after a single oral administration at concentrations known to alter gene expression and also in
human breast tissue after a single dose of broccoli sprout in healthy women undergoing reduction
mammoplasty [126]. These findings provided a strong rationale for evaluating the protective effects
of a broccoli sprout preparation, claiming sulforaphane as a good candidate in the adjuvant therapy
based on natural molecules against several types of cancer [127]. However, some studies indicate
that this compound might exert pro-survival effects in cancer cells [128] and potentially interfere with
the successful application of immunotherapy [129]. Table 2 contains some of the studies conducted
in this field. In a recent review [130] discussing potential combinations of a conventional anticancer
drug (cisplatin or doxorubicin) and a known antioxidant (sulforaphane or curcumin), it has emerged
the necessity of preclinical evidence confirming that the natural compounds can potentiate the
anti-cancer effect of traditional drugs but also reduce the side toxicity in normal tissues. A review
by Robledinos-Anton et al. [65] provides the information on current clinical trials in progress based
on NRF2 activators and their potential clinical use in various chronic disorders, including cancer.
Namely, sulforaphane is in the phase-II clinical trial for the use in treatment of prostate cancer [131]
(NCT01228084) and for breast cancer [132] (NCT00843167), while it has entered the phase-II for
lung cancer prevention (NCT 03232138). Also, curcumin has entered phase-III for the treatment
of prostate cancer [133] (NCT02064673) and resveratrol is in the phase-I for the treatment of colon
cancer [134] (NCT00256334). In an attempt to improve their biological activity, many semisynthetic
and synthetic NRF2 activators have been synthesized and these substances are preferentially used in
clinical practice compared to the natural counterpart. For example, Bardoxolone methyl (CDDO-Me),
a semisynthetic triterpenoid with the ability to protect cells and tissues from oxidative stress by
increasing the NRF2 transcriptional activity, has demonstrated its efficacy as an anticancer drug
in different mouse model [135]. So far, three clinical trials focusing on the use of CDDO-Me in
cancer treatment have been registered. In a phase-I clinical trial investigating the tolerability, safety,
efficacy and pharmacokinetics of CDDO-Me in advanced solid tumors and lymphoid malignancies,
complete response was observed in a patient with mantle cell lymphoma and partial response in
a patient with anaplastic thyroid carcinoma [136]. However, phase-III of the clinical trial designed
to investigate the efficacy of CDDO-Me in patients with stage 4 chronic kidney disease and type 2
diabetes revealed significant increase of heart failure within four weeks of treatment [137]. In any case,
since no evidence of direct cardiotoxicity was found [138,139], trials on this compound are still ongoing.
Another triterpenoid analog, omaveloxolone, has been selected for cancer treatment in three clinical
trials, out of which one is ongoing. Early clinical trials for the treatment of melanoma and NSCLC have
been giving promising results [140]. Dimethyl fumarate (DMF) is a synthetic NRF2 activator which
has already been used for the treatment of multiple sclerosis [141] and is currently tested in a number
of clinical trials, mainly investigating its efficacy in lymphoma, leukemia and melanoma. However,
it should be emphasized that DMF can also exert NRF2-independent effects, suggesting that its activity
might also rely on alternative pathways as evidenced by a recent study [142]. Finally, Oltipraz is an
organosulfur compound which has also entered clinical trials, namely phase-I trial to study its efficacy
in preventing lung cancer in smokers (NCT00006457). However, further clinical trials are needed
to confirm or challenge its possible use as a chemopreventive agent. In conclusion, while the list of
natural, semisynthetic and synthetic NRF2 activators is steadily increasing, it is evident that the drug
development is moving slowly due to the pleiotropic effects of NRF2 activators. More studies on
detailed molecular mechanisms are necessary for their possible application in cancer chemoprevention,
especially in consideration of the possible oncogenic role of NRF2 in cancer cells.
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3. NRF2 in Cancer Promotion and Therapeutic Implications
3.1. Pro-Oncogenic Roles of the NRF2-KEAP1 Pathway
Given that NRF2 promotes cell survival in stress conditions [143], it is consequently accepted that
enhanced NRF2 activity can be tumor promoting through several molecular mechanisms that protect
cancer cells (Figure 3). This is a way by which cancer cells gain advantages over the normal cells, such as
enhanced tumorigenic capacity, resistance to therapeutic agents and increased antioxidant activity
leading to “NRF2 addiction” that turns this cellular guardian into a cancer driver [3]. Several important
studies suggest that common oncogenes, such as KRAS, BRAF, and MYC, can directly promote the
transcription of NRF2 through the modulation of signaling pathways such as the Raf-MEK-ERK-Jun
cascade [14,53,144]. This overactivation of NRF2 leads to enhanced cytoprotective activity and,
remarkably, to a decrease in ROS levels. Thus, probably oncogenes partly boost cancer development
through an NRF2-dependent creation of a more favorable intracellular milieu for tumor cells selection.
Constitutive activation of NRF2 in cancer promotion and the mechanisms that lead to this condition, are
under debate. Many researchers have spotted cancer-associated mutations that activate NRF2 [145–150].
Mutations in NRF2 that lead to gain-of-function can be detected mainly in squamous cell carcinomas
of the oesophagus, lung, larynx, and skin [151]. Additionally, aberrant NRF2 activation in cancer cells
leads to remarkably increased expression of TKT and G6PD metabolic enzymes that contribute to
metabolic reprogramming and cell proliferation [53]. Other evidence indicates that deficiencies in
autophagy, and therefore activation of NRF2 and overexpression of p62, might promote induction of
hepatic tumors [152]. As for the hormone related cancers, it has been reported that specific hormones
lead to significant upregulation of NRF2 in ovarian cancer cell lines [153]. Epigenetic modifications
seem to control the expression of KEAP1/NRF2 system and therefore it is important to investigate this
type of regulation in cancer [154–156]. Another major topic is the enhancement of chemoresistance
and radioresistance in cancer cells. For example, overactivation of NRF2 by pretreatment with a
synthetic antioxidant was found to increase the survival of neuroblastoma cells treated with three
chemotherapeutic drugs [157]. Finally, it has been demonstrated that radiation therapy leads to
generation of ROS and depletion of GSH, frequently causing enhanced synthesis of antioxidant
enzymes such as GCLC, HO-1 and TXRD1 by NRF2 activation, as reported in a recent study on
prostate cancer cells [158]. One question that needs to be addressed, however, is whether the increase
in NRF2 levels is a key step in cancer development. The existing body of evidence suggests that KRAS
and BRAF increase the levels of JUN that in turn binds to well-known transcription starting sites of
NRF2 promoting its induction. This finding suggests that some of these effects can be direct [14].
Moreover, many findings indicate that ROS levels should be suppressed in order to prevent cancer
development due to their involvement in promoting and sustaining carcinogenesis [62,159]. It has
also been proposed that utilizing drugs that boost ROS production can be an effective way of killing
cancer cells [160]. Concomitantly, it is of utmost importance to determine the specific pathways and the
equilibrium between ROS and NRF2 so as to elucidate the paradoxical role of KEAP1/NRF2 pathway
in cancer. A schematic illustration of the pro-oncogenic functions of NRF2 is presented in Figure 3.
In the following sections we will describe more in detail some of the most relevant hallmarks of cancer
cells that are regulated by NRF2 activation.
3.1.1. Sustained Proliferation
The KEAP1-NRF2 pathway is a vital defense system against oxidative and electrophilic
stress in normal cells as well as cancer cells that use it to foster their unrestricted growth [3].
Temporary activation of NRF2 is critical for the survival of non-cancerous cells and protection
against carcinogenesis [161]. However, constant activation of this pathway is detrimental especially
in a cancerous context since NRF2 exerts a pro-tumoral function by supporting sustained cancer
cells proliferation through various mechanisms [3]. Studies with lung cancer, pancreatic cancer,
and hepatocellular carcinoma cell lines showed that NRF2-KEAP1 status directly affects their
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proliferation rates since NRF2-negative cells proliferate slower, while KEAP1-deleted cells proliferate
faster than their wild type counterparts [162–164]. Moreover, NRF2 was seen to promote oncogenic
K-RasG12D-initiated tumor formation and proliferation of pancreatic and lung cancers in vivo and
K-RasG12D, BRAF V619E, and MYC-induced NRF2 transcription [14,165]. The role of NRF2 on
cancer cell proliferation relies on the functions of the genes regulated by its own transcriptional
activation [166]. The genes that regulate the proliferative capacity of normal cells such as NOTCH1,
NPNT, BMPR1A, IGF1, ITGB2, PDGFC, VEGFC, and JAG1 are known NRF2 targets and contribute
to cancer cells survival [51]. On top of these genes, NRF2 also regulates the expression of genes
needed to fulfill the constant demand of protein synthesis of cancer cells such as PHGDH, PSAT1,
PSPH, SHMT1, and SHMT2 by activating the critical effector ATF4 [51,167]. Apart from increased
protein synthesis, highly proliferating cells also require energy and small building blocks to synthesize
other macromolecules [168]. In this context, NRF2 regulates the expression of enzymes such as
G6PD,TKT, TALDO1, PPAT, MTHFD2, IDH1, and ME1 in lung cancer cells [53]. Furthermore, NRF2 is
involved in the regulation of genes required for the synthesis of GSH (reduced glutathione) and
NADPH (reduced Nicotinamide adenine dinucleotide phosphate), two crucial molecules for cell
proliferation [169]. Besides glucose metabolism, NRF2 also regulates genes involved in fatty acid
and lipid metabolism [170]. There is also evidence of indirect involvement of NRF2 on cancer cell
proliferation by regulating several non- coding microRNAs, such as mir-1 and miR-206. These miRNAs
normally inhibit TKDT and G6PD genes, and their repression by HDAC4 through NRF2 supports
cancer cells growth [171]. In summary, it is clear that the increased activation of NRF2 allows
cancer cells to proliferate faster as a consequence of cytoprotective genes induction and metabolic
reprogramming [168]. Due to the advantages granted by its activation, the cancer cells acquire a
phenotype of “NRF2 addiction” which is characterized by aberrant NRF2 accumulation in both murine
and human cancers [3]. Thus, the impairment of NRF2 pathway is expected to repress tumor growth,
and this is the basis of developing drugs against NRF2 in a context-dependent manner for the targeted
therapy of various cancers [172].
3.1.2. Angiogenesis Induction
The presence of constantly growing cells in tumor microenvironment causes depletion of oxygen
and nutrients and creates an urgent need for a continuous supply of blood flow to fulfill the increased
metabolic demand and to remove wastes and carbon dioxide [173]. Hypoxic tumor microenvironment
induces the expression of VEGF through the transcription factor HIF-1a for the generation of new blood
vessels, a process known as angiogenesis [174]. Other than VEGF, PDGF, angiopoietin, angiogenin and
extracellular matrix elements participate also to the regulation of angiogenesis [175]. NRF2 modulates
angiogenesis by itself and through its targeted genes [176]. Depletion of NRF2 decreases the levels of
HIF-1a, which in turn causes reduction of blood vessels formation through regulation of VEGF in rat
gastric epithelial cells, glioblastoma and colon cancer xenograft models [177–179]. In recent studies,
it was reported that regulation of VEGF by NRF2 also depends on PI3K/AKT/mTOR pathways in
endothelial cells [180,181]. These data suggest that both proliferative and pro-angiogenic effects of
PI3K/AKT/mTOR and NRF2 pathways cooperate in favor of cancer cells. NRF2 also indirectly regulates
HIF-1a levels by preventing its proteasomal degradation by the aid of NQO1 [161,182]. Angiogenesis is
also regulated by common effectors of NRF2 and HIF1a including HO-1, platelet-derived growth factor
(PDGFC), and fibroblast growth factor (FGF2) [183–185]. Among these genes, HMOX1 was shown to
promote angiogenesis in various cancers such as glioma, pancreatic cancer, and melanoma [176,186].
Intriguingly, there is an interplay between NRF2 and HIF1-a pathways since VEGF can in turn activate
NRF2 via ERK1/2 signaling [187]. Another evidence supporting the crosstalk between NRF2 and
HIF-1a pathway comes from the recent data showing that PIM kinases, upstream regulators of HIF-1a,
promote NRF2 nuclear accumulation in response to hypoxia and in normoxia, leading to increased
cancer cells survival in the hypoxic tumor microenvironment [188]. In conclusion, the induction of
angiogenesis can be counted as one of the critical roles of NRF2 in promoting tumorigenesis.
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Figure 3. NRF2 rewires cancer cells metabolism to support the redox homeostasis. The enzymes marked
in red are positively regulated while those in green are negatively modulated by NRF2. NADPH
(reduced Nicotinamide adenine dinucleotide phosphate) production is indicated in violet while NADPH
consumption in black. The abbreviations are: ACC1, Acetyl-CoA Carboxylase 1; ACL, ATP-Citrate
Lyase; CPT, Carnitine PalmitoylTransferase; ELOVL, fatty acid Elongase; FADS, Fatty Acid Desaturase;
FASN, Fatty Acid Synthase; G6PD, Glucose-6-Phosphate Dehydrogenase; GCLC, Glutamate-Cysteine
Ligase, Catalytic subunit; GCLM, Glutamate-Cysteine Ligase, Modifier subunit; GLS, Glutaminase;
GS, Glutathione Synthetase; IDH1, Isocitrate Dehydrogenase 1; ME1, Malic Enzyme 1; MTHFDL,
MethyleneTetraHydroFolate Dehydrogenase 2; PGD, 6-phosphogluconate dehydrogenase; PHGDH,
phosphoglycerate dehydrogenase; PPAT, phosphoribosyl pyrophosphate amidotransferase; PSAT1,
phosphoserine aminotransferase; PSPH, phosphoserine phosphatase; SCD1, stearoyl CoA desaturase;
SHMT 1-2, serine hydroxymethyltransferase 1 and 2; TALDO, transaldolase; TKT, transketolase; TXN,
thioredoxin; UCP3, uncoupling protein 3; xCT, glutamate/cystine antiporter. G6P, glucose-6-phosphate;
F6P, fructose-6-phosphate; F1,6BP, fructose-1,6-bisphosphate; GA3P, glyceraldehyde-3-phosphate; 3PG,
3-phosphoglycerate; PEP, phosphoenol pyruvate. PPP: 6PGL, 6-phosphoglucono-d-lactone; 6PG,
6-phosphogluconate. PRPP, 5-phospho-D-ribosyl-1 pyrophosphate; IMP, inosine monophosphate.
Ser/Gly synthesis: 3PHP, 3 phosphohydroxypyruvate; 3PSer, 3-phosphoserine; THF, tetrahydrofolate;
MTHF, methylenetetrahydrofolate; 5,10-FTHF, 5,10-methenyl-tetrahydrofolate. b-Oxidation: Acyl-CoA,
acyl-coenzyme A; Ac-CoA, acetyl-coenzyme A. FA, fatty acid. GSH, glutathione, reduced.
3.1.3. Resistance to Apoptosis
NRF2 protects healthy cells from endogenous ROS and is a critical regulator of drug metabolism
and antioxidant enzymes [21,46]. NRF2 leads to diminished apoptosis and increased drug
resistance [189,190]. Inhibition of NRF2 signaling enhances apoptosis in response to oxidative
insults [105,191]. Conversely, activation of NRF2 by chemopreventive agents decreases the number of
apoptotic cells [192–194]. There are many studies showing elevated expression of NRF2 in various
types of tumors such as non-small cells lung cancer (NSCLC), esophageal squamous cell cancer
(ESCC), gastric cancer (GC), head and neck cancer (HNC), breast cancer (BC), ovarian cancer (OC),
and endometrial cancer (EC) [46]. NRF2 signaling is activated during malignant transformation in
response to radiotherapy/chemotherapy and it protects cancer cells from cell death by upregulating
a number of ROS-scavenging enzymes that counterbalance the increased ROS production [195].
Moreover, NRF2 allows the cancer cells to escape death by cooperating with other pathways playing
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a role in apoptosis regulation. For instance, the tumor suppressor p53 inhibits NRF2 signaling by
down regulating the expression of NRF2 target genes such as x-CT, NQO1, and GST1 and triggers
cell cycle arrest and apoptosis [196–198]. Under mild cellular stress conditions, the p21 protein,
a major p53 target, binds to the DLG motif and prevents KEAP1-mediated NRF2 proteasomal
degradation, activating the antioxidant response [199]. Additionally, other studies have shown that
mutant p53 leads to constitutive NRF2 activation without affecting its expression and enhances
cancer cells survival [200,201]. Glutathione-S-transferase pi 1 (GSTP1) is one of the downstream
targets of NRF2 that inhibits proapoptotic c-Jun N-terminal kinases (JNKs) activity and promotes
cell survival [202]. Importantly, p62 is another NRF2 target, which mediates autophagic degradation
of KEAP1 and therefore enhances NRF2 stability, suppressing apoptosis [203]. Finally, Bcl-2 is a
well-known anti-apoptotic protein that promotes increased cell survival and drug resistance [204,205].
NRF2 upregulates Bcl-2 expression through direct binding of the ARE sequence on its promoter,
which induces oncogenesis [206]. All of these studies indicate that NRF2 plays a critical role in tumor
survival and drug resistance through the inhibition of apoptosis via different pathways.
3.1.4. NRF2 Signaling in Metastasis
Epithelial to mesenchymal transition (EMT) is a biological process that contributes to cancer
metastasis and tissue invasion [207,208]. During EMT, the expression of E-cadherin and other
epithelial phenotype-related genes is repressed while conversely the expression of mesenchymal
phenotype-related genes such as vimentin and N-cadherin is activated by EMT regulators (Snail,
Slug, Twist, Zeb, etc.) [209,210]. As a result, epithelial cells turn into mesenchymal cells by losing
their cell–cell adhesion and cell polarity features and acquiring invasive and metastatic properties.
Constitutively active NRF2 has been shown in human cancers with higher metastatic capacity [211].
In addition, the correlation of NRF2 expression with cancer progression, metastasis and drug resistance
has been reported in many different studies [14,15,46,212]. NRF2 promotes EMT and invasion in
pancreatic adenosquamous carcinoma cells through downregulation of E-cadherin gene expression [213].
NRF2 knockdown (KD) increases E-cadherin expression and downregulates N-cadherin and matrix
metalloproteinase 2 and 9 (MMP2, MMP9) genes expression and reduces migration and invasion
capacity of NSCLC cells [214]. Overexpression of NRF2 in BC cells promotes cell proliferation and
metastasis via activating NRF2 target gene NOTCH1 that in turn induces the expression of genes
promoting EMT [215]. NRF2 also positively regulates the RhoA gene, which is a critical factor for growth
and metastasis, while NRF2 down regulation inhibits proliferation of BC cells [216]. Furthermore,
recent findings demonstrate that NRF2 expression is upregulated in human hepatocellular carcinoma
(HCC) and that NRF2 promotes proliferation and tumor metastasis by regulating Bcl-xL and MMP-9
genes expression [164]. In contrast, other studies have shown that low expression levels of NRF2 also
play a critical role in cancer progression and metastasis formation. In human prostate cancers (PC),
NRF2 and its target genes were shown to be significantly decreased during the metastatic process [217].
Additionally, it has also been reported that repression of NRF2 in HCC cell lines increased cell metastasis
and invasiveness via TGF-β/Smad-dependent signaling [218]. Moreover, NRF2 deregulation was also
shown in other cancers like OC, lung adenocarcinoma (LUAD), human head and neck squamous
cell carcinoma (HNSCC) [217,219]. Taken together, all these studies demonstrate that NRF2 has both
metastatic and anti-metastatic activity in different types of tumor and stages of cancer progression.
It seems like cancer cells utilize both upregulation and downregulation of NRF2 signaling for their
advantages. To interfere with cancer metastasis, it will be necessary to fully elucidate the role of NRF2
expression in the metastatic microenvironment.
3.1.5. Metabolic Reprogramming by NRF2: NADPH Links Tumor Growth and Redox Balance
It is well known that cancer cells reprogram their central metabolism to meet the energetic
needs imposed by their uncontrolled growth. Initial studies mainly focused on the Warburg
effect, while subsequent work also investigated changes in the one-carbon and fatty acids
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metabolism, pentose phosphate pathway (PPP), tricarboxylic acid cycle (TCA) and glutamine
catabolism [173,220,221]. In general, NRF2 can control multiple metabolic routes by two different
mechanisms, similarly to other oncogenes (e.g., MYC or KRAS): the first involves direct transactivation
of key metabolic enzymes [222], while the second relies on the modulation of proteins controlling
other signaling pathways such as PPARγ [223], Notch [215,224], AHR [225,226] and PI3K/AKT [53].
It is known that alterations of tumor metabolism are often paralleled by an increased antioxidant
capacity, which is also part of the adaptive response mounted by cancer cells to face adverse
conditions, including OS [173,227–230]. With this respect, certain metabolic reactions can play a dual
role, providing intermediates for biosynthetic processes or essential cofactors used to modulate the
intracellular redox balance [231–235]. Among them, NADPH represents a key player in supporting
anabolic reactions and ROS-scavenging antioxidant systems. As first, NADPH is essential for
the regulation of the glutathione/glutaredoxins (GRXs) system, that regenerates the reduced form
of glutathione (GSH) once it is oxidized (GSSG) [236]. Secondly, NADPH is a key cofactor for
the glutathione peroxidases (GPXs) that scavenge hydrogen peroxide or potentially harmful alkyl
hydroperoxides. Lastly, NADPH is indispensable for the thioredoxin reductases (TRXRs), a class of
enzymes that restore the reduced form of thioredoxins (TRXs) and indirectly contribute to the regulation
of thiol groups in redox-sensitive proteins [237,238]. Importantly, NRF2 can enhance the expression of
genes codying for NADPH-producing enzymes such as G6PD (Glucose-6-Phosphate Dehydrogenase)
and PGD (Phospho Gluconate Dehydrogenase), or enzymes that regenerate glycolytic intermediates
that can be diverted into the oxidative PPP branch, such as TKT (Transketolase) and TALDO1
(Transaldolase-1) [53,182,215,239]. Mechanistically, either direct or indirect genes transactivation
can occur, depending on the genetic and biological context of NRF2 activation. Indeed, by using
H1437, A549 NSCLC and DU145 PC cells, Singh et al., reported that genetic induction of PPP genes
was mediated by NRF2-dependent repression of miR-1 and miR-206, two negative regulators of
G6PD, PGD and TKT expression, through yet unknown epigenetic mechanisms involving the histone
deacetylase HDAC4 [240]. Also miR-1 inhibition was found to underlie NRF2-mediated upregulation
of G6PD in HCC cells, an event that positively correlated with grading, metastasis number and
poor prognosis in HCC patients [241]. Instead, a direct induction of G6PD, PGD, TKT, TALDO1 and
other NADPH-producing enzymes was reported in A549 NSCLC cells with sustained PI3K/AKT
pathway activation [53], in agreement with previous ChIP-seq studies [48,182,242]. Also, Xu et al.,
demonstrated that NRF2 can bind to the AREs within intron 1 and 4 of the TKT gene, inducing its
expression in HCC cells (SMMC and MHCC97/L) [239]. Consistently, the presence of functional
NRF2 binding sites within the AREs of the TKT promoter was also reported in MEFs and A549
NSCLC cells, suggesting a direct transactivation mechanism [240]. Also, other data indicate that
NRF2 overexpression or KEAP1 KD can upregulate the mRNA and protein levels of G6PD and
TKT, enhancing tumor proliferation, migration and invasion of MCF7 and MDA-MB-231 BC cells
by promoting EMT through G6PD/HIF-1α activation of Notch1 signaling, while NRF2 silencing or
KEAP1 overexpression reverted these changes [215]. Interestingly, some studies suggest that NRF2 can
control the expression of NADPH-producing enzymes involved in one-carbon metabolism such as
MTHFD2 (Methylenetetrahydrofolate Dehydrogenase 2) or in the TCA cycle, such as IDH1 (Isocitrate
Dehydrogenase 1) and ME1 (Malic enzyme 1) [53,239,243], while others indicate that NRF2-dependent
induction of the folate-cycle enzyme MTHFDL1 (Methylenetetrahydrofolate Dehydrogenase 1-like)
can increase the NADPH levels in HCC cells, supporting proliferation and redox homeostasis [58].
3.1.6. NRF2 Regulates Metabolic Processes Leading to GSH Synthesis and TCA Cycle Anaplerosis
In line of principle NRF2 can also regulate the redox balance of cancer cells via transcriptional
induction of metabolic enzymes or membrane channels that control the availability of cysteine,
glutamate and glycine, essential precursors in the GSH synthesis. In this regard, NRF2 was
shown to enhance the expression of key enzymes for serine/glycine biosynthesis such as PHGDH
(Phosphoglycerate Dehydrogenase), PSAT1 (Phosphoserine Aminotransferase 1), PSPH (Phosphoserine
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Phosphatase) and SHMT1-2 (Serine Hydroxymethyltransferase 1-2) in a panel of NSCLC cells [167].
Also, a recent work underlined the importance of the NRF2-ATF4 pathway in the regulation of
aminoacid metabolism in cancer. Indeed, NRF2 was seen to enhance the ATF4 transcriptional activity
in autophagy-deficient HCT116 CRC cells, promoting the expression of genes (SLC6A9, SLC36A4,
SLC38A1, and SLC38A3) codying for AATs (aminoacid transporters) involved in the uptake of glycine
and glutamine. Notably, AATs inhibition sensitized autophagy-deficient CRC cells but not wild-type
cells to apoptosis induced by glutamine withdrawal [244]. Other work has focused on xCT, an antiporter
that couples the efflux of glutamate with the uptake of cystine (CySS), that is intracellularly reduced to
cysteine (2x Cys) by GSH, TRX1 or TRP14 [245–249]. For example, Habib et al., showed that in MCF7
BC cells exposed to OS, an enhanced NRF2 nuclear translocation was responsible for the SLC7A11
(solute carrier family 7 member 11) gene upregulation, leading to an increase in the xCT mRNA and
protein levels and marked glutamate release. Of note, these changes were phenocopied by NRF2
overexpression or KEAP1 KD and reverted by its overexpression [250]. In a later study, NRF2 and
SLC7A11 expression was found to be positively correlated across 947 cancer cell lines from the CCLE
dataset [251], especially within 59 different BC cell lines. Here, NRF2 KD markedly decreased SLC7A11
expression and glutamate extrusion in Hs578T and MDA-MB-231 BC cells, improving cell viability
upon glucose depletion while in the same conditions NRF2 activation by DMF impaired cell viability.
Thus, despite the enhanced activation of the NRF2-xCT axis might efficiently preserve the redox
homeostasis of BC cells under OS, it might also decrease their metabolic flexibility, unveiling a specific
vulnerability that can be therapeutically exploited [252]. In a study on human melanoma cells with
constitutive BRAF activation (BRAFV600E), Khamari et al., explored potential metabolic changes
promoting resistance (A375RIV1 cells) or sensitivity (A375-v cells) to the BRAF inhibitor Vemurafenib,
by using an in vivo long-term treated xenograft mouse model. Here, A375RIV1 cells exhibited a
strong activation of the NRF2 signaling, followed by an increased expression of genes involved in ROS
scavenging (i.e., GPX1, GPX2), GSH synthesis (i.e., GCLM, and xCT) and NADPH-generation (i.e., TKT,
TALDO1), compared to the A375-v counterpart. Of note, NRF2 KD by siRNA decreased the protein
content of its target genes in A375RIV1 cells, partly reversing their resistance to Vemurafenib [253].
Thus, the xCT system is key regulator of cancer cells redox balance, while its inactivation might
sensitize malignant cells to OS inducers. Of note, xCT overexpression is expected to promote glutamine
catabolism to support TCA cycle anaplerosis or GSH synthesis [254]. In this respect, a recent study
from Sayin et al., reported that LOF mutations of the KEAP1 gene can mediate glutamine addiction in
both mouse (KPK) and human KRAS-driven LUAD cell lines. Here, NRF2 increased activation led to
enhanced xCT/SLC7A11 expression, causing an imbalance in the TCA cycle and sensitization of KPK
cells to pharmacologic or metabolic glutamine depletion. Importantly, the glutaminase inhibitor CB-839,
impaired cell growth in a panel of tumor cells including melanoma, colon, renal, bone, squamous and
urinary-tract cancers with KEAP1 LOF mutations while the use of KI696, a small-molecule activator
of NRF2, conversely sensitized KEAP1 WT cancer cells previously refractory to CB-839 [255]. Thus,
oncogenic alterations in the NRF2-KEAP1 axis can induce defects in central carbon metabolism of
cancer cells and reveal metabolic vulnerabilities that can be targeted. Notably, glutamine is the most
abundant aminoacid in human serum and is essential for many cancer cells to generate TCA cycle
intermediates and support the biosynthesis of nucelotides, N-acetyl glucosamines, fatty acids, GSH and
other aminoacids [254]. Intriguingly, NRF2 can control different steps of glutamine fate, from its uptake
to its metabolism. For example, early studies reported that NRF2 can induce the expression of the
glutamine importer SLC1A5 in HeLa cells through the ATF4 transcription factor [256] while a recent
ChIP-Seq analysis on KEAP1-/- mice and human ESCC cells, revealed that NRF2 causes metabolic
reprogramming by enhancing the expression of the SLC1A4 glutamine transporter and other metabolic
enzymes [257]. Lastly, the enzyme glutaminase, catalyzing the conversion of glutamine into glutamate,
was found to be a direct NRF2 target gene in MCF7 and MCF10 BC cells treated with Sulforaphane or
subdued to KEAP1 KD by siRNA [258]. Therefore, NRF2 is profoundly implicated in the control of
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glutamine metabolism of cancer cells and most likely this regulatory node will be the focus of extensive
research in the next future.
3.1.7. NRF2 in the Regulation of Fatty Acids Metabolism
Interestingly, NRF2 has been found to exert opposite changes in the metabolism of fatty acids,
since a repression of FAS (fatty acid synthesis), but a stimulation of FAO (fatty acid oxidation) has
been reported in isolated mitochondria, MEFs (mouse embryonic fibroblasts) and tissues of transgenic
mice [259]. Despite the lack of data on malignant tumors a study on HEK-293T cells suggests
that NRF2 might control the expression of CPT1 and CPT2, two isoforms of the enzyme carnitine
palmitoyltransferase (CPT) that catalyzes the rate-limiting step of FAO [260]. Another mechanism by
which NRF2 can potentially support the redox balance of cancer cells is through the suppression of
NADPH-consuming processes, including lipid biosynthesis. Indeed, by using murine models with
variable NRF2 expression, Wu et al., showed that NRF2-null mice exhibited increased hepatic mRNA
levels of the enzymes fatty acid synthase (FASN), fatty acid desaturase (FADS1, FADS2), stearoyl-CoA
desaturase (SCD1), fatty acid elongases (ELOVL2,3,5,6 and CYB5R3), acetyl-CoA carboxylase-1 (ACC1)
and ATP-citrate lyase (ACLY), while the opposite was seen in KEAP1-KO mice suggesting that
NRF2 restrains lipogenesis and desaturation to prevent NADPH depletion [261]. On the other hand,
NRF2 activation in mouse lung was conversely seen to induce the transcription of FAO genes and
lipases, promoting degradation of damaged lipids and providing reducing equivalents in the form of
NADPH [262]. In conclusion, the activity of NRF2 can significantly affect the efficiency of FAO and
lipid biosynthesis, ultimately affecting bioenergetics as well as NADPH-linked antioxidant systems,
underscoring the intimate connection between metabolic processes and redox homeostasis.
3.2. Strategies to Negatively Modulate NRF2 Signaling/Pathway
Tumors are complex entities composed by heterogeneous cell populations that dynamically adapt
to their microenvironment driven by genetic/epigenetic alterations and metabolic rewiring [263–267].
Thus, cancer cell populations that become prevalent during certain phases of the malignant progression
can frequently develop resistance to treatment [268–271]. Moreover, due to patients’ individualities
and tumors heterogeneity, variable response rates are often observed making the identification of more
effective drugs very urgent [272,273]. In this regard, the concomitant inhibition of antioxidant circuits
and metabolic pathways that support the redox balance of malignant cells, delineates a promising
anti-cancer strategy [274–283]. It is known that most of the metabolic changes promoting cancer
cells proliferation and tumor growth induce also an increased ROS generation, counterbalanced
by an antioxidant response that prevents cell death [234,284,285]. Of note, since the cytotoxicity
of conventional anti-cancer therapies largely relies on efficient ROS accumulation, the augmented
antioxidant capacity of cancer cells constitutes a key determinant of therapy-resistance [286–288].
At the same time, given the strong dependency of malignant cells to their antioxidant systems,
interfering with their redox control can induce OS-dependent cell death [289]. Since the NRF2 signaling
plays a key role in tumorigenesis, malignant progression [290–292] and drug sensitivity [293–295],
this transcription factor has emerged as a promising therapeutic target [16,282,296–298]. In this regard,
several studies have tried to identify NRF2 activators to prevent ROS-dependent carcinogenesis while
others have focused on the development of NRF2 inhibitors to overcome therapy resistance [299–301].
In the following sections, the most promising NRF2 inhibitors, described so far in the literature, will
be presented.
3.2.1. Natural Compounds That Impair NRF2 Signaling by Interfering with Protein Synthesis
Despite the increasing demand for negative modulators of NRF2, selective inhibitors are
neither currently available nor under clinical trial evaluation. Yet, alternative strategies have been
explored based on the pharmacologic manipulation of various NRF2 modulators through natural
and synthetic compounds [302,303]. Historically, many natural compounds have been used to
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treat human pathologies, including cancer. Importantly, these compounds have been often used to
potentiate the efficacy of ROS-inducing agents against therapy-resistant cancers, by altering their
redox homeostasis. Among the others, many studies focused on Brusatol, a quassinoid from the
plant Brucea javanica [304–306], and its derivatives [307,308]. The antitumor effects of Brusatol have
been ascribed both in solid and in hematologic tumors to the inhibition of proliferation and the
disruption of antioxidant defenses caused by NRF2 depletion, due to global suppression of protein
synthesis [309–311]. For instance, in A549 NSCLC cells resistant to radiation, Brusatol was found to
dose-dependently decrease the NRF2 protein levels and to enhance the efficacy of ionizing radiations,
by inducing ROS-dependent DNA damage and cell death [312]. Also, Brusatol was recently found
to impair cell growth and proliferaton of human A375 melanoma cells both in vitro and in vivo
(NOD/SCID xenografted mice) when used in combination with UVA treatment, leading to increased
ROS generation and apoptosis due to AKT impairment [313]. Also, Karathedath et al., reported that
NRF2 overexpression in AML cell lines and primary AML samples caused resistance to Cytarabine,
Daunorubicin and Arsenic trioxide (ATO). Importantly, Brusatol was found to markedly decrease the
NRF2 content and consequently the expression of its target genes GCLC, GCLM, HMOX-1, and NQO1,
promoting ROS accumulation and apoptosis [314]. Finally, in a recent study from Xiang et al., the
overactivation of NRF2 signaling was found to mediate Gemcitabine resistance in human PANC-1,
PATU-8988 and BXPC3 pancreatic ductal adenocarcinoma cancer (PDAC) cell lines. Here, Brusatol
induced ROS accumulation, growth inhibition and apoptosis by decreasing the protein levels of
NRF2 and its target genes HO-1 and NQO-1. Notably, Brusatol enhanced the antitumor activity of
Gemcitabine in vivo by reducing the growth rate of PANC-1 xenografts implanted in BALB/c nude
mice [315]. Similarly, other work has been directed to Halofuginone from the plant Dichroa febrifuga,
which is rapidly emerging as one of the most promising NRF2 inhibitors. Indeed Halofuginone has
been shown to impair proliferation, migration and invasion of HepG2 HCC cells [316] and MCF7 BC
cells [317,318], to reverse the radioresistance of Lewis lung cancer cells (LLCC) [319], or to improve the
drug delivery in PDAC cells [320]. In a recent study from Tsuchida K. et al., Halofuginone was seen
to repress protein synthesis through prolyl-tRNA synthetase inhibition and to prevent NRF2 nuclear
accumulation causing the impaired expression of enzymes involved in drug metabolism and transport,
iron metabolism, GSH metabolism and ROS scavenging. As a result, KYSE70 human esophageal
cancer (HEC) or A549 NSCLC cells, became more susceptible to Cisplatin based on in vitro and in vivo
experiments, with limited side-effects [321]. It should be emphasized that Halofuginone has a very
similar mechanism of action to that of Brusatol, confirming that the inhibition of protein synthesis
remains a valid strategy to block NRF2 signaling.
3.2.2. Natural Compounds That Impair NRF2 Signaling by Acting on Functional Regulators
Other works have explored the potential use of Chrysin, a natural flavone found in many plant
extracts such as honey, propolis, and blue passion flowers, endowed with anticancer effects against
different tumors [322,323]. In an earlier study on BEL-7402 human HCC cells resistant to Doxorubicin,
Chrysin significantly reduced NRF2 expression both at the mRNA and protein levels, by interfering
with PI3K/AKT and ERK pathways. As a result, the expression of NRF2-related target genes HMOX-1,
AKR1B10 and MRP5, was significantly reduced and the chemoresistance attenuated [324]. In another
work form Wang J. et al., Chrysin was seen to suppress the proliferation, migration and invasion
of human T98, U251 and U87 glioblastoma (GBM) cells and to abrogate the in vivo tumorigenicity
of U87 xenografts in BALB/c mice. Mechanistically, Chrysin impaired NRF2 nuclear translocation,
by decreasing the protein levels of phospho-extracellular signal-regulated kinase-1/2 (ERK1/2) and two
antioxidant enzymes HO-1 and NQO-1 [325].
3.2.3. Natural and Synthetic Compounds Blocking NRF2 Pathway by Still Unknown Mechanisms
Oridonin, a diterpenoid isolated from the herb Rabdosia rubescens, represents another promising
compound whose potent antitumor effects have been described in leukemia [326], BC [327] and CRC
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cells [328]. Very recently, Oridonin was found to promote mitochondrial-dependent apoptosis by
activating PPARγ and suppressing both NF-κB and NRF2 pathways in MG-63 and HOS osteosarcoma
cells. Here, Oridonin prevented NRF2 nuclear translocation and decreased the expression of the
HMOX1, NQO1 genes and their encoded antioxidant proteins, leading to ROS-dependent apoptosis,
in vitro and in vivo [329]. Also Plumbagin, a natural naphthoquinone from Plumbago zeylanica L.,
has received substantial attention as a potent inducer of apoptosis in pancreatic, lung, breast and
prostate cancer cells caused by ROS overproduction [114,330]. With this respect, by using human
ovarian (OVCAR3), breast (SKOV3, MCF7), and endometrial (ECC1) cancer cells, a recent study
has shown that Plumbagin promotes ROS generation via the mETC complexes I-III and synergizes
with Brusatol to block NRF2 pathway, triggering cell death [331]. In another work, a SILAC-based
quantitative proteomic approach was used to characterize the biological changes induced by Plumbagin
in SCC25 tongue squamous cell carcinoma (TSCC) cells. Here, Plumbagin was seen to decrease the
NRF2 nuclear translocation and to suppress the induction of its target genes. As a result, unbalanced
ROS overproduction led to cell cycle arrest and stemness attenuation, triggering apoptosis [332].
Extensive research has also been pursued on the alkaloid Trigonelline, a coffee extract initially identified
as a negative modulator of NRF2 signaling in HT29 human colorectal cancer cells (CRC), with the ability
to decrease the nuclear and total content of NRF2 and to inhibit its target genes transactivation [333].
In a later study, the effects of Trigonelline on NRF2-mediated apoptosis evasion were studied in
MiaPaca2, PANC-1, and Colo357 PDAC cell lines and in the human pancreatic duct cell line H6c7. Here,
Trigonelline was shown to strongly suppress NRF2 activity by preventing its nuclear accumulation and
to increase the efficacy of TRAIL and Etoposide both in vitro and in vivo, with few side-toxicity [334].
Importantly, three different studies from the group of Shin D. recently focused on the impact of
Trigonelline on chemoresistance by using experimental models of HNC. First, using HNC cells
resistant to Cisplatin, Trigonelline was found to restore the chemosensitivity of HN 2-10 and SNU
cells both in vitro and in vivo when combined with inhibitors of GSH synthesis and TRX system [287].
Interestingly, in the same experimental model, NRF2 was seen to promote resistance to the ferroptosis
inducer Artesunate, while conversely the combination with Trigonelline resulted in strong cytotoxicity
due to ROS accumulation. Remarkably, the effect was restricted to Artesunate- or Cisplatin-resistant
HNC cells, sparing normal oral keratinocytes and oral fibroblasts [301]. Lately, the same group reported
that in HNC cells, suppression of NRF2 signaling by Trigonelline could reverse the resistance to
ferroptosis both in vitro and in vivo [335]. Thus, Trigonelline is emerging as a promising molecule
for combination regimens against tumors with widespread chemoresistance. Importantly, the use
of high throughput screening (HTS) has played a major role in the discovery of NRF2 inhibitors.
For example, AEM1, a benzodioxole substituted analog recently identified in A549 NSCLC cells,
was seen to strongly suppress NRF2-mediated genes expression, without altering NRF2 protein stability,
its phosphorylation or the KEAP1 content. Importantly, AEM1 reduced the growth rate of A549
NSCLC cells both in vitro and in vivo, enhancing also their sensitivity to Etoposide and 5-Fluorouracil.
Of note, AEM1 was also able to decrease the NRF2-dependent induction of HMOX1 in H838 and H460
NSCLC cells with LOF mutations of the KEAP1 gene, suggesting that AEM1 might preferentially target
tumor cells with constitutive NRF2 activation [336]. Similarly, Singh et al., conducted a quantitative
high-throughput screening (qHTS) of the Molecular Libraries Small Molecule Repository (MLSMR)
and identified a compound named ML385 that was able to reduce the transcriptional activity of NRF2
by preventing the binding of the NRF2-MAFG complex to the ARE sequence in the promoter of NSCLC
cells. More in detail, ML385 attenuated NRF2 pathway by affecting the DNA binding activity of the
NRF2-MAFG protein complex through direct interaction with NRF2. As a result, ML385 induced
selective toxicity in both A549 and H460 NSCLC cells harboring KEAP1 mutations, enhancing the
cytotoxic effects of Doxorubicin, Carboplatin and Paclitaxel without affecting the non-tumorigenic
BEAS2B cells. Importantly, the therapeutic efficacy of ML385 as a single agent and in combination with
carboplatin was also confirmed in orthotopic lung cancer xenografts subcutaneously implanted in nude
mice [25]. Moreover, in a very recent study from Hori R. et al., the K-563 compound was isolated from
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Streptomyces sp. after HTS screening of almost 10000 culture broth samples. Of note, K-563 abrogated
the expression of NRF2 target genes such as GCLC, GCLM, AKR1C1 (reductase family 1 member C1),
ME1, NQO1 and TXNRD1 in A549 NSCLC cells and in the human gallbladder cancer (GBC) cell
line TGBC24TKB, without altering the NRF2 protein levels, its ARE-binding ability, or its nuclear
localization. As a result, K-563 promoted ROS accumulation and synergized with either Cisplatin or
Etoposide in A549 NSCLC cells, suppressing also cell proliferation in GBC cells (TGBC24TKB) without
affecting normal human lung cells (BEAS-2B) [337]. In the context of hematologic tumors, Zhang et al.,
identified 4f, a pyrazolyl hydroxamic acid derivative with potent antineoplastic effects in human
THP-1, HL60 and U937 AML (acute myeloid leukemia) cells. Here, 4f was found to decrease the NRF2
protein content and the mRNA levels of HMOX1 and GCLC genes, promoting increased caspase-3
and PARP cleavage. Besides, 4f suppressed the growth of THP-1 xenografts seeded onto the CAMs of
chicken eggs and also impaired blood vessels formation in vivo in a gelatin sponge assay, suggesting
that 4f might be a promising treatment in advanced AML [338]. In summary, very promising results
have been reported in case of repressors of protein synthesis, an evidence that might pave the way to
the design of novel strategies to target the NRF2 pathway in cancers. Taken together, these studies
provide a strong rationale for the identification and validation of compounds with the ability to disrupt
the redox control exerted by NRF2 in solid as well as hematologic tumors. Moreover, it is expected that
other experimental work as well as refined clinical trials will better define the molecular mechanisms,
the specific context and the types of tumors wherein this approach might ensure the optimal efficacy in
patients with advanced cancers.
3.2.4. Natural and Synthetic Compounds Targeting Functional Regulators of the
NRF2-KEAP1 Pathway
An alternative strategy to hamper the pro-tumoral effects of NRF2 is through the modulation of
functional regulators that ultimately converge on this signaling pathway. This approach offers at least
two significant advantages. First, it relies on already established drugs with proven anticancer activity
and, more importantly, it does not require selective NRF2 inhibitors. Of note, recent work supports
the applicability of this strategy. For example, LGK-974, a specific inhibitor of the O-acyltransferase
porcupine (PORCN) used to disrupt the WNT signaling, was recently found to prevent NRF2 nuclear
translocation and its expression in HepG2 cells, presumably by impairing the WNT3A-dependent
formation of the GSK-3/β-TrCP protein complex. As a result, the HepG2 cells were sensitized to
otherwise non-toxic radiation doses, due to downregulation of NRF2 target genes such as HMOX1
and NQO1 and increased ROS production [339]. Also Wogonin, a flavonoid isolated from Scutellaria
baicalensis Georgi, has emerged as a promising anticancer agent, due to its chemosensitizing ability in
Doxocycline-resistant MCF7 BC cells [340]. Further investigations revealed that Wogonin reduced the
NRF2 nuclear translocation and promoted increased ROS production, potentiating the cytotoxicity of
Hydroxy-Camptothecin, Cisplatin and Etoposide also in HepG2 cells [341]. Other work was conducted
on chronic myelogenous leukemia (CML) cells sensitive (K562) or resistant (K562/AO2) to Adriamycin
(ADR). As first, Wogonin was found to decrease the NRF2 mRNA and protein levels in CML cells,
causing a marked reduction in the HO-1, NQO1 and MRP1 proteins [342]. In a later work the same
authors showed that Wogonin could decrease the binding of both p65 and p50 NF-kB subunits to
the NRF2 promoter in K562/A02 cells, enhancing their sensitivity to ADR. In vivo, transplantation
experiments of K562/A02 cells into NOD/SCID mice proved that the combination of ADR and
Wogonin could reduce the nuclear content of NF-κB p65 and NRF2 [343]. Hence, Wogonin represents
a promising inhibitor of NRF2 and a potent chemosensitizer in solid and hemathologic tumors.
Also, Gao et al., explored the anti-cancer potential of Apigenin, a natural bioflavonoid found in
many fruits and vegetables. As first, Apigenin was seen to reduce the expression of NRF2 and its
targets HO-1, AKR1B10 and MRP5 both at the mRNA and protein levels in a KEAP1-independent
way, by downregulating the PI3K/AKT pathway and to strongly sensitize BEL-7402/ADM cells to
Doxorubicin both in vitro and in vivo, blocking tumor growth [344]. Additional work, led to the
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identification of the microRNA mir-101, as a modulator of NRF2 functions in HCC cells. Here,
mir-101 was found to be downregulated in BEL-7402/ADM (resistant) and conversely highly expressed
in BEL-7402 (sensitive) cells, while the NRF2 mRNA sequence analysis revealed the presence of
a complementary site for mir-101 in the 3’-UTR. Importantly, mir-101 mimics markedly decreased
the NRF2 protein levels in BEL-7402/ADM cells exerting chemo-sensitizing effects, while opposite
changes were induced by antimir-101. Collectively, these data indicate that mir-101 re-expression
might be a novel mechanism to blunt NRF2 signaling in HCC resistant cells [345]. Also, Retinoic
acid, a Vitamin A metabolite, has emerged as a potential anticancer agent inducing differentiation,
growth arrest, and apoptosis of cancer cells [346]. Initial studies on solid tumors have shown that
All-Trans Retinoic Acid (ATRA) can induce RARα expression, which in turn forms a protein complex
with NRF2 and antagonizes its transactivation [347,348], sensitizing chemoresistant neuroblastoma
(NB) HTLA-230 cells to the proteasome inhibitor Bortezomib [349]. Other experimental work from
Valenzuela M. et al., extended these observations to AML and APL cells treated with the ROS-inducer
Arsenic Trioxide (ATO). Here, the combined use of ATRA and ATO was seen to prevent NRF2
nuclear translocation and to suppress the antioxidant response in HL-60 and THP-1 AML and in
NB4 APL cells, inducing cytotoxicity. Additionally, the authors also showed that the ATRA-mediated
inhibition of NRF2 depended on RARα, since ATRA was ineffective when parental NB4 cells were
pre-treated with the RARα antagonist Ro-41-5253 or when applied to mutant NB4-R2 cells lacking
RARα expression [350].
4. Conclusions and Future Perspectives
Since its discovery in 1994 [27] NRF2 has been connected to various cellular mechanisms, such as
response to oxidative stress, mitochondrial respiration, stem cell quiescence, mRNA translation and
autophagy [51]. The NRF2-KEAP1 pathway is a master regulator of cell protection mechanisms against
exogenous or endogenous stress sources. Thus, in the past decade, NRF2 has emerged as an important
target in cancer therapy. Many questions have arisen in relation to risks and benefits of negative
modulators of NRF2 signaling. Recent research suggest that suppression of antioxidant mechanisms
involving NRF2 might potentially induce a pro-oxidizing shift in tumor microenvironment and promote
ROS-dependent cell death in many cancer types. Despite the absence of specific and selective NRF2
inhibitors, convincing indications show that the use of natural compounds with known therapeutic
action might be effectively used in different types of tumors [351,352]. NRF2 has been recognized as one
of the critical factors regulating an array of genes that protect cells against xenobiotics. NRF2-mediated
transcriptional regulation is coordinated by a number of specific events within the cellular environment.
Among them, the triggering stimulus, the cooperation with other activators and repressors, the interplay
with different signaling pathways and the epigenetic landscape of the target gene promoters, can be
regarded of utmost importance. Many approaches have been devised to target the NRF2 signaling
pathway in cancer such as regulating NRF2 expression at the transcriptional level, controlling the
NRF2 nuclear translocation, targeting the KEAP1-NRF2 binding for modulating NRF2 protein stability
and regulating NRF2 binding to its target genes promoters. Several small-molecule NRF2 activators
and inhibitors have been developed and successfully employed in cancer treatment. The important
drawbacks of targeted therapy include resistance of cancer cells and difficulties of developing drugs to
some tumor-specific targets [191,353]. Studies suggest that in tumors, high levels of NRF2 can occur in
absence of genomic alterations in the NRF2 and KEAP1 genes. Additional research will help to increase
the specificity of NRF2-based therapies. For example, crystallographic investigations of KEAP1 might
provide chances to design and synthesize molecules that selectively interfere with the KEAP1-NRF2
binding [354]. Moreover, accumulating evidence suggests that NRF2 can interact with other pathways
implicated in cell survival [355]. These important points offer great opportunities for pharmacological
intervention to control the level of NRF2 and its therapeutic effects. NRF2 was firstly described as a
tumor suppressor involved in the inhibition of tumor initiation and cancer metastasis. Recent evidence
showed that it can also act as a pro-oncogenic factor. It is now well accepted that NRF2 has a dual role
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in carcinogenesis and that pharmacological induction of the NRF2 pathway might be chemopreventive
in the early stages of tumorigenesis. However, adverse effects might occur in advanced stages of cancer
by inducing therapy resistance [356,357]. Chemotherapy resistance is one of the crucial problems
for the effective treatment of many cancers, and NRF2 inhibition might be a promising approach to
overcome this phenomenon. Being located at the crossroad of many defensive pathways influencing
cell life during chemical, oxidative, and metabolic stress, the NRF2-KEAP1 pathway has been the focus
of broad research aimed at revealing its role in cancer [105]. Aberrant activation of the NRF2-KEAP1
pathway is often recognized in many tumors, promoting cancer growth, survival, metastasis formation
and therapy resistance [358,359]. It is known that NRF2 activation in response to oxidative stress
promotes cells survival. NRF2 also induces metabolic changes that sustain cell proliferation. Because
of these benefits, cancer cells with sustained NRF2 activation frequently develop “NRF2 addiction” [3].
Disruption of NRF2 signaling is a promising therapeutic approach against NRF2-addicted cancers and
some effective NRF2 inhibitors such as brusatol and halofuginone have been employed, while many
others are under investigation. Nevertheless, administration of systemic NRF2 inhibitors may cause
off-target effects on patients and this represents a key aspect for the identification of novel compounds
that should ideally possess high specificity, bioactivity and limited side-toxicity [26]. To prevent these
side effects, mechanistic insights should be revealed and new pharmacological targets besides NRF2
should be studied. Depending on metabolic fluxes of NRF2-addicted cancer cells, thorough metabolite
examination might help to identify specific diagnostic markers. Research have suggested that the
over-activation of NRF2 promotes tumor development, prevents cell apoptosis and enhances the
therapy-resistance of cancer cells. We know that both NRF2 inducers and NRF2 inhibitors possess
anticancer activity against different targets. NRF2 inducers protect normal cells from carcinogen
effects, while NRF2 inhibitors halt cancer cells proliferation. The question is what we need exactly,
NRF2 activators or inhibitors? According to the numerous recent studies related to the oncogenic
activity of NRF2, the synthesis of novel selective inhibitors of NRF2-KEAP1 pathway could be the
better strategy for cancer prevention and therapy [64]. The dilemma of whether NRF2 can be used
as a pharmacological target needs to be harmonized with the research of clinical application and
participation of mediators of oxidative stress in the anticancer therapy. In conclusion, the discovery,
design, and synthesis of NRF2-centered methodologies are important and challenging tasks that might
pave the way to novel therapeutic approaches in cancer treatment.
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Abstract: Psychostimulants and non-psychostimulants are the medications prescribed for the
treatment of attention-deficit/hyperactivity disorder (ADHD). However, several adverse results have
been linked with an increased risk of substance use and side effects. The pathophysiology of ADHD is
not completely known, although it has been associated with an increase in inflammation and oxidative
stress. This review presents an overview of findings following antioxidant treatment for ADHD and
describes the potential amelioration of inflammation and oxidative stress using antioxidants that might
have a future as multi-target adjuvant therapy in ADHD. The use of antioxidants against inflammation
and oxidative conditions is an emerging field in the management of several neurodegenerative and
neuropsychiatric disorders. Thus, antioxidants could be promising as an adjuvant ADHD therapy.
Keywords: antioxidants; ADHD; inflammation; oxidative stress; Nrf2
1. Introduction
1.1. Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioural disorder
and is a chronic, often lifelong, condition [1,2]. The pooled worldwide prevalence of ADHD is 7.2% for
children and adolescents and 3–5% for adults [3–5]. Boys are more than twice as likely as girls to receive
a diagnosis of ADHD [6]. Approximately 50% of individuals diagnosed in childhood and adolescence
persist with symptoms into adult life [1,7]. Comorbidity in ADHD is very common at roughly 70%,
the main disorders being emotional or behavioural conditions, such as anxiety, oppositional defiant,
depression and substance use disorders, and developmental conditions, such as learning and language
disorders, autism spectrum disorders (ASD), and physical conditions (tics and sleep apnoea) [8–10].
The diagnosis of ADHD is based on the fifth edition of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5) and the criteria include: inattention and/or hyperactive and impulsive symptoms
for the last six months or more, onset before the age of 12 years old, and symptoms causing at least
moderate psychological, social, and/or educational or occupational impairments based on interview
and/or direct observation in multiple settings [6].
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1.2. Pathophysiology
The pathophysiological mechanisms of ADHD are still not understood. However, biochemical,
psychological, and environmental factors have generally been accepted as causes of the disorder.
Several studies have suggested deregulation in catecholaminergic neurotransmission to be the
cause [11,12]. Moreover, increasing evidence indicates a critical role for neuroinflammation [13,14].
Also, the involvement of oxidative stress is highlighted as a pathophysiological cause of ADHD [15,16].
1.3. Pharmacological Treatment
The management of ADHD comprises multimodal treatments that include psychosocial and
educational interventions [6]. Nevertheless, pharmacological treatment is the first choice of therapy
to improve symptoms, using psychostimulants such as methylphenidate (MPH) and amphetamines,
which inhibit the reuptake of dopamine and norepinephrine, thus increasing catecholaminergic
activity in the prefrontal cortex, striatum, and hippocampus, improving symptoms [6,17]. The second
choice of therapy is with non-psychostimulants such as atomoxetine (ATX), which is a selective
norepinephrine reuptake inhibitor, guanfacine, and clonidine, which are selective α-2 adrenergic
receptor agonists [18,19].
However, psychostimulants have been associated with side effects such as appetite loss,
headache, stomach pain, agitation, sleep disturbance, anxiety, and insomnia [2,20]. Moreover, these
medications have a persistent effect on decreasing growth velocity and hallucinations or other psychotic
symptoms [21]. Furthermore, non-psychostimulants are associated with changes in cardiovascular
parameters, cardiovascular events, somnolence, gastrointestinal tract symptoms, nausea, diarrhoea,
vomiting, decreased appetite, fatigue, and dizziness [2,22].
Neuroinflammation and oxidative stress play a role in the pathophysiology of ADHD due to genetic
and environmental factors, catecholaminergic dysregulation, and medications used for treatment,
all factors which could produce inflammation and oxidative stress, which increases the symptoms
and, as a consequence, leads to establishing a vicious circle (Figure 1). Hence, antioxidants against
inflammation and oxidative stress have been used to manage other disorders such as Alzheimer’s
disease, Parkinson’s disease, Huntington’s disease, autism, schizophrenia, and depression [23–28].
Accordingly, antioxidant modulators could be helpful as a multi-target adjuvant therapy in ADHD.
Figure 1. Role of inflammation and oxidative stress in the pathophysiology of ADHD and
potential adjuvant therapy. Environmental and genetic factors, catecholaminergic dysregulation
and pharmacological treatment can establish a vicious circle, producing inflammation and oxidative
stress, therefore contributing to increase the symptoms. SFN, sulforaphane; NAC, N-Acetylcysteine;
omega-3 FAs, omega-3 fatty acids; MPH, methylphenidate; ATX, atomoxetine.
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2. Inflammation and the Relationship with ADHD
Increasing evidence supports the role of neuroinflammation in the pathophysiology of ADHD [14].
Inflammation in the brain is characterized by the activation of glial cells (oligodendrocytes, astrocytes,
microglia and ependymal cells) and the production of cytokines, chemokines, prostaglandins, nitric oxide
(NO), reactive oxygen species (ROS), and immune cell infiltration, including monocytes/macrophages,
neutrophils, dendritic cells, T cells, and B cells. Glial cells, principally microglia (brain-resident immune
cells), are responsible for the maintenance of homeostasis after brain injury [29,30].
Increased ADHD symptoms have been reported in patients with an uncontrolled inflammatory
environment. Thus, elevated levels of interleukin-6 receptor (IL-6R), RANTES (regulated upon
activation, normal t cell expressed and secreted) and tumour necrosis factor-α (TNF-α) in children with
ADHD were associated with a major intensity of symptoms such as hyperactivity and inattention [31].
Moreover, serum levels of IL-6 and IL-10 were significantly higher in ADHD children compared with
healthy controls. However, IL-6 levels did not correlate with the severity of ADHD symptoms [32,33].
In an animal model of ADHD, using spontaneously hypertensive rats (SHR), the serum levels of IL-1α,
MCP-1, RANTES, and IP-10 were elevated in five-week-old compared to control rats. Interestingly,
serum levels of IL-6 were similar in five-week-old animals of both strains, with elevated levels in
10-week-old SHR, which correlates with that found in children with ADHD [34]. The association
between the dysregulation of the inflammatory response and the pathophysiology of ADHD is possible
as a result of the role of inflammation in neurogenesis, differentiation, and neuronal function [30,35–37].
Furthermore, neuroinflammation can induce aggravating factors such as blood–brain barrier disruption,
altered neurotransmitter metabolism, oxidative stress, and neurodegeneration [38].
The inflammatory mechanisms and the association of dysregulation in ADHD remain to be fully
clarified but involve genetic and/or environmental factors. Several studies have reported an association
between ADHD and the polymorphism of cytokines such as IL-2, IL-6 and TNF-α [39]. However,
there are controversial results for interleukin-1 receptor antagonist (IL-1RA; also known as IL-1RN)
gene variable number tandem repeat (VNTR) polymorphism: the four-repeat allele was associated
with increased risk and the two-repeat allele with reduced risk for ADHD [40]. On the other hand,
no association of this IL-1RN polymorphism with ADHD was found in a larger sample [41]. Comorbidity
with allergic and autoimmune disorders such as atopic eczema, allergic rhinitis and asthma is another
factor that could increase the risk for ADHD and future research may lead to a better understanding of
the mechanisms underlying the observed comorbidity [38,42–44]. In a meta-analysis and a large-scale
genome-wide association study (GWAS), associations between asthma and ADHD were found in both
children and adults [45,46]. Also, patients with ADHD and asthma had similar brain region dysfunctions
and higher levels of cytokines and IgE compared to healthy children, resulting in alterations to the
regions in the brain associated with emotional and behavioural control [38,42,47]. The involvement
of autoantibodies in ADHD has been suggested but this is an unknown causal association [33,48].
High antibody levels of anti-Purkinje cells (anti-Yo), anti-basal ganglia and anti-dopamine transporter
were found in patients with ADHD [33,48–50]. Moreover, elevated anti-Yo antibody levels were
correlated with IL-6 and IL-10 levels [33]. Further studies are needed to clarify the comorbidity or
causal relationship between allergic and autoimmune disorders and ADHD. Maternal history of
autoimmune disease has also been associated with an increased risk of ADHD. The inflammation
caused during prenatal development by several maternal diseases, such as infections, asthma, diabetes,
obesity, and autoimmune disease, was associated with ADHD in offspring [13,51].
3. Antioxidant Treatment Against Inflammation in ADHD
3.1. Sulforaphane Exerts Anti-Inflammatory Activity
Sulforaphane (SFN) is found in highest concentrations in vegetables such as cauliflower and
broccoli sprouts, and it has been shown that SFN is an activator of nuclear factor erythroid 2-related
factor 2 (Nrf2) [52]. Nrf2 is a transcription factor widely recognized as a master regulator of cellular
141
Antioxidants 2020, 9, 176
redox homeostasis [53,54]. Regulation is carried out by binding Nrf2 to a specific DNA sequence
known as the antioxidant response element (ARE) found in the promoter regions of genes that encode
detoxification enzymes such as NADPH quinone oxidoreductase 1 (NQO1), haem oxygenase 1 (HO-1)
and glutathione peroxidase 1 (GPx1), among others [55]. Nrf2 regulates enzymes responsible for GSH
syntheses, such as the glutamate-cysteine catalytic subunit (GCLC) and glutamate-cysteine ligase
modifier subunit (GCLM), and enzymes related to GSH utilization, such as glutathione S transferase
(GST), glutathione peroxidase, and glutathione reductase [54]. Thus, SFN activates Nrf2 and stimulates
transcription of genes involved in GSH synthesis.
SFN has been considered as a therapeutic target in several inflammation-associated diseases,
including neurodevelopmental disorders such as psychosis and autism spectrum disorder [56–58].
Action mechanisms of antioxidants used against inflammation are shown in Figure 2.
Figure 2. Overview of the mechanisms of SFN, NAC and Omega-3 FAs used as modulators
against inflammation and oxidative stress. DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid;
DAT, dopamine transporter; PGE, prostaglandins; ROS, reactive oxygen species; NO, nitric oxide;
GCL, glutamate cystine ligase; GPx, glutathione peroxidase; GSH, glutathione; SOD, superoxide
dismutase; GR, glutatione reductase; GSS, glutathione synthetase; glutathione peroxidase-4, GPx-4.
The molecular mechanism by which SFN exerts its anti-inflammatory function is by inducing
Nrf2 pathway activation, which contributes to the anti-inflammatory process by regulating HO-1 gene
expression [59–61]. Nrf2 leads to the inhibition of nuclear factor kappa B (NF-κB), activator protein-1
(AP-1) and mitogen-activated protein kinase (MAPK) classical inflammatory pathways, resulting in
decreased expression of the inflammatory mediators (iNOS, COX-2, NO and prostaglandins) and
pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β). In addition, Nrf2/HO-1 activation increases
anti-inflammatory cytokines (IL-10 and IL-4) [62–65]. Moreover, SFN has a prophylactic and
a therapeutic effect by inhibiting both the inflammatory response and microglial activation [62].
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Inflammasomes are multiprotein complexes necessary for the release of pro-inflammatory
cytokines (IL-1α and IL-18). Interestingly, it has been reported that SFN inhibited the activation
of NLRP1, NLRP3, and NLRC4 inflammasomes [66,67]. However, the precise mechanism by which
it does so is controversial, inasmuch as the SFN-mediated inhibition of the inflammasomes was
independent of caspase-1 activity, ROS modulation, and Nrf2 synthesis [66]. Contrary to these
findings, other studies showed that ROS generation and Nrf2 were required for inflammasome
activation [67,68]. SFN protected against neuroinflammation by preventing the increase of NF-κB
activity, TNF-α, and depletion of the IL-10 level in the cortex and hippocampus of okadaic-acid-treated
rats by the activation of the Nrf2/HO-1 pathway [69]. Recently, it was shown that treatment with SFN in
ASD-induced improvement of social interaction and behavioural deficits may be due to the inhibition
of STAT3 expression and suppression of Th17 cell response [27,70]. Although SFN supplementation
in patients with ADHD has not been studied, this could constitute a promising approach against
inflammation linked with ADHD. Nevertheless, more studies are needed to confirm safety, efficacy,
therapeutic doses, effect in combination with conventional therapy and long-term side effects to be
considered as adjuvant therapy in ADHD. The effects of antioxidants and the main outcomes are
summarized in Table 1.
Table 1. Summary of the findings on the potential beneficial effects of antioxidants against inflammation
and oxidative stress.
Against Inflammation Type of Study Outcome
SFN Mouse model of atopic dermatitis [61] Reduced inflammation, suppressed JAK1/STAT3 signaling andactivated Nrf2/HO-1 pathway
SFN Microglial cells [62]
Reduced inflammatory mediators (iNOS, COX-2, NO,
and PGE2) and proinflammatory cytokines (TNF-α, IL-6,
and IL-1β), increased anti-inflammatory cytokines (IL-10 and
IL-4) and increased the expression of Nrf2 and HO-1.
SFN Mouse model of acute lung injury andMacrophages [63,65]
Decreased lactate dehydrogenase, IL-6, TNF-α, NF-kB, PGE2
production, COX-2, MMP-9 and iNOS protein expression
SFN Mouse model of peritonitis [66] Inhibited inflammasome activation and IL-1β secretion andinhibited cell recruitment to peritoneum.
SFN Mouse macrophages [67] Blocked activation of NLRP3 and NLRC4 inflammasomes andIL-1β secretion
SFN Rat [69] Inhibited NF-kB activity and TNF-α secretion and preventdecreased IL-10
SFN Mouse model of autism and Autismpatients [27,70]
Reduced Th17 response and expression of NF-kB and iNOS
Randomized double-blind study; decreased symptoms
NAC Mild-stress rat model [71] Inhibited pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α)
NAC Bipolar depression patients [72] Randomized placebo-controlled trial; no effects on the biologicalparameters evaluated
NAC Systemic lupus erythematosuspatients [73,74]
Randomized double-blind placebo-controlled trial and
randomized controlled trial; reduced the ADHD symptoms and
also inhibited the autoimmune inflammatory process by
suppression of the mammalian target of rapamycin (mTOR) and
increased regulatory T cells
NAC Human retinal pigment epithelial cellline [75]
Decreased IL-18, IL-1β mRNA, ROS and blocked
inflammasome activation
NAC Rat [76]
Improved brain oxidant/antioxidant status and reversed
the overproduction of pro-inflammatory cytokines
in brain and serum
Omega-3 FAs Macrophage and mouse dendritic celllines [77,78]
Inhibited dimerization and recruitment of TLR2 and TLR4
recruitment to lipid rafts and reduced T-cell proliferation and
increased the proportion of T cells expressing FoxP3
Omega-3 FAs Mouse [79,80] Regulated CD4
+ T-cell function and reduced
Th17cell polarazation
Omega-3 FAs Children with ADHD [81] Double-blind study; decreased plasma inflammatory mediators
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Table 1. Cont.
Against Oxidative Stress Type of Study Outcome
SFN Mouse [82] Increased dopamine, DOPAC and dopamine transporterimmunoreactivity in the striatum
SFN Rat [69] Activation of HO-1, glutamate-cysteine ligase catalytic subunitand Nrf2 and protected against memory impairment
SFN Mouse model of autism [70] Improved the autism-like symptoms and upregulated SOD,glutathione reductase and GPx
SFN and NAC Rat with epilepsy [83]
Reduced oxidative stress, delayed the onset of epilepsy,
blocked disease progression and reduced the frequency
of spontaneous seizures
SFN Healthy subjects [26] Clinical pilot study; increased GSH
NAC Rats [84] Protected against amphetamine-induced damage
NAC Paediatric Tourette’s syndrome [85] Randomized double-blind placebo-controlled trial; did not showa significant difference with placebo
NAC A girl with ADHD [86] A case-study; reduced the frequency of self-cutting and reducedthe symptoms and depression
NAC Mouse model of postoperativecognitive dysfunction [87]
Reduced oxidative stress and inflammation in the hippocampus
and improved cognitive function by activation of the
Nrf2/HO-1 pathway
Omega-3 FAs Children with ADHD [81] Double-blind study; decreased oxidative stress
Omega-3 FAs Children with ADHD [88]
Randomized controlled trial; no significant differences among
the treatments. One subgroup improved spelling, reading and
attention and decreased hyperactivity
Omega-3 FAs Children with ADHD [89,90] Randomized pilot study and placebo-controlled trial; nosignificant improvement
Omega-3 FAs Children with ADHD [91–94]
Pilot studies and randomized placebo-controlled trials;
improved working memory function and improved symptoms
and behaviour
Omega-3 FAs Rat astrocytes [95] Increased glutamate-cysteine ligase, Nrf2, glutathionesynthetase and glutathione peroxidase-4 proteins
3.2. N-Acetylcysteine Decreases Inflammatory Response
N-Acetylcysteine (NAC), a precursor of L-cysteine and the antioxidant glutathione (GSH),
is found in plants, especially the onion [96–98]. NAC has been used as an adjuvant therapy in many
psychiatric disorders (e.g., Alzheimer´s disease, schizophrenia, autism, addiction, substance abuse,
obsessive-compulsive and mood disorders [24,99–104]), with promising results and no relevant side
effects after its administration against inflammation [97]. The use of NAC in a chronic unpredictable
mild-stress animal model inhibited the levels of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α)
in the hippocampus and prefrontal cortex and exhibited antidepressant-like effects [71]. However, in
a recent study, NAC treatment did not show any effect on the serum levels of IL-6, IL-8, TNF-α, IL-10, or
C-reactive protein in a clinical trial for bipolar depression, possibly due to the small sample size used in
this study [72]. On the other hand, a study derived from an ADHD self-report scale symptom checklist
revealed that NAC reduced the ADHD symptoms in patients with systemic lupus erythematosus
and also inhibited the autoimmune inflammatory process via suppression of the mammalian target
of rapamycin (mTOR) and increased regulatory T cells [73,74]. Moreover, NAC has been reported to
block inflammasome activation as well as IL-18 and IL-1β production [75]. Recently, NAC protected
against cisplatin-induced toxicity in rat brain by modulation of inflammation and oxidative stress [76].
Thus, more studies are required to support the efficacy of NAC as a possible adjuvant treatment
for ADHD.
3.3. Omega-3 Fatty Acids Prevent Inflammation
Omega-3 fatty acids (omega-3 FAs) are polyunsaturated fatty acids, whose primary sources are in
oily fish. They are components of neuronal membranes and have a main role in neurotransmission,
neuronal development and function [105]. Two of the main omega-3 FAs are docosahexaenoic
acid (DHA) and eicosapentaenoic acid (EPA) and it has been demonstrated that supplementation
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with omega-3 FAs has beneficial effects in several neurodegenerative and neuropsychiatric
disorders such as Parkinson´s and Alzheimer´s diseases, depression, bipolar disorder, anxiety,
and schizophrenia [106,107]. These omega-3 FAs are also known to have anti-inflammatory
effects [108,109]. It has been demonstrated that DHA decreased the TLR-dependent inflammatory
signalling pathway by inhibiting dimerization and the recruitment of receptors to lipid rafts, which
resulted in the reduced production of pro-inflammatory cytokines [77,110]. DHA also reduces T-cell
activation, proliferation and promoted polarization into regulatory T cells (Treg; CD4+/CD25+/FoxP3+)
and interferes with the polarization of Th17 cells [78–80]. In a double-blind study, supplementation
with omega-3 FAs for eight weeks was shown to decrease the plasma IL-6 level and any hyperactivity
symptoms in children with ADHD [81]. However, a similar eight-week study found no effect on
ADHD, but this could be due to the dose of omega-3 FAs [111]. Thus, further studies are needed to
confirm the therapeutic dose, safety, and effectiveness of omega-3 FAs as a possible therapy against
inflammation in ADHD.
4. Oxidative Stress and the Relationship with ADHD
There is increasing evidence for the involvement of oxidative stress in the pathophysiology of
ADHD [15,16], but some studies have shown low levels of malondialdehyde (MDA) and the DNA
damage indicator 8-hydroxy-2′-deoxyguanosine (8-OHdG) in ADHD children [112,113]. MDA is
the degradation product of the main chain reactions that lead to the oxidation of polyunsaturated
fatty acids, and therefore serves as an oxidative stress marker. Recently, it was reported that the total
antioxidant capacity, catalase and GSH were significantly lower but that MDA was not significantly
different in children with ADHD [114]. However, high levels of MDA have been observed in both
adults [115,116] and children with ADHD [117], and increased plasma MDA and urinary 8-OHdG levels
were found in children with ADHD compared to healthy children [118]. Another study has shown low
total antioxidant levels in children with ADHD [119]. Furthermore, the SHR model showed an increase
in ROS production in the hippocampus, cortex, and striatum [120]. It was shown that paraoxonase-1
(PON1) and arylesterase activity were decreased (the arylesterase activity linked to PON1 is known
to protect lipoproteins from oxidation) and there was also a decrease in the total antioxidant status.
Moreover, the total oxidant status and oxidative stress index were increased in children with ADHD,
suggesting that there is significantly increased oxidative stress in ADHD [121]. It seems that nitrosative
stress also has a role in ADHD because of increased oxidative and nitrosative stress and impaired
oxidant–antioxidant balance has been demonstrated in children with ADHD [122]. The NO levels
were significantly higher in children, adolescents and adults [117,123] and also significant increases in
NO synthase activity were observed in children and adolescents with ADHD [124]. Although there
are inconsistent results regarding the relationship of oxidative stress and ADHD, in a meta-analysis it
was confirmed that ADHD is associated with increased oxidative stress in ADHD patients [16]. Taken
together, the data suggest that both oxidative and nitrosative stress in ADHD have the potential to
contribute to this condition [15].
On the other hand, it has been shown that dopamine and norepinephrine can easily undergo
auto-oxidation, forming ROS [125,126], which could lead to cell damage and damage to DNA [127,128].
Also, it has been shown that ATX treatment increases extracellular norepinephrine and dopamine
levels [19,129], which would produce an increase in oxidative stress and, as a consequence, cell damage
and mitochondrial dysfunction [130]. The brain is particularly susceptible to oxidative stress because of
its high lipid content and the high demand for energy consumption [131]. Neurons use mitochondria
as the main producers of ATP. Mitochondria regulate ion homeostasis and the redox state, and they
are also both producers of ROS and targets of ROS-induced damage, with such effects leading to
the collapse of bioenergetic function and the initiation of cell death [132]. For this reason, oxidative
stress could also be involved or interrelated with the catecholaminergic pathway in ADHD. However,
the exact relationship between both processes and ADHD remains unclear.
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Regarding ADHD medication, several reports have demonstrated that MPH has an impact on the
generation of oxidative damage. Increases in DNA damage have been found mainly in the striatum of
young and adult rats after MPH treatment [133]. In specific regions of the brain of young rats, chronic
treatment with MPH increased oxidative damage, as assessed by the thiobarbituric acid reactive species
and protein carbonyl assays, and this effect was dependent on the dose [134]. Furthermore, acute or
chronic treatment with MPH altered the activity of catalase and superoxide dismutase (SOD) enzymes
in the brain of young rats [135]. One study showed that acute and chronic treatment with MPH in the
SHR model increased oxidative stress [136]. Finally, the acute administration of high doses of MPH
can cause oxidative and inflammatory changes in brain cells and induce neurodegeneration in the
hippocampus and cerebral cortex of adult rats [137].
Hence, the growing research in looking for alternative therapies for ADHD has focused on
the neuroprotective effects of natural products as antioxidants because they may be high-efficiency
alternative treatments with fewer side effects [2].
5. Antioxidant Treatment Against Oxidative Stress in ADHD
As a consequence of oxidative stress, cells have the capacity to increase their antioxidant defences
through the activation of Nrf2. Thus, Nrf2 pathway activation takes place to act against the accumulation
of ROS. Consequently, Nrf2 activators have been proposed as antioxidant targets in neurodegenerative
and neuropsychiatric disorders (Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, autism,
schizophrenia, and depression) to counteract the increase in oxidative stress [138–140]. The action
mechanisms of the antioxidants used against oxidative stress are shown in Figure 2.
5.1. Sulforaphane Exerts Antioxidant Activity
In mice, the repeated administration of amphetamines induced decreases of dopamine and
3,4-dihydroxyphenylacetic acid DOPAC levels, as well as dopamine transporter immunoreactivity in
the striatum, and such effects were significantly attenuated by the treatment with SFN [82]. Activation
of the cellular antioxidant machinery (HO-1, glutamate-cysteine ligase catalytic subunit and Nrf2)
resulted in SFN-mediated protection against memory impairment in rats treated with okadaic acid [69].
Moreover, in a mouse model of autism, SFN improved the autism-like symptoms and upregulated
antioxidant defences such as SOD, glutathione reductase, and GPx [70]. The combination of NAC and
SFN significantly reduced oxidative stress, delayed the onset of epilepsy, blocked disease progression,
and reduced the frequency of spontaneous seizures in animals [83]. Also, in a clinical pilot study,
treatment with SFN increased the antioxidant GSH, suggesting a need to explore possible correlations
between GSH and clinical/neuropsychological measures and any positive influence that the treatment
of SFN could have on neuropsychiatric disorders [26]. Even though the antioxidative effect of SFN
supplementation in ADHD has not been studied, this could constitute a promising approach for
oxidative imbalances linked with ADHD. Nevertheless, more research is needed to confirm the efficacy,
therapeutic doses, and effect in combination with conventional therapy to be considered as adjuvant
therapy in ADHD. The effects of antioxidants and the main outcomes are summarized in Table 1.
5.2. N-Acetylcysteine Exerts Antioxidant Activity
The NAC molecule scavenges ROS and there has been growing evidence of its role in attenuating
psychiatric and neurological disorders and associated pathophysiological processes such as oxidative
stress, mitochondrial dysfunction and glutamate and dopamine dysregulation [96,97,141]. In rats,
amphetamine produces oxidative stress (by increasing hydroxyl radical formation and MDA) and
dopaminergic neurotoxicity, but treatment with NAC protected against amphetamine-induced
damage [84]. The treatment of paediatric Tourette´s syndrome with NAC in a randomized, double-blind
placebo-controlled trial did not show a significant difference between NAC and placebo for reducing
tic severity or any secondary outcomes such as depression, anxiety and ADHD [85]. In a case-study,
a 17-year-old girl was successfully treated with NAC, reducing the frequency of self-cutting and
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the symptoms of ADHD and depression [86]. Finally, in a mouse model of postoperative cognitive
dysfunction, NAC reduced oxidative stress and inflammation in the hippocampus and improved
cognitive function by activation of the Nrf2/HO-1 pathway [87]. Thus, it seems that part of the
protection produced by NAC is via the activation of antioxidant pathways that involve Nrf2. However,
more research is required to support the efficacy of NAC as a possible treatment for ADHD.
5.3. Omega-3 Fatty Acids Exert Antioxidant Activity
The omega-3 FAs supplementation can be an enhancer factor in the antioxidant defence against
ROS [142] and has been demonstrated to be effective against oxidative stress in the treatment of ADHD.
A pilot study demonstrated that supplementation with alpha-linolenic acid, an omega-3 FAs, improved
ADHD symptoms [91]. The findings of a small pilot study demonstrated that supplementation with
high doses of EPA and DHA improved the behaviour of children with ADHD [92]. In a double-blind
study, eight weeks of EPA and DHA supplementation decreased oxidative stress in children with
ADHD [81]. Supplements with high EPA, DHA or omega-6 FAs as a control demonstrated no significant
differences among the treatments. However, in one subgroup of children there was improvement
in spelling, reading and attention and a decrease in hyperactivity [88]. On the other hand, in
one study, EPA and DHA supplementation in children with ADHD demonstrated no significant
improvements in outcome [89]. Furthermore, no beneficial results were observed in a randomized
placebo-controlled clinical trial with EPA and DHA supplementation in children with ADHD [90].
There were increased EPA and DHA concentrations in erythrocyte membranes and improved working
memory function on supplementation with a mix of omega-3 FAs [93]. The effects of dietary omega-3
FAs supplementation on ADHD showed a reduction in ADHD symptoms [94]. Finally, omega-3
FAs improved the antioxidant defence (by increasing glutamate-cysteine ligase, Nrf2, glutathione
synthetase and glutathione peroxidase-4 proteins) in astrocytes treated with hydrogen peroxide,
and Nrf2 activation was dependent on the proportion of DHA to EPA incorporated into the membrane
phospholipids [95]. Thus, omega-3 FAs could be improving the antioxidant defences at least in part
through the activation of the Nrf2 pathway.
6. Conclusions
The association of ADHD with an increase in inflammation and oxidative stress could play a role
in the pathophysiological process. Nowadays, ADHD has no therapeutic option able to counteract the
progression of the disorder, and therapy with MPH and amphetamines might be increasing oxidative
stress. Thus, all evidence points towards inflammation and oxidative stress as factors which are
influencing ADHD, whereas antioxidants may perhaps be able to ameliorate ADHD progression due to
their anti-inflammatory and antioxidant properties. Consequently, some of the antioxidants discussed
in this review might establish a new therapeutic approach for the treatment of ADHD. While the use
of natural antioxidants for diverse disorders has been considered as a safe and healthier approach
for patients, they are still far from being standard treatments, due to the lack of controlled clinical
studies that may well corroborate both their high efficacy and safety. Accordingly, better designed and
more rigorous research and clinical trials are required before they can be established as a therapeutic
alternative and further studies would also be necessary to corroborate the use of these antioxidants
administered as a co-treatment with the current medications. Nevertheless, antioxidants could be
considered as a multi-target adjuvant therapy for ADHD.
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Abstract: Cancer is one of the leading causes of death worldwide and it can affect any part of the
organism. It arises as a consequence of the genetic and epigenetic changes that lead to the uncontrolled
growth of the cells. The epigenetic machinery can regulate gene expression without altering the
DNA sequence, and it comprises methylation of the DNA, histones modifications, and non-coding
RNAs. Alterations of these gene-expression regulatory elements can be produced by an imbalance
of the intracellular environment, such as the one derived by oxidative stress, to promote cancer
development, progression, and resistance to chemotherapeutic treatments. Here we review the
current literature on the effect of oxidative stress in the epigenetic machinery, especially over the
largely unknown ncRNAs and its consequences toward cancer development and progression.




Cancer is a generic term defining a wide and heterogeneous group of diseases that can affect any
part of the organism. It is considered a multiphasic disease primarily characterized by the appearance
of abnormal cells in tissues, with uncontrolled growth beyond their limits and that can invade adjacent
organs, disseminating to other parts of the body [1]. According to the World Health Organization,
cancer is one of the leading causes of death being responsible for 9.6 million of deaths in 2018 (17% of
the total death worldwide). As stated by the World Cancer Report in its edition of 2014, the five most
frequently diagnosed tumors among men were lung, prostate, colorectal stomach and liver cancers,
whereas among women were breast, colorectal, lung, cervix and stomach cancers [1,2].
Cancer development is a consequence of molecular alterations of genetic and/or epigenetic origin.
These can be initiated by the accumulation of genetic changes in DNA that affect the DNA sequence,
such as mutations and chromosomal rearrangements, or by modifications in DNA, histones and
non-coding RNAs that do not change the original sequence (epigenetic modifications). All of these
changes promote the clonal selection of those cells that show a more aggressive phenotype. In 2000,
different diseases were first grouped together and collectively referred to as cancer based on their major
molecular alterations: self-sufficiency in growth signals, insensitivity to antigrowth signals, evading
apoptosis, limitless replicative potential, sustained angiogenesis and tissue invasion and metastasis [3].
Afterwards, in 2009, another five characteristics related to the metabolic, proteotoxic, mitotic and
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oxidative stress, and DNA damage were also considered when defining cancer [4]. The last revision to
the molecular definition of a cancer cell was done in 2011 by Hanahan and Weinberg, who determined
new features and defined the presence of a tumor microenvironment developed by the cells along
the multiple steps of tumorigenesis [5]. Together, all these properties encompass the most up-to-date
definition of the cancer cell.
1.2. Epigenetics
Epigenetics is the discipline that studies the inheritable changes of gene expression that are
produced by chemical alterations of DNA, histones, and the involvement of non-coding RNAs, rather
than changes in the original sequence of DNA. All these changes lead to the remodeling of chromatin
to promote or impede gene expression. The silencing of gene expression at the chromatin level is
necessary for the normal life of eukaryotic organisms, and it is particularly important in the regulation
of biological processes such as the embryonic development, differentiation, or genomic imprinting [6].
There are three major mechanisms of epigenetic regulation described.
1.2.1. DNA Methylation
DNA methylation is the most studied and best known epigenetic mechanism. Generally, DNA
methylation is a synonym of genic silencing, as it shapes an inaccessible state of the chromatin for the
transcription process. This chemical modification consists of the addition of a methyl group (CH3) in
carbon 5 of a cytosine located, generally, in 5’-Cytosine-phosphate-Guanine-3’ (CpG) dinucleotides
regions. CpG dinucleotide distribution is asymmetric along the genome and its accumulation,
preferentially in promoter regions, is called CpG Island (CGI) [7,8]. In the human genome, there
are approximately 30,000 unmethylated CGIs that warrant the potentially active configuration of
constitutive genes. The methylation pattern of DNA is responsible for cell differentiation; thus,
its dysregulation leads to a number of diseases, including cancer [9].
The process of DNA methylation is catalyzed by the DNA-Methyltransferases (DNMTs). There are
four types of DNMTs, two involved in de novo methylation of DNA during development (DNMT3A
and 3B), one responsible for maintaining the methylation patterns after DNA replication (DNMT1),
and one without catalytic site that acts in conjunction with the de novo DNMTs to recruit chromatin
remodeling complexes [8,10]. This process, which is essential in embryonic development, is related to
the dosage compensation in mammals (X chromosome inactivation) [11–13] and genomic imprinting
(selective silencing of either maternal or paternal genes) [14]. Although this silencing is mediated by
DNA methylation, it is necessary for the involvement of the whole epigenetic machinery for the correct
development of the process.
1.2.2. Histone Modifications
Another well-known epigenetic mechanism consists of the chemical modification of histones
that are part of nucleosomes in chromatin. Similar to other proteins, histones can undergo
posttranslational modifications such as acetylation, methylation, phosphorylation, ribosylation,
ubiquitination, sumoylation, or glycosylation (reviewed in [15,16]), whose main function is the
regulation of DNA accessibility. In general, phosphorylation [17–19] and ribosylation [20,21]
promote euchromatin and gene transcription, whereas sumoylation triggers gene silencing [22,23] and
ubiquitination can play a dual role [24–26]. In the present review, we will mainly address the acetylation
and methylation of histones, which consist of the addition of NH3 groups through the action of Histone
Acetyl Transferases (HAT) and CH3 groups by the Histone Methyltransferases (HMTs) in specific
residues. Cooperation between DNA methylation and histones modifications induce the recruitment
of other chromatin modifiers to promote an active or inactive conformation of chromatin [16] (Table 1).
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Table 1. Relationship between the epigenetic modifications and the state of the chromatin.
Spot of Epigenetic Modification Potentially Active Chromatin Potentially Inactive Chromatin
DNA DNA methylation outside CpGislands









Chromatin conformation Open CondensedConstitutive Heterochromatin
1.2.3. Non-Coding RNAs
Non-coding RNAs (ncRNAs) are a newly identified group of epigenetic regulators that can
fine-tune gene expression without altering the DNA sequence. Prior to the discovery of their regulatory
capacity, ncRNAs were considered junk sequences accumulated during evolution, since they occupy
regions of the genome with no apparent coding function [27]. However, the Encyclopedia of DNA
Elements (ENCODE) project contributed to the classification of non-coding RNAs with previously
known functions (ribosomal or transcriptional RNA) [28] but also to the identification of novel
ncRNAs [29,30]. Nowadays, transcriptional ncRNAs are classified into small ncRNAs and long
ncRNAs (lncRNAs). Small ncRNAs can be divided into microRNAs (miRNAs), PIWI (P-element
Induced Wimpy)-interfering RNAs (piRNAs), and small interfering RNAs (siRNAs).
2. Implication of Epigenetics in the Development of Cancer
A number of studies have shown that cancer cells experience global changes in chromatin that
first affect the whole epigenome through a process of general hypomethylation leading to the genomic
instability, and second affect the loss of function by the hypermethylation of specific tumor suppressor
genes that regulate the signaling pathways involved in the cell differentiation process, such as APC,
GATA-4, or p16, allowing the clonal growth and the abnormal survival of cells [31]. In hematological
malignancies (leukemia, lymphomas, and myelomas) mutations in epigenetic modifiers such as JAK2,
DNMT3A, IDH2, or EZH2 are common hallmarks of these diseases [32–34]. This leads to alterations of
the chromatin structure and the silencing of a number of genes such as p15, RASSF1A [33,34], TET2,
CYP1B1 [35], PDZD2, CSDA [36], DAPK1, ZAP70 [37], TERT, or TWIST2 [38] to promote the growth of
cancer cells in these malignancies. The involvement of DNA methylation and histones modifications
in cancer is a well-known event that has been long studied in the last decades [39–44]. However,
the implication of non-coding RNAs and their regulation in cancer is still largely unknown, although
in the past years this knowledge has increased considerably [45,46]. Therefore, in the present section,
we will analyze the implication of non-coding RNAs in the development of solid tumors.
2.1. microRNAs
microRNAs are a group of non-coding small RNAs (measuring 19–23 nucleotides in length) that
regulate gene expression through posttranscriptional regulation without altering their DNA sequence.
Regulation occurs through miRNA binding to the 3′-untranslated region (3′UTR) of the messenger
RNA (mRNA) of a target gene [47].
miRNAs are transcribed as primary microRNAs (pri-miRNAs) by RNA polymerase II from DNA.
Afterwards, this molecule suffers two endonucleasic cuts mediated by the (1) Drosha and the Di
George Syndrome critical region 8 gene (DGCR8) protein inside the nucleus [48], and (2) Dicer in
the cytoplasm. The Drosha cut generates a hairpin of 60–100 nucleotides that is termed the miRNA
precursor (pre-miRNA), which is exported to the cytoplasm by the nuclear membrane transporter
‘Exportin-5′. Once in the cytoplasm, Dicer cuts this structure to generate a double-strand RNA molecule
of 19–23 nucleotides. The RISC complex (RNA-Induced Silencing Complex) selects one of the strands,
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which provokes the degradation of the other one and searches for the homology region in the 3′UTR of
a mRNA to block its transcription or favor its degradation [47].
miRNAs were first related to cancer in 2002; those that were downregulated were defined as tumor
suppressor miRNAs, such as the miR-15a/16-1 cluster in chronic lymphocytic leukemia [49]. In addition,
there is another type of microRNAs, such as the miR-17-92 cluster, whose induction increases cell
proliferation, survival, and tumor angiogenesis. The gaining or loss of these miRNAs can increase
or decrease the activity of several signaling pathways in cancer cells [50]. Moreover, miRNAs can be
involved in epigenetic regulation through the activation or inactivation of DNA-methyltransferases.
An example of this is the miR-29 family, which is a well-studied tumor-suppressive microRNA that
targets the DNA-methyltransferases DNMT1, DNMT3A and DNMT3B [51] in a number of tumors
such as ovarian [52], lung [53], liver [54], melanoma [55], and also hematological malignancies [56,57].
Some well-known tumor suppressors and oncogenes, such as c-MYC or p53, regulate the expression of
miRNAs to promote cancer progression. For instance, the oncogene c-MYC activates miR-17, miR-19a,
or miR-9 to promote cell cycle progression, inhibition of apoptosis, or metastasis (reviewed in [58]).
The loss of p53 also promotes cell cycle progression, cell survival, or stemness phenotypes through the
p53-activated miRNAs miR-34, miR-200, miR-15a/16-1 or miR-145 (reviewed in [59]). Although still
not much is known about gene and miRNA epigenetic regulation in cancer and their implications for
chemotherapy response, another regulatory mechanism of miRNA expression is the DNA methylation
of CpGs close to the sequence of the miRNAs of intronic regions or even in regulatory promoter regions
of the gene in which they are located [59–61].
2.2. piRNAs and siRNAs
PIWI-interfering RNAs and small interfering RNAs are groups of small non-coding RNAs of
approximately 24–31 and 20–22 nucleotides long, respectively. The main difference between them
resides in its processing: siRNAs mature from a double-strand RNA precursors such as miRNAs,
whereas piRNAs are processed from single-strand RNA precursors [62]. piRNAs bind to PIWI proteins
and siRNAs form the RISC (RNA interfering silent complex) complex. Both piRNA–PIWI [63] and
RISC complexes [64,65] can transcriptionally repress gene expression by recruiting the chromatin
silencing machinery (methyltransferases and deacetylases) or directly bind to the target mRNA by
sequence complementary to induce post-transcriptional gene silencing.
piRNAs were initially discovered a short RNAs in Drosophila that inhibit the expression of
the Stellate gene in a germ line [66]. However, follow-up studies showed that piRNA elements are
conserved along evolution and also control biological processes in somatic cells (reviewed in [62]).
Moreover, recent evidences suggest that piRNAs are related with human cancers. For example,
piR-651 [67,68] and piR-55490 [69] promote tumor cell proliferation in lung cancer, piR-36712 [70] and
piR-021285 [71] suppress cell proliferation and invasion in breast cancer, piR-1245 induces tumor growth
and is a poor prognostic biomarker in colorectal cancer [72], and piR-52207 stimulates tumorigenesis
in ovarian cancer [73].
siRNAs were discovered in the 1990s, after the injection of transgenes into Petunia plants [74]
and Double-stranded (ds) RNA specific to a genomic region into C. elegans [75] that resulted in RNA
interference (RNAi) associated gene expression changes. A few years later, a transient silencing with
synthetic exogenous siRNA in mammalian cells was observed [76], confirming their existence and
their gene-repressive function. Since then, the increasing knowledge about siRNAs has been directed
more toward the development of the siRNA as therapeutic tools rather than as biomarkers, which
have supposed a great advance for the understanding and therapeutics of cancer disease (reviewed
in [77,78]).
2.3. Long Non-Coding RNAs
Long non-coding RNAs (lncRNAs) are RNA transcripts of more than 200 nucleotides in length
that lack evident open reading frames [79]. lncRNAs are transcribed at lower levels than mRNAs,
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most of them are poorly conserved along evolution, and their expression seems to be more cell and
tissue-specific than mRNAs. As RNA molecules, they show a dual activity that allows them to interact
with proteins and other nucleic acids to form complex structures to enhance their regulatory role. Their
implication in gene expression regulation is wider than the one exerted by microRNAs; therefore, their
regulation is also stricter [80,81].
lncRNAs can be classified according to their chromosomal location and type of regulation
regarding their associated coding genes. Those lncRNAs encoded within the sequence of a coding gene
are classified as “overlapping lncRNAs”, including sense, antisense, bidirectional, exonic, and intronic
lncRNAs. Conversely, lncRNAs located between two genes are termed “long intergenic non-coding
RNAs” (lincRNAs) [82–85]. The action of lncRNAs can act in cis when they regulate the expression of
another gene encoded in the 1–300 kb upstream region [84,85]. Trans-acting lncRNAs can also regulate
genes that are encoded anywhere in the genome. In addition, lncRNAs whose function is exclusively
limited to the nucleus are guiders of chromatin modifying elements—such as DNMTs, Polycomb
Repressor Complex (PRC), and/or HATs—to repress or activate the transcription. There is another
group of lncRNAs that exert their function in the cytoplasm to regulate the expression of mRNAs and
microRNAs in different ways [30,82,86].
The first lncRNAs identified are crucial for the correct embryonic development, since they regulate
the chromosome dosage compensation (Xist) and the genomic imprinting and silencing of maternal
or paternal genes (H19) [11,87,88], which exemplifies the important role of lncRNAs regulating the
normal functioning of the cell and the organism. Thus, alterations in lncRNAs contribute to the
development and progression of human diseases, including cancer. In cancer, the metastasis-associated
lung adenocarcinoma transcript 1 (MALAT1), which regulates mRNA splicing, is the most studied
cancer-associated lncRNA [89]. The expression of MALAT1 is upregulated in Non Small Cell Lung
Cancer (NSCLC) and ovarian cancer metastatic tumors [90,91], promotes aggressive phenotypes [91–93],
and can be used as a prognostic biomarker in stage I NSCLC [90]. In addition, MALAT1 is reported to be
overexpressed in uveal melanoma [94], melanoma [95], hematological malignancies [96–98], and other
tumor types [99]. Moreover, recent research have identified a number of lncRNAs such as PVT1
(Plasmacytoma Variant Translocation 1), HOTAIR (HOX Transcript Antisense RNA), GAS5 (Growth
Arrest Specific-5), SAMMSON (Survival Associated Mitochondrial Melanoma Specific Oncogenic
Non-Coding RNA), CASC15 (Cancer Susceptibility 15), or MEG3 (Maternally Expressed Gene 3) that
promote cancer development and progression and can be used as biomarkers of the disease (reviewed
in [100–103]). Given the role of epigenetic mechanisms in cancer development and progression,
studying how changes in the epigenetic machinery promote aggressive phenotypes would contribute
to the development of new therapeutic approaches and better biomarkers in the clinic.
3. Oxidative Stress and Its Effect in the Epigenetic Machinery to Promote Cancer
Oxidative stress is defined as an imbalance between reactive oxygen species production (ROS)
and the response of antioxidant enzymes. The major signaling pathway that regulates oxidative
stress is NRF2 (Nuclear factor erythroid 2-related factor 2)–KEAP1 (Kelch-like ECH-associated
protein 1) [104–107]. An intracellular ROS increase triggers the activation of NRF2 by KEAP1
inhibition. Nrf2 is translocated to nucleus and dimerizes with other proteins, such as small MAFs
(musculoaponeurotic fibrosarcomas), to bind to the Antioxidant Response Element (ARE) sequences in
the DNA. The Nrf2–sMAF (small MAF family) dimer works similar to a DNA transcription factor,
recognizing AREs and activating several antioxidants genes [108–110]. Alteration of the NRF2–KEAP1
pathway is one of the most common and most studied events in cancer regarding pro-oncogenic
disorders of oxidative stress. Furthermore, the increase of ROS triggers a multitude of response in
different signaling pathways such as MAPK (Mitogen-activated protein kinase) [111], NF-κB (nuclear
factor kappa-light-chain-enhancer of activated B cells) [112], STAT3 (Signal transducer and activator
of transcription 3) [113,114], or PPARγ (Peroxisome proliferator-activated receptor gamma) [115]
that promote antioxidant gene expression, proliferation, and survival in response to oxidative stress,
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which allow cancer cells to progress. While the activation of these pathways can control antioxidant
gene expression independently, all these signaling pathways are also interconnected, highlighting the
complex regulatory network that controls the response to oxidative stress.
Increased oxidative stress derived from the augmented metabolism of cancer cells is a common
event in many tumor types to promote and maintain its tumorigenic potential. In fact, oxidative
stress produces genomic instability and genomic damage that can lead to tumorigenesis [5,116,117].
It has been shown that the hypoxic state of tumor cells increases the oxidative stress situation, which
leads to structural and epigenetic changes mediated by the Hypoxia-Inducible Factor (HIF)-1 [118,119].
In another study, continuous exposure to the oxidative stress of non-tumoral kidney cells results in
malignant transformation [120]. Oxidative stress leads to an expression imbalance both at the level of
histones (HDAC1, HMT1, and HAT1) and of epigenetic regulators (DNMT1, DNMT3a, and MBD4) in
these cells. However, the acquired tumorigenic potential of these non-tumoral kidney cells decreased
after treatment with the DNA demethylating agent 5-aza-2′-deoxycytidine [120], which supports the
notion of an implication of the epigenetic machinery in tumor development. Moreover, several studies
indicate a link between glutathione (GSH) metabolism and the control of epigenetics mechanisms
at different levels. GSH is an important antioxidant enzyme that intervenes in several biological
processes. Alterations in GSH synthesis or GSH depletion produce global DNA hypomethylation that
could be due a decrease of S-adenosylmethionine (SAM) [121,122], which is a methyl group donor
required for the action of DNMTs and HMTs [122,123]. Before DNMTs and HMTs obtain methyl groups
from SAM, it suffers a catalytic transformation from methionine into SAM through the methionine
adenosyltransferase (MAT) [122,123]. Both MAT and methionine synthase (MS) are very sensitive to
oxidative stress and the balance of GSH synthesis, which explains a low activity of methyl transferase
enzymes and a decrease of the genomic methylation level in redox imbalance situations (reviewed
in [121,122]. All these changes in the oxidative state of the cell lead to the modulation of the epigenetic
machinery at every level and alterations that promote tumor development.
3.1. Effect over DNA Methylation
Changes in DNA methylation derived from oxidative stress are mainly due to alterations of
the activity and function of DNMTs (see above). Several studies suggest that the induction of
oxidative stress mediated by hydrogen peroxide increases the activity of DNMT1 and its binding to
the promoters of tumor suppressor genes as RUNX3 [118]. In addition, hydroxyl radicals promote a
global hypomethylation due to the interference in DNMTs–DNA binding capacity [124]. In addition,
a high oxidative stress state induces changes in the catalytic cycle of iron and therefore to the inhibition
of DNA demethylases of the TET family, thus increasing the levels of DNA methylation [119].
Moreover, high oxidative stress situations induced by ROS production increase 8-
hydroxydeoxyguanosine (8-OHdG) levels in some cancer types. 8-OHdG triggers a conformational
modification that changes the chromatin active state to chromatin repressive state. Therefore, 8-OHdG
could promote tumorigenesis due to changes in the methylation patterns of tumor suppressor
genes [125]. In addition, 8-OHdG blocks DNMTs–DNA binding, leading to a global hypomethylation
of the genome [126,127].
One element that contributes enormously to the oxidative stress and thus in alterations of the
epigenetic machinery is the tobacco smoke [128]. Apart from being a potent carcinogen, tobacco
smoke induces high levels of ROS that result in the development of diseases such as the chronic
obstructive pulmonary disease (COPD), which also leads to the alteration of the DNA methylation
patterns [128,129].
3.2. Effect over Histone Modifications
It is also well known that oxidative stress induce changes in the acetylation and methylation of
histones as it acts over the enzymes that maintain the chromatin state (see above). Oxidative stress
induced by hydrogen peroxide can recruit histone modifiers complexes to promoters of active tumor
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suppressor genes to inhibit them [118,119]. Despite oxidative stress affecting the posttranslational
modifications of histones that regulate the chromatin, it does not act in the same way due to the
different sensibility to the oxidative stress of the HMTs, HDMs, and HATs [119].
In a similar manner to DNA methylation, one of the most remarkable changes in histone
deacetylases (HDAC), which reduce their activity, is produced as consequence of cigarette smoke [130].
COPD patients show a decrease in HDAC2 activity that increases acetylation in histones H3 and H4 of
the NF-κB promoter and thus to the dysregulation of proinflammatory genes [128].
In addition, there is evidence of a clear interaction between HIF1α and several HDACs and lysine
acetyltransferases (KATs) in hypoxia context. The HIF1-directed transcriptional response appears
to be responsible, in part, for the increased stabilization of HIF1α due to the action of HDACs and
KATs [131,132].
3.3. Effect over Non-Coding RNAs
Similarly, transcriptional regulation mediated by non-coding RNAs is also altered in several ways
by oxidative stress, as it has been shown for DNA and histones modifications.
Currently, there are a number of microRNAs whose alteration on their expression pattern is
due to changes in the cellular oxidative stress [133,134]. For example, miR-200c is upregulated in
epithelial cells as a result of increasing ROS and leads to an increase of apoptotic and senescent cells
through the action of its target gene ZEB1 [135]. Other miRNAs whose expression is induced by
transcription factors that are sensitive to increased levels of ROS are miR-27a/b through c-MYC [136],
miR-200 and miR-506 through p53 [137,138], and miR-206 through p38 (reviewed in [134]). In addition,
the processing of miRNAs from their primary form is regulated by DGRC8–Drosha complexes. Recent
reports demonstrate that increased oxidative situations decrease the processing capacity of DGRC8,
which relies on Fe(III) for its action, and therefore the downregulation of the corresponding mature
miRNA [139,140].
There are several miRNAs involved in the NRF2–ARE detoxification pathway, some due
to the direct targeting of NRF2 or its natural inhibitor KEAP1, and others due to the indirect
action over genes that regulate this signaling pathway (Table 2). For instance, miR-101 inhibits
the expression of NRF2 in breast cancer cells to enhance their sensitivity to oxidative stress and
suppress proliferation [141]. miR-432-3p binds directly to the KEAP1 coding region, downregulating it
and upregulating the transcription of downstream genes of the NRF2–ARE pathway in esophageal
squamous cell carcinoma [142]. miR-7 relieves the oxidative stress of neuroblastoma cells by targeting
KEAP1, which promotes an increased expression of NRF2 and the transcription of antioxidant
genes such as HO-1 and GLCGM [143]. miR-200a binds to the KEAP1 3′UTR sequence leading to the
degradation of its mRNA in breast cancer cell [144], hepatocellular carcinoma cells [145], and esophageal
squamous cell carcinoma cells [146] (Figure 1). However, further research is needed to fully understand
the complex regulatory network between miRNAs and the KEAP1/NRF2 axis.
Table 2. MicroRNAs involved in the antioxidant response in cancer disease.




MIR-101 Breast NRF2 downregulated [141]
MIR-28 Breast NRF2 downregulated [147]
MIR-153 Breast NRF2 downregulated [148]
MIR-432-3P Esophageal Squamous KEAP1 upregulated [142]
MIR-200A Breast, Hepatocelullar,Esophageal squamous KEAP1 upregulated [144–146]
MIR-23A Leukemic KEAP1 upregulated [149]
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MIR-7 Neuroblastoma KEAP1 upregulated [143]
MIR-7 Non small cell lung MAFG downregulated [150]
MIR-148B Endometrial ERMP1 downregulated [151]
MIR-500A-5P Breast TXNRD1and NFE2L2 downregulated [152]
MIR-143 Colon SOD1 downregulated [153]
MIR-139-5P Breast MAT2A downregulated [154]
MIR-29B Ovary SIRT1 upregulated [155]
MIR-31 Oral squamous SIRT3 downregulated [156]
MIR-33A Glioma SIRT6 downregulated [157]
MIR-517A Melanoma JNK sig.path. downregulated [158]
MIR-144-3P Lung NRF2 downregulated [159]
MIR-340 Hepatocelullar NRF2 downregulated [160]
MIR-141 Ovary KEAP1 upregulated [161]
Figure 1. Regulation of NRF2/Keap1 by microRNAs. Oxidative stress can induce or repress some
microRNAs that regulate the posttranscriptional expression of Keap1 or NRF2. Red lines with rounded
end indicate inhibition. Green arrows indicate activation.
On the other hand, and despite that lncRNAs are a relative recent discovery, the alteration
of these non-coding RNAs have also been linked to oxidative stress. The lncRNA “nuclear lung
cancer associated transcript 1” (NLUCAT1) is upregulated in hypoxia in lung cancer cells through
HIF2A, NF-κB, and NRF2 transcription factors [162]. This lncRNA promotes oncogenic abilities
and cell survival in the presence of cisplatin treatment probably by upregulating the expression of
antioxidant genes (ALDH3A1, GPX2, GLRX, and PDK4) through a mechanism still not understood [162].
In hepatocellular carcinoma cells, cell death produced by erastin, a strong inductor of ferroptosis,
is mediated by GABPB1-AS1 lncRNA [163]. This lncRNA blocks GABPB1 mRNA recruitment to
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polysomes to decrease its protein expression and reduce the transcription of peroxidase proteins, which
in turn increases ROS production and cell death [163]. The exposure of renal cell carcinoma cells to
H2O2 to induce oxidative stress leads to a downregulation of the lncRNA ‘secretory carrier membrane
protein 1′ (SCAMP1) and to apoptosis of the cells [164]. In this situation, SCAMP1 acts as a competitive
endogenous RNA (ceRNA) with ZEB1 and JUN to sequester miR-429. Thus, the downregulation of
SCAMP1 increases the availability of miR-429 to target ZEB1 and JUN and this way decreases cell
viability [164]. This mechanism of “sponging” microRNAs through lncRNAs is a common feature
to regulate gene expression by which RNA molecules sequester microRNAs to prevent them for
targeting other RNAs. For instance, the expression of HULC and H19 is triggered by oxidative stress
to upregulate Interleukin-6 (IL-6) and the C-X-C chemokine receptor type 4 (CXCR4) sequestering
Let-7a/b and miR-372/-373, respectively, to promote cholangiocarcinoma migration and invasion [165].
In multiple myeloma, MALAT1 positively regulates NRF1 and NRF2 through the transcriptional
inhibition of Keap1 by EZH2 [96], which is a component of the PRC that induces H3K27me3 [166]
through a mechanism still under study. In addition, MALAT1 and EZH2 also interact to inhibit miR-29
in this disease [97], which is interesting due to the negative regulation of Keap1 through miR-29 [167]
and its implication in the regulation of ROS [168], as it has been shown in other diseases. While all
these reports clearly describe oxidative stress responses mediated by lncRNAs, as summarized in
Table 3, a detailed regulation of these non-coding RNAs by reactive oxygen species and their role in
cancer development and progression is still under study.
Table 3. Long non-coding RNAs (lncRNAs) regulated by the antioxidant response in cancer disease.




NLUCAT1 Lung cancer HIF2A, NF-KB, NRF2 Upregulated [162]
GABPB1-AS1 Hepatocellularcarcinoma GABPB1 Upregulated [163]
SCAMP1 Renal cellcarcinoma miR-429/ZEB, JUN Downregulated [164]
HULC Cholangiocarcinoma Let-7a, Let-7b/IL-6 Upregulated [165]
H19 Cholangiocarcinoma miR-372,miR-373/CXCR4 Upregulated [165]
UCA1 Non-small cell lungcancer miR-495/NRF2 Upregulated [169]
UCA1 Hepatocellularcarcinoma miR-184/OSGIN1 Upregulated [170]
4. Chemotherapy-Induced Oxidative Stress: Epigenetics and Cisplatin Resistance
One of the main problems associated with cancer treatment is the development of resistance to
different treatments. This resistant state in cancer cells can be explained by intrinsic and/or acquired
mechanisms of desensitization to the drug’s action. There are several ways proposed by which cancer
cells develop drug resistance such as cellular plasticity, clonal selection due to pharmacological stress,
signaling pathways plasticity, or the epigenetic mechanism, among others.
4.1. Cisplatin Resistance Mechanisms
Cisplatin (CDDP) is the first-line chemotherapeutic treatment in a multitude of tumors. Cisplatin is an
alkylating agent that intercalates in DNA strands, forming adducts that cause genomic damage [171–174].
Moreover, one consequence of cisplatin administration is the production of high levels of ROS and
nitrogen (RNS), which increase the oxidative stress in tumor cells that can promote alterations in the
epigenetic machinery [175–177]. Although cisplatin is a potent inductor of cell apoptosis due to the
increased intracellular oxidative imbalance, amongst other functions, the main limitation of its use is
that the disease almost invariably progresses to a platinum-resistant state.
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There are a number of events underlying the phenomenon of cisplatin resistance in cancer.
One such event consists of alterations in DNA repair mediated by the activation of the epidermal
growth factor receptor (EGFR) pathway resulting in cellular proliferation or the nuclear interaction
of the receptor with proteins responsible for rejoining double-strand breaks [170]. Other proposed
mechanisms include the reduced intracellular accumulation of cisplatin due to the overexpression
of molecular ABC transporters that act by transporting the drug out of the cell, the activation of
transcription factors that induce cell proliferation, the increase of antiapoptotic proteins, such as
BCL-2, and alterations in the epigenetic regulatory machinery, mostly in DNA methyltransferases that
modify the expression of a number of genes [172,178–180] (Figure 2). Despite the efforts to unravel
the specific mechanisms for developing cisplatin resistance, it seems to be a multifactorial effect that
includes several of the above-named mechanisms. Thus, understanding these molecular mechanisms
of resistance development is a crucial step to improve the treatment of the disease.
 
Figure 2. Effect of cisplatin inside the cell. Cisplatin is a platinum-derived drug that acts by generating
aqueous species that bind to the N7 position in the guanine and causes inter and intra-strand cross-links
in DNA that activate the mechanisms of cell cycle arrest or programmed cell death (1). In addition,
cisplatin increases the oxidative stress of the cells, which leads to apoptosis (1), but also to alterations
in the epigenetic enzymes and regulatory non-coding RNAs that change the epigenetic patterns (2).
An increase of the DNA repair machinery (3), the reduced intracellular accumulation of cisplatin (4),
or changes in the epigenetic machinery as a result of oxidative stress (5) lead to the development of
cisplatin resistance and thus to the therapeutic limitation of its use. Red lines with rounded ends
indicate inhibition. Green arrows indicate activation.
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4.2. DNA Methylation and Histone Modifications
As we mentioned above, cisplatin-resistance development is related to the activation of DNMTs,
whose activity can be modified due to the oxidative stress produced by cisplatin treatment. The process
of DNA methylation in tumor cells leads to the silencing of specific genes that are crucial in normal
conditions for the correct functioning of the cells. This silencing can be direct, if hypermethylation
occurs in the promoter region of the gene that becomes inactive, or indirect in those cases where
hypermethylation is on regulatory regions of coding and non-coding genes, silencing them and
therefore increasing the expression of their target genes.
In fact, the transcriptional silencing of some genes, such as the arginine–succinate–synthetase,
mediated by the hypermethylation of the CpG dinucleotides of its promoter, is a frequent epigenetic
event associated to the development of cisplatin resistance in ovarian cancer [181]. Other studies
describe the loss of expression of IGFBP-3 (Insulin-like Growth Factor Binding Protein-3) in NSCLC as
an effect of cisplatin administration. The silencing of this gene is produced by the hypermethylation of
its promoter region in cisplatin-resistant cancer cells and leads to the development of cisplatin resistance
through the activation of the Insulin-like growth factor receptor (IGF-IR)/AKT pathway [182,183].
There is increasing knowledge about the genes whose promoters are hypermethylated in cancer and
that are related to cisplatin resistance as a consequence of the epigenetic silencing that they are suffering.
However, the number of coding and non-coding genes identified up to date remains limited [184].
Alterations in the expression in histones deacetylases and demethylases can also contribute to
the development of a cisplatin-resistant state in some tumor types. An example of this occurs in
NSCLC in which the increased expression of these enzymes, the histone deacetylase-6 (HDAC6)
specifically, decreases sensitivity to cisplatin through the reduction of apoptosis and prevention of
DNA damage [185]. On the other side, oxidative stress induced by cisplatin administration leads to
changes in histone demethylases, altering the methylation pattern of histones and being a silencing
mechanism in cancer [183]. Moreover, cisplatin and other chemotherapeutic regimens also promote
ROS induction and ubiquitination of the histone variant H2AX, which determine the sensitivity to the
drug [186], reinforcing the importance on histones modifications in redox balance.
The interest of studying the link between epigenetic modifications of non-coding RNAs regulatory
regions and the development of platinum-resistant phenotypes has increased in the recent past years.
Therefore, in the next sections, we will discuss how alterations of non-coding RNAs promote resistance
to cisplatin treatment.
4.3. microRNAs
One of the regulatory mechanisms of miRNAs expression is their silencing by the methylation of
their regulatory regions, thereby increasing the expression of their target genes [45,187]. One of the
first miRNAs identified to be regulated by this mechanism was miR-200c, whose hypermethylation of
its regulatory region is responsible for the downregulation of this miRNA and therefore the subsequent
development of resistance to chemotherapy in NSCLC cell lines [188]. The silencing of miR-493 by
DNA hypermethylation is also involved in promoting cisplatin resistance in lung cancer cells by
increasing the expression of its target gene TCRP1 [189], which is a gene linked to cisplatin resistance
in lung, ovarian, and tongue cancer cells [190,191].
There are also a number of miRNAs that regulate the expression of KEAP1/NRF2 to control cisplatin
response. miR-144-3p is downregulated in lung cancer to increase NRF2 expression and promote better
cell survival in the presence of cisplatin treatment [159]. In cisplatin-resistant hepatocellular carcinoma
cell lines, miR-340 is downregulated, which increases NRF2 activity, thus promoting resistance to the
treatment [160]. In addition, miR-141, which targets KEAP1, is upregulated in ovarian cancer cell
lines to promote cisplatin resistance [161]. Although the authors of this study conclude that NF-KB,
and not the NRF2 pathway, is responsible for the observed phenotype, it might be worth studying the
miR-141/KEAP1/NRF2 axis due to the known role of NRF2 in promoting cisplatin resistance in other
tumor types.
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miR-7/MAFG/ROS axis
Interestingly, some miRNAs can target the binding partners of NRF2 to affect cisplatin response.
An example of this is the miR-7/MAFG/ROS axis that leads to cellular and biological responses
that promote tumor development and progression in different tumor types. The main epigenetic
mechanism involved in this aberrant alteration is the DNA methylation at the CpG Island surrounding
the chromosomal location of miR-7 that has been associated with cancer progression [150]. In this
study, the authors worked with cellular models of cisplatin resistance established after the chronic
exposure to the cisplatin treatment of initially cisplatin-sensitive NSCLC and ovarian cancer cell
lines [150,192]. These cisplatin-resistant cell lines share a common downregulation of miR-7 expression,
compared to the parental sensitive cells, due to the hypermethylation of a CpG island located on its
promoter [150]. Most importantly, lung adenocarcinoma patients harbor a hypermethylated miR-7
promoter when compared to healthy controls [193]. In addition, these patients show lower overall and
progression-free survival rates, suggesting that the hypermethylation of miR-7 could be involved in
the early establishment of the disease [193]. In fact, miR-7 hypermethylation constitutes a molecular
event that accounts mainly at the expense of the emphysema patients, as analyzed from a huge COPD
cohort. Patients with emphysema phenotype are considered the group of COPD patients that have a
higher risk of developing lung cancer than other COPD phenotypes [194], indicating that the silencing
of miR-7 through DNA hypermethylation might be one of the main determinants explaining the
higher incidence of lung cancer in these patients [195]. Similarly, studies in ovarian cancer have also
shown that the hypermethylation of miR-7 is associated with a worst response to platinum-derived
chemotherapy, which is indicated by lower overall survival and progression-free survival rates when
miR-7 promoter is methylated [150]. One of the effects of miR-7 silencing in cisplatin-resistant lung and
ovarian cancer cell lines is the upregulation of its target gene MAFG (Musculoaponeurotic Fibrosarcoma
Oncogene Family, protein G) [150,196] (Figure 3).
MAFG is a bZIP transcription factor that belongs to the small MAF family (sMAFs) of proteins.
The sMAFs harbor a basic region motif for DNA binding and a leucine zipper motif for dimerization and
are thought to have compensating roles. sMAFs can homodimerize with themselves or heterodimerize
with other bZIP transcription factors such as the Cap’N’Collar (CNC) family or the Bach family
to activate or repress gene expression in response to oxidative stress. Therefore, miR-7 silencing
promotes low levels of ROS in cisplatin-resistant cancer cells due to the upregulation of MAFG. In fact,
cisplatin-resistant NSCLC cell lines show lower ROS levels than the sensitive counterpart in response
to cisplatin treatment (Figure 3). This effect can be overcome by sequestering MAFG through specific
aptamers against the protein, as it results in a decrease of cell viability due to an increase of ROS
production. In fact, knockout (KO) experiments in mice have shown that the small Mafs are essential
for the activation of ARE-dependent genes. MafG KO mice showed mild thrombocytopenia and
motor ataxia that improved with age, while MafK and MafF KO mice did not show an apparent
phenotype [197], suggesting that the role of MafG is not well compensated by the other sMafs.
In addition, the double KO MafG/MafF compromised the expression of NQO1 and other oxidative
stress-response genes [110]. Moreover, other authors have described the essential role of sMafs in
regulating the expression of cytoprotective genes [110]. Importantly, ChIP-seq experiments to identify
the binding sites of NRF2 and MAFG have demonstrated that, when heterodimerized, they can regulate
genes involved in antioxidant and metabolic networks such as NQO1, HMOX1, IDH1, PGD, and G6PD,
amongst others [109].
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Figure 3. Proposed mechanism for the acquired resistance to cisplatin in NSCLC and ovarian cancer
cells through miR-7 methylation and Musculoaponeurotic Fibrosarcoma Oncogene Family, protein G
(MAFG) overexpression. Sensitive cells are represented on the left. The unmethylation of the miR-7
CpG Island allows its transcription, thus targeting the mRNA of MAFG, which promotes an increase of
ROS and cell death. Cisplatin-resistant cells, right, harbor a methylated CpG island of miR-7, therefore
allowing MAFG translation into protein, interaction with NRF2, and the transcription of antioxidant
genes. CDDP, cisplatin; ROS, Reactive Oxygen Species.
Despite sMafs have been associated with cellular response, little is known about their implication
in human pathologies. However, there are a number of reports that relate the overexpression of MAFG
to cancer development and progression. Several studies demonstrate that MAFG promotes aggressive
phenotypes in hepatic tumors [198–200], bladder cancer [201], and colon cancer [202,203].
In addition to its role in actively repressing or promoting gene expression, MAFG has recently
been involved in the regulation of the methylator phenotype in colon and melanoma [204,205]. In both
studies, hyperactivation of the MAPK pathway derived by oncogenic BRAFV600E or EGFRG719S prevents
the ubiquitination of MAFG by phosphorylation of the S124 through ERK. This posttranslational
modification leads to the formation of a protein complex orchestrated by MAFG stabilization and
formed by BACH1, CDH8, and DNMT3B. The activation of these complexes leads to the increased
methylation of CpG islands located in the tumor suppressive genes of both melanoma and colon
cancer [204,205]. Therefore, the implications of MAFG in regulating gene expression are more complex
than initially thought and worth studying in the future in order to identify potential biomarkers
and therapeutic targets. Most importantly, since the KO mice of MAFG did not show a strong
phenotype [197], targeting MAFG as a therapeutic approach, as it has been previously done to restore
cisplatin sensitivity in lung cancer cells through DNA aptamers [196], provides promising results and
potential therapeutic strategies in the future.
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Apart from being stabilized by a posttranslational regulation, MAFG expression is also regulated
at different levels. The ChIP-seq experiment mentioned above also confirmed that MAFG transcription
can be regulated by NRF2 [109], which is an observation that was previously reported in mouse [206],
suggesting a regulatory feedback between MAFG and NRF2 in response to oxidative stress in order to
cope with high levels of ROS. However, MAFG can also be regulated at the post-transcriptional level
by microRNAs. Although the coding sequence of MAFG is relatively small, the 3′UTR is over 4000
nucleotides long and over than 50 miRNAs are predicted to regulate MAFG. Some reported examples
include miR-218 in smoking-induced disease processes in lung [207] and miR-7 in NSCLC and ovarian
cancer cells [150].
Interestingly, as we mentioned above, miR-7 can also regulate the expression of genes that promote
or reduce oxidative stress in the cell. One example is the regulation of KEAP1 in neuroblastoma
cells [143]. In these cells, miR-7 relieves oxidative stress by targeting KEAP1, which promotes an
increased expression of NRF2 at the posttranslational level, which will promote the transcription of
antioxidant genes such as HO-1 and GLCGM. Besides, miR-7 can regulate the expression of proteins
that promote oxidative stress situations. A-synuclein is a protein involved in synaptic activity through
the regulation of vesicle docking, fusion, and neurotransmitter release [208–210]. One of the hallmarks
of Parkinson’s disease is the aggregation of a-syn in neurons to cause an intracellular toxic burden.
This promotes mitochondrial dysfunction, the decreased activity of the superoxide dismutase 1 (SOD1),
and low GSH, which in turn results in increased ROS production [211,212]. miR-7, whose expression is
mostly present in neurons, can reduce a-syn expression by targeting the 3′UTR region of the mRNA,
protecting the cells against the a-syn-mediated proteasome impairment and susceptibility to oxidative
stress [209]. In addition, the role of miR-7 regulating a-syn has been studied in the ischemic brains of
rodents. In this case, cerebral ischemia in rodents decreases miR-7 expression, which induces α-Syn
expression and promotes cell death. Interestingly, the administration of an miR-7 mimic in pre-ischemic
rats has a neuroprotective effect and decreased brain damage in post-ischemic brains, while these
effects were lost in a-syn-/- mice [208]. Although these reports are not focused on cancer, due to the
important role of miR-7 as a tumor suppressor (reviewed in [213]), it would be worth studying its role
in regulating oxidative stress through these proteins in cancer.
4.4. Long Non-Coding RNA
Different CpG island methylation patterns have also been described between different types
of lncRNAs depending on their chromosomal location in several tumor types as a result of chronic
treatment with cisplatin [112]. However, the specific role of these silenced lncRNAs in cisplatin
resistance remains unknown. Recent evidence suggests that lncRNAs are involved in chemoresistance
to various anticancer therapies. One example is HOTTIP, an lncRNA regulating 5′ HOXA gene
transcription, which has been associated with cell proliferation, invasion, and chemoresistance in
osteosarcoma, liver, and pancreatic cancers [113,114]. The lncRNAs UCA1 and ROR have been
associated with the resistance of cancer cells to platinum-based treatments in bladder [115] and
nasopharyngeal cancers [116], respectively. In addition, some miRNAs are regulatory intermediates
between UCA1 and oxidative stress produced by cisplatin [117] or arsenic treatment [96] in which
UCA1 acts as ceRNA with other microRNA target genes. In this context, UCA1 upregulation promotes
a competing situation for miR-495 and miR-184 with NRF2 [117] and ‘oxidative stress induced growth
inhibitor 1′ (OSGIN1) [96], respectively, to upregulate their expression and promote a better survival
to drug treatments of NSCLC cells [117] and hepatocellular carcinoma (HCC) cells [96]. Although
these reports show the implication of lncRNAs in promoting drug-resistant phenotypes, the specific
mechanism by which lncRNAs regulate chemotherapy resistance is yet a novel field for exploration.
5. Conclusions and Future Directions
The relevance of epigenetic mechanisms in cancer has increased in the last years considerably.
DNA methylation, histone modifications, and ncRNA are crucial elements that regulate both oncogenes
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and tumor suppressor genes. In this review, we bring out the importance of the relationship between
these epigenetics mechanisms and oxidative stress in cancer disease. Indeed, when an increase of
oxidative stress occurs, different pathways are activated—among them, the regulation of epigenetic
mechanisms, in order to activate antioxidant response. This happens to maintain a high metabolism,
which is a characteristic of cancer cells, and also to avoid apoptosis induced by oxidative stress and
genomic damage, for example, in the development of therapy resistance.
Specifically, the way in which miRNAs and lncRNAs regulate key oxidative stress genes is a
promising horizon that we can approach to lead anticancer therapies in the future. An example of this is
the miR-7/MAFG axis regulation in NSCLC and ovarian cancer. miR-7 methylation is able to modulate
the antioxidant response over ROS production by MAFG downregulation. Furthermore, MAFG seems
to be leading a methylator program of specific genes in colorectal and melanoma cancer, so that its
increase could affect the methylation profile of different tumor suppressor genes, promoting the cancer
cell survival. Interestingly, ROS can both trigger MAFG transcription, to respond to oxidative stress,
but it also can promote the MAPK pathway hyperactivation that leads to the stabilization of MAFG,
thus suggesting a new molecular mechanism that changes the epigenetic patterns through ROS/MAFG.
Advances and the development of new technologies would allow in the future targeting these
elements that are critical for the cell. For example, the identification of aptamers that block MAFG
function has opened new research directions for re-sensitizing cisplatin-resistant cells in vitro. Although
other aptamers have been used in preclinical models to target cellular membrane receptors, targeting
MAFG would be challenging, as it mainly located in the nucleus. Therefore, the development of new
delivery approaches will be needed to use MAFG aptamers as a functional therapy. For example,
the use of nanoparticles would be a powerful approach to deliver these inhibiting molecules, as it has
been shown for microRNAs.
Although the current review focused on ncRNAs and their effectors in response to oxidative
stress in solid tumors, it is important to highlight the crucial role of the other well-known epigenetic
modifications of DNA and histones, as well as alterations of the enzymes that affect these modifications,
not only in solid tumors but also in hematological malignancies. There are a substantial number
of epigenetic modifiers that are approved for their use in cancer treatment [214,215]. Inhibitors of
DNMTs, HDACs, or other chromatin modifier complexes, such as EZH2 inhibitors, have increased the
variety of therapeutic approaches for the treatment of cancer. In addition, in the past years, the use
of miRNA mimics in clinical trials [216,217], such as miR-29 or mir-34, for the treatment of cancer
and other diseases has opened new possibilities for therapeutic strategies. In line with this, another
potential approach to re-sensitize cisplatin-resistant cells would be to overexpress miR-7 agonists
through nanoparticles. Although these approaches have yet to be studied, their feasibility has proven
to be effective with other microRNAs.
Conclusively, understanding the relationship between oxidative stress and epigenetics mechanisms
is crucial to both understanding cancer development and gaining insight into the cancer disease,
to finally allow new innovative approaches through the use of specific therapeutic strategies.
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Abstract: Vitamin C (L-ascorbic acid, AA) is an essential cellular antioxidant and cofactor for
several α-ketoglutarate-dependent dioxygenases. As an antioxidant, AA interacts with vitamin E
to control oxidative stress. While several reports suggest an interaction of AA with folate (vitamin
B9) in animals and humans, little is known about the nature of the interaction and the underlying
molecular mechanisms at the cellular level. We used an untargeted metabolomics approach to
study the impact of AA on the metabolome of C2C12 myoblast cells. Compared to untreated cells,
treatment of C2C12 cells with AA at 100 μM resulted in enhanced concentrations of folic acid (2.5-fold)
and 5-methyl-tetrahydrofolate (5-methyl-THF, 10-fold increase) whereas the relative concentrations
of 10-formyl-tetrahydrofolate decreased by >90% upon AA pretreatment, indicative of increased
utilization for the biosynthesis of active THF metabolites. The impact of AA on the folate-mediated
one-carbon cycle further manifested itself as an increase in the levels of methionine, whose formation
from homocysteine is 5-methyl-THF dependent, and an increase in thymidine, whose formation from
deoxyuridine monophosphate (dUMP) is dependent on 5,10-methylene-THF. These findings shed
new light on the interaction of AA with the folate-mediated one-carbon cycle and partially explain
clinical findings that AA supplementation enhances erythrocyte folate status and that it may decrease
serum levels of homocysteine, which is considered as a biomarker of cardiovascular disease risk.
Keywords: vitamin C; folic acid; one-carbon metabolism; C2C12 cells; metabolomics;
mass spectrometry; ascorbic acid
1. Introduction
Vitamin C (ascorbic acid, AA) has important functions in animals and humans to maintain health
and prevent disease [1]. AA acts as a cofactor for several α-ketoglutarate-dependent dioxygenases,
such as prolyl hydroxylase involved in collagen synthesis [2]. Its capacity to donate electrons
gives AA antioxidant properties [1] and ability to scavenge electrophiles in Michael additions [3,4].
The antioxidant properties of AA can manifest in many ways and affect a multitude of metabolic
pathways. For example, AA supplementation in humans lowers the production and urinary excretion
of lipid peroxidation-derived reactive aldehydes [5]. From metabolomics analyses of zebrafish fed a
diet lacking sufficient AA, we established that AA deficiency, which causes oxidative stress, activates
the purine nucleotide cycle to regenerate ATP [6]. Recently, we reported that AA prevents cellular
nitrate tolerance in glyceryl trinitate-treated porcine renal epithelial cells, which is relevant to angina [7].
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Using a mass spectrometry-based metabolomics approach, we found that AA protects xanthine oxidase
from glyceryl trinitrate-induced inactivation, which is relevant because this enzyme plays a role in
the conversion of glyceryl trinitrate into the vasoactive metabolite, nitric oxide [7]. These examples
illustrate how a data-driven metabolomics approach can reveal novel functions of AA.
AA is well known to interact with vitamin E in cellular redox cycles to control oxidative stress [2]
and prevent oxidative stress damage to proteins and DNA [8]. Interactions between AA and folic
acid (vitamin B9) have also been reported [9,10], although the underlying mechanism remains
poorly understood. Folic acid plays a key role as a one-carbon carrier molecule in methylation
reactions—notably, the conversion of homocysteine (Hcy) into methionine and the conversion of
deoxyuridine monophosphate (dUMP) into deoxythymidine monophosphate (dTMP) [11]. Given that
elevated plasma Hcy is considered a risk factor for cardiovascular disease [12] and given the reports of
an AA–folate interaction [9,10], AA supplementation has been explored as an attractive way to increase
circulating levels of folic acid and to reduce Hcy levels, with mixed results [10,13], although the clinical
significance of the interaction and the underlying molecular mechanism remain poorly understood.
Humans cannot synthesize AA and depend on dietary AA for their survival. Most non-primate
animals produce AA in the liver [14]. Thus, human and most mammalian cell lines grown in culture
do not synthesize AA. Unless cultured cells are supplemented with AA, they are less protected against
oxidative stress than their in vivo counterparts. To elucidate the biochemical pathways modulated
by AA supplementation, we examined the changes in the metabolome of mouse C2C12 cells in
response to AA supplementation. We selected these cells because they are metabolically active
and susceptible to oxidative stress [15]. Using an unbiased, untargeted mass spectrometry-based
metabolomics approach, we measured major shifts in pool sizes of tetrahydrofolate (THF) metabolites
and of substrates of methylation reactions, which prompted us to focus our investigation on the
effects of AA supplementation on the folate-mediated one-carbon cycle and associated pathways.
Because metabolomics measures relative levels of individual metabolites, the technique provides
clues as to which pathways and which enzymatic steps in those pathways are modulated by AA
treatment. Here we report that AA facilitates the reductive steps in the conversion of 10-formyl-THF
into 5-methyl-THF, which provides new insights in the interaction between AA and folic acid and how
the interaction promotes methylation reactions to provide substrates for amino acid and DNA synthesis.
2. Materials and Methods
2.1. Reagents
LC–MS-grade methanol and water were purchased from EMD Millipore (Burlington, MA, USA).
Formic acid ACS reagent was from Fisher Chemicals (Suwanee, GA, USA). ACS reagents folic acid,
folinic acid (5-formyltetrahydrofolic acid), 5-methyltetrahydrofolic acid, methionine-(methyl-d3) (used
as internal standard) and butylated hydroxytoluene were purchased from Sigma Aldrich (St. Louis,
MO, USA). Sodium ascorbate was from Merck. 13C6-ascorbic acid was from Omicron Biochemicals,
Inc. (South Bend, IN, USA). DMEM was from Life Technologies (Grand Island, NY, USA). Penicillin,
streptomycin and fetal bovine serum were from Invitrogen (Carlsbad, CA, United States).
2.2. Cell Culture and Treatment
C2C12 cells were obtained from ATCC (Manassas, VA, USA) and were first propagated in 75 cm2
flasks using a culture medium consisting of DMEM, 10% fetal bovine serum, 100 units/mL penicillin,
and 100 μg/mL streptomycin. The cells were harvested from the flask using trypsin and seeded in 10 cm
culture dishes containing 10 mL of the supplemented DMEM medium, which contains 14 amino acids,
including methionine, serine, and glycine, and nine vitamins including folic acid but no vitamin C.
Immediately after seeding, the cells were treated with 100 μM sodium ascorbate or 100 μM 13C6-AA by
adding 10 μL of the respective 100 mM stock solution. The rationale behind using the two isotopologues
of AA was that this approach offered us a tool to assign mass spectral features to AA or its metabolites
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in the metabolomics dataset. At this concentration, AA supplementation did not change the pH of the
medium. Control cells were grown in the absence of AA. All three groups (biological triplicates) were
maintained under sterile conditions with 5% CO2 at 37 ◦C. After 48 h of incubation, cells were scraped,
counted using a Hemacytometer Counting Chamber Bright-line Neubauer Cell counter (Hausser
Scientific, Horsham, PA, USA) according to the manufacturer’s instructions, and spun down at 4 ◦C at
500× g for 5 min. The pellets (equivalent to 3.5 × 106 cells per dish) were washed three times with cold
PBS and transferred to 1.7 mL Eppendorf tubes. The pellets were frozen and stored at –80 ◦C until
sample preparation for LC–MS/MS analysis.
2.3. LC–MS/MS Analysis
Cells were resuspended in 300 μL of ice-cold 50:50 (v:v) methanol:ethanol containing 0.02% w/v
of butylated hydroxytoluene (to prevent post-harvest oxidation) and disrupted by sonication for
3 × 15 s in a Fisher Scientific sonifier (1/2 inch disruptor horn, 4 kHz) on ice with 30 s between steps.
Samples were spun for 10 min at 14,000× g at 4 ◦C and the supernatant was transferred to mass
spectrometry vials (Microsolv, Leland, NC, USA). LC–MS/MS was carried out with a method previously
described [6,7,15] with some differences. Briefly, data-dependent acquisition (DDA) in both the positive
and the negative ion mode was conducted using a Shimadzu Nexera UPLC system connected to an AB
SCIEX TripleTOF® 5600 mass spectrometer (AB SCIEX, Concord, Canada). Samples were randomized
before injections. A quality control (QC) sample, obtained by mixing equal aliquots of all samples,
was analyzed every five LC runs. The injection volume was 5 μL. Chromatographic separation was
performed using an Inertsil Phenyl-3 column (4.6 × 150 mm, 100 Å, 5 μm; GL Sciences, Rolling Hills
Estates, CA, USA). A gradient with two mobile phases (A, water with 0.1% v/v formic acid and B,
methanol with 0.1% v/v formic acid) was used. The elution gradient was as follows: 0 min, 5% B; 1 min,
5% B; 11 min, 30% B; 20 min, 100% B; 25 min, 100% B; 30 min, 5% B; and 35 min, 5% B. Period cycle
time was 950 ms; accumulation time 100 ms; m/z scan range 100–1200; and collision energy 35 V with
collision energy spread (CES) of 15 V. Mass calibration was automatically performed after every fifth
LC run.
2.4. Metabolomics Data Processing
Raw data processing was performed using Progenesis QITM software with MetlinTM plugin
V1.0.6499.51447 (NonLinear Dynamics, United Kingdom) for peak picking, retention time correction,
peak alignment, data normalization and metabolite annotations. Annotation confidence was
achieved in accordance with reporting criteria for chemical analysis suggested by the Metabolomics
Standards Initiative (MSI) [16,17]. Thus, level 1 (L1) annotations were made based on accurate mass
(error < 10 ppm), fragment ion spectral pattern (library score > 50), isotope pattern (library score > 80),
and retention time (error < 5%) comparison of analytes with those of authentic standards in our
in-house library (> 700) analyzed under identical conditions.
For metabolites not present in our in-house library, level 2 (L2, tentative) annotations were
made according to the MSI guidelines [16,17] and based on accurate mass, fragment ion spectral
pattern, and isotope pattern comparison with online data available in METLIN (which has MS/MS
experimental data) and the Human Metabolome Database (which contains in silico generated MS/MS
data). Ions generated from QC samples were retained for annotation and included in the dataset if
the coefficient of variation (CV) of their abundance did not exceed 25% (QC distribution is shown
in supplementary Figure S1). When metabolites were detected in both ion modes, the one with the
highest signal-to-noise ratio for a particular metabolite was kept. Relative quantities of metabolites
were determined by calculating their corresponding peak areas.
2.5. Statistical Analysis
The area under the curve of molecular ions was selected for relative quantitation of annotated
metabolites. Only annotated metabolites were used for statistical analysis. Figures (principal component
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analysis, heatmaps, dendrograms and biplots) were generated with MetaboAnalyst 4.0 (Montreal,
Quebec, Canada) [18] and PowerPoint 2016 (Microsoft, Redmond, WA, USA). Plots were generated
with GraphPad Prism 8.3.0 (La Jolla, CA, United States). Metabolite changes were tested by a one-way
analysis of variance followed by Tukey’s HSD (honestly significant difference) post-hoc analysis and
Holm FDR (false discovery rate) correction, with a p-value of < 0.05 indicating significance. Unless
otherwise stated, data are presented as the mean ± SD of three independent experiments (n = 3/group).
In the tables, the two vitamin C treatment groups were collapsed into a single AA group (n = 6).
To compensate for unequal variance or non-normal distribution, data were logarithmically transformed
and Pareto scaled (mean centered and divided by the square root of the standard deviation). No outliers
were excluded from the statistical analyses.
3. Results
Metabolomics analysis was performed on mouse skeletal muscle-derived C2C12 myoblasts
that were AA deficient or AA supplemented. We selected C2C12 cells because we have experience
with metabolome measurements of this cell line, they are metabolically active, and because they are
susceptible to oxidative stress [15]. We exposed the cells to two isotopologue forms of AA, sodium
ascorbate and 13C6-ascorbic acid, because the approach allowed us to distinguish between exposure
compounds (AA and its metabolites or degradation products) and the effects of the exposure on the
metabolome. We did not find evidence that exogenous AA supplementation interfered with annotation
of endogenous metabolites. We also did not detect AA in the non-supplemented cells, which is
expected because mice produce AA in the liver and not in muscle tissue (Figure S2).
The identity of 102 metabolites was assigned using our in-house library (L1 metabolites,
supplementary Table S1), while an additional 102 metabolites were assigned by comparison with
spectral data available from METLIN and the HMDB (L2 metabolites, supplementary Table S1).
The resulting 204 metabolites were further investigated to determine how and to what extent AA
exposure altered the cellular metabolome. Figure 1 shows an analysis of similarities and dissimilarities
among the treatments. Principal component analysis (PCA) grouped together supplemented cells
and separated them from AA-deficient cells (Figure 1a), which demonstrates that the cells responded
similarly to exposure to either sodium ascorbate or 13C6-ascorbic acid.
A PCA biplot, a representation that shows an overlay of the score and loading plots, visualizes
the changing metabolome in response to AA supplementation (Figure 1b). It revealed that the
following metabolites were most prominently associated with the group separation of the AA-deficient
(controls) from the AA-supplemented cells in the scatter plot of the PCA (Figure 1a): folic acid,
10-formyl-tetrahydrofolate (10-formyl-THF), 5-methyl-THF, homocysteic acid (oxidized form of
homocysteine, Hcy), and uridine-5´-diphosphate (UDP) (Figure 1b). A heatmap of the top 40 most
differentiating metabolites also shows that the AA-supplemented cells responded differently from the
control group (Figure 1c). Using the variation in all 204 annotated metabolites, a similar dendrogram
representation emerged (Figure 1d), in which the non-supplemented cells clustered together as
did the AA-supplemented cells without distinction between sodium ascorbate- and 13C6-ascorbic
acid-treated cells.
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Figure 1. Analysis of treated C2C12 cells with ascorbic acid and with ascorbate 100 μM. (a) Principal
component analysis (PCA) scores plot, where each dot represents a sample analysis (thus, 6 dots per
experiment resulting from biological triplicates and technical duplicates); (b) PCA biplot visualizes
which metabolites contribute most to the separation of the experimental groups; (c) heatmap visualizing
the top 40 most differentiating metabolites. Color coding indicates greater deviation from the mean of all
samples for a particular metabolite; (d) dendrogram indicating the degree of similarity among samples,
constructed on the basis of all 204 metabolites. The analysis was performed using MetaboAnalyst V4.0.
Of the three folic acid metabolites we detected, the formyl derivative of THF was not identical
with an authentic standard of 5-formyl-THF with regard to retention time and MS/MS fragmentation
pattern (Figure 2). Comparison of the spectra of both formyl derivatives revealed that 5-formyl-THF
produced a low-mass fragment with m/z 120.0437 which was absent in the spectrum of the regioisomer
shown in Figure 2a. Instead, the corresponding fragment of the regioisomer appeared at m/z 132.0427.
We identified the m/z 120.0437 fragment of 5-formyl-THF as +H2N=(C6H4)=C=O and the m/z 132.0427
fragment ion of the regioisomer as CH2=N–(C6H4)–C≡O+, the difference corresponding to an imino
substituent on the nitrogen atom. As this nitrogen atom corresponds to atom position 10 in the
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precursor ion and considering that the imino group is formed upon loss of a H2O molecule from the
formyl substituent, we can identify the regioisomer as 10-formyl-THF.
Figure 2. Positive ion mode MS/MS spectra of the two detected formyl-tetrahydrofolate (THF) isomers
and the proposed structures of their fragment ions (CE 35 V; CES of 15 V). (a) 10-formyl-tetrahydrofolate
(10-formyl-THF) and (b) 5-formyl-tetrahydrofolate (5-formyl-THF, authentic standard). Peak labels
denote accurate masses and fragment ion m/z values denote exact masses.
One-way ANOVA of the top 50 differentiating metabolites (Table 1) revealed that the relative
cellular levels of folic acid, 5-methyl-THF, 10-formyl-THF, methionine sulfoxide, UDP, glycine,
and thymidine changed significantly in response to AA-treatment (n = 3/group, p < 0.05, Figure 2 and
supplementary Table S1). Although homocysteine was below the limit of integration, its oxidized
form (homocysteic acid) was quantifiable but the change did not reach statistical significance (FC 0.69,
p = 0.08; AA/Control, supplementary Table S1). These metabolites are either part of the folate-mediated
one-carbon cycle or associated pathways (Figure 3). Their change in relative cellular levels in response
to AA-treatment, shown in bar graphs, indicates that AA facilitates the reductive conversion of
10-formyl-THF into 5-methyl-THF.
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Table 1. Top 50 annotated compounds (one-way ANOVA followed by Tukey’s HSD (honestly significant
difference) post-hoc analysis and Holm FDR (false discovery rate) correction; FC > 1.2, p ≤ 0.005) sorted
by the significance of p-value for the comparison AA/Control. The complete list for the 204 annotated
compounds in alphabetical order is presented in Table S2.
Compound m/z Retention
Time (min)
Formula Error 1 FC 2 p-Value
5-methyl-THF 460.1938 14.28 C20H25N7O6 0.26 9.97 8.07 × 10−9
10-formyl-THF 474.1731 16.96 C20H23N7O7 0.05 0.08 6.31 × 10−7
Pantothenic acid 218.1035 10.51 C9H17NO5 1.08 1.60 8.35 × 10−7
Guanidinoacetate 118.0603 4.74 C3H7N3O2 4.32 2.67 4.17 × 10−6
Methionine sulfoxide 166.0526 4.99 C5H11NO3S 4.08 0.71 4.90 × 10−5
Phosphodimethylethanolamine 192.0320 5.10 C4H12NO4P 0.92 1.95 7.95 × 10−5
PE(22:1/14:0) 746.5671 26.99 C41H80NO8P 1.19 1.57 1.91 × 10−4
Urate 169.0351 5.97 C5H4N4O3 0.63 2.69 2.63 × 10−4
LysoPC(18:1) 522.3545 25.88 C26H52NO7P 0.78 1.47 4.31 × 10−4
Phenylacetylglycine 192.0665 17.88 C10H11NO3 0.59 1.66 7.95 × 10−4
PE(18:1/18:0) 744.5530 26.96 C41H80NO8P 0.11 1.77 8.59 × 10−4
Adenosine-5’-diphosphoglucose 428.0365 4.87 C10H15N5O10P2 0.44 0.60 9.18 × 10−4
6-keto-PGF1 393.2249 22.40 C20H34O6 0.34 3.37 9.93 × 10−4
PE(22:1/14:1) 744.5529 26.99 C41H78NO8P 0.33 1.43 1.22 × 10−3
D-glucose 6-phosphate 259.0225 4.25 C6H13O9P 0.16 0.38 1.31 × 10−3
Adenosine 5’-monophosphate 346.0558 5.41 C10H14N5O7P 0.15 0.57 1.61 × 10−3
Glycerate 105.0188 5.03 C3H6O4 2.27 4.38 1.65 × 10−3
Uridine diphosphate (UDP) 405.0094 4.07 C9H14N2O12P2 1.36 0.42 1.73 × 10−3
Thymidine 241.0831 11.03 C10H14N2O5 3.33 1.90 1.81 × 10−3
Glycocholate 464.3009 23.90 C26H43NO6 6.89 1.81 1.85 × 10−3
LysoPG(16:0) 507.2694 24.33 C22H45O9P 0.42 1.38 1.96 × 10−3
LysoPE(18:1) 478.2934 24.90 C23H46NO7P 2.54 1.39 1.97 × 10−3
Glycerol 2-phosphate 171.0060 4.44 C3H9O6P 0.25 1.28 2.08 × 10−3
Hippurate 180.0650 17.08 C9H9NO3 1.02 1.46 2.13 × 10−3
Adenosine 5’-diphosphate 426.0221 4.85 C10H15N5O10P2 0.21 0.60 2.38 × 10−3
LysoPC(16:1) 538.3144 25.28 C24H48NO7P 1.77 1.35 2.46 × 10−3
Glycine 76.0385 4.79 C2H5NO2 1.84 2.31 2.86 × 10−3
5’-CMP 324.0591 4.77 C9H14N3O8P 0.03 0.65 2.97 × 10−3
Adenosine 3’,5’-diphosphate 450.0186 4.97 C10H15N5O10P2 0.20 0.58 4.39 × 10−3
NAD 662.1024 6.27 C21H27N7O14P2 3.00 0.50 4.51 × 10−3
Guanosine 5’-monophosphate 362.0507 5.26 C10H14N5O8P 2.98 0.60 4.63 × 10−3
Aminoadipic acid 162.0755 4.92 C6H11NO4 4.20 0.78 4.70 × 10−3
N-acetyl-D-galactosamine 220.0826 5.16 C8H15NO6 1.29 0.46 4.80 × 10−3
Deoxyguanosine 5’-monophosphate 346.0556 6.99 C10H14N5O7P 0.55 0.36 5.54 × 10−3
PE(16:0/18:1) 716.5231 26.78 C39H76NO8P 0.62 1.54 6.36 × 10−3
PS(16:0/16:1) 732.4822 26.53 C38H72NO10P 0.07 0.67 7.14 × 10−3
PE(18:0/18:1) 766.5385 27.08 C41H80NO8P 1.01 1.38 8.03 × 10−3
Succinate 117.0188 6.72 C4H6O4 2.85 0.64 8.12 × 10−3
CMP 322.0447 4.74 C9H14N3O8P 0.49 0.66 8.79 × 10−3
Glycerylphosphorylethanolamine 214.0486 4.49 C5H14NO6P 11.19 0.75 1.19 × 10−2
Phosphocreatine 212.0427 4.97 C4H10N3O5P 3.82 0.69 1.19 × 10−2
PE-NMe(22:5/18:1) 850.5601 29.08 C46H80NO8P 0.10 1.50 1.29 × 10−2
D-ribose 5-phosphate 229.0119 4.46 C5H11O8P 0.08 0.44 1.29 × 10−2
Indolelactic acid 204.0666 18.62 C11H11NO3 0.13 1.33 1.31 × 10−2
Pyridoxine 170.0806 6.74 C8H11NO3 0.66 1.29 1.38 × 10−2
Cytidine diphosphate choline 489.1149 5.33 C14H26N4O11P2 0.64 0.68 1.40 × 10−2
N-acetyl-D-glucosamine 222.0968 5.17 C8H15NO6 0.50 0.80 1.42 × 10−2
Cytidine 2’,3’-cyclic monophosphate 306.0486 5.17 C9H12N3O7P 0.14 1.37 1.44 × 10−2
Folic acid 442.1468 17.85 C19H19N7O6 0.34 2.45 1.45 × 10−2
PE(15:0/24:1) 832.6058 28.87 C44H86NO8P 0.73 1.34 1.52 × 10−2
Abbreviations: PE—phosphatidylethanolamine, PG—phosphatidylglycerol, and PS—phosphatidylserine. 1 Error in
ppm. 2 Fold change AA/control.
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Figure 3. Simplified one-carbon cycle and associated pathways. Relative cellular levels of indicated
metabolites are presented in the bar graphs (y-axes indicate peak areas expressed as 103 counts per
second). Enzyme abbreviations: DHFR, dihydrofolate reductase; Glu, glutamic acid; MTHFD1,
5,10-methylene-THF dehydrogenase 1; MTHFR, 5,10-methylene-THF reductase; SHMT, serine
hydroxymethyl transferase; TS, thymidylate synthase. Asterisks (*) indicate statistical significance
between the control and treatment (*: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001).
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4. Discussion
The most significant changes in our untargeted metabolomics data as the result of exposure to AA
were related to the folate-dependent one-carbon cycle and associated pathways that branch off this
cycle (Figure 3). The observed AA-related decrease in 10-formyl-THF and concomitant increase in
the cellular levels of 5-methyl-THF indicates that AA increases the activity of the folate-dependent
one-carbon cycle. Stokes made a similar observation in a scurvy patient whose major urinary folate
was 10-formyl-THF before AA treatment and 5-methyl-THF after AA therapy, concluding that AA
“keeps the folate metabolism pool in action” [19]. Although we did not detect 5,10-methylene-THF,
the intermediate in the conversion of 10-formyl-THF into 5-methyl-THF, we did observe an AA-related
increase in the 5,10-methylene-THF-dependent formation of thymidine (a dTMP metabolite) and
decrease in UDP. In DNA synthesis, UDP forms dUMP, which is the substrate of thymidylate synthase
to form dTMP. THF can be converted directly into 5-methyl-THF by the enzyme serine hydroxymethyl
transferase (SHMT, Figure 3), which consumes serine and produces glycine [20]. Although we observed
a significant increase in the levels of glycine following AA treatment with no change in serine levels,
we cannot draw conclusions regarding this pathway because both amino acids are components of
the DMEM growth medium and because both amino acids are non-essential and can be formed
and consumed in a multitude of other pathways. Regarding 5-methyl-THF as a co-substrate for the
methionine synthase-mediated conversion of homocysteine into methionine, we observed an increase
in the levels of methionine (Figure 3). This increase in methionine reflects its regeneration from
homocysteine because the total amount of methionine, an essential amino acid, was provided by the
growth medium. Taken together, the AA-induced changes in the metabolome of C2C12 cells appear to
be a reflection of AA facilitating the folate-dependent one-carbon cycle and associated biochemical
pathways (Figure 3). As the steps involved in the reductive conversion of 10-formyl-THF into
5-methyl-THF via 5,10-methylene-THF, are catalyzed by the NAD(P)H-dependent enzymes MTHFD
and MTHFR, respectively, it is conceivable that AA plays a role in sparing NAD(P)H for reductive
folate cycling. In scorbutic guinea pigs, for instance, cells can utilize a bioavailable form of glutathione
(GSH) to delay the fall in tissue AA concentrations [21]. The authors conclude that AA and GSH “can
spare each other” [21]. Because both AA and GSH require reducing equivalents from NADPH for
the enzymatic recovery of their reduced forms in redox reactions [8], AA supplementation effectively
spares NADPH by partially covering for GSH. The available NADPH can be used for a multitude of
dehydrogenases involved in the detoxification ROS as well as their products [8]. We have previously
observed that THP1 monocytes grown in the absence of AA showed greater cellular protein damage
than AA-adequate cells due to AA’s ability to facilitate the detoxification of the lipid peroxidation
product, 4-hydroxy-2(E)-nonenal [22], by enhancing the activities of the NADPH-dependent enzyme
aldo-keto reductase and the NADH-dependent enzyme alcohol dehydrogenase [23]. AA can also
directly scavenge the lipid peroxidation-derived acrolein by forming a Michael adduct [3] which
would spare NADPH for other biochemical pathways, including the reductive part of the folate cycle.
Conversely, Fan et al. [24] have shown that in proliferating HEK293T cells, grown in the absence of AA,
the folate cycle turns counterclockwise to generate 10-formyl-THF and NADPH. This finding is in
agreement with our results that in AA-deficient cells the levels of 10-formyl-THF are higher than in
AA-adequate cells. We attribute the lack of change in cellular GSH and NADPH levels following AA
supplementation to compensatory effects.
The distribution of folate metabolite pools in our study is in agreement with the principal
folate metabolites found in foods, i.e., 10-formyl-THF and 5-formyl-THF [20]. However, food folates
and intracellular folates of mammalian cells are primarily present in the form of polyglutamic acid
derivatives that contain 3–9 Glu units conjugated with the carboxyl group of the p-aminobenzoic acid
moiety of folate. In vivo, these polyglutamate units are hydrolyzed to mono-Glu forms which are
recognized by specific folate receptors for cellular uptake [20]. We did not detect oligo- or poly-Glu
forms of the folate metabolites in the lysates of C2C12 cells, which indicates that the form provided by
the growth medium, i.e., the mono-Glu form of oxidized folic acid, is not converted into poly-Glu forms
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in C2C12 cells, which requires pteroylpolyglutamate synthetase (ligase) enzymes. By contrast, human
fibroblasts and Chinese hamster ovary cells grown in culture accumulate polyglutamate folates [25,26].
The higher levels of oxidized monoglutamate folic acid in the AA-supplemented cells cannot be
explained by higher ligase activity in the AA-deficient cells and probably reflects higher degradation
of folates into pteridine and p-aminobenzoic acid products in the control cells.
10-Formyl-THF is a co-substrate for the de novo biosynthesis of purines as it delivers two carbon
atoms of the purine ring structure [11]. Although we observed lower levels of 10-formyl-THF in the
AA-treated cells consistent with its utilization for purine biosynthesis, the expected increase in levels
of the purine, guanine, did not reach significance (1.3-fold, p = 0.055). There are multiple explanations
for the metabolic changes because purine biosynthesis involves other substrates, including glutamine,
glycine, and aspartate, and because there are multiple ways to interconvert purine forms such as their
(deoxy)ribonucleoside and (deoxy)ribonucleotides [11]. We detected only one N-formyl derivative of
THF which we identified as 10-formyl-THF by careful analysis of its MS/MS fragmentation pattern
which unequivocally placed the formyl substituent on the nitrogen atom of the p-aminobenzoic acid
moiety of THF, i.e., position 10 in THF. We excluded the possibility that the N-formyl form was
5-formyl-THF based on chromatographic and mass spectral comparison with an authentic sample
of 5-formyl-THF. The detection of only one N-formyl regioisomer is somewhat unexpected because
both forms can be reversibly interconverted by isomerization [11] and thus both would be detected
assuming similar detection limits.
Despite the increase in the relative cellular levels of methionine following AA exposure, we
observed an AA-related decrease in methionine sulfoxide. Methionine is highly sensitive to oxidation
by reactive oxygen species (ROS) and thus the levels of methionine sulfoxide can be considered a
cellular biomarker of oxidative stress. The lower levels of methionine sulfoxide in the AA-treated cells
compared to the control cells reflects the cellular antioxidant activity of AA (Figure S3). This effect can
be explained by AA’s ability to scavenge ROS, thus preventing oxidation of methionine, or by AA
facilitating the enzymatic recovery of methionine from methionine sulfoxide, which is catalyzed by
methionine sulfoxide reductase (Msr) in a thioredoxin (Trx)- and NADPH-dependent manner [8,27,28].
As thioredoxin is integral to preserving an adequate redox status of cells as well, for instance by
recovering reduced glutathione (GSH) from oxidized glutathione (GSSG) [29], AA indirectly assists
Trx in its antioxidant activity by scavenging ROS thereby sparing NADPH needed for the regeneration
of Trx from its oxidized form.
Elevated plasma levels of homocysteine (Hcy) are associated with cardiovascular disease while
a causal relationship has not been established and the underlying mechanism(s) remain(s) poorly
understood. Several clinical studies have tested the hypothesis that lowering Hcy by nutritional or
pharmacological means reduces cardiovascular risk [30]. One such approach is folate therapy (with or
without co-supplementation with vitamins B6 and B12) aimed at facilitating the conversion of Hcy into
methionine by increasing the activity of the 5-methyl-THF-dependent enzyme, methionine synthase.
A meta-analysis of several such trials revealed an average 25% reduction in plasma Hcy levels but
the folate supplementation had no significant effect on major vascular events [30]. On the other hand,
the China Stroke Primary Prevention Trial with 20,702 individuals reported a significant beneficial
effect of folate supplementation in primary stroke prevention [31]. Unsatisfactory evidence-based
support for the folate/Hcy hypothesis has led to the notion that perhaps Hcy is not the root cause
of cardiovascular disease but that it creates or reflects a prooxidant environment characterized by
decreased bioavailability of nitric oxide which negatively affects vascular function. Others have
suggested that prolonged exposure to high plasma Hcy levels induces proatherogenic epigenetic
alterations that persist long after subsidence of plasma Hcy [32]. Therefore, low-cost therapies that
lower Hcy levels may be attractive for patients with hyperhomocysteinemia.
In an observational study with 20 men and 40 women older than 50 years, serum Hcy correlated
negatively with circulating levels of ascorbate (r = −0.30, p < 0.05) and folate (r = −0.31, p < 0.05) [33].
AA supplementation (500 mg/day) resulted in a significant 40% increase in erythrocyte folate in a
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study population comprising 65 male and 35 female Italian smokers without lowering Hcy levels [10].
High-dose AA supplementation (4.5 g/day) in 44 patients with coronary heart disease and without
clinical ascorbate deficiency did not change plasma Hcy levels despite a marked increase in plasma
ascorbate [34]. Our present cell culture study suggests that co-supplementation with folic acid and
AA may activate the folate-mediated one-carbon cycle thereby promoting the conversion of Hcy
into methionine while reducing cellular oxidative stress. ClinicalTrials.gov lists some 20 studies
aimed at lowering Hcy with folic acid, combinations of B vitamins, prescription drugs, or with
vitamin-prescription drug combinations, but none of the studies include(d) co-supplementation
with AA. [35]. Acknowledging the limitation that the experiments were performed with one
non-human-derived cell line, we propose a mechanism-based rationale for co-supplementation
with folic acid and AA in humans, especially in elderly patients diagnosed with hyperhomocysteinemia
and who are at risk for developing inadequate vitamin C status [2].
5. Conclusions
Our experiments with C2C12 myoblasts grown in the presence and absence of AA suggest that AA
activates the folate-mediated one-carbon cycle thereby promoting the 5,10-methylene-THF-dependent
formation of thymidine and facilitating the 5-methyl-THF-dependent conversion of Hcy into methionine.
From a mechanistic perspective, AA appears to spare NAD(P)H and so increase availability of reducing
equivalents for the reductive steps from 10-formyl-THF to 5-methyl-THF via 5,10-methylene-THF.
The findings are relevant to nutritional or pharmacological treatment of hyperhomocysteinemia because
the activity of the folate cycle appears to depend on AA concentration. Furthermore, our mechanistic
findings provide a rationale for exploring the benefits of low-cost co-supplementation with AA in
folate therapy of hyperhomocysteinemia.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3921/9/3/217/s1,
Figure S1: Principal component analysis of the metabolomes of sham- and AA-treated C2C12 cells. Each set of
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declustering was implemented by using the Progenesis deconvolution algorithm. Table. S2. One-way analysis of
variance followed by Tukey’s HSD post-hoc analysis and Holm FDR correction. Annotated compounds sorted by
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Abstract: Iridoids, which have beneficial health properties, include a wide group of cyclopentane [c]
pyran monoterpenoids present in plants and insects. The cleavage of the cyclopentane ring leads
to secoiridoids. Mainly, secoiridoids have shown a variety of pharmacological effects including
anti-diabetic, antioxidant, anti-inflammatory, immunosuppressive, neuroprotective, anti-cancer, and
anti-obesity, which increase the interest of studying these types of bioactive compounds in depth.
Secoiridoids are thoroughly distributed in several families of plants such as Oleaceae, Valerianaceae,
Gentianaceae and Pedialaceae, among others. Specifically, Olea europaea L. (Oleaceae) is rich in
oleuropein (OL), dimethyl-OL, and ligstroside secoiridoids, and their hydrolysis derivatives are
mostly OL-aglycone, oleocanthal (OLE), oleacein (OLA), elenolate, oleoside-11-methyl ester, elenoic
acid, hydroxytyrosol (HTy), and tyrosol (Ty). These compounds have proved their efficacy in
the management of diabetes, cardiovascular and neurodegenerative disorders, cancer, and viral
and microbial infections. Particularly, the antioxidant, anti-inflammatory, and immunomodulatory
properties of secoiridoids from the olive tree (Olea europaea L. (Oleaceae)) have been suggested as a
potential application in a large number of inflammatory and reactive oxygen species (ROS)-mediated
diseases. Thus, the purpose of this review is to summarize recent advances in the protective role of
secoiridoids derived from the olive tree (preclinical studies and clinical trials) in diseases with an
important pathogenic contribution of oxidative and peroxidative stress and damage, focusing on
their plausible mechanisms of the action involved.
Keywords: immunomodulation; inflammation; olive tree; oxidative stress; secoirioids
1. Introduction
Iridoids, which have beneficial health properties, include a wide group of cyclopentane [c] pyran
monoterpenoids present in plants and insects. The name iridoid derived from Iridomyrmex, a genus of
fornices from which iridomirmecin and iridodial compounds were isolated. These products have been
considered as defensive compounds. In fact, the biosynthesis of these derivatives of monoterpenes
takes place in the different organisms by similar pathways; defense is its main role, and in the case of
insects, they are used as sex pheromones [1].
Iridoids were first isolated in the latter part of the 19th century, but Halpern and Schmid proposed
the basic skeleton of the iridoids in their investigation of the structure of plumieride in 1958 [2].
Particularly, they are secondary metabolites of terrestrial and marine flora and fauna, being found
in a large number of plants families, usually as glycosides. For this reason, some of them are
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chemotaxonomically useful as markers of genus in various plant families. Besides, they exhibit a
wide range of bioactivities including anti-inflammatory, antibacterial, anti-carcinogenic, and antiviral
activities [3]. In fact, they are used as bitter tonics, sedatives, antipyretics, cough drugs, remedies for
skin disorders, and as hypotensive agents. In addition, they are useful as an antidote in mushroom
intoxications by Amanita type.
The cleavage of the cyclopentane ring of iridoids leads to secoiridoids. Mainly, secoiridoids
have shown a large variety of pharmacological properties including anti-diabetic, anti-inflammatory,
immunosuppressive, neuroprotective, anti-cancer, and anti-obesity. This fact encouraged us to study
the bioactivities of these phytochemicals in depth and update the latest preclinical and clinical data on
its bioactivity and potential therapeutic uses.
1.1. Structure and Classification
Several classifications have been developed over the years, given the variety and complexity of
iridoids and secoiridoids [4,5].
From 1980 to date, bibliographic data has used the classification proposed by El-Naggar and Beal [2],
who categorize these compounds according to the number of carbons included in their structure:
• Group 1: C8 iridoids (di-nor-iridoids)
• Group 2: C9 iridoids (nor-iridoids)
• Group 3: C10 iridoids, which occur mainly as glycosides
• Group 4: Aglycones and some iridoids included in the other three groups lacking a sugar residue
in their structure
• Group 5: Iridoids derivatives. This group comprises compounds derived from the opening of the
pyran ring
• Group 6: Included bis-iridoids as a result of condensation of two monomers, (a) directly as in
iridolinalin A, or (b) through a sugar residue as in globuloside A.
At the same time, there are other classifications of secoiridoids according to the presence of these
compounds in certain families, including the Oleaceae family. In fact, a total of 232 secoiridoids
(aglycones, glycosides, derivatives, and dimers) have been isolated from nine genus of the family
Oleaceae. These genera include Fontanesia, Fraxinus, Jasminum, Ligustrum, Olea, Osmanthus,
Phillyrea, Picconia, and Syringa, and these secoiridoids were classified into other five groups [6]:
• Simple secoiridoids: Generally, for the simple secoiridoids, positions C7 and C11 have either a free
carboxylic acid group or a methyl ethyl ester derivative of the acid. The configurations of the
positions C1 and C5 are S.
• Conjugated secoiridoids: This group of compounds is the most numerous secoiridoids isolated
from the Oleaceae family. The name of the class derives from the type of compound that is linked
or conjugated to the secoiridoid nucleus. Based on this, this class is further categorized into seven
subgroups: aromatic-conjugated, sugar-conjugated, terpene-conjugated, cyclopentane-conjugated,
coumarin-conjugated, lignans-conjugated, and other secoiridoids. Normally, the conjugations
occur in C7 due to this position, which is is usually oxidized to a carboxylic acid and esterified
with diverse groups.
• 10-Oxyderivative of oleoside secoiridoids: This group contains the oleoside nucleus with distinct
structural differences. The C8 and C9 positions exist as double bonds, with a hydroxy group
at the C8 position or an ester formed by an oxygen atom with different groups. A total of 40
10-Oxyderivative of oleoside secoiridoids have been isolated from the Oleaceae family.
• Z-Secoiridoids: This class of secoiridoids is characterized by the presence of double-bond
geometry at the C8 in Z-configuration; however, only five compounds have been isolated from the
Oleaceae family.
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• Secologanosides and oxidized secologanoside secoiridoids: Compounds of this class are based
on the secologanoside nucleus. They are differentiated by the positions on the C–C double bond
between C8 and C10 and C10 oxidation level.
1.2. Main Naturally Occurring Iridoids and Secoiridoids Present in Olea europaea L
Iridoids and secoriridoids are thoroughly distributed in the plants of class Magnoliopside,
concretely belonging to the following families: Scropulariaceae, Verbenaceae, Lamiaceae, Apocynaceae,
Loganiaceae, Bignoniaceae, Plantaginaceae, Rubiaceae, Pedaliaceae, Cornaceae, Acantheceae, Loasaceae,
Lentibulariaceae, Gentianaceae, Oleaceae, Nyctanthaceae, Caprifoliaceae, Dispsacaceae, and Valerianaceae.
For instance, Valeriana officinalis L. (Valerianaceae), Harpagophytum procumbens L. (Pedaliaceae),
Genciana lutea L. (Gentianaceae), Fraxinus excelsior L. (Oleaceae) and Olea europaea L. (Oleaceae) are
the most representative medicinal plants commonly used in medicine, due to their iridod/secoiridoid
content [3]. Particularly, Olea europaea L. (Oleaceae) is a small evergreen tree with firm branches and a
grayish bark. The leaves are lanceolate, opposite, short-petioled, mucronate, green above and hoary
on the underside. On the other hand, the flowers are small, short, erect racemes, axillary, very much
shorter than the leaves, and the fruit is a small smooth, purple, or green drup, with a nauseous, bitter
flesh, enclosing a sharp-pointed stone [7].
Olea europaea L. preparations have been traditional used in folk medicine in the European
Mediterranean area, Arabia peninsula, India and other tropical and subtropical regions, as a diuretic,
emollient, hypotensive, and for urinary and bladder infections [8]. Most of the plant parts of Olea
europaea L. are used in the traditional system of medicine around the world. Oil is taken with lemon
juice to treat gall stones [9]. Leaves are taken orally for stomach and intestinal diseases and used as
mouth cleanser [10], and the decoction of dried leaves is taken orally for diabetes [11]. An extract of
the fresh leaves is taken orally to treat hypertension and to induce diuresis [12], whereas an infusion of
the fresh leaves is taken orally as an alternative treatment for inflammatory diseases [13]. Similarly,
essential oil extracted from the fruit is also used to treat rheumatism, promote blood circulation [14],
and as a laxative [15].
The main biophenol secoiridoids found in the olive tree include: oleuropein (OL), dimethyl-OL,
ligstroside, and their hydrolysis derivatives such as OL-aglycone, oleocanthal (OLE), oleacein (OLA),





Figure 1. Chemical structures of secoiridoids most abundant in olive trees. OL: oleuropein, OLA:
oleacein, OLE: oleocanthal.
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1.3. Biosynthesis and Biotransformation of Secoiridoids in Olive Tree
The amount and distribution of secoiridoids present in olive tissues depend on various
environmental factors such as the ripening cycle, geographical origin, and cultivation practices,
among others. Besides, the content of phenolic glycosides as patterns and the activity of endogenous
enzymes can play a role in the quantitative composition of secoiridoids in the olive tree [16].
The fact that secoiridoids are mostly present in early stages is due to the enzymatic and chemistry
reactions that take place in the maturation time. In this sense, three different states in fruit maturation
have been described: growth phase, green maturation phase, and black maturation phase, which is
characterized by the presence of anthocyans.
OL is mainly abundant in early stages, although its levels decrease during the maturation process.
In fact, OL decreases quickly in black crops and is not present in some varieties of Oleaceae.
The main precursor of OL and ligstroside is oleoside 11-methyl ester (elenolic acid glucoside).
Firstly, geraniol synthase (GES) catalyzes the transformation of genaryl diphosphate to geraniol,
which is converted to 10-hydroxygeraniol by the geraniol 10-hydroxylase enzyme. The iridioids
in Oleaceae must be formed from this point with 10-hydroxygeraniol as the starting compound
via irididal and iridotrial up to deoxyloganic acid, which is the precursor of loganin and loganic
acid, as well as secologanin and secologanic acid [17]. From this point, up to five routes have been
proposed to explain the origin of all iridoids found in this family. However, it is known that most
of the secoiridoids present in Olea europaea L. are derived from deoxyloganic acid as a common
intermediate [17,18]. Following this line, nicotinamide adenine dinucleotide deshydrogenase (NADH)
acts on 10-hydroxygeraniol to form deoxyloganic acid aglucone. The transfer of glucosyl groups
to deoxyloganic acid aglucone (precursor of monoterpene indolic alcaloids and OL) is catalyzed by
glucosyltransferase (GT). Deoxyloganic acid experiments a 7-α-hydroxylation of the cyclopentane
ring and forms 7-epiloganic acid, which quickly goes to 7-ketologanic acid through hydroxyl group
oxidation. Loganic acid methyltransferase catalyzes 7-ketologanin syntheses. In this point, secologanin
synthase (SLS) oxides a ketonic group to form 11-methyl oleoside, which is immediately glucosylated
by GT. Finally, 7-β-1-D-glucopyranosyl-11-methyl oleoside is esterified with Ty to produce ligstroside,
and then OL is formed [17,19] (Figure 2).
Figure 2. Biosynthesis and biotransformation of secoiridoids in Olea europaea L.
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Secoiridoids are distributed throughout the tissues of the olive tree, but their nature and
concentration change among different parts of the plant. Thus, biosynthetic or mechanicals
transformation during production are decisive to quantify alterations of the bioactive small
molecules [18]. Particularly, OL is the major secoiridoid constituent of unripe drupes (peel, pulp,
and seed). The amount of OL decreases along fruit maturation, as commented above, whereas its
aglycon form increases its levels. OL-aglycone is formed by the cleavage of the glycosidic bond
mediated by β-glucosidase activity. Ligstroside has been described as a common phenolic component
in different olive tissues (leaf, fruit pulp, and stone) and olive oil, but it has been rarely found in olive
seeds [20].
In the course of maturation, OL and ligstroside are considered pattern components. Both of them
are present in the olive fruit, but they are almost non-existent in olive oil (85–95% reduction) [21,22].
β-glucosidase acts by decreasing OL and ligstroside levels, aglycon forms from OL, and ligstroside can
be detected as isomers due to the keto-enolic tautomeric equilibrium of the elenolic acid moiety [23,24].
Other dialdehydics structurally related to these secoiridoid precursors are OLA and OLE. Different
authors have reported that both OLA and OLE levels increase during ripening due to OL and ligstroside
degradation, respectively [25]. Thus, they concluded that OL and ligstroside are natural precursors of
OLA and OLE as breakdown products resulting from enzymatic activity during the extraction and
maturation processes [26–29].
OL and ligstroside have been detected in olive leaves. In turn, OLA and OLE levels are augmented
in mature fruits, such as OL and ligstroside aglycons. Moreover, OLA and OL-aglycone are more
plentiful in olive oil [16].
1.4. Functional and Physiological Chemistry of the Main Secoiridoids of Potential Medical Interest
ROS have a remarkable role in the development of oxidative stress and also in the pathology of
numerous diseases. For example, oxidative stress is one of the major cellular features in the onset
of many pathological conditions such as Alzheimer’s and Parkinson disease, renal injury, diabetes,
cardiovascular diseases, cancer and aging; it occurs when excessive ROS accumulation produced
during the normal cell metabolic processes is unbalanced by the antioxidant defence system [30],
and it may induce the oxidative modification of cellular macromolecules including lipids, proteins,
and nucleic acids [31].
Previous epidemiological studies show that the Mediterranean diet is associated with a low
incidence of cardiovascular disease or cancer. This may reflect the nutritional effects of the bioactive
compounds contained in its major source of fatty acids, i.e., extra-virgin olive oil (EVOO), which is
rich in phenolic compounds [32,33]. The phenolic compounds contained in EVOO include HTy, Ty,
and their secoiridoids precursors such as OL, OLE, or OLA, among others.
A large number of studies highlighted the antioxidant properties of these compounds including
their abilities to promote the activity of ROS-detoxifying enzymes, such as superoxide dismutase (SOD),
catalase (CAT), glutathione reductase (GSR) and glutathione S-transferase (GST), to compete with
coenzyme Q as an electron carrier in the mitochondrial electron transport chain, which is a site of
ROS generation, to act as free-radical-scavenging antioxidants and to inhibit lipid peroxidation [31,34].
In particular, it was shown that dietary OL and OLE treatments were associated with reductions in
the production of superoxide anion radical in human monocytes from healthy donors [35]. Similarly,
OL administration significantly increased the SOD and glutathione peroxidase (GPx) activity levels
in the obstructed kidneys from rats with unilateral ureteral obstruction induced-kidney injury [36].
These results are in accordance with other reports showing that OL was able to increase the amount
of enzymes such as GPx and SOD in gentamicin-induced renal toxicity and cisplatin-induced renal
injury models [37,38]. The phenolic compounds present in Olea europaea L. activated enzymatic and
non-enzymatic antioxidant defense mechanisms, particularly preventing cell membrane damage by
high-dose UV-B rays [39].
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Vitamin E (α-tocopherol) is an essential micronutrient in the diet of all mammals, and it is a potent
antioxidant in biological systems. This compound is the main chain-breaking antioxidant that prevents
the propagation of free radicals reactions, and consequently prevents the tissue damage. In this sense,
it has been reported that supplementing the diet with OL for 21 days maintained higher levels of
α-tocopherol in liver of female Wistar rats [40].
The most important antioxidant activity of the olive tree phenolic compounds is related to the
free-scavenging ability because they inhibit the propagation chain during the oxidation process through
the donation of radical hydrogen to alkylproxyl radicals and the formation of stable derivatives
during this reaction. These compounds also act as metal chelators, preventing the generation of
high concentrations of hydroxyl radicals [41]. This capacity may be reduced by the presence of the
–COOOH3 fragment in several secoirioids structures, because it seems to cause a decrease in the
antioxidant activity which is related to the inability of this group to act as an H-donor [42]. In fact,
OL-aglycone presents better radical-scavenging capacity than single hydroxyl substitutions, such as Ty,
and also protects low-density lipoprotein (LDL) from oxidation [43].
The relationship between oxidative stress and inflammation has been established by many authors.
The pathogenic role of mixed advanced glycoxidation products (AGE) and advanced lipid peroxidation
products (ALE) generated in the course of oxidative stress and their adducts with cell biomolecules,
such as proteins and nucleic acids, in a number of chronic inflammatory and autoimmune diseases is
well documented [44].
On the other hand, in the past years, the leaves of Olea europaea L. have been considered as an
important source of antioxidant compounds. In this case, OL is the most predominant and active
phenolic compound (60–90 mg/g dried olive leaves), and it is usually considered as an antioxidant
reference in comparison with other secoirioids [45,46]. OL contains active components in its molecule
with conferred a potential antioxidant activity. It has been suggested that these properties are related to
the H-atom donation from the phenolic groups present in OL. For example, OL administration showed
a protective effect against ROS production in endothelial cells since OL showed good cytocompatibility
and antioxidant activity, which revealed effectiveness in controlling the oxidative stress upon exposure
to H2O2 [47]. In addition, OL presented slightly weaker radical scavenging activity than HTy by
2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) and ABTS methods [48] and the ability to inhibit
LDL oxidation by scavenging free radicals [49].
Although the studies about the antioxidant activity of OLE are limited, it has been demonstrated
that OLE could inhibit nicotinamide adenine dinucleotide phosphate oxidase (NOX) in isolated human
monocytes, and also OLE was able to reduce intracellular ROS levels in SH-SY5Y cells. Recently,
Montoya et al. have also showed that OLE produced a potent reduction of intracellular ROS and
nitrites production in LPS-induced murine peritoneal macrophages [50].
OLA is one of the major phenolic compounds present in the olive tree, but its antioxidant profile is
more unknown in comparison with other secoirioids, such as OL. However, OLA has demonstrated to
be a potent scavenger of HOCl and myeloperoxidase release and exerts a stronger inhibitory capacity
of neutrophil’s oxidative in comparison to OL [32].
1.5. Pharmacokinetics of Secoiridoids from the Olive Tree
Numerous investigations have revelead the beneficial effects of olive leaves and olive oil for the
treatment of many diseases. The possibility that their constituents may achieve any biological effects
depends on the chance of reaching molecular targets in a specific tissue or organ at a sufficient dose,
which is dependent on their metabolism and bioavailability [51].
The mechanism of intestinal absorption of olive oil phenols is unclear, as it does not appear to be
strictly dependent on the polarity of these compounds. For example, OL, which is apolar, is able to
diffuse through the lipid bilayer of the epithelial cell membrane. However, also, the more polar HTy
appears to be absorbed via a passive bidirectional diffusion mechanism [52,53].
202
Antioxidants 2020, 9, 149
To date, reports regarding the bioavailability of the phenolic compounds present in olive oil are
extended, whereas bioavailability studies concerning secoiridoids derivatives such as OL, OLE, and
OLA have been scarcely studied. Thus, data on the bioavailability of these secoiridoids compounds in
human and even animals would be of great interest in order to establish their potential health benefits.
Generally, secoiridoids from Olea Europaea L. are mainly present in glycosylated forms (OL and
ligstroside). For this reason, after oral administration, enzyme from saliva starts a hydrolysis process
continued in the stomach by digestive enzymes and β-glycosidases. The unmodified forms could be
absorbed to the small intestine or colon, where they are hydrolyzed, finally [54]. The result of this
hydrolytic process is the formation of derived aglycon forms. At the same time, the aglycons that
were formed could be absorbed in the small intestine or colon. The chemical structure and vehicle
of administration are decisive for the rate and extension of gastrointestinal absorption. Structural
modifications occur via conjugation in small intestinal epithelial cells or in liver, after transport through
the portal system. Metabolites reach the general blood circle, from which they are excreted in the
urine [55].
Related to OL, some authors suggest that it could be absorbed in the small intestine or colon.
In this sense, Kendall et al. reported that OL diffuses in the stomach and remained stable and intact at
the gastric level during digestion being absorbed in the small intestine in healthy young adults [56].
Similarly, several studies have established that OL is stable at the gastric level during digestion, since
the bioavailability of its main metabolite HTy is higher [57]. On the contrary, Corona et al. determined
that OL was absorbed in the colon and degraded by gut microbiota in rat intestinal segment that
produces HTy, which expresses biological activity [58]. Further studies developed in rats confirmed
that OL and HTy were present in plasma, feces, and urine as such, and also conjugated as glucuronide
after oral OL administration [59–61]. Besides, there are several studies that focus on the study of the
colonic pathway of phenolic compounds present in the olive tree. For example, Mosele et al. have
demonstrated that OL hydrolysis formed OL-aglycone, elenoic acid, HTy and HTy-Ac in vitro, which
is probably a consequence of the hydrolytic transformation making all of them less resistant to the
gastric acidic hydrolysis in comparison to OL and more sensitive to temperature, pH, and enzyme
activity. However, OL administration detected other related metabolites such as homovanillic acid in
rats [62]. These divergences could be explained taking into account the differences found between
both murine and human models.
Surprisingly, it has been postulated that plasma peak at 1 hour (h) after OL administration for
humans or 2 h for a murine model, although OL could be detected after 10 minutes (min) [56,63].
In addition, glucuronides and OL sulfate derivatives could be detected in plasma (at 23 min) or in the
urine (at 8 h) after ingestion. Particularly, De Bock and colleagues described a heterogeneous effect in
OL leaf extract bioavailability and metabolism that was dependent on a number of factors, including
preparation (capsule/liquid) and gender [63]. In fact, they found that compared to capsules, OL leaf
extract in a liquid formulation led to a greater OL peak levels and area under the curve (AUC) in
plasma and described that males may be more efficient at conjugating OL.
The production of metabolites during the metabolism process of these compounds could be
interesting given that these new compounds may also exert beneficial effects on the organism.
The metabolism of secoiridoids can be carried out by phase I (hydrogeneration, hydroxylation,
hydratation, etc) or phase II reactions (glucuronidation, methylation, sulfation, etc.). A perfused
rat intestinal model determined that the major small intestine metabolites from OL-aglycone were
glucoronide conjugates, so they are not absorbed in parental form [64]. OL-aglycone and ligstroside
aglycone present a 55%–66% rate of absorption in humans. The aglycon forms were excreted in urine as
HTy or Ty [65]. Particularly, during gastric digestion, OL, OL-aglycone, and other phenolic compounds
are transformed into HTy, which is throughout transformed into its phase II metabolites (glucuronide
and sulfate conjugates) and into HTy-Ac by effect of the acetyl-CoA enzyme [66]. OL and ligstroside
formed sulfate and glucuronide conjugates during absoption after undergoing extensive first-pass
intestinal/hepatic metabolism, whereas concentrations of their free forms are not detected in the body
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fluids. These compounds were absorbed quickly after oral administration and then were metabolized
and excreted in the urine mainly as glucuronide [67]. The catabolism of OL could produce phenylacetic
and phenylpropionic catabolites which then could be absorbed and subsequently transforme into phase
II metabolites. Thus, compounds such as ligstroside or OL could be absorbed as such or reabsorbed in
the form of their respective glucuronide conjugates [58,68].
The bioavilability of OLE is still very limited. Ligstroside aglycone and OLE are hydrolyzed in the
acidic gastric environment in the stomach, leaving free Ty after 30 min. OLE is absorbed in the small
intestine mediated by passive diffusion through the membrane, which is favorable given an adequate
coefficient of partition (log P = 1.02) and stability in acid gastric [69]. In fact, Romero et al. verified
that OLE was stable in gastric acid conditions at 37 ◦C for 4 h [70]. Although it has been postulated
that OLE is mainly metabolized by Phase I (hydrogenation, hydroxylation, and hydration) [71,72],
some hydrogenated metabolites pass to Phase II of metabolism as glucoronidated forms [54], whereas
methylated or sulfate forms of OLE have not been detected in any study in humans to date [71,72].
The report published by García-Villalba et al. revealed that OLE and several secoiridoids metabolites
were excreted in human urine between 2 and 6 h after olive oil ingestion [72].
On the other hand, OLA may be absorbed in the small intestine by passive diffusion through the
membrane due to its favorable partition coafficient. OLA was found to be stable at gastric acid remaing
unalterated after 4 h of incubation [73]. After the consumption of olive oil, De las hazas et al. [66]
described that OLA was hydrolyzed into HTy and elenoic acid in the digestive system and further
metabolized by the enzymatic systems.
In conclusion, there are a lot of plants that have been used as medicines since time immemorial;
specificallys, Olea europaea L. is a species rich in compounds that have proven their efficacy in the
management of several complex diseases including cardiovascular disorders, diabetes, and viral and
microbial infections, but additional works are still really necessary to explore the evidences for other
traditional uses of this plant. Particularly, the antioxidant, anti-inflammatory, and immunomodulatory
properties of secoiridoids from the olive tree (leaves and fruits) have been suggested as a potential
application in several oxidative stress-mediated diseases including cancer, cardiovascular disorders,
neurodegeneration, the aging process and immunoinflammatory diseases. Thus, the purpose of this
review is summarize recent advances in the protective role of these secoiridoids derived from olive
tree (preclinical and clinical studies) in these pathologies derived from oxidative stress and focusing on
their plausible mechanisms of action involved.
2. Protective Role of the Olive Tree Secoiridois in Diseases with an Important Pathogenic
Contribution of Oxidative and Peroxidative Damage
2.1. Olive Tree Secoiridoids and Cancer
Cancer is a complex chronic degenerative disease characterized by a multistep process in which
normal cells turn into malignant cells, acquiring several properties such as abnormal proliferation and
reduced apoptosis.
The main factors that cause the majority of cancer cases are tobacco and dietary habits. In fact,
there is an estimation that around 30% of all cancers may be avoidable by changing food intake [74,75].
Therefore, the identification and characterization of foods and their components, which could
prevent the incidence and development of cancer, is an important objective for modern nutritional
research [74,76]. In this sense, it is important to take into account that populations who are living
near to the Mediterranean area have a lower incidence of cancer compared to other regions. This fact
is probably due to the consumption of the diet known as the Mediterranean diet [77]. Besides, it is
well-known that the pathophysiology of common diseases states such as cancer, cardiovascular disease,
arthritis, and neurodegenerative diseases, among others, are associated with chronic inflammation [78].
There are a large numbers of studies that support the chemopreventive role of natural compounds
derived from EVOO and the olive tree such as OL, OLE, OLA, or ligstroside against different cancers
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and inflammation process. Particularly, the role of secoiridoids derived from Olea europaea L. has been
investigated in different types of cancerous processes (Tables 1 and 2).
Table 1. Most recent in vitro studies that corroborate the important role of secoiridoids from the olive
tree in the control and progression of different types of cancer.
Phenolic
Compound
Cell Line Concentration Effects Reference
OL
NL-Fib: normal human skin
fibroblasts; LN-18: poorly
differentiated glioblastoma; TF-1a:
erythroleukemia; 786O: renal cell
adenocarcinoma; T-47D: infiltrating
ductal carcinoma of breast-pleural







0.025% of OL in
fibroblast tissue culture
medium
OL inhibited cell growth, motility
and invasiveness [79]
HT29 and SW260 human colon
adenocarcinoma cell line [0–100 μM]
OL might induce anti-proliferative
and pro-apoptotic effects [80]
HT29 200, 400, and 800 μM
OL limited the growth and
induced apoptosis via the p53
pathway
[81]
MDA-MB-231 human breast cancer
cell line 200 μg/mL
OL produced the up-regulating of




MDA-MB-231; MCF-10A and MCF-7
human breast cancer cell lines [0–300 μM]
OL exhibited specific cytoxicity
against breast cancer cells, which
is probably mediated through the
induction of apoptosis via
mitochondrial pathway
[83]
SKBR3 breast cancer cell line 100 μM
OL worked as G-protein-coupled
receptor (GPER) inverse agonists
in estrogen receptor (ER)-negative
and GPER-positive SKBR3
[84]
MCF-7 100 and 200 μM
OL induced apoptosis in breast
tumor cells via p53-dependent
pathway
[85]
MDA-MB-231 and MCF-7 [0–100 μM]
OL inhibited the viability of breast
cancer cells and induced




OL suppressed cells migration
through suppression of
epithelial-mesenchymal transition
and could reduce DOX-induced




OL decreased the expression of
both HDAC2 and HDAC3,
induced apoptosis, and retarded
cell migration and cell invasion in
a dose-dependent manner
[88]
MCF-7 200, 400, 600, and 1000
μM
OL inhibited the proliferation and




OL reduced cell viability in a
dose-dependent manner;
suppressed HGF or 3-MA, and








Cell Line Concentration Effects Reference
MCF-7 [0–250 μM] OL inhibited protein tyrosinephosphatase 1B (PTB1B) [91]
HepG2 and Huh7 human HCC cell
lines [0–100 μM]
OL induced apoptosis in HCC
cells via the suppression of
PI3K/Akt
[92]
HepG2 100, 200 and 300 μM
OL could control the influencing
of pro-nerve growth factor (NGF)
and NGF balance via affecting
MMP-7 activity without affecting
the gene expression of NGF in
HCC.
[93]
LNCaP human prostate cancer
androgen-responsive and DU145
androgen non-responsive cell lines
100 and 500 μM OL reduced cell viability andinduced thiol group modification [94]
TCP-1 and BCPAP thyroid tumor cell
line 10, 50, and 100 μM
OL was able to inhibit in vitro
thyroid cancer cell proliferation
acting on the growth-promoting
signal pathway
[95]
HeLa human cervical carcinoma cell
line 150 and 200 μM
OL-induced apoptosis was
activated by the JNK/SPAK signal
pathway
[96]
SH-SY5Y human neuroblastoma cell
line 350 μM
OL caused cell cycle arrest by
down-regulating CyclinD1,
CyclinD2, CyclingD3, CDK4, and
CDK6 and up-regulating p53 and
CDKN2A, CDKN2B, CDKN1A
gene expressions. OL also
induced apoptosis
[97]
U251 and A172 human glioma cancer
cell lines 0, 200, and 400 μM
OL inhibited cell viability and
reduced the expression levels of
MMP-2 and MMP-9. In addition,
a specific PI3K inhibitor enhanced
the pro-apoptotic and
anti-invasive effects induced by
OL
[98]
HNE1 and HONE1 human
nasopharyngeal carcinoma (NPC) cell
lines
0 and 200 μM
OL treatments reduced the activity
of the HIF-1α-miR-519d-PDRG1
pathway, which is essential to the
radio-sensitizing effect of OL
[99]
A549 human non-small cell lung
cancer (NSCLC) [0–200 μM]
OL caused a decrease in
mithocondrial membrane
potential, increase in Bax/Bcl2
ratio, release of mithocondrial
cytochrome C, and activation of
caspase 9 and caspase 3
[100]
H1299 lung cancer cell line [0–200 μM]
OL-induced apoptosis via the
mitochondrial apoptotic cascade
was activated by the p38 MAPK
signaling pathway in H1299 cells
[101]
A549 and BEAS-2B human
noncancerous cell line 50 and 150 μM
OL induced apoptosis in A549
cells [102]
MIA PaCa-2, BxPC-3, and CFPAC-1
pancreatic cancer and HPDE
non-tumorigenic pancreas cell lines
200 μM
OL arrested cell cycle, increased
the Bax/Bcl-2 ratio, increased the
activation of caspase 3/7, and
induced apoptosis in MIA-PaCa-2
[103]
A375 human melanoma cell line [250–500 μM]
OL was able to stimulate
apoptosis (500 μM), while at a
dose of 250 μM it affected cell
proliferation and induced the
down-regulation of the pAkt/pS6
pathway
[104]
OE-19 human esophagical cancer (EC)
cell line 200 μM
OL inhibited the growth of EC
cells as well as inhibiting HIF-1α
and up-regulating BTG








Cell Line Concentration Effects Reference
143B human osteosarcoma (OS) cell
line 100 μM
OL showed alone and in
combination with
2-methoxyestradiol a potent
anti-cancer potential in highly
metastatic OS cell
[106]
AGS Human gastric adenocarcinoma
cell line [0–1000 μg/mL]
Magnetic nano-OL could trigger
apoptosis in the AGS cell line [107]
OL-aglycone
SH-SY5Y and RIN-5F insulinoma cell
lines 100 μM
OL-aglycone triggered autophagy




HT29 and HCT-116 human colon
adenocarcinoma cell line 1, 2, 5, and 10 μg/mL
OLE produced an inhibition of
AP1 activity and cyclooxygenase 2
(COX2) expression in HT29 cells
[109]
MDA-MB-231, MCF-7, and PC3
prostate cancer cell lines [0–20 μM]
OLE inhibited the proliferation,
migration, and invasion of the
epithelial human breast and




BT-474, MDA-MB-231, and MCF-7 [0–60 μM]
OLE reduced the c-Met kinase
activity, cell growth, migration,
and invasion of breast cancer cells
and induced G1 cell cycle arrest















MDA-MB-231 5 mg/mL OLE was able to control breastcancer progression [114]
BT-474 and MDA-MB-231 [0–200 μM]
OLE with the dual HER2/EGFR
inhibitor, LP, induced synergistic
tumor growth inhibition
[115]
MCF-10A, MDA-MB-231, and MCF-7 1, 10, and 20 μM
OLE could be responsible for the
selective activation of
TRCP6-dependent Ca2+ influx
and TRCP6 down-regulation at
low μM concentrations
[116]
Huh-7, HepG2, and HCCLM3 HCC
cancer cell lines [0–80 μM]
OLE inhibited proliferation and
cell cycle progression and also
inhibited HCC cell migration and
invasion
[117]
Huh-7, HepG2, and HCCLM3 5 and 10 μM OLE reduced cell proliferationand increased cell death [118]
U937 hystocytic lymphoma cancer
cell line 30 μM
OLE significantly inhibited the
expression of Hsp90, a chaperone
with a key role in cancer and
neurodegeneration
[119]
A375: A2058; HUVEC and HaCat
cancer cell lines [0–60 μM]
OLE suppressed STAT3
phosphorylation, decreased





stimulated with epidermal growth
factor
[0–100 μM]
OLE promoted the inhibition of
ERK and Akt phosphorylation








Cell Line Concentration Effects Reference
OLA
Inmortalized human keratinocytes
stimulated with epidermal growth
factor
[0–100 μM]
OLA promoted the inhibition of
Erk and Akt phosphorylation and
the suppression of B-raf
expression
[121]
HL60 human promyelocytic leukemia
cell line [0–10 μM]
OLA reduced the DNA damage at
concentrations as low as 1 μM
when co-incubated in the medium
with H2O2
[43]
NCI-H929; RPMI-8226; U266; MM1S
and IIN3 human MM cancer cell lines 2.5, 5 and 10 μM
OLA elicited significant antitumor
activity by promoting cell cycle
arrest and apoptosis either with a
simple agent or in combination
with Carfilzomib
[122]
Table 2. Most recent in vivo studies that corroborate the important role of secoiridoids from the olive
tree in the control and progression of different types of cancer.
Phenolic
Compound
Animal Model Doses Effects Reference
OL
Swiss albino with soft tissue sarcomas 1% OLE in drinkingwater
OL inhibited cell growth, motility,
and invasiveness [79]
Male hairless mice (5 weeks old) were
UVB irratied (36–180 mJ/cm2) 10 and 25 mg/Kg/day
OL increased the skin thickness
and reductions in skin elasticity,
skin carcinogenesis, and tumor
growth
[123]
DSS-induced CRC in C57BL/6 mice 50 and 100 mg/Kg
OL prevented the development of
colonic neoplasia in by
ameliorating colon inflammatory
processes and limiting the
activation of the main
transcription factors involved
[124]
Male Sprague–Dawley rats that
received an injection of cisplatin
(7 mg/Kg)
50, 100, and 200
mg/Kg/day
OL enhanced antioxidant activity
and prevented oxidative stress,
which it turn reduced
8-hydroxy-2’deoxy-guanosine
(8-OH-dG) levels in lymphocytes
of cisplatin-treated animals
[125]
HNE1 and HONE1 injected into
6–8-week-old BalB/c mice [0–200 μM]
OL was a radiation-sensitizing
agent of NPC cells in an in vivo
model
[99]
Four-week-old C57BL/6N mice with
HFD with or without OL and which










Male Sprague–Dawley rats that
received an injection of cisplatin
(7 mg/Kg)
50, 100, and 200
mg/Kg/day
OL significantly decreased the
formations of DNA damage and
the level of malondialdehyde
(MDA), and it increased the levels
of total antioxidant status in
pancreas tissue samples
[127]
BalB/c OlaHsd-foxn1 injected with
MDA-MB-231 50 mg/Kg
The combined treatment with OL
and DOX downregulated the
antiapoptosis and proliferation
protein, nuclear transcription
factor-kappa B (NF-κB), and its
main oncogenic target Cyclin D1.




mice (6 weeks-old) that received a
subcutaneous injection of OE-19
cancer cells
200 μM
OL inhibited the growth of
xenograft EC tumor as well as
inhibited HIF-1α and upregulated








Animal Model Doses Effects Reference
OL-aglycone
Transgenic hemizygous CRND8 mice
harboring a double-mutant gene of
APP695 and wild-type control
lettermates with 4 and 10 months of
age
100 μM








Swiss albino mice (6 weeks old) 10 mg/Kg/day




Female athymic nude mice
(Foxn1nu/Foxn1+) (4-5 weeks-old)




recurrence in luminal HER2+/ER+
BT-474 tumors
[129]
Orthotopic tumor model of HCC in
BalB/c mice 0, 5 and 10 mg/Kg/day
OLE suppressed tumor growth
and impeded HCC metastasis in
an in vivo lung metastasis model.
OLE inhibited STAT3 activation
and increased the activity of
protein tyrosine hosphatase
[117]
OL is the most abundant of the phenolic compounds in olives. It could scavenge reactive oxygen
and nitrogen species as well as promote nitric oxide (NO) production in macrophages. In fact,
it has been postulated that OL may be the major factor responsible for the beneficial effects of the
Mediterranean diet against tumor growth [79].
There are several studies describing the potential role of OL in breast cancer. For example,
researchers have established the beneficial effects of OL in MCF-7, MCF-10A, and MDA-MB-231 human
breast cancer cells where OL was able to decrease the expression of histone deacetylase II (HDAC2),
HDAC3, and HDAC4, induce apoptosis, and retard cell migration and invasion in a dose-dependent
manner [88,89]. Besides, OL produced tissue inhibitors of metalloproteinases (TIMPs) overexpression
and metalloproteinases (MMPs) genes down-regulation, which could help in the prevention of breast
cancer metastasis [82]. Similarly, OL treatment reduced MDA-MB-231 cell viability in a dose-dependent
manner and significantly suppressed hepatocyte growth factor (HGF) and 3-methyladenine (3-MA)
inducing cell migration and invasion [90].
In human HT29 colon adenocarcinoma cell line, OL limited the growth and induced apoptosis via
p53 pathway activation, adapting the hypoxia-inducible factor 1-α (HIF-1α) response to hypoxia [81].
In addition, OL induced anti-proliferative and pro-apoptotic effects in a range of doses from 0 to
100 μM in HT29 cells [80].
On the other hand, OL induced apoptosis in hepatocellular carcinoma (HCC) via the suppression of
the phosphatidylinositol 3-kinase and protein kinase B (PI3K/Akt) pathway [130]. In fact, in combination
with other compounds, such as cisplatin, OL could lead to more effective chemotherapeutic combination
against HCC [130]. Similarly, in HeLa human cervical carcinoma cells, OL-induced apoptosis was
activated by the c-Jun N-terminal kinase (JNK)/Ste20-like proline alanine rich kinase (SPAK) signal
pathways [96], and both OL and its peracetylated derivative were able to inhibit thyroid cancer cell
proliferation acting on the growth-promoting signal pathway in the TCP-1 and BCPAP thyroid tumor cell
lines [95]. Likewise, OL reduced cell viability in human prostate cancer androgen-responsive cells [94],
induced autophagy and caused cell cycle arrest in SH-SY5Y human neuroblastoma cells [97,108], and
reduced cell viability in U251 and A172 human glioma cancer cells [98].
Similarly, there are several in vivo studies that have showed the beneficial effects of OL in different
cancer models. For example, Giner et al. have demonstrated that OL prevented the development
of colonic neoplasia in dextran sulfate sodium (DSS)-induced colorrectal cancer (CRC) in mice by
ameliorating colon inflammatory processes [124]. Besides, there was a relation between the consumption
of a high-fat diet (HFD) and the development of solid tumors, which was satisfactorily suppressed
with OL-enriched diets reducing the HFD-induced expression of angiogenesis, lymphangiogenesis,
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and hypoxia markers [126]. Elamin et al. have shown that OL and doxorubicin (DOX) combined
treatment down-regulated the antiapoptosis and proliferation protein in a murine model of breast
cancer [83].
OLE is a bioactive micronutrient in the Mediterranean diet that may be associated with positive
findings in some epidemiological studies that suggest a fewer incidences of breast, colon cancer,
and other malignancies compared to western and other populations. There are several studies to
enhance the beneficial role of OLE in this type of disease (Tables 1 and 2). In fact, authors believe
that consuming more EVOO with high OLE content is a prudent dietary approach to prevent cancer
with the caveat that dietary oils convey calories and consequently other caloric sources will have
to yield to avoid obesity [131]. OLE is a unique tyrosine-protein kinase Met (c-MET) inhibitor for
the control of breast cancer progression and loco regional recurrence [113,114]. The combination of
OLE with lapatinib (LP) treatment would allow the use of reduced dose of targeted therapies such
as LP, which would reduce future resistance emergence and drug toxicity while maintaining maximal
therapeutic activity [115]. Besides, OLE has been able to reduce c-MET kinase activity, cell growth,
and the migration and invasion of breast cancer cells; induce G1 cell cycle arrest and apoptosis; as well
as inhibit c-MET-dependent signaling in cultured breast cancer cells and tumorigenicity in in vivo
murine models [111].
OLE showed the capacity to inhibit breast cancer locoregional recurrence in luminal HER2+/ER+
BT-474 tumors. The prevention of tumor recurrence was associated with the down-regulation of MET
and HER2 receptors and suppression of receptor activation [129]. OLE showed a strong anti-proliferative
role against several breast cancer cell lines; for example, OLE was able to down-regulate the expression
of phosphorylated mammalian target of rapamycin (mTOR) in metastatic MDA-BD-231 breast cancer
cell lines [112] and inhibit the proliferation, migration, and invasion of the epithelial human breast
cancer and prostate cancer cell lines (MCF7; MDA-BD-231; and PC3). In addition, LeGendre et al.
demonstrated that OLE selectively and rapidly induces cell death in cancer cells without being
cytotoxic to noncancerous cells. OLE induced cell death by entering the lysosome and inhibiting
acid sphingomyelinase (ASM) activity, which induced lyposomal membrane permeabilization (LMP).
Even the consumption of 10 mg/Kg oral daily OLE water emulsion treatment significantly suppressed
the MDA-BD-231 tumor growth by 90% [132].
Multiple myeloma (MM) is another disease that would be approached with OLE treatment. MM
is a plasma cell malignancy that causes devastating bone destruction by activating osteoclasts in the
bone marrow milieu. OLE produced the inhibition of macrophage inflammatory 1 alpha (MIP-α)
expression and secretion in MM cells proliferation by inducing the activation of apoptosis mechanisms
and by down-regulating extracellular signal-regulated kinase (ERK)1/2 and protein kinase B (Akt) signal
transduction pathways [133]. Besides, OLE was able to inhibit hepatocellular cancer tumor growth
and metastasis by preventing signal transducer and activator of transcription (STAT)3 in in vitro and
in vivo models. In fact, OLE inhibited proliferation and cell cycle progression in different HCC cell
lines, and it also inhibited HCC cells migration and invasion in in vitro models [117].
OLA, also known as 3,4-(dihydrophenyl) ethanol (3,4-DHPEA-EDA) has antioxidant,
anti-inflammatory, and anti-microbial activities well documented in previous studies, but its effects on
tumor biology are still poorly defined [122]. Particularly, published studies reporting the beneficial
properties of OLA in the development of several cancers have been summarized in Tables 1 and 2.
In this sense, OLA was able to reduce the DNA damage in HL60 promyelocytic leukemia cells when
co-incubated with H2O2 in the medium [43] and also presented similar effects to OLE in the reduction
of viability and migration of non-melanoma skin cancer cells and in the inhibition of proliferation
of ERK and Akt phosphorylation and particularly through the reduction of B-Raf expression [121].
Likewise, OLA reduced the viability of MM primary samples and cell lines even in the presence of
bone marrow stromal cells (BMSCs) [84].
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2.2. Olive Tree Secoiridoids and Cardiovascular Diseases
The Global Burden of Disease indicates that cardiovascular diseases are still the main cause of
global death, representing about 31% of total deaths in the world in 2015 [134]. These pathologies
affect heart and vessels, as coronary heart disease, cerebrovascular disease, peripheral arterial disease,
and pulmonary embolism, among others [135]. There is evidence that suggests a possible link
between inflammation, endothelial dysfunction, and cardiovascular diseases are increased by oxidative
stress. Oxidative stress plays a critical role in the development and progression of atherosclerosis
and their complications including characteristics affections such as the regulation of vascular tone,
vascular smooth muscle growth, monocyte adhesion, platelet function, and fibrinolytic activity, among
others [136]. In terms of risk factors, the three world leading factors for cardiovascular diseases are
(i) high systolic blood pressure (SBP), (ii) smoking, and (iii) high body mass index (BMI). Proper
nutrition habits and healthy lifestyle play a major preventive role [134].
It has been widely reported that secoiridoids play a beneficial role against cardiovascular diseases
based on their antioxidant and anti-inflammatory activities. Interesting studies performed with animal
and cell models suggest that secoiridoids intake may be beneficial for the prevention and adjuvant
treatment of such diseases (Tables 3 and 4). Catalán et al. confirmed changes at proteomic level in
cardiovascular tissues (aorta and heart tissues), down-regulating proteins related to the proliferation
and migration of endothelial cells and occlusion of blood vessels in the aorta, and proteins related to
heart failure in heart tissue in Wistar rats fed a secoiridoids-enriched diet [137].
Table 3. Beneficial effects of secoiridoids from the olive tree in the control and progression of different
types of cardiovascular diseases: in vitro studies.
Phenolic
Compound
Cell Line Concentration Effects Reference
OL
Healthy human LDL 10 mM











Endothelial progenitors cells (CD31+
and VEGFR-2+) [1–10 μM]
OL reduced senescent cells and
reactive oxygen species (ROS)
formation; restoration of
migration, adhesion, tube
formation, and the up-regulation
of Nrf-2 and HO-1 expressions.
[140]
OL-aglycone
Human umbilical vascular endotelial
cells 5 and 25 mM
OL-aglycone reduced cell surface
expressions and mRNA levels of
ICAM-1 and VCAM-1
[141]
Mouse atrial myocites HL-1 60 mM OL-aglycone inhibitedtranthyretin toxicity [142]
OLA
Human neutrophils and monocytes [1–10 μM]




oxidative bursts in neutrophils
and myeloperoxidase release
[32]
Human neutrophils 50 and 100 mM OLA reduced elastase release,IL-8, MMP-9, and NEP activity [143]
Human macrophages 10–20 mM OLA increased IL-10, HO-1, andCD163 expression [144]
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Table 4. Beneficial effects of secoiridoids from the olive tree in the control and progression of different




Animal Model Doses Effects Reference
OL
Ischemia–reperfusion in insolated rat
hearts 20 μg/g
OL reduced the creatine kinase,




hypercholesterolemic rabbits 10 or 20 mg/Kg/day





cardiotoxicity rats 100 or 200 mg/Kg
OL modulated the CPK, lactate
deshydrogenase, aspartate and




cardiotoxicity in rats 100 or 200 mg/Kg
OL reduced the acetate and succinate
levels. Restore metabolic changes [148]
Doxorubicin-induced chronic
cardiomyopathy in rats 1000 or 2000 mg/Kg




Rabbit model of atherosclerosis 100 mg/Kg
OL decreased lipids, cholesterol, LDL





OL increased oxygen consumption,
fat oxidation, and myocardial
β-hydroxyacyl coenzyme A
dehydrogenase activity and the




diabetes 2 rats 20, 40, or 60 mg/Kg/day
OL reduced blood pressure, blood
glucose, serum total cholesterol, LDL,
and triglycerides levels. Raised HDL
levels.
[152]
Diabetic hypertensive rats 20, 40, or 60 mg/Kg/day
OL lowered blood pressure, MDA,
creatine kinase, and the induction of
HDL levels
[153]
Diabetic hypertensive rats 20, 40, or 60 mg/Kg/day
OL decreased blood pressure, glucose,
and serum MDA levels. OL increased
of HDL and erythrocyte SOD
[154]
Spontaneous hypertensive rats 10 mg/Kg
OL reduced the oxidative stress,
carotid and renal hemodynamics,
blood pressure, and heart rate
[155]
Rats fed with high-cholesterol diet 3 mg/Kg
OL modulated total cholesterol,
triglycerides, LDL and HDL levels,
and liver antioxidant enzymes
[156]
OL-aglycone
Neonatal rats ventricular myocytes
with MAO-A enzyme overexpressed 100 μM
OL-aglycone decreased oxidative
stress, autophagic flux blockade and
cell necrosis
[157]
Mature and progenitor endotelial cells 10 μM
OL-aglycone down-regulated NF-kB,
IL-8, vascular endothelial growth
factor (VEGF), MMP-2, and MMP-9
[158]
Rats fed with high-cholesterol diet 3 mg/Kg
OL-aglycone modulated total
cholesterol, triglycerides, LDL and






Experimental System Concentration Effects Reference
OL
232 hypertensive patients 500 mg twice daily
OL lowered systolic and diastolic
blood pressure, triglycerides, and
LDL levels
[159]
One of the best-documented cardiovascular protector secoiridoids is OL. OL inhibited in a
dose-dependent manner the copper sulfate-induced oxidation of LDL, reducing the formation of
lipid peroxides and malondhial dehydelysine and 4-hydroxynonenol-lysine adducts [138]. These data
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indicated the protection of the apoprotein layer. Additionally, OL was able to scavenge superoxide
anions generated by either polymorphonuclear cells or by the xanthine/xanthine oxidase system [139].
In this line, pretreatment with 20 μg/g of OL before ischemia–reperfusion in isolated rats hearts resulted
in a significant reduction in creatine kinase and glutathione release, supporting experimental evidences
of a direct cardioprotective effect of OL [145]. More recently, Parzonko and colleagues described
that OL-treated endothelial progenitors cells (type CD31+ and VEGFR-2+) showed a decrease in
the percentage of senescent cells and ROS formation and restored migration, adhesion, and tube
formation. This effect was related to nuclear factor E2-related factor 2 (Nrf2) and heme oxigenase-1
(HO-1) expressions [140] (Table 3).
Relating to animal models, Andreadou and co-workers have developed several in vivo
experimental models with OL treatment, defining the potential effect of this secoiridoid as a
cardioprotector. Ischemia-treated rabbits fed with 10 or 20 mg/Kg/day OL-supplemented diets
showed a reduction in infarct size, total cholesterol, and triglyceride concentrations [146]. Similarly,
OL administrated via intravenous decreased some markers of cardiovascular disease in DOX-induced
acute cardiotoxic rats such as creatine phosphokinase (CPK), lactate deshydrogenase, aspartate and
alanine aminotransferase, and lipid peroxidation in myocardial tissue [147]. Completing this study,
these authors revealed that OL down-regulated acetate and succinate levels and restored metabolic
changes to normal levels in myocardial tissue [148]. Finally, Andreadou et al. concluded that OL
administration could also prevent cardiomyopathy [149] (Table 4).
Concerning studies of atherosclerosis, OL could decreased serum lipids and tumor necrosis
factor alpha (TNF-α) levels, which was accompanied by a down-regulation of monocyte chemostactic
protein-1 and vascular cell adhesion molecule [150]. Ebaid et al. studied the effects of OL intake in
obesity-induced cardiac metabolic changes. They found that an OL diet showed an increase of oxygen
consumption, fat oxidation, and myocardial β-hydroxyacyl coenzyme A dehydrogenase activity and a
reduction in the levels of lipid hydroperoxide and up-regulation of antioxidant enzyme confirmed that
OL improved myocardial oxidative stress in standard-fed conditions [151].
With regard to OL antihypertensive effects, there are several studies performing different animal
models. In this line, diabetic and hypetensive rats receiving 20, 40, or 60 mg/Kg/day of OL presented
significantly reduced blood pressure, blood glucose, serum total cholesterol, LDL, triglyceride, MDA,
coronary effluent creatine kinase, and coronary resistance. The animals also had high-density
lipoprotein (HDL), erythrocyte SOD, left ventricular develop pressure, rate of rise, and rate of decrease
of ventricular pressure [152–154]. Antihypertensive activity has also been supported by Ivanov et al.,
who reported significant changes in carotid and renal hemodynamics, reducing cardiovascular risk
and improving vascular resistance in spontaneous hypertensive rat oxidative stress [155].
Regarding lipid regulation, the administration of OL and its aglycone form significantly
down-regulated the serum levels of total cholesterol, triglycerides, and LDL and up-regulated HDL
and liver antioxidant enzymes in Wistar rats fed a cholesterol-rich diet. These results demonstrated
that secoiridoids administration could control the lipid peroxidation process, enhancing antioxidant
enzyme activity [156].
The clinical trials of the effects of secoiridoids on cardiovascular diseases are scant. In this regard,
232 hypertension patients were involved in a clinical study subjected to a 500-mg oral dose of an
OL-enriched extract administration twice daily for 8 weeks. The patients presented a significant
reduction of systolic and diastolic blood pressure as well as the levels of triglycerides and LDL [159,160]
(Table 4). Stock and colleagues measured cholesterol efflux capacity from free cholesterol-enriched
macrophages to apolipoprotein B-depleted serum as the cholesterol acceptor in patients with coronary
artery disease. OL showed a positive behavior against LDL oxidation, promoting cholesterol efflux
and suggesting preventive effects against coronary artery diseases and enhanced atheroprotective
actions [161].
According to OL aglycone, only few studies have been carried out. Dell’agli et al. described
that OL aglycone exerted a modulation in early atherogenesis, reducing cell surface expressions of
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intracellular and vascular cell adhesion molecules (ICAM-1 and VCAM-1) in human umbilical vascular
endothelial cells [141]. Similar to OL, the aglycone form was studied in rats fed with a cholesterol-rich
diet by Jemai el at. The results suggested that the hypocholesterolemic effect of OL-aglycone might be
due to its abilities to lower serum total cholesterol, triglycerides, and LDL cholesterol levels, slowing
the lipid peroxidation process and enhancing SOD and CAT antioxidant enzyme activities, exhibiting
a cardioprotective role against lipid oxidation and cholesterol efflux [156].
More recently, Leri et al. reported that OL-aglycone was able to reduce transthyretin toxicity in
mouse atrial myocytes, so it could be used as treatment for severe cardiac symptoms [142]. In addition,
Miceli and coworkers explored the effects of OL-aglyone in myocytes with an overexpression of
monoamine oxidase-A (MAO-A), which is an enzyme that causes oxidative stress, autophagy flux
blockade, and cell necrosis as a model of cardiac stress characterized by autophagy dysfunction.
They observed that OL-aglycone counteracted the cytotoxic MAO-A effects [157]. Margheri et al.
also reported the effects of OL aglycone on capillary morphogenesis induced by MRC5 fibroblast
"senescense associated secretory phenotype" and progenitor endothelial cells, establishing that this
secoiridoid could modulate angiogenesis indirectly on senescent fibroblasts [158] (Table 4).
To date, OLE cardioprotective activity has been slightly investigated. Even so, some authors
defend its cardioprotective property based on its capacity to inhibit COX-1 and COX-2 expression.
It is well-known that thrombotic and cardiovascular disorders are linked to an imbalance in
prostanoid homeostasis, particularly prostaglandin or thromboxane production, which are involved in
vasodilatation or vasoconstriction, respectively, and platelet aggregation [162]. OLE has exerted strong
inhibitory effects on COX-1 and COX-2 in several studies [50,163,164]; nevertheless, future studies are
needed to confirm the property of OLE in cardiovascular disorders (Table 3).
The cardiovascular protection effects of OLA were tested in vitro in human neutrophils and
monocytes. This compound was able to scavenge O2−, H2O2, and NO levels, among other parameters,
which are implicated in tissue injury and chronic diseases, as atherosclerosis [32,165]. In a similar
work, Czerwinska et al. studied the capacity of OLA on neutral endopeptidase (NEP) activity and
other functions of human neutrophils, such as elastase, MMP-9 and interleukin (IL)-8 production,
which was markedly increased in patients with myocardial infarction [32]. The authors concluded
that OLA could play a role in the cardiovascular protective effects described by olive oil by inhibiting
NEP activity, adhesion molecules expression, and elastase release. Likewise, Filipek and colleagues
showed that OLA increased CD163 expression in human macrophages, supporting the significant role
in attenuation of plaque destabilization induced by hemorrhages [144]. Later, these authors reported
the beneficial effects of OLA in attenuating the destabilization of carotid plaque in 20 patients with
hypertension. This work revealed the ability of OLA to modulate IL-10, HO-1, MMP-9, and high
mobility group protein-1, which is a specific biomarker of cell lethality [166]. Thus, this compound
could be potentially useful in the reduction of ischemic stroke risk. Concluding, the preventive and
curative role of OLA, in terms of cardiovascular injury, could be attributed to its ability to regulate
LDL oxidation and MPO activity, to reduce the expression of adhesion molecules, as angiotensin II
production, and to confer protection to erythrocytes from oxidative hemolysis [33,73].
2.3. Olive Tree Secoiridoids and Neurodegeneration
Neurodegeneration is a process that leads to a progressive loss of structure or function of
neurons, irreversible neuronal damage, death, and a common final pathway present in aging and
neurodegenerative diseases. In addition, oxidative stress induced by impaired mitochondrial functions
has been also reported [167]. Particularly, superoxide anion formation and the production of hydrogen
peroxide are triggered by the induction of NADPH oxidase (NOX) subunit. This condition together
with a high NO level, produced by the induction of inducible nitric oxide synthase (iNOS) results
in the formation of peroxynitrite and nitrative stress [69]. Examples of neurodegenerative diseases
include Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease, amyotrophic lateral
sclerosis, frontotemporal dementia, and the spinocerebellar ataxias [168]. These diseases represent a
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primary health problem, especially in the aging population. Powerful experimental model organisms
such as the mouse, fruit fly, nematode worm, and even baker’s yeast have been used for many years to
explore neurodegenerative diseases and have provided key insights into these brain disorders.
Several epidemiological and observational studies support the belief that traditional alimentary
regimens such as the Mediterranean diet where olive oil is the primary source of added fat is associated
with improved aging and a reduced incidence of age-related diseases, including cardiovascular diseases,
cancer, and cognitive decline [169]. Particularly, olive leaves and EVOO contain many functional
phenolics that have been demonstrated to be able to reduce risk and offer protection against several
aging and lifestyle-related diseases, including neurodegeneration, in both animal and human’s models.
In fact, EVOO consumption has well-documented antioxidant, anti-inflammatory, anti-proliferative,
anti-carcinogenic, and antibacterial effects [170]. Among the 200 different chemical compounds detected
in olive oil, quantitatively, the class of secoiridoids is the most abundant. A number of different studies
investigated the effects of secoiridoids from olive trees in both in vitro and in vivo models of AD and
PD (Tables 5 and 6).




Cell Line Concentration Effects Reference
OL




OL decreased cell damage and
reduce biochemical markers of
PC12 cell death
[171]
PC12 cells exposed to the potent
parkinsonian toxin 6-OHDA 10
−12 M
OL showed neuroprotective
effects in an in vitro model of PD
when administered preventively
as a pretreatment. OL
significantly decreased neuronal
death. OL could also reduce the
mitochondrial production of ROS






growth of toxic Aβ1-42 oligomers
and blocked their successive
growth into mature fibrils
following its interaction with the
peptide N-terminus
[173]
Exposure of SH-SY5Y cells with Aβ42 [10–1000 μM]
OL were able to attenuate cell




toxicity after 24 h
[174]
NBM of adult male Wistar rats 450 μM
An apparent reduction in the
amount of soluble A11-positive
oligomers was detected in the
NBM injected with Aβ42
aggregated with OL as compared




Mouse brain endothelial cells (bEnd3) 25 and 50 μM
Treatment of bEnd3 cells with
OLE resulted in significant
increase in P-gp and LRP1 levels
[173]
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Animal Model Doses Effects Reference
 
OL-aglycone
Double transgenic TgCRND8 mice, a







the cognitive performance of
young/middle-aged TgCRND8








extracts (OLE) from 7




deposition (p < 0.001) in cortex
and hippocampus in comparison
[174]
Transgenic CL2006 and CL4176
strains of C. elegans 50 and 100 μM
OL-aglycone-fed CL2006 worms
displayed reduced Aβ plaque
deposition, less abundant toxic
Aβ oligomers, remarkably
decreased paralysis, and increased
lifespan
[177]
Systemic amyloidosis murine model 15 μM
OL-aglycone hindered amyloid
aggregation of Aβ(1-42) and its
cytotoxicity and eliminated the
appearance of early toxic
oligomers, favoring the formation
of stable harmless protofibrils,
which were structurally different
from the typical Aβ(1-42) fibrils
[178]
TgCRND8 mice 50 mg/Kg of dietduring 8 weeks




interfering both with Aß42 and
pE3-Aß aggregation
[175]
TgCRND8 (Tg) mice AD
Diet supplementation
with OL-aglycone at
12.5 or 0.5 mg kg-1of
diet
An OL-aglycone supplementation
diet and the mix of polyphenols
were found to improve
significantly cognitive functions (p
< 0.0001). Aß42 and pE-3Aß
plaque area and number were
significantly reduced in the cortex
[179]
OLE
5xFAD mouse model of AD EVOO rich with OLE
EVOO-rich OLE consumption in
combination with donepezil




Daily i.p. with 5




amyloid load in the hippocampal
parenchyma and microvessels,
which was associated with
enhanced cerebral clearance of Aβ
across the BBB
[181]
C57BL/6 wild-type male mice
10 mg/Kg of OLE twice
daily from 7 to 8 weeks
of age andcontinued
for 2 weeks (i.p.)
OLE enhanced clearance of Aβ
from the brain. A significant
increase in the expression of P-gp
and LRP1 was also observed in
the brain microvessels
[182]
AD is characterized by the increased accumulation of intracellular neurofibrillary tangles (NFTs) of
hyperphosphorylated tau protein and of extracellular Aβ protein deposits (Aβ plaques) derived from
amyloid precursor protein (APP) cleavage by γ-secretase and β-secretase. Dietary supplementation
of OL (50 mg/Kg of diet) strongly improved the cognitive performance of young/middle-aged/aged
TgCRND8 mice, and it also reduced ß-amyloid levels and plaque deposits. Moreover, OL-aglycone-fed
mice brain displayed an astonishingly intense autophagy reaction [175,176,179]. Similar results were
described in transgenic mice (APPswe/PS1dE9), where OL treatment showed significantly reduced
amyloid plaque deposition in the cortex and hippocampus as compared to control mice [174]. Moreover,
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OL hindered the amyloid aggregation of Aβ (1-42) and its cytotoxicity and eliminated the appearance
of early toxic oligomers, favoring the formation of stable harmless protofibrils, which were structurally
different from the typical Aβ (1-42) fibrils [178]. Using transgenic CL2006 and CL4176 strains of
C. elegans strains expressing Aβ42, as a simplified invertebrate model of AD, Diomede et al. evidenced
that 50–100 μM OL-fed CL2006 worms displayed reduced Aβ plaque deposition, less abundant toxic
Aβ oligomers, remarkably decreased paralysis, and increased lifespan with respect to untreated
animals. A protective effect was also observed in CL4176 worms but only when OL was administered
before the induction of the Aβ transgene expression [177] (Table 6).
In vitro studies have revealed that OL prevented the growth of toxic Aβ1-42 oligomers and blocked
their successive growth into mature fibrils following its interaction with the peptide N-terminus and
attenuated SH-SY5Y cell death caused by Aβ42, copper-Aβ42, and laevodihydroxyphenylalanine
(l-DOPA)-Aβ42-induced toxicity after 24 h treatment, and a marked attenuated Aβ-induced astrocytes
and microglia reaction was also found in the nucleus basalis magnocellularis (NBM) from adult male
Wistar rats injected with Aβ42 aggregated with OL [171,174,177] (Table 5).
The potential protective effect of OLE in AD has been also investigated in TgSwDI mice.
Mice treated for 4 weeks with OLE significantly decreased amyloid load in the hippocampal parenchyma
and microvessels. This reduction was associated with enhanced cerebral clearance of Aβ across the
blood–brain barrier (BBB), which was accompanied by an increase of P-glycoprotein (P-gp) and low
density lipoprotein receptor-related protein 1 (LRP1) expressions, and activated the ApoE-dependent
amyloid clearance pathway in the mice brains. The anti-inflammatory effect of OLE in the brains of
these mice was also obvious where it was able to reduce astrocytes activation and IL-1β levels [181].
Similarly, 10 mg/kg of OLE administrated twice daily from 7 to 8 weeks of age and continued for 2 weeks
(i.p.) enhanced the clearance of Aβ from C57BL/6 wild-type male mice brain and significantly increased
the expression of P-gp and LRP1 [182]. In mouse brain endothelial cells (bEnd3), 25 and 50 μM OLE
treatment resulted in a significant increase in P-gp and LRP1 levels [182]. Moreover, in a 5xFAD mouse
model of AD, OLE-rich EVOO consumption, in combination with donepezil, significantly reduced Aβ
load and related pathological changes, up-regulated synaptic proteins, enhanced BBB tightness, and
reduced neuroinflammation associated with Aβ pathology [180] (Tables 5 and 6).
PD is characterized by a progressive loss of dopaminergic neurons in the midbrain region known
as substantia nigra pars compacta and by the presence of cytoplasmic protein aggregates called the Lewy
body as well as Lewy neurites in remaining neurons.
Previous studies showed that OL inhibited αSN amyloidogenesis by directing αSN monomers
into small αSN oligomers with lower toxicity, thereby suppressing the subsequent fibril growth
phase [183]. The neuroprotective effect of OL has been explored in PC12 cells exposed to the potent
parkinsonian toxin 6-hydroxydopamine (6-OHDA). OL treatment significantly decreased neuronal
death and reduced the mitochondrial production of ROS resulting from blocking superoxide dismutase
activity. Moreover, the quantification of autophagy and acidic vesicles in the cytoplasm alongside the
expression of specific autophagy markers uncovered a regulatory role for OL against autophagy flux
impairment induced by bafilomycin A1 [171,172].
2.4. Olive Tree Secoiridoids and Ageing
Aging is a natural biological process that involves the gradual decline of physiological function and
the eventual failure of organism homeostasis followed by death. Aging is the process of accumulation
of damages to cells, tissues, and organs of an individual that is universal and unique, thereby reducing
the overall health of the organism. It is evident that aging can induce stress inside the system in the form
of ROS or other stressors, reduce overall health, and induce age-associated neurological diseases [184].
The maintenance of homeostasis between the formation and elimination of damaged proteins is a key
process in the development and growth of organisms [185]. To date, very few studies concerning the
anti-aging effects of secoiridoids have been performed. However, secoiridoids suggest a potential
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age-related damage regulation based on their antioxidant, anti-inflammatory, and neuroprotector
effects (Tables 7 and 8).
Several in vitro studies have supported the potential of OL on the proteasome, which regulates
the balance of cellular viability and is crucial in stress, aging, or senescent conditions [185]. The
treatment of cell lysates from human embryonic fibroblast IMR90 enhanced three major proteasome
catalytic activities: the chymo-trypsin-like (ch-L), the peptidylglutamyl-peptide hydrolase (PGPH)
activity, and the trypsin-like (T-L). This activity was supported by Katsiki et al. OL-treated cells
retained proteasome function during replicative senescence, and human embryonic fibroblast cultures
exhibited a delay appearance of senescence morphology [186]. Santiago-Mora et al. reported the
effects of OL on osteoblastogenesis and adipogenesis in mesenchymal stem cells from human bone
marrow. OL stimulated osteoclastogenesis rising cellular matrix mineralization and inhibited bone
desorption [187] (Table 7).
In terms of epigenetic, it has been postulated that oxidative damage to mitochondrial DNA
(mtDNA) is one of several signs of age-related physiological consequences [188]. Fabiani and
colleagues reported that OL and OL-algycone form counteracted DNA alterations in HL60 cells
and peripheral blood mononuclear cell (PMBC) H2O2-induced DNA damage [43]. Moreover, OL
counteracted bone loss and reduced α-1-acid glycoprotein plasma concentrations in senile osteoporosis
rats [189]. Nikou et al. studied the effects of OLE and OLA in Drosophila flies, reporting that dietary
administration of both of them was able to increase the T-L proteasome activity and 20S and 19S
proteosomal subunits expression, leading to a significant reduction of ROS levels. Subsequently, it was
reported that OLA up-regulated the gene expression of the proteasome, antioxidant response, and
molecular chaperones in human skin fibroblasts [190] (Table 8). These data confirmed a potential
anti-aging of both secoiridoids and suggested that these compounds could be critical nutraceuticals
as preventive and therapeutic treatment of different age diseases. Nevertheless, clinical studies that
confirm these suggestions need to be developed in the future.
Table 7. Potential role of secoiridoids obtained from the olive tree in anti-aging: in vitro studies.
Phenolic
Compound
Cell Line Concentration Effects Reference
OL
Human embryonic fibroblast (IMR90) [0.1–50 mM] OL enhanced ch-L, PGPH, andPGPH proteasome activity [185]
Human embryonic fibroblast
OL retained proteasome function
during replicative senescence and
delayed in the appearance of
senescence morphology
[186]
Mesenchymal stem cells from human
bone marrow [1–100 μM]
OL enhanced osteogenic gene
expression markers and osteoblast
phenotypic characteristic
[187]
Human promyelocitic leukemia cells
(HL60) 10 μM OL restored DNA damage [43]
OL-aglycone
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Table 8. Potential role of secoiridoids obtained from the olive tree in anti-aging processes: in vivo studies.
Phenolic
Compound
Animal Model Doses Effects Reference
OL
Senile osteoporosis rats model 15 mg/kg






Drosophila in vivo model
Dietary
supplementation of
OLE: 400 nM, 200 nM,
and 100nM.
OLE increased the ch-L
proteasome activity and the
expression of 20S and 19S
proteasomal subunits and
decreased of ROS levels in
somatic tissues of Drosophila flies
[190]
OLA
Drosophila in vivo model
Dietary
supplementation of
OLA: 400 nM, 200 nM,
and 100 nM
OLA increased the ch-L
proteasome activity and the
expression of 20S and 19S
proteasomal subunits and
decreased of ROS levels in
somatic tissues of Drosophila flies.
[190]
2.5. Secoiridoids Olive Tree in Autoimmune Diseases
Autoimmune diseases are heterogeneous groups of diseases whose condition is that your immune
system mistakenly attacks your body. In the normal state, the immune system is able to differentiate
between foreign cells, such as viruses and bacteria, and its own cells. However, in an autoimmune
disease, the immune system recognizes our own cells as foreign cells and it releases proteins called
autoantibodies that attack healthy cells. These types of diseases could appear at any stage of life with
higher or lower severity. For example, there are types of autoimmune disease that target only one
organ, such as type 1 diabetes mellitus (T1DM), which damages the pancreas, whereas there are other
diseases, such as systemic lupus erythematosus (SLE), which affect the whole body.
The National Institutes of Health (NIH) estimates that up to 23.5 million Americans suffer from
autoimmune disease and that the prevalence rose in 2019. For this reason, autoimmune diseases
are recognized as a major health problem. Nowadays, researchers have identified 80–100 different
autoimmune diseases and suspect at least 40 more diseases of having an autoimmune basis. These
diseases are chronic, can be life-threatening, and are responsible for death in female children and
women in all age groups up to 64 years old [191]. The most characteristic examples of these kinds
of autoimmune diseases are rheumatoid arthritis (RA), SLE, Crohn’s disease, ulcerative colitis (UC),
and T1DM.
RA can be defined as a chronic inflammatory disease with a systemic autoimmune component,
and it is mainly characterized by aggressive synovial hyperplasia, synovitis, the progressive destruction
of cartilage, and bone erosion with the painful swelling of small joints, fatigue, prolonged stiffness
and fever caused by immune responses, and specific innate inflammatory processes [192]. Worldwide,
the annual incidence of RA is approximately three cases per 10,000 people, and the prevalence rate is
approximately 1% increasing with age and peaking between the ages of 35 and 50 years old. RA affects
all populations, although it is much more prevalent in some groups (e.g., 5–6% in some Native American
groups) and much less prevalent in others (e.g., black persons from the Caribbean region) [193].
SLE can be defined as a chronic inflammatory and autoimmune disease that can affect multiple
organ systems, including skin, joints, kidneys, and the brain, among others [194]. SLE is characterized
by a deposition of immune complexes, which are formed in large amounts as antinuclear antibodies
bind to the abundant nuclear material in blood and tissues, along with disturbances in both innate and
adaptive immunity and T-cell signaling. In addition, SLE is characterized by its clinical and pathogenic
complexity, difficult diagnosis, and the high number of complications that can affect the patient’s
quality of life [195]. There are worldwide differences in the incidence and prevalence of SLE that vary
with sex, age, ethnicity, and time. The highest estimates of incidence and prevalence of SLE were in
North America: 23.2/10000 persons/years and 24/10000, people respectively. The lowest incidences
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of SLE were reported in Africa and the Ukraine (0.3/10000 persons/years), and the lowest prevalence
was observed in Northern Australia (0 cases in sample of 847 people). Women were more frequently
affected than men for every age and ethnic group. Incidence peaked in middle adulthood and occurred
later for men. People of black ethnicity had the highest incidence and prevalence of SLE, whereas those
with white ethnicity had the lowest incidence and prevalence. This appeared to be an increasing trend
of SLE prevalence with time [196].
Crohn’s disease and UC are important chronic inflammatory disorders of the gastrointestinal
system that contribute to the inflammatory bowel conditions, such as diarrhea with or without blood,
abdominal pain, fever, weight loss, inflammation, and ulcers. These diseases have uncertain etiology
but can be associated with multifactorial conditions in terms of immunity, genetics, and non-immune
conditions such as environmental factors [197]. The total number of new cases of Crohn’s disease
diagnosed each year (incidence) was 10.7 per 100,000 people or approximately 33,000 new cases per
year. The total number of new cases of UC diagnosed each year was 12.2 per 100,000 people or
approximately 38,000 new cases per year [198].
T1DM is considered an autoimmune disease that results from the destruction of pancreatic β-cells
and is mediated by the immune system. This is caused by an autoimmune reaction where the body’s
defense system attacks the cells that produce insulin. As a result, the body produces very little or
no insulin. Multiple genetic and environmental factors found in variable combinations in individual
patients are involved in the development of T1DM. Genetic risk is defined by the presence of particular
allele combinations, which in the major susceptibility locus (the HLA region) affect T-cell recognition
and tolerance to foreign and autologous molecules. T1DM can affect people at any age, but it usually
develops in children or young adults. Around 10% of all people with diabetes have T1DM [199].
Due to the high prevalence and rising incidence of this kind of disease, nowadays, there is a
requirement to investigate to develop palliative remedies or treatments that help us improve the
symptoms and management of these types of diseases to improve the quality of life of patients. A new
source of news alternative for autoimmune diseases is based on the use of natural compounds obtained
from natural resources, such as Olea europaea L., which is traditionally used as diuretic, hypotensive,
emollient, laxative, febrifuge, skin cleanser, and it is also used for the treatment of urinary infections,
gallstones, bronchial asthma, and diarrhea. The published studies related to the effects of secoiridoids
from the olive tree in these autoimmune diseases are summarized in Tables 9 and 10.
Table 9. Effective mechanisms and concentrations of bioactive secoiridoids from the olive tree in
in vitro models of immunoinflammatory diseases.
Phenolic
Compound
Cell Line Concentration Effects Reference
OL
LPS-stimulated murine peritoneal
macrophages. 25 and 50 μM
OL reduced pro-inflammatory
cytokines levels and interferon
(IFN)-γ, as well as iNOS and
COX-2 overexpressions
[200]
Human synovial fibroblasts cell line
(SW982) 50 and 100 μM
OL pre-treatment down-regulated
mitogen active protein kinase
(MAPK)s and NF-κB and






OLE showed a potent reduction of
ROS, nitrites, and
pro-inflammatory cytokines levels.




J774 LPS-stimulated macrophages 50 μM
OLE inhibited LPS-induced NO
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Table 10. Effective mechanisms and concentrations of bioactive secoiridoids from the olive tree in




Animal Model Doses Effects Reference
OL
Diabetes type I model induced by
subcutaneous alloxan monohydrate






the levels of urea, nitrite, and




myocarditis (EAM) model induced by
porcine cardiac myosin in Lewis rats
Oral gavage
20 mg/Kg/day of OL
OL improved cardiac functions




Chronic colitis model induced by DSS
(1% in first and second cycles and 2%
in third and fourth cycle) in female









Acute colitis model induced by DSS
(5%) for 7 days in BALB/c mice (6–8
weeks at age weigthing 18–20 g)
Diet supplemented
with 1% OL
Oral administration of OL
attenuated the extent and severity





Collagen type II-induced arthritis
(CIA) in three-week-old male DBA-J/1
Oral gavage 40
mg/Kg/day of OL








Cells Concentration Effects Reference
OL
14 outpatients biopsies with
Ulcerative Colitis
3 μM OL from olive
leaves from Olea
europaea L.
OL reduced the expression of
COX-2 and IL-17 in samples





There is evidence indicating that secoiridoids from the olive tree has a large potential as a therapy
for a wide variety of ROS-related diseases. Interesting studies performed with animal and cell models
suggest that secoiridods intake may be beneficial for the prevention and adjuvant treatment of such
diseases. Particularly, dietary supplementation of OL, OL-aglycone, or OLE strongly improved the
cognitive performance as well as reduced β-amyloid levels and plaque deposits favoring the formation
of stable harmless protofibrils in transgenic mice models of AD. Likewise, using transgenic strains
of C. elegans, OL-fed CL2006 worms displayed reduced Aβ plaque deposition, less abundant toxic
Aβ oligomers, remarkably decreased paralysis, and increased lifespan. Besides, OL prevented the
growth of toxic Aβ1-42 oligomers and cell death in SH-SY5Y cells, increased P-gp and LRP1 levels in
mouse brain endothelial cells, and a marked attenuated Aβ-induced astrocytes and microglia reaction
was also described in the NBM of adult male Wistar rats injected with Aβ42 aggregated with OL.
The neuroprotective effect of OL secoiridoid has been slightly explored in PD. OL treatment has
been demonstrated to inhibit αSN amyloidogenesis, suppressing the subsequent fibril growth phase,
decreasing neuronal death, and reducing the mitochondrial production of ROS resulting from blocking
superoxide dismutase activity in PC12 cells exposed to 6-OHDA.
The best-documented cardiovascular protector secoiridoid is OL. The literature reviewed here
validates that the treatment of cells and animal models with OL could be beneficial in combating
oxidative stress and thereby protect individuals from cardiovascular diseases. The beneficial effects of
secoiridoids have been attributed to their antioxidant capacity and their ability to modulate cellular
antioxidant defense mechanisms. In addition, OL has been shown to modulate a variety of targets,
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which include iNOS and NO, TNFα, IL-8 and MMP-2 and MMP-9 in addition to VCAM-1 and ICAM-1,
and modulating signaling pathways by altering MAPK, NFκB, and Nrf2/HO-1, among others. Finally,
secoiridoid supplemented diets exerted a reduction in infarct size, total cholesterol, and triglyceride
concentrations. On the contrary, the cardiovascular protection effects of OLE and OLA as well as
clinical trials of the effects of these secoiridoids on cardiovascular diseases are very scant, and future
studies are needed to confirm them in cardiovascular disorders.
OL has also shown considerable anti-cancer effects against many types of cancer, including breast
cancer, colorectal cancer, prostate cancer, pancreatic cancer, cervical carcinoma, and thyroid cancer
both in vitro and in vivo. OL is believed to exert its anticancer activity via multiple mechanisms,
interfering with different cellular pathways and inducing/inhibiting the production of various types
of cytokines, enzymes, or growth factors such as MAPKs, NF-κB, Akt, COX-2, and STAT3. On the
contrary, the studies reporting the anti-cancer effects of OLE and OLA are very circumscribed to breast
cancer, hepatocellular carcinoma, and hematologic neoplasias.
On the other hand, the remarkable anti-inflammatory and immunomodulatory effects of these
bioactive compounds have been reported in several in vitro and experimental models of RA, SLE,
inflammatory bowel disease (IBD), T1DM, and multiple sclerosis (MS). Particularly, OL, OLA, and
OLE may exert a remarkable inmmunodulatory and anti-inflammatory effects reducing the induced
inflammatory response in murine macrophages and human fibroblasts. This was accompanied by
amelioration of the production of essential pro-inflammatory cytokines involved in the regulation
of the immune system response through the prevention of MAPKs and NF-κB pathways activation.
Moreover, OL and OLA secoiridoids were effective in preventing the induced immuno-inflammatory
response in animal experimental models of UC, MS, T1DM, and SLE. Finally, very few studies about
secoiridoids’ anti-aging effects have been performed to date. Nevertheless, secoiridoids suggest
posing a potential age-related damage regulation based on their antioxidant, anti-inflammatory,
and neuroprotector effects.
In conclusion, the published data revealed, in general, consistent and very satisfactory results;
however, the knowledge is very limited, especially in clinical trials. In this sense, further efforts
are needed to mechanistically clarify the underlying biochemical and biological activities and
pharmacokinetics/pharmacodynamics of secoiridoids from the olive tree in additional preclinical and
clinical studies of ROS-related diseases.
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AGE advanced glycoxidation products
Akt Protein kinase B
ALE Advanced lipid peroxidation products
APP Amyloid precursor protein
ASM acid sphingomyelinase
AUC area under the curve
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BBB Blood-brain barrier
BMI Body mass index
BMSC Bone marrow stromal cells
BTG3 B-cell translocation gene 3
ch-L Chymo-trypsin-like
CIA Collagen-induced arthritis




DSS Dextran sulfate sodium
EAM Experimental autoimmune myocarditis
EC Esophagical cancer
ER Estrogen receptor
ERK Extracellular signal-regulated kinases
EVOO Extra virgin olive oil
GES Geraniol synthase







HFD High fat diet
HGF Hepatocyte growth factor
HIF-1α Hypoxia-inducible factor 1α
HO-1 Heme oxigenase-1
HTy Hydroxytyrosol
IBD Inflammatory bowel disease
ICAM-1 Intracellular adhesión molecule-1
IL Interleukin
iNOS Inducible nitric oxide synthase
i.p. intraperitoneally
JNK c-Jun N-terminal kinase
LDL Low-density lioprotein
LMP Lyposomal membrane permeabilization
LP Lapatinib










mTOR mammalian target of rapamycin
NADH Nicotinamide adenine dinucleotide reduced form
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NF-κB Nuclear transcription factor-kappa B
NGB Pro-nerve growth factor




Nrf2 Nuclear factor E2-related factor 2









PBMC Peripheral blood mnonuclear cells
PTB1B Protein tyrosine phosphatase 1B
RA Rheumatoid arthritis
ROS Reactive oxygen species
SBP Systolic blood pressure
SLS Secologanin synthase
SPAK Ste20-like proline alanine rich kinase
SLE Systemic lupus erythematosus
STAT Signal transducer and activator of transcription
T1DM Type 1 Diabetes mellitus




VCAM-1 Vascular cell adhesión molecule-1
VEGF Vascular endotelial growth factor
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97. Seçme, M.; Eroğlu, C.; Dodurga, Y.; Bağcı, G. Investigation of Anticancer Mechanism of Oleuropein via
Cell Cycle and Apoptotic Pathways in SH-SY5Y Neuroblastoma Cells. Gene 2016, 585, 93–99. [CrossRef]
[PubMed]
98. Liu, M.; Wang, J.; Huang, B.; Chen, A.; Li, X. Oleuropein Inhibits the Proliferation and Invasion of Glioma
Cells via Suppression of the AKT Signaling Pathway. Oncol. Rep. 2016, 36, 2009–2016. [CrossRef] [PubMed]
99. Xu, T.; Xiao, D. Oleuropein Enhances Radiation Sensitivity of Nasopharyngeal Carcinoma by Downregulating
PDRG1 through HIF1α-repressed microRNA-519d. J. Exp. Clin. Cancer Res. 2017, 36, 3. [CrossRef]
100. Cao, S.; Zhu, X.; Du, L. P38 MAP Kinase is Involved in Oleuropein-Induced Apoptosis in A549 Cells by a
Mitochondrial Apoptotic cascade. Biomed. Pharmacother. 2017, 95, 1425–1435. [CrossRef]
101. Wang, W.; Wu, J.; Zhang, Q.; Li, X.; Zhu, X.; Wang, Q.; Cao, S.; Du, L. Mitochondria-Mediated Apoptosis Was
Induced by Oleuropein in H1299 Cells Involving Activation of p38 MAP Kinase. J. Cell. Biochem. 2019, 120,
5480–5494. [CrossRef]
102. Antognelli, C.; Frosini, R.; Santolla, M.F.; Peirce, M.J.; Talesa, V.N. Oleuropein-Induced Apoptosis Is
Mediated by Mitochondrial Glyoxalase 2 in NSCLC A549 Cells: A Mechanistic Inside and a Possible Novel
Nonenzymatic Role for an Ancient Enzyme. Oxidative Med. Cell. Longev. 2019, 2019, 8576961. [CrossRef]
103. Goldsmith, C.D.; Bond, D.R.; Jankowski, H.; Weidenhofer, J.; Stathopoulos, C.E.; Roach, P.D.; Scarlett, C.J.
The Olive Biophenols Oleuropein and Hydroxytyrosol Selectively Reduce Proliferation, Influence the Cell
Cycle, and Induce Apoptosis in Pancreatic Cancer Cells. Int. J. Mol. Sci. 2018, 19, 1937. [CrossRef]
104. Ruzzolini, J.; Peppicelli, S.; Andreucci, E.; Bianchini, F.; Scardigli, A.; Romani, A.; La Marca, G.; Nediani, C.;
Calorini, L. Oleuropein, the Main Polyphenol of Olea europaea Leaf Extract, Has an Anti-Cancer Effect on
Human BRAF Melanoma Cells and Potentiates the Cytotoxicity of Current Chemotherapies. Nutrients 2018,
10, 1950. [CrossRef] [PubMed]
105. Zhang, F.; Zhang, M. Oleuropein Inhibits Esophageal Cancer through Hypoxic Suppression of BTG3 mRNA.
Food Funct. 2019, 10, 978–985. [CrossRef] [PubMed]
229
Antioxidants 2020, 9, 149
106. Przychodzen, P.; Wyszkowska, R.; Gorzynik-Debicka, M.; Kostrzewa, T.; Kuban-Jankowska, A.;
Gorska-Ponikowska, M. Anticancer Potential of Oleuropein, the Polyphenol of Olive Oil, With
2-Methoxyestradiol, Separately or in Combination, in Human Osteosarcoma Cells. Anticancer. Res.
2019, 39, 1243–1251. [CrossRef] [PubMed]
107. Barzegar, F.; Zaefizadeh, M.; Yari, R.; Salehzadeh, A. Synthesis of Nano-Paramagnetic Oleuropein to Induce
KRAS Over-Expression: A New Mechanism to Inhibit AGS Cancer Cells. Medicina (Kaunas) 2019, 55, E388.
[CrossRef]
108. Rigacci, S.; Miceli, C.; Nediani, C.; Berti, A.; Cascella, R.; Pantano, D.; Nardiello, P.; Luccarini, I.; Casamenti, F.;
Stefani, M. Oleuropein Aglycone Induces Autophagy via the AMPK/mTOR Signalling Pathway: A
Mechanistic Insight. Oncotarget 2015, 6, 35344–35357. [CrossRef]
109. Khanal, P.; Oh, W.-K.; Yun, H.J.; Namgoong, G.M.; Ahn, S.-G.; Kwon, S.-M.; Choi, H.-K.; Choi, H.S.
p-HPEA-EDA, a Phenolic Compound of Virgin Olive Oil, Activates AMP-Activated Protein Kinase to Inhibit
Carcinogenesis. Carcinogenesis 2011, 32, 545–553. [CrossRef]
110. Elnagar, A.; Sylvester, P.; El Sayed, K. (−)-Oleocanthal as a c-Met Inhibitor for the Control of Metastatic Breast
and Prostate Cancers. Planta Medica 2011, 77, 1013–1019. [CrossRef]
111. Akl, M.R.; Ayoub, N.M.; Mohyeldin, M.M.; Busnena, B.A.; Foudah, A.I.; Liu, Y.-Y.; Sayed, K.A.E. Olive
Phenolics as c-Met Inhibitors: (-)-Oleocanthal Attenuates Cell Proliferation, Invasiveness, and Tumor Growth
in Breast Cancer Models. PLOS ONE 2014, 9, e97622. [CrossRef]
112. Khanfar, M.A.; Bardaweel, S.K.; Akl, M.R.; Sayed, K.A. El Olive Oil-derived Oleocanthal as Potent Inhibitor
of Mammalian Target of Rapamycin: Biological Evaluation and Molecular Modeling Studies. Phyther. Res.
2015, 29, 1776–1782. [CrossRef]
113. Tajmim, A.; Siddique, A.B.; Sayed, E.; El Sayed, K. Optimization of Taste-Masked (–)-Oleocanthal Effervescent
Formulation with Potent Breast Cancer Progression and Recurrence Suppressive Activities. Pharmaceutics
2019, 11, E515. [CrossRef]
114. Qusa, M.H.; Siddique, A.B.; Nazzal, S.; El Sayed, K.A. Novel Olive Oil Phenolic (−)-Oleocanthal
(+)-Xylitol-Based Solid Dispersion Formulations with Potent Oral Anti-Breast Cancer Activities. Int.
J. Pharm. 2019, 569, 118596. [CrossRef] [PubMed]
115. Siddique, A.B.; Ebrahim, H.Y.; Akl, M.R.; Ayoub, N.M.; Goda, A.A.; Mohyeldin, M.M.; Nagumalli, S.K.;
Hananeh, W.M.; Liu, Y.-Y.; Meyer, S.A.; et al. (−)-Oleocanthal Combined with Lapatinib Treatment Synergized
against HER-2 Positive Breast Cancer in Vitro and in Vivo. Nutrients 2019, 11, 412. [CrossRef] [PubMed]
116. Diez-Bello, R.; Jardin, I.; Lopez, J.J.; El Haouari, M.; Ortega-Vidal, J.; Altarejos, J.; Salido, G.M.; Salido, S.;
Rosado, J.A. (−)-Oleocanthal Inhibits Proliferation and Migration by Modulating Ca2+ Entry through TRPC6
in Breast Cancer Cells. Biochim. Biophys. Acta - Mol. Cell Res. 2019, 1866, 474–485. [CrossRef]
117. Pei, T.; Meng, Q.; Han, J.; Sun, H.; Li, L.; Song, R.; Sun, B.; Pan, S.; Liang, D.; Liu, L. (−)-Oleocanthal Inhibits
Growth and Metastasis by Blocking Activation of STAT3 in Human Hepatocellular Carcinoma. Oncotarget
2016, 7, 43475–43491. [CrossRef] [PubMed]
118. De Stefanis, D.; Scimè, S.; Accomazzo, S.; Catti, A.; Occhipinti, A.; Bertea, C.M.; Costelli, P.; Stefanis, D.
Anti-Proliferative Effects of an Extra-Virgin Olive Oil Extract Enriched in Ligstroside Aglycone and
Oleocanthal on Human Liver Cancer Cell Lines. Cancers 2019, 11, 1640. [CrossRef] [PubMed]
119. Margarucci, L.; Cassiano, C.; Mozzicafreddo, M.; Angeletti, M.; Riccio, R.; Monti, M.C.; Tosco, A.; Casapullo, A.
Chemical Proteomics-Driven Discovery of Oleocanthal as an Hsp90 Inhibitor. Chem. Commun. 2013, 49, 5844.
[CrossRef]
120. Gu, Y.; Wang, J.; Peng, L. (−)-Oleocanthal Exerts Anti-Melanoma Activities and Inhibits STAT3 Signaling
Pathway. Oncol. Rep. 2017, 37, 483–491. [CrossRef]
121. Polini, B.; Digiacomo, M.; Carpi, S.; Bertini, S.; Gado, F.; Saccomanni, G.; Macchia, M.; Nieri, P.; Manera, C.;
Fogli, S. Oleocanthal and Oleacein Contribute to the in Vitro Therapeutic Potential of in Oil-Derived Extracts
in Non-Melanoma Skin Cancer. Toxicol. Vitr. 2018, 52, 243–250. [CrossRef]
122. Juli, G.; Oliverio, M.; Bellizzi, D.; Cantafio, M.E.G.; Grillone, K.; Passarino, G.; Colica, C.; Nardi, M.; Rossi, M.;
Procopio, A.; et al. Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple
Myeloma. Cancers 2019, 11, 990. [CrossRef]
123. Kimura, Y.; Sumiyoshi, M. Olive Leaf Extract and Its Main Component Oleuropein Prevent Chronic Ultraviolet
B Radiation-Induced Skin Damage and Carcinogenesis in Hairless Mice. J. Nutr. 2009, 139, 2079–2086.
[CrossRef]
230
Antioxidants 2020, 9, 149
124. Giner, E.; Recio, M.C.; Ríos, J.L.; Cerdá-Nicolás, J.M.; Giner, R.M. Chemopreventive Effect of Oleuropein in
Colitis-Associated Colorectal Cancer in c57bl/6 Mice. Mol. Nutr. Food Res. 2016, 60, 242–255. [CrossRef]
[PubMed]
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Abstract: A human organism depends on stable glucose blood levels in order to maintain its metabolic
needs. Glucose is considered to be the most important energy source, and glycolysis is postulated
as a backbone pathway. However, when the glucose supply is limited, ketone bodies and amino
acids can be used to produce enough ATP. In contrast, for the functioning of the pentose phosphate
pathway (PPP) glucose is essential and cannot be substituted by other metabolites. The PPP generates
and maintains the levels of nicotinamide adenine dinucleotide phosphate (NADPH) needed for the
reduction in oxidized glutathione and protein thiols, the synthesis of lipids and DNA as well as
for xenobiotic detoxification, regulatory redox signaling and counteracting infections. The flux of
glucose into a PPP—particularly under extreme oxidative and toxic challenges—is critical for survival,
whereas the glycolytic pathway is primarily activated when glucose is abundant, and there is lack of
NADP+ that is required for the activation of glucose-6 phosphate dehydrogenase. An important role
of glycogen stores in resistance to oxidative challenges is discussed. Current evidences explain the
disruptive metabolic effects and detrimental health consequences of chronic nutritional carbohydrate
overload, and provide new insights into the positive metabolic effects of intermittent fasting, caloric
restriction, exercise, and ketogenic diet through modulation of redox homeostasis.
Keywords: glucose; pentose phosphate pathway; NADPH; redox balance; glycogen; glycolysis; stress
resistance; insulin resistance
1. Introduction
The glucose level in blood is one of the most important homeostatic parameters and is strictly
regulated [1]. The complex interplay of signals from central and autonomic branches of the nervous
system, and the impact of multiple hormones and cytokines, all support coordinated glucose flows
within the body according to the actual needs and availability, in order to maintain its concentration in a
narrow range [2]. Since severe alterations of glucose metabolism take place in many diseases—including
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diabetes, that affects hundreds of millions of patients worldwide—there is a wealth of information
about health effects and biochemical changes due to high (over 10.0 mM) or low (under 3.5 mM) glucose
levels. The pathways of glucose metabolism and its regulation such as glycolysis/glycogenolysis,
pentose phosphate pathway (PPP), gluconeogenesis, polyol pathway, insulin signaling pathway and
many others are very well studied and their physiology and pathophysiology are firmly established.
It is well documented that hyperglycemia is associated with oxidative stress and that the severity of
diabetes correlates with the levels of accumulation of lipid peroxidation products, oxidatively modified
proteins and advanced glycation products; therefore, glucose itself is recognized by many prooxidant
factor. Short-time higher than physiological glucose levels (more than 10.0 mM) cause certain degree of
damage due to increased rate of non-enzymatic glycation of proteins but are usually not life-threatening
if blood glucose does not exceed 20.0 mM and is associated with diabetic ketoacidosis due to insulin
insufficiency. In contrast, low blood concentrations (2.5 mM and lower) can cause severe brain damage
and potentially death within the periods of time as short as 5–6 h [3]. Brain and particularly neurons
are the most sensitive to glucose deprivation, while other tissues and cells show a wide divergence in
resistance to hypoglycemia [1] that is very much dependent on their function, peculiarities blood flow
and capability to store glucose in the form of glycogen.
In the present review we would like to focus on the other aspects of glucose metabolism that are
not sufficiently addressed in the literature, namely physiological aspects of involvement of glucose and
its stores in the form of glycogen in regulation/maintenance of redox balance in cells and tissues. The
role of glucose as a fundamental source of reducing equivalents to antioxidant intracellular machinery
very often underestimated or ignored due to its reputation of primary source of energy. Understanding
the involvement of glucose in redox processes will enable not only better explanation of its metabolic
role, but also will open new possibilities to address poorly understood nature of insulin resistance,
and metabolic changes in diabetes overall. Our interpretation is also consistent with the mounting
epidemiological evidence and can explain deleterious health effects of excessive dietary consumption
of carbohydrates and sedentary lifestyle.
2. Basic Overview of Glucose Metabolism and Its Role in Maintenance of Redox Balance
It is well-known that most of the glucose in human metabolism is utilized intracellularly in
glycolytic pathway with further degradation of products in the tricarboxylic acid (TCA) cycle in order
to produce NADH and ATP [4]. Glycolysis is effectively activated by insulin in conditions of glucose
abundance, and a number of intermediates are also used for synthesis of needed amino and fatty
acids as well as other important metabolites [2]. However, in conditions of limited glucose supply
and/or excessive metabolic needs there are numerous alternative ways to generate enough NADH
and ATP, for example by the oxidation of fatty and amino acids, and the utilization of ketone bodies.
Flexibility and interchangeability of cellular energy supply provides sustainable and at the same time
variable flow of metabolites that is capable to accumulate them when the nutrients are in abundance
and consume them in a most effective way when there is their deficit. In periods of starvation or
glucose deficit, the activation of catabolic programs is capable to maintain energy production in most
of the organs [5]. Since neurons do not accumulate glycogen and total accumulation of glycogen in
central nervous system being extraordinarily low is limited to astrocytes, neurons rely on glucose
supply from the bloodstream [6]. Interestingly, in periods of starvation the brain can effectively use
ketone bodies as a primary fuel accounting for more than 75% of its energetic needs, pointing out the
possibility that glucose may be used for other purposes in this case [7]. This is further confirmed by
the observation that glycolysis in neurons is actively downregulated by proteasomal degradation of
6-phosphofructo-2-kinase/fructose-2,6-bis- phosphatase-3, preventing the utilization of glucose for
bioenergetics purposes. This mechanism, as suggested by authors, spares glucose in neurons for
maintaining antioxidant status, especially in conditions of limited glucose supply [8].
The importance of other major pathway of glucose metabolism, which to certain degree is an
alternative or parallel to upper glycolysis, a pentose phosphate pathway (PPP) is also long known. It
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is believed that its major function is the generation of reducing equivalents in the form of NADPH
needed for de novo lipogenesis, synthesis of DNA and aromatic amino acid [9]. Indeed, proliferating
cells use most of the NADPH for DNA and fatty acid synthesis [10]. The other major functions of
NADPH are the reduction in oxidized thiols and glutathione, generation of superoxide anion and
hydrogen peroxide during respiratory burst to fight infections and to provide redox signals to regulate
cell functions. In addition, it is also needed for detoxification of xenobiotics [11]. A growing number of
publications point out rerouting of glucose into a PPP as a major protective mechanism employed to
counteract acute and severe oxidative stress [9,12,13]. According to the calculations, the full oxidation
of one molecule of glucose in the PPP yields 12 molecules of NADPH reduced from NADP+ [14].
This aspect highlights the extraordinary efficiency and prompt responsiveness of this mechanism
in balancing redox homeostasis in conditions of acute oxidative challenge. Indeed, activation of
redox-sensitive transcription factors such as Nrf2 or FOXOs, in response to oxidative stress will result
in induction of antioxidant enzymes within hours [15], while rerouting of glucose into the PPP to
generate reducing power for antioxidant enzymes takes place almost immediately [14]. With the use
of 13C flux analysis in neurons, it was recently shown that glucose metabolism through the PPP may
be much more significant than was previously estimated [16]. Moreover, the authors demonstrated
that about 73% of produced labeled pyruvate was exported from neurons as lactate [16]. This may
indicate that neurons remove glucose that cannot be fully utilized in TCA away from the cells. In
case of increased functional activity, oxidative stress or glucose deficit during starvation, most of the
glucose flux may be redirected into the PPP.
The PPP is a major source of NADPH; however, it is not the only one. Substantial amounts of
NADPH are generated in folate-dependent NADPH-producing pathway [10] as well as by cytosolic
isocitrate dehydrogenase and malic enzyme [11]. However, these sources are often coupled with
synthetic pathways; for example, isocitrate is in abundance when glycolysis is activated and contributes
to fatty acid synthesis, therefore, it is difficult to expect their substantial contribution to the regeneration
of NADPH in cases of oxidative stress. To a certain degree, the metabolism of amino acids can
compensate for functional lack of glucose, and contribute to the maintenance of NADPH, but this seems
to be the mechanism with limited power under extreme exposures. Noteworthily, recently it was shown
that malic enzyme and 6-phosphogluconate dehydrogenase (6PGD) form a hetero-oligomer to promote
the activity of 6PGD, independently on activity of malic enzyme [17]. It is likely that the other structural
and functional interactions may exist in the cells in order to couple synergistic metabolic processes
in response to oxidative stress. The activity of alternative pathways provides robustness of NADPH
supply and, to some extent, compensates for the deficit of PPP flux in patients with glucose-6 phosphate
dehydrogenase (G6PD) deficiency—one of the most common genetic diseases in humans [18]. Patients
with G6PD deficiency generally have no symptoms and their lifespan is not affected by disease, but
it was shown that in addition to increased hemolysis they are less resistant to some poisonings [18]
and have higher risk of diabetes and metabolic syndrome [19]. Glucose-6 phosphate (G6P) is an
exclusive substrate for G6PD, a rate limiting enzyme of the PPP that can be supplied from extracellular
space in the form of glucose, then phosphorylated by hexokinase in human organisms. Alternatively,
glucose-1 phosphate released from glycogen—if the latter is available in the cell—is converted by
phosphoglucomutase to G6P. Some tissues—namely in the liver, kidneys or intestine [7], and to some
extent the glial cells—can generate glucose via gluconeogenesis. Furthermore, tumor cells may reverse
glycolysis in order to maintain their biosynthesis in glucose-free conditions [20]. Noteworthily, the
expression of most of the enzymes in the PPP is controlled by Nrf2, a redox sensitive transcription
factor involved in the upregulation of antioxidant and detoxifying genes, the degradation of damaged
proteins and metabolic reprogramming during stress [21], pointing out the tight conjugation of redox
balance maintenance and glucose metabolism. In other words, on the cellular and organism levels,
responses to local or systemic oxidative stress are associated with increased glucose release/production
by the liver and subsequently hyperglycemia, which may be physiological adaptive response in healthy
subjects and may also take place as a chronic metabolic deterioration in diabetic patients.
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3. Oxidative PPP Is Thermodynamically More Favorable Compared to Upper Glycolysis under
Conditions of Limited Glucose Supply
In physiological conditions (without metabolic/oxidative stress) the ratio of reduced and oxidized
forms of this coenzyme NADPH/NADP+ is very high (in the range of approximately 100/1, but is highly
tissue-dependent) and the lack of free NADP+ prevents G6P from entering the PPP [14]. However,
as soon as NADPH is oxidized (e.g., in conditions of oxidative stress) the increased availability of
NADP+ immediately redirects metabolic flow to the PPP and suppresses further steps of glycolysis
and the downstream utilization of glucose metabolites in TCA [8,13]. In other words, cells prioritize
the metabolism of glucose through the PPP over standard reactions of upper glycolysis in order to
maintain a sufficient NADPH/NADP+ ratio needed for the counteraction of acute oxidative challenge
(prompt enzymatic reduction in glutathione and other oxidized thiols), biosynthesis and/or generation
of superoxide during immune responses or as physiological redox signaling (Figure 1). Glucose
availability for the PPP—either from extracellular space, or from intracellular glycogen stores—is
essential for acute antioxidant responses ensuring the survival of cells and organism(s) in extreme
conditions. Stable and robust liver glucose output in cases of severe stress (including oxidative stress),
infection, starvation and extreme exercise is protected by the development of insulin resistance in order
to provide sufficient glucose flow to balance redox homeostasis. In absolute quantities, especially at rest,
glucose flow into the PPP may be low compared to standard upper glycolysis, but under conditions
when the NADPH/NADP+ ratio drops, amounts of glucose entering the PPP will correspond to the
degree of NADPH depletion.
 
(a) (b) 
Figure 1. Schematic presentation of the conventional (a) and pentose phosphate pathway-centric (b)
views of glucose metabolism. Abbreviations: G1P—glucose 1 phosphate, G6P—glucose 6 phosphate,
PPP—pentose phosphate pathway, TCA—tricarboxylic acid cycle, NOX—NADPH oxidase, NOS—nitric
oxide synthase.
A key factor leading G6P into the PPP is the presence of NADP+. The first reactions of the
PPP as well as other reactions producing NADPH are energetically very favorable and are basically
irreversible [22]. In contrast, most of the reactions of glycolysis are reversible. The activation of glucose
utilization through glycolysis in physiological conditions takes place when the NADPH/NADP+ ratio
is high (usually 50–100/1), glucose is relatively abundant and the insulin signaling is not compromised.
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Glycolysis serves as a source of pyruvate for TCA cycle and a number of anabolic intermediates in
conditions of high carbohydrate availability, and is supposed to be fully activated only occasionally
under physiological conditions, often switching to the oxidation of fatty acids when glucose availability
is limited. This shift takes place in concert with activation of transcription factors involved in
antioxidant defense (for example Nrf2 and isoforms of FOXO transcription factor) as a part of systemic
antioxidant response aimed to balance redox homeostasis, where gluconeogenesis and activation of the
PPP are fundamental parts of it (Figure 2). A sedentary lifestyle plus an abundance of carbohydrates
in food lead to an imbalance of nutritional consumption and actual metabolic needs; therefore, redox
dysregulation contributes to metabolic syndrome and diabetes type 2, and is an important factor that
increases the incidence of cancer that is discussed in more detail in the next section.
 
Figure 2. Glucose availability is a major factor in the maintenance of redox homeostasis through the
reduction in oxidized NADP+, which is used for the subsequent reduction in oxidized glutathione
and thiols. At the same time NADPH is used for synthesis of DNA and fatty acid synthesis and
is needed for activities of NADPH oxidases, NO-synthase and other processes. The scheme is
simplified and regulatory networks functioning in living systems are much more complex and include
other mechanisms and feedback loops. For example, it was recently shown that the deletion of
Nrf2 in mice can be—to a large extent—compensated by other adaptive mechanisms in conditions
of caloric restriction [23]. This suggests that robust regulatory network beyond Nrf2 and FOXO
transcription factors exists in order to maintain redox balance. Abbreviations: PPP—pentose
phosphate pathway, NOX—NADPH oxidase, NOS—nitric oxide synthase, GSH—glutathione,
GSSG—glutathione disulfide, Pr—protein, PrSSPr—disulfide bonds between/within the proteins
and other molecules, ARE—antioxidant response element, InsR—insulin receptor, cAMP—cyclic
adenosine monophosphate, FOXO—forheadkbox O transcription factors, Prx3—peroxiredoxin 3,
Nrf2—Nuclear factor (erythroid-derived 2)-like 2 transcription factor, MnSOD—manganese superoxide
dismutase, NF-kB—nuclear factor kappa-light-chain-enhancer of activated B cells.
4. The Epidemiological Evidence of Glucose Overload in Human Population: Current vs.
Historical Nutritional/Behavioral Patterns and a Growing Potential of Pharmacological
Interventions
As currently observed, massive nutritional carbohydrate overload associated with dramatic
decreases in physical activity has caused an epidemic of non-communicable diseases such as obesity,
metabolic syndrome, type 2 diabetes, atherosclerosis, hypertension and cancer [24]. A large-scale
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epidemiological cohort study pointed out that high carbohydrate consumption is a major factor for
all-cause mortality, while different types of fat were not associated with increased mortality. Thus,
authors question the current dietary guidelines suggesting an urgent need for their reconsideration [25].
On the other hand, the results of a large prospective cohort study indicate that health outcomes
depend rather on quality of food rather than just limiting carbohydrate or saturated fat in the diet. In
addition, “unhealthy” low carbohydrate and/or fat diet may increase all-cause mortality in studied
population [26]. Together with other evidences, including numerous animal studies, a serious demand
for strategies on how to counteract carbohydrate overload is indicated. Different approaches, including
pharmacological interventions [27] as well as public health and food regulation policies, are increasingly
discussed in the literature [28]. The careful evaluation of multiplicity of factors must be in place
in order to determine the optimal nutritional pattern for health preservation and the prevention of
age-related diseases.
In fact, an abundance of carbohydrates in food during human evolution was rather rare and more
of a short-term and often seasonal luxury [29]. Human neonates grow very rapidly and their need for
carbohydrate supply is probably higher than in adults than in other species due to the relatively large
brain and rapid development of the nervous system; however, human breast milk “only” contains
about 6.7 g per 100 mL of lactose accounting for up to 40% of calories—still the highest compared
to other mammals [30,31]. It is not likely that adults need more carbohydrates than babies as a
percent of calories intake in usual conditions without regular vigorous physical activity. The excessive
consumption of carbohydrates and low physical activity are major contributors to increasing rates of
metabolic syndrome and obesity in children and adolescents [32].
At high growth rate, the intensive physical activity as well as strong immunity needed for
resistance to infections and occasional poisonings requires the maintenance of sufficient levels of
glucose in blood, despite prolonged periods of carbohydrate deficit. Dietary glucose—as well as other
carbohydrates—were precious food components with limited, often seasonal availability promoting
survival under extreme conditions [29]. Therefore, an evolutionary sweet taste developed to detect
sources of digestible carbohydrates [33]. Only the development of agriculture about 10,000 years ago
enabled higher consumption of grain, increasing the share of carbohydrate in the diet. Even though
carbohydrates became more available, any possible overload would rather not take place considering
intensive physical activity of most of the people at that time. Thus, the gradual increase in basic food
availability and elimination of physical work created a massive nutritional carbohydrate overload at
the organism’s level causing respective health consequences [25]. Consistent with this, a metabolic
core model was recently used to evaluate how increased glycolytic utilization of glucose together with
glutamine-dependent lactate production promotes cancer growth [34]. Hyperglycemia may directly
contribute to increased risk of cancer as it was recently shown by Wu et al. [35]. Overall, there is
growing evidence—both mechanistic and epidemiological—that confirms previous predictions of
interrelationships between risk of cardiovascular/metabolic diseases and cancer risks [36–38].
Consistent with this is recent data generated on a C. elegans model regarding the integration of
stress-induced responses of nervous system with metabolic adaptations [39]. It was shown that the flight
response mediated by tyramine (worm analog of catecholamines) in the end leads to the stimulation of
insulin-IGF-1 signaling and has the opposite effect to longevity-promoting stress responses to heat,
starvation, glucose restriction or exercise [40–42]. If hypothetically translated to modern humans,
it can provide accurate mechanistical explanations as to why emotional stress accompanied with
sedentary behaviors may have detrimental health consequences associated with both excessive insulin
and adrenaline signaling causing atherosclerosis [24], contributing among the other factors to insulin
resistance and accelerated aging [43], but can be reversed by exercise or fasting [44]. In this sense
psycho-emotional stress prepares the organism to the impact of “expected” extreme factor in near
future, and in cases of “false alarms”, the excess of glucose needs to be utilized by the activation of
insulin signaling contributing to pathologic continuum that leads to atherosclerosis [24].
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In regard to glucose balance/overload and its crucial role in metabolic diseases, new data obtained
in clinical trials is very important, where patients were exposed to sodium glucose co-transporter
2 (SGLT-2) inhibitors. Designed initially to improve glycemia in patients with type 2 diabetes that
are not optimally controlled by metformin monotherapy—canagliflozin, dapagliflozin, empagliflozin
and others are continuously surprising clinicians and researchers by new positive effects far beyond
glycemia, including—but not limited to—the improvement of insulin resistance, reducing body
weight [45], preventing acute cardiovascular events [46], exerting a normalizing effect on blood
pressure, kidney function [47] and reversing manifestations of heart failure [46]. A plethora of positive
effects convincingly confirmed in strictly controlled clinical trials according to the highest standards of
evidence-based medicine by simply getting rid of approximately 50–70 g of (excessive) glucose per
day makes a significant difference for patients, and may potentially find its place among preventive
interventions. It is worth pointing that some contribution to the effect may potentially come from
sodium reabsorption inhibition, however, it is clear that the role of glucose excretion is prominent.
Thus, from the evolutionary point of view, the human organism was rather not used to the
consumption of large amounts of glucose and has had to optimize its metabolism in order to be able
to produce its sufficient amounts in accordance with metabolic needs. The importance of the PPP
evolved in order to provide resistance to oxidative challenges that are crucial for survival in acute
extreme conditions in multicellular organisms. The upregulation of PPP under oxidative stress is tightly
coupled with enhanced glucose output from glycogen stores and/or stimulation of gluconeogenesis.
Glucose 6-phosphate is a specific substrate for the PPP that makes glucose so important and strictly
regulated in maintaining redox homeostasis in human organisms [1].
5. Glycogen Protects against (Not Only) Oxidative Stress
According to our hypothesis, availability of intracellular glycogen is supposed to be protective
against oxidative stress, and vice-versa; its absence exposes cells to higher risk. Indeed, neurons,
which are unable to accumulate glycogen appear to be among the most sensitive cells to oxidative
stress, and they apply sophisticated mechanisms to direct the flow of glucose into the PPP in order
to protect themselves [8]. Severe hypoglycemia may result in seizures, loss of consciousness, coma
and—if glucose is not administered/ingested for longer periods (more than 5–6 h)—death [48]. Very
similar clinical manifestations have been observed in cases of hyperbaric oxygen exposure (so called
oxygen poisoning) that also causes severe redox imbalance in brain [49].
A recent C. elegans study demonstrated the crucial role of glycogen stores in resistance to acute
oxidative stress [50]. Moreover, the excessive accumulation of glycogen from a high-glucose diet and
with impaired glycogen degradation resulted in decreased lifespan of the worms [50]. Insecticide
poisonings causing oxidative stress in the fruit-eating bat Artibeus lituratus causes glycogen stores
depletion [51]. It was recently shown that hawkmoths, who have one of the highest metabolic rates
among known animals, use nectar sugar directed through the PPP to counteract oxidative damage
resulting from flight (extremely intensive exercise) [52]. In humans, the inability to deplete muscular
glycogen in patients with glycogen phosphorylase deficiency (McArdle disease) is associated with
severe exercise-induced oxidative stress and a risk of rhabdomyolysis [53]. This points out the
possibility that the function of glycogen in muscles is not only as an energy store during periods of
intensive contraction, but also for counteracting oxidative challenges associated with exercise.
It was noted that main life- and health-span promoting interventions such as caloric restriction,
intermittent fasting and exercise have in common that the depletion of glycogen stores [44], thus
reducing the protective capacity of glycogen and exposing the cells to moderate hormetic oxidative
stress. Glycogen stores are not simply an intracellular source of glucose, they also have an important
signaling function [54] and are protective against a number of stressful situations, namely hyper/hypo
osmotic stress [55], anoxia/hypoxia [56]. In addition, growing evidence indicates that a metabolic switch
from utilization of glucose, which is abundant in western diets, to ketone bodies use derived from
fatty acids is an evolutionarily conserved trigger-point responsible for health effects from intermittent
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fasting, caloric restriction and exercise [57]. Furthermore, a complex interplay of hormones including
insulin, glucagon, leptin, adiponectin and others regulate metabolic adjustments in conditions of food
abundance and deficit to provide needed glucose levels and energy in the organism [58–60].
6. Epigenetics and Posttranslational Protein Modification Modulate Oxidative Stress Responses
Epigenetics regulates gene expression, modifying DNA methylation and chromatin structure.
This regulatory mechanism works differently in each tissue to guarantee specific genetic responses
to environmental factors (i.e., nutrition, chemicals, stress), without any changes in the sequence of
nucleotides [61,62]. Epigenetics plays a key role starting from early life, where it is the master director
of cell differentiation, X-inactivation and the programming of adult health [63]; epigenetic changes can
be transferred to the progenies and, sometimes, they can be reverted [64].
DNA methylation consists of the methylation of Cytosine at CpG islands in the promoter region of
genes which has been associated with gene silencing, while different responses (activation or inhibition
of gene expression) derives from the methylation of CpG islands located in the regulatory regions
of genes. Histone modifications are changes that are more complex, because functional groups (i.e.,
acetyl, methyl, P, etc.) deriving from oxidation of nutrients, can be added to histones’ amino acid
residues, thus remodeling chromatin. The final result of histone modification is chromatin remodeling
at specific genes, leading to increased/decreased gene expression associated with healthy or unhealthy
regulatory responses [63].
Oxidative stress related with metabolic responses linked to hyperglycemia can enhance DNA
methylation interfering with S-adenosyl-L-methionine (SAM), the key methyl donor for the DNA
methyltransferases (DNMTs) which catalyze CpG methylation [65]. In particular, the deprotonation
by superoxide anion of cytosine C5 at CpG islands can support the formation of DNA-SAM complex
leading to the final cytosine methylation; furthermore, DNA methylation has been associated with the
increase in DNMT1 and DNMT3B expression due to reactive oxygen species (ROS) [65,66]. Glucose
can mediate epigenetic modification not only through ROS, but also because the high level of glucose
can interfere with DNA demethylation via TET2 and AMPK [67].
However, oxidation at the level of guanine leading to 8-hydroxydeoxyguanosine (8-OHdG)
in CpG islands, can also decrease cytosine methylation and reduce the binding of transcription
factors to the promoter region. The oxidation of 5-methylcytosine (5mC) due to Ten-Eleven
Translocation (TET) proteins leads to 5-hydroxymethylcytosine (5hmC) formation, which is deaminated
to 5-hydroxymethyluracil and then replaced with unmethylated cytosine [68]. Oxidative stress can
also inhibit the NAD+ dependent deacetylase SIRT1 that controls inflammatory responses, lipid
storage, telomerase activity, mitochondrial respiration and ROS production [69,70]. In this context, a
high-fat/glucose diet that decreases NAD+ content can negatively regulate Sirtuin activity.
The regulation of responses to oxidative stress is complex and includes many mechanisms [71]
such as oxidative modifications of macromolecules by ROS [72], signaling through lipid peroxidation
and their products [73] and involvement of different transcription factors (i.e., mentioned above
FOXOs and Nrf2) [74,75]. Considering ubiquitous expression of these transcription factors as
well as their crucial cellular functions it is very difficult to modulate them by pharmacological
interventions [72,76]. Similarly, lipid peroxidation products play important physiological functions,
for example in gastrointestinal tract [77]. Considering the significance of the regulatory functions of
4-hydroxynonenal and other lipid peroxidation products they also start attracting interest as a target
for pharmacological interventions in major stress-associated disorders [78].
7. The Evidence from Glucose-6 Phosphate Dehydrogenase Deficiency
G6PD deficiency is one of the most common genetic human diseases and affects more than 400
million people worldwide [18], therefore, much can be learned from the published evidence. Since
G6PD is a gateway to such an important metabolic pathway as the PPP, dramatic consequences to the
patients could be expected. However, this is very often not the case. As was already mentioned in
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the introductory section, these patients have few or no symptoms, with generally positive prognoses
and their expected lifespan is no different than that of the general population [18]. There are two
basic explanations for this evidence: first, most of the patients have a moderate degree of G6PD
deficiency and the PPP is still functioning at some level and, also, alternative pathways generate
sufficient amounts of NADPH; second, humans with modern lifestyles are exposed to relatively low
intensity stressors and there is simply no need for acute responses to stress. In contrast, severe G6PD
deficiency does indeed have a detrimental effect on the immune system and causes higher susceptibility
to infections [79]. In addition, G6PDH-deficient athletes and patients with this genetic defect may have
severe hemolytic crises after physical exertion [80]; however, the severity of susceptibility of individual
subjects may vary widely [81]. Complete G6PD knockout in mammals is incompatible with life, but
in embryonic mice stem cells it led to the severe susceptibility of cells to oxidative stress induced
by hydrogen peroxide or diamide and reduced cloning efficiency. However, the later was restored
when the oxygen concentration was reduced [82]. Therefore, in conditions of substantial oxidative
challenge, the proper function of the PPP and generation of NADPH are essential for survival [83].
Conversely, G6PD overexpression may be expected to increase resistance to oxidative stress. Indeed,
recent reports indicate that G6PD overexpression extends the lifespan of Drosophila melanogaster [84],
which is consistent with some of the results obtained using a G6PD overexpressing mouse model, where
it leads to the extension of the health-span of mice and increased resistance to oxidative damage [85].
8. Redox Dependence of Pancreatic Regulation of Blood Glucose Levels
A growing body of evidence indicates that the release of insulin from pancreatic β-cells depends
on the function of the PPP. It was shown that insulin levels in G6PD deficient patients are lower
compared to unaffected controls, and these patients have significantly reduced insulin responses to
the elevation of blood glucose [86]. More recently, with the use of metabolomics approach it was
shown that insulin release is controlled by the direct implication of the PPP [87]. According to a recent
review, among the most important amplifiers/regulators of insulin secretion by β-cells are high levels
of NADPH and glutathione [88]. So, insulin release is taking place in conditions of “metabolic welfare”
and oxidative stress may reduce the ability of β-cells to release insulin [89]. α-сells also have their
intrinsic mechanisms of glucose sensing relying on intracellular redox balance, but they are activated
by pro-oxidant situations [90]. Interestingly, under physiological conditions β-cells do not accumulate
glycogen but are able to do so under prolonged hyperglycemia and may prolong insulin secretion
even after normalization of glucose concentration. In contrast, α-cells do not accumulate glycogen,
so when the concentration of blood glucose drops, they can be quickly activated without delay [91],
which is extremely important in case of emergencies such as hypoglycemia.
One may argue that there are many other mechanisms for the regulation of insulin and
glucagon that can either enhance or inhibit respective secretion, including paracrine δ-cells secreting
somatostatin [92,93], effects of glucagon-like peptide-1 (GLP-1) [94], glucose-dependent insulinotropic
peptide (GIP) [95], leptin/adiponectin axis [96], and autonomic nervous system [97,98]. However, the
effects of all these regulators are integrated at the level of α- and β-cells and their metabolism resulting
shifts of redox potential [87,88,90].
9. Inflammation, Insulin Resistance and Redox Homeostasis
NADPH produced by the PPP or by other pathways is also used by NADPH oxidases and nitric
oxide synthase to produce superoxide anion. This is important for proper functioning of the immune
system and for redox regulation of multiple processes in the tissues including endothelial function [99].
It was shown, that pro-inflammatory interleukin 1β enhances glucose uptake under hyperglycemic
conditions in cultured human aortic smooth muscle cells. It also activates PPP and promotes the
production of superoxide by NADPH oxidase contributing to vascular damage [100] pointing out a
particularly dangerous combination of inflammation and hyperglycemia. Since immune cells require
glucose for their function, they send regulatory signals, for example TNF-α [101] or microRNAs [102] to
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the liver to enhance hepatic glucose output and thus, chronic inflammatory conditions may cause insulin
resistance [103]. The opposite effects are mediated by anti-inflammatory interleukin-10 [104] and the
spleen plays a particularly important role in these regulatory interactions [105]. The autonomic nervous
system may also be involved in regulation of interactions of local inflammatory conditions and oxidative
stress [106]. Autonomic output is actively involved in the regulation of glucose homeostasis and can
adjust the rates of glucose production and utilization independently of hormonal influences [107]. The
healing of oxidative stress-associated conditions, therefore, may improve autonomic balance [108].
Chronic carbohydrate overload and reduced physical activity cause obesity and metabolic syndrome,
and for these conditions, insulin resistance is very typical [109]. Thus, there exist complex multilevel
regulatory interactions to provide a sufficient flow of glucose to tissues in order to maintain a redox
balance. Prompt adjustments of redox homeostasis are critical for the immune defense where the PPP
plays a major role. Insulin resistance developing in this case seems to be adaptive and to some extent a
protective mechanism [110], but, if dysregulated, it leads to detrimental health consequences.
10. Glucose—“Oxidant” or “Antioxidant” after All? Sola Dosis Facit Venenum
There is a certain degree of confusion in the literature concerning the role of glucose in the
maintenance of redox homeostasis. It was long known, that diabetes and hyperglycemia obviously
cause redox dysregulation, oxidative stress and accelerated ageing [111]. On the other hand, glycogen
clearly protects against the oxidative stress and at the same time decreases lifespan and health
span [50,112]. Starvation and stress-induced gluconeogenesis clearly support survival and improve
health and lifespans [112,113], but are associated with the increased generation of ROS [40]. Moreover,
the complete withdrawal of glucose hence leads to short-term fall in ATP production, and surprisingly
causes a rise in ATP and increased mitochondrial content shortly after that is associated with the
activation of the protein deacetylase SIRT1. At the same time increased ROS production or possibly
insufficient ROS utilization is documented [114]. This suggests that there are a variety of effective
metabolic adaptations to compensate lack of glucose for ATP production, but a subsequent deficit of
reducing power to counteract to increase in ROS production is much more difficult to compensate.
Exercise, intermittent fasting/caloric restriction all lead to functional glucose/glycogen depletion
through activation of autophagy and support healthy aging that requires certain degree of oxidative
stress that leads to metabolic shift to catabolism and activate endogenous protective mechanisms that
include enhanced protein quality control, stimulation of endogenous antioxidant defense including
gluconeogenesis [57,111,115].
The other interesting aspect of glucose involvement in redox homeostasis is that supraphysiological
concentrations of glucose in the cells may actually lead to the increased production of hydrogen
peroxide by mitochondria through the inhibition of mitochondria-bound hexokinase [116]. Similarly,
chronically high levels of NADPH may contribute to the enhanced generation of superoxide and/or
hydrogen peroxide by NADPH-oxidases (NOX) as well as enhance the reduction in glucose in polyol
pathway (Figure 2) [99]. Involvement of NOX in regulation and maintenance of redox homeostasis
is very complex and depends on its isoforms that are expressed differently in tissues. For example,
cardiomyocytes express NOX2 and NOX4 isoforms and use the generation of hydrogen peroxide
for the regulation of cellular metabolism and contractile function (NOX4 activation acts similarly
as beta-blockers decreasing inotropy) [117]. NOX isoforms are increasingly studied as potential
therapeutic targets in order to modulate redox balance in the cells during cardiovascular and metabolic
diseases [118].
Diabetes, both type 1 and 2 are well documented diseases associated with oxidative stress.
The fundamental feature of diabetes is chronic hyperglycemia due to excessive glucose production
and/or impaired its utilization by the tissues. There are several mechanisms contributing to oxidative
stress in conditions of hyperglycemia that include but are not limited to non-enzymatic glycation
and formation of advanced glycation products, the activation of polyol pathway that results in
a depletion in NADPH (decreased rate of enzymatic reduction in oxidized glutathione and thiol
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groups of proteins), an increase in NADH and a depletion in NAD+ (increased superoxide anion
production in mitochondria), the inhibition of histone deacylation and excessive histone acetylation
due to the accumulation of acetyl-CoA, as well as the generation of excessive amounts of sorbitol and
fructose [119].
Taken together, the evidence indicates that there exists a delicate balance between the protective
and damaging redox effects of glucose and chronic dietary carbohydrate overload may affect the
regulatory mechanisms that developed during evolution to maintain redox homeostasis (Figure 3).
Bell-shaped antioxidant activity of glucose explains well necessity to regulate it strictly within the
narrow range, while both excessively high and/or low levels of glucose/carbohydrates lead to oxidative
and metabolic stress that quickly becomes damaging [120]. The dysregulation of glucose metabolism
that takes place in diabetes closes vicious cycle further exacerbating redox dysregulation that was
actually meant to be fixed by induction of hyperglycemia.
Figure 3. The dependence of redox effects of glucose on its concentration (hypothetic relationship
suggested by the authors). Hypothetical simplified model describing the influence of the blood
concentration of glucose on redox potential in human organisms. Multiple additional factors influencing
redox potential such as concentration of oxygen, availability of amino and fatty acids, type of cells
and effects of either hormones (insulin, glucagon) or cytokines are not considered. Concentrations of
glucose as well as the shape of the curve are roughly estimated and not confirmed by actual experiments
and may significantly vary depending on conditions and tissue type.
11. Important Implications
Glucose is a central metabolite and depending on its availability and metabolic need can play
different roles in the organism. Glucose flows within the human body are strictly regulated and
promptly adjustable in order to maintain metabolic flexibility and provide robust resistance to different
types of stressing factors (Figure 4). The role of glucose is not limited to merely generating enough
ATP (which is the case in conditions of glucose abundance and low stress), but more importantly, it is
responsible for the emergency mechanisms of the maintenance of redox potential that is essential for
survival in extreme situations (fight or flight reactions, infections, and poisoning).
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Figure 4. Role of redox sensors (pancreatic α and β cells), immune system and central nervous system
in the regulation of blood glucose concentrations by liver. Glucose release or absorption by the liver
integrates signals from nervous and immune systems, and peripheral redox sensors. The system is
highly flexible and tunable, providing redox modulation that is dependent on actual needs. The other
way around, glucose flows and redox state regulate the function of immune system [121]. Failure of
feedback loops and distorted signaling—either from CNS (stress), the immune system (inflammation)
or the malfunction of peripheral sensors—lead to excessive, uncontrolled (poorly controlled) glucose
release and/or the activation of gluconeogenesis, leading to diabetes.
Since TCA-cycle reactions and oxidative phosphorylation can be effectively maintained in almost
absence of glucose by oxidation of fatty and amino acids, its residual amounts are—in catabolic
conditions—redirected into the PPP to maintain redox balance in the cells. At the same time, the
anabolic state requires redirecting excess glucose into energy production and biosynthesis (growth,
proliferation, hypertrophy), when the primary life-supporting and life preserving needs ensured
by glucose have already been met (“survival—first, growth—follows”). The proposed principle is
helpful for understanding the regulation of glucose metabolism aimed primarily to maintain redox
balance, especially in acute extreme conditions requiring prompt and massive antioxidant responses.
Oxidative stress, infections/inflammation, starvation, exercise, aging and many other pathological
conditions or processes decrease GSH/GSSG and NADPH/NADP+ ratios. Sensors sense these changes
and drive glucose flows to compensate for these metabolic disturbances at the organismic level.
In this regard insulin resistance develops as a protective “antioxidant” adaptive mechanism that
stimulates glucose production and prevents its waste in order to cope with increased needs. When
dysregulated and chronically over-activated, though, this leads to detrimental consequences caused by
hyperglycemia [110].
The other important issue, which is often not taken into consideration by researchers, is that the
presence of glucose stores in the form of glycogen or extracellular glucose availability provide enhanced
resistance to oxidative stress. It is also possible that glucose—by strengthening the reductive power of
NADPH-dependent antioxidant enzymes—prevents the activation of redox-sensitive regulatory factors
such as Nrf2. That means that glucose nutritional overload affects physiological redox signaling, and
the chronic over-activation of insulin signaling causes metabolic diseases, as described in detail [24].
On the other hand, severe glucose overload itself can serve as a source of oxidative stress in the cells
through the participation of glucose in polyol pathway, over-the activation of NADPH oxidases and
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increased production of ROS by mitochondria. Exercise, caloric restriction, intermittent fasting, a
ketogenic diet and some drugs have something in common—in that they deplete organisms’ glycogen
stores [44], reduce glucose availability for the cells, restore the physiological redox signaling suppressed
by chronic excessive glucose consumption and lead to a dramatic improvement of life- and health-spans
in model organisms and humans (Figure 2). Metabolic changes caused by carbohydrate overload in
the general population often take place far before clinically significant changes occur [43]. That is why
relevant and sensitive instruments for the early detection of these metabolic shifts are needed.
12. Limitations of the Analysis and Directions of Further Research
In this review we presented mainly general principles of glucose metabolism in the cells and
its importance for maintenance of redox balance. However, different cells in different tissues have
their specific metabolic patterns, specific functions, and own physiological peculiarities. We tried
to focus on the most important findings and inconsistencies in the literature from our point of view
rather than focusing on biochemical details, different pathways, tissue differences and to show how
the clinical and experimental evidence may be interpreted when the glucose will be considered as
redox mediator rather than simply fuel “burned” to generate ATP. Glucose metabolism may differ
substantially depending on the specifics of tissues and cells, proliferation activity, redox balance
required to maintain the functions, expression and activities of involved enzymes. It is not possible to
accurately describe all the evidence that is published in the literature, and we are aware that many
important details may be missing from our analysis. Nevertheless, we hypothesize that convincing
literature evidence indicates that glucose flows in the organism are primarily targeted to maintain
redox homeostasis and counteract possible oxidative challenges.
It may be argued that the actual flow through PPP is relatively low in the brain (as has been
shown by Gaitonde M. et al. [122]) and it only increases substantially to approximately 20% of total
glucose utilization by neurons in cases of severe oxidative stress induced by hydrogen peroxide [123]
or during experimental brain injury [124]. However, a closer look into the methods used in the studies
reveals that non-physiologically high concentrations of glucose were used, namely 22.3 mM in the
medium and 50.0 mM for perfusion in [123] and 23.9–26.9 mM plasma glucose after infusion in [124]).
The flow of glucose into the PPP is inhibited in conditions of high NADPH/NADP+ ratio, therefore as
soon as the levels of NADPH are restored, glucose is redirected into glycolysis or glycogen storage.
Our reconsiderations may provide better understanding of the physiology of glucose regulation
in health and diseases and lead to the shift of the general paradigm of glucose-induced oxidative
stress—which is, however true for hyperglycemia and diabetes—towards understanding the redox
effects of glucose in a concentration-dependent manner. In other words, glucose maintenance at
physiological levels is a fundamental mechanism of counteracting excessive oxidation due to its
involvement in PPP and NADPH production. Endogenous antioxidant systems using glucose provide
sufficient antioxidant defense in physiological conditions. Moreover, redox modulating agents that
have some health benefits when supplemented often turn out to be rather prooxidant than antioxidant,
and lead to the stimulation of endogenous antioxidant defenses and the improvement of glucose
metabolism. Therapeutic approaches to applying antioxidant substances in order to reduce oxidative
damage and the administration of compounds with the pure purpose to provide reducing equivalents
appears weak [125] in contrast to often-high in vitro activities [126], and in comparison to existing
endogenous antioxidant mechanisms based on glucose as a source of reducing power for the generation
of NADPH and recycling oxidized glutathione and thiols, and can in some cases be deleterious since
they may interfere with redox sensors—for example protein thiol groups, and cause dysregulations.
The other important issue is the lack of convenient, informative, sensitive and specific ways of
glucose and/or glycogen determination in tissues for research and clinical use. As we suggested earlier,
glycogen determination, preferably in a simple, affordable and noninvasive way could potentially
be a good biomarker for redox biomedicine [44]. Unfortunately, there are too many technical issues
preventing the development of such equipment for clinical use so far, but some efforts have been made
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to enable label-free glycogen estimation in C. elegans, an important animal model for metabolic and
aging research [127].
13. Conclusions
Our critical analysis of the current literature unveiled significant controversies and an insufficient
general understanding of metabolic role of glucose, particularly regarding redox homeostasis.
The important function of glucose metabolism in the PPP for the maintenance of redox homeostasis is
very often underestimated. In light of recent epidemiological evidence and advancements in the field
of redox biology, it is hypothesized that a specific physiological function of glucose is its metabolism in
the PPP, to provide stress resistance to unfavorable factors by the reduction in NADP+ to NADPH
in order to maintain redox homeostasis and the correct functioning of immune cells. Meanwhile,
glycolysis takes place in favorable redox conditions when glucose is in abundance. This approach
and interpretation explains—in a simple way—the adverse metabolic effects and detrimental health
consequences of nutritional carbohydrate overload, and provides new details in explaining the positive
metabolic effects of intermittent fasting, caloric restriction, exercise, and a ketogenic diet. A better
understanding of the evolutionary adaptations and biological role of glucose may serve as an important
theoretical background for future experimental and clinical studies related to glucose metabolism,
aging, and diabetes, as well as other adjacent fields.
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Abstract: Pre-clinical studies suggested potential cardiovascular benefits of dipeptidyl peptidase-4
inhibitors (DPP4i), however, clinical trials showed neither beneficial nor detrimental effects in patients
with type 2 diabetes mellitus (T2DM). We examined the effects of DPP4i on several circulating
oxidative stress markers in a cohort of 32 T2DM patients (21 males and 11 post-menopausal females),
who were already on routine antidiabetic treatment. Propensity score matching was used to adjust
demographic and clinical characteristics between patients who received and who did not receive
DPP4i. Whole-blood reactive oxygen species (ROS), plasma advanced glycation end products (AGEs),
advanced oxidation protein products (AOPP), carbonyl residues, as well as ferric reducing ability of
plasma (FRAP) and leukocyte DNA oxidative damage (Fpg sites), were evaluated. With the exception
of Fpg sites, that showed a borderline increase in DPP4i users compared to non-users (p = 0.0507),
none of the biomarkers measured was affected by DPP4i treatment. An inverse correlation between
estimated glomerular filtration rate and AGEs (p < 0.0001) and Fpg sites (p < 0.05) was also observed.
This study does not show any major effect of DPP4i on oxidative stress, assessed by several circulating
biomarkers of oxidative damage, in propensity score-matched cohorts of T2DM patients.
Keywords: type 2 diabetes; dipeptidyl peptidase-4 inhibitors; biomarkers; oxidative stress
1. Introduction
Dipeptidyl peptidase-4 inhibitors (DPP4i) are oral agents used for the pharmacological treatment
of adults with type 2 diabetes mellitus (T2DM). By preventing glucagon-like peptide 1 (GLP-1)
breakdown, DPP4i enhance endogenous insulin secretion and suppress that of glucagon, resulting
in the reduction of blood glucose levels [1]. Several clinical trials demonstrated that these agents are
effective in reducing glycated hemoglobin (HbA1c) with a low risk of hypoglycemia and neutral effects
on weight, compared to sulphonylureas [2–4].
A meta-analysis of short and medium-term trials with metabolic endpoints, showed that the
treatment with DPP4i was associated with reduced incidence of major adverse cardiovascular events
(MACE) and all-cause mortality [5]. Later on, trials with cardiovascular events as major endpoints,
showed a neutral effect of DPP4i with respect to the incidence of MACE in T2DM patients with
cardiovascular disease [6–8]. Moreover, a post hoc analysis from the SAVOR-TIMI 53, found a
moderate increase in the risk of hospitalization due to hearth failure with saxagliptin compared to
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placebo [6], not observed in the EXAMINE and TECOS trials with alogliptin and sitagliptin [8,9].
More recently, in the CARMELINA trial, no increased risk of heart failure with linagliptin compared to
placebo was reported in patients at high cardio renal risk [10]. The results of the CAROLINA trial also
demonstrated that linagliptin was non-inferior to glimepiride on the prevention of MACE in patients
with elevated cardiovascular risk [11].
Oxidative stress is a significant risk factor in the development and progression of T2DM and
associated vascular complications [12–14]. Increased levels of circulating oxidative stress biomarkers
have been consistently found in T2DM patients compared to healthy controls as well in T2DM patients
with micro and macrovascular complications compared to those without [15].
Experimental in vitro and in vivo studies showed that DPP4i protect against oxidative stress,
suggesting potential cardiovascular benefits that have not been observed in human studies.
In endothelial and tubular cells, linagliptin inhibited reactive oxygen species (ROS) production
and inflammation induced by advanced glycation end products (AGEs) [16,17]. Vildagliptin attenuated
vascular injury by suppressing the AGEs-receptor for AGEs (RAGE)-oxidative stress axis in diabetic
rats [18]. Saxagliptin prevented vascular remodeling and oxidative stress in T2DM mice by abolishing
nicotinamide adenine dinucleotide phosphate NAD(P)H oxidase-driven endothelial nitric oxide
synthase (eNOS) uncoupling [19] and prevented increased coronary artery stiffness and collagen
deposition in a mini swine model of heart failure, partly by decreasing AGEs [20]. However, prolonged
DPP4 inhibition let to the development of cardiac fibrosis in old, diabetic, high fat-fed mice [21].
Some studies were also conducted in T2DM patients, yielding conflicting results: isoprostanes,
markers of lipid peroxidation, were not affected by the addition of sitagliptin to metformin [22];
similarly, no effect of vildagliptin on urinary isoprostanes levels [23] and of alogliptin on circulating
AGEs, was observed [24]. Nomoto et al. demonstrated that sitagliptin improved antioxidant capacity
but did not modify reactive oxygen metabolites-derived compounds (d-ROMs) levels [25]. However,
some positive results were also reported: serum malondialdehyde-modified low-density lipoproteins
and the soluble form of RAGE were reduced after treatment with linagliptin [26] and alogliptin [24],
and both sitagliptin and vildagliptin reduced plasma nitrotyrosine levels [27].
These controversial results led us to further explore the effects of DPP4i on oxidative stress in
patients with T2DM who were already on other antidiabetic treatment, evaluating a set of circulating
biomarkers of oxidative damage to lipids, proteins and DNA.
2. Methods
2.1. Patients
Thirty-two T2DM patients (21 males and 11 post-menopausal females) from the Diabetology
Unit, Careggi Teaching Hospital, Florence, Italy, were included in this study. Patients were given
detailed explanations of the study protocol and all patients provided written informed consent prior to
enrollment. The study protocol was approved by the Ethical Committee of Careggi Teaching Hospital,
Florence, Italy on October, 25, 2018, registry number 13469_bio.
The inclusion criteria were as follows: (1) diagnosis of T2DM, (2) age ≥ 40 years, (3) treatment
with diet and/or metformin and/or basal insulin analogues and/or DPP-4i and (4) no modifications of
the antidiabetic therapy within the last 6 months.
The exclusion criteria were as follows: (1) use of antioxidant supplements (2) treatment with
SGLT-2 inhibitors (3) treatment with GLP-1 receptor agonists.
Demographic and clinical characteristics obtained from the medical record included age, sex,
height, weight, body mass index (BMI) and lipid profiles. The patients’ history of coronary heart disease,
peripheral vascular disease, diabetic retinopathy and nephropathy were also collected from the hospital
records. Peripheral blood samples were collected by venipuncture into ethylenediaminetetraacetic
acid (EDTA)-treated tubes and all plasma samples were stored at −20 ◦C until analysis, which was
undertaken within 30 days.
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2.2. Reactive Oxygen Species (ROS) Determination
ROS were determined using the Free Oxygen Radical Testing (Callegari 1930, Parma, Italy)
according to [28]. Whole blood (20 μL) was added to acidic buffer and to phenylenediamine derivative
[2CrNH2]. Samples were then centrifuged (3500 rpm) for 1 min and incubated for 6 min at room
temperature. Absorbance was determined at 505 nm.
2.3. Ferric Reducing Ability of Plasma (FRAP)
The ferric reducing ability of plasma (FRAP) assay was performed to measure the total antioxidant
capacity of plasma, according to the method by Benzie and Strain [29]. Plasma samples (30 μL)
were added to 90 μL of distilled water and freshly prepared FRAP solution (300 mM acetate buffer
(pH 3.6), 10 mM 2,4,6-tripyridyl-S-triazine (TPTZ) in 40 mM HCl and 20 mM FeCl3·6H2O (10:1:1)).
The absorbance was measured at 595 nm. FRAP was estimated from a standard curve of FeSO4·7H2O
and expressed in μM. All the reagents were purchased by Sigma Aldrich, Milan, Italy.
2.4. Advanced Oxidation Protein Product (AOPP)
Advanced oxidation protein product (AOPP) levels, markers of protein oxidation and
inflammation, were determined by using 20 μL of plasma added to 980 μL of potassium phosphate
buffer (PBS), 50 μL of KI 1.16 M and 100 μL of acetic acid according to the method by Witko-Sarsat
et al. [30]. The absorbance was read at 340 nm. AOPP were expressed as μmol/mg of proteins.
Chloramine-T (Sigma-Aldrich, Milan, Italy) was used for the calibration curve.
2.5. Carbonyl Residues
Carbonyl residues, markers of protein oxidation, were determined using the method of
Correa-Salde and Albesa [31]. Plasma samples (100 μL) were derivatized with 900 μL of 0.1%
dinitrophenylhydrazine in 2 M HCl (Sigma Aldrich, Milan, Italy city, country), for 1 h at room
temperature (RT) followed by the addition of 400μL of 10% trichloroacetic acid (TCA) and centrifugation
at 10,000× g for 20 min at 4 ◦C. The pellets were washed three times with ethanol/ethyl acetate (1:1) and
centrifuged at 10,000× g for 3 min at 4 ◦C. The pellets were then dissolved in 1.5 mL guanidine HCl
(6M) in 20 mM phosphate-buffered saline (PBS) pH 7.5 and incubated at 37 ◦C for 30 min. Insoluble
debris were removed by centrifugation. Carbonyl residues were calculated from absorbance readings
at 370 nm using a molar absorption coefficient of 22,000 M−1 cm−1 and expressed as nmol/g of proteins.
Protein content was measured with the Bio-Rad DC protein assay kit (Bio-Rad, Milan, Italy).
2.6. Thiobarbituric Acid Reactive Substances (TBARS)
Thiobarbituric acid reactive substances (TBARS), markers of lipid peroxidation, were evaluated
using 100 μL of plasma, according to the method by [32]. Briefly, after the addition of 100 μL TCA,
the resulting supernatant (160 μL) was added to 32 μL thiobarbituric acid, 0.12 M (Sigma-Aldrich, Milan,
Italy city, country) and heated at 100 ◦C, for 15 min. The samples were then placed for 10 min in ice and
centrifuged at 1600× g at 4 ◦C, for 10 min. The absorbance of the supernatants was measured at 532 nm
by using a Wallac 1420 Victor3 Multilabel Counter (Perkin Elmer, Waltham, MA, USAmanufacturer,
city, country). The amount of TBARS, expressed as μM, was calculated using a molar absorption
coefficient of 1.56 × 10−5 M−1 cm−1.
2.7. Advanced Glycated End-Products (AGEs)
Plasma samples (100 μL) were diluted in H2O (1:5) and fluorescence intensity was read at 460 nm,
after excitation at 355 nm. AGEs levels were expressed in arbitrary units (AU) [33].
259
Antioxidants 2020, 9, 233
2.8. FPG Sites
For the analysis of DNA damage in peripheral blood cells, whole blood aliquots (100 μL) were
frozen at −80 ◦C as described in [34] and stored for 3 months before analysis. Briefly, the comet assay
was performed as follows: 50 μL of cell suspension containing 10 μL of frozen whole blood and 40 μL
Roswell Park Memorial Institute (RPMI) were mixed with 150 μL 1% low melting-point agarose in
PBS in order to achieve 0.75% LMP agarose final concentration, and used to prepare duplicate gels for
each patient (20,000 cells/gel) on Gelbond Films (Lonza, Basel, Switzerland). As a reference control
for inter-experimental variability of electrophoresis conditions, we used HeLa cells aliquots prepared
from a single culture and stored at −80 ◦C. One aliquot was used in each experiment to prepare
2 gels (20,000 cells/gel) and run with the experimental samples. We then followed the procedure
described in [34]. For oxidatively generated damage detection, the enzyme formamidopyrimidine
DNA glycosylase (Fpg) enzyme was used (crude E. Coli extract kindly provided by Prof. A.R. Collins,
University of Oslo, Norway) at 1:1000 dilution, i.e., the optimum concentration established by titration.
2.9. Statistical Analyses
The Kolmogorov–Smirnov test was used to verify the normal distribution of the results. Continuous
variables and those that resulted to be normally distributed were expressed as means ± standard
deviation (SD). When data were not normally distributed, they were reported as median and
interquartile range.
For the analysis, we used propensity score matching to adjust patient characteristics and disease
severity between the two groups.
Among demographic and clinical characteristics at baseline of enrolled patients, putative
determinants of referral to the DPP-4i treatment were identified in the whole sample by means
of comparisons between treated and untreated subjects, using chi square tests for categorical
variables and either unpaired Student’s t test or Mann–Whitney test depending on the (normal
or non-normal) distribution.
Variables significantly associated to the DPP-4i treatment were then inputted as covariates in a
logistic regression model, with DPP-4i treatment (0/1) as dependent variable. The model was used to
build an equation for the calculation of a propensity score. We estimated the propensity score using a
logistic regression model, in which individuals at the time of hospital admission was regressed on
measured baseline characteristics. Covariates for inclusion in the propensity score model were chosen
based on their potential to be associated with the outcomes. Propensity score-matched analyses, using
the 1:1 nearest neighbor technique with a small caliper of 0.05, were carried out to ensure better balance.
The propensity score-matched two cohorts were therefore compared for DPP-4i treatment in order
to evaluate differences in the levels of a set of circulating biomarkers of oxidative damage to lipids,
proteins and DNA.
Comparison of continuous variables between matched pairs were performed using the paired t-test
(when data were normally distributed) or Wilcoxon test (when data were non-normally distributed).
Differences between proportions were assessed using the Fisher exact test. p values < 0.05 were
considered significant.
3. Results
3.1. Clinical Characteristics of the Patients
The clinical characteristics of the study groups after propensity score matching are shown in
Table 1. After propensity score matching, there were no significant differences between the two groups
in the levels of HbA1c and lipid profiles, body mass index (BMI) and in the male-to-female ratio.
The distribution of diabetes-related micro and macro vascular complications was also similar. However,
duration of diabetes was significantly higher in the DPP4i group compared to those who did not
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receive the treatment (p < 0.01). eGFR was also significantly reduced in T2DM patients treated with
DPP4i compared to those not treated (p < 0.01).
Table 1. Demographic and clinical characteristics of the study groups after propensity score matching.
−DDP4i +DDP4i p Value
Number of Patients 16 16
Gender F/M 5/11 6/10 ns
Age (yrs) 69.8 ± 2.2 72.38 ± 2.98 ns
Body Mass Index (BMI) 28.12 ± 1.33 25.6 ± 1.26 ns
Duration of Diabetes (yrs) 7.87 ± 1.81 20.94 ± 3.18 0.0015
HbA1c (mmol/mol) 52 (43.75–63.25) 49 (45.25–54) ns
Total Cholesterol (mg/dL) 166.2 ± 10.14 152.2 ± 8.07 ns
High Density Lipoprotein (HDL) (mg/dL) 47.5 (37.5–56) 49.5 (41.75–56) ns
Triglycerides (mg/dL) 144.9 ± 13.48 122.1 ± 11.14 ns
Estimated glomerular filtration rate (eGRF) (mL/min) 79 (68.5–90) 54.5 (27.25–89.75) 0.0027
Micro Complications (yes/no) 4/12 10/6 ns
Macro Complications (yes/no) 4/12 5/11 ns
Data are expressed as means ± standard deviation (SD). Non-normally distributed variables are expressed as median
and interquartile range.
3.2. Plasma Oxidative Stress Markers, Antioxidant Status and Oxidative DNA Damage
After propensity score matching, the plasma levels of AGEs, ROS, TBARS, AOPP and carbonyl
residues were not significantly different in T2DM patients taking DPP4i compared with non-users.
The plasma antioxidant capacity (FRAP) between patients taking DPP4i was also similar to those
not treated (Figure 1, panels A,B,D,E,F,G). On the contrary, Fpg sites were borderline significantly
higher in DPP4i users in comparison with matched non-users (p = 0.0507) (Figure 1, panel C). Several
positive correlations among oxidative stress biomarkers were found; in particular, a strong correlation
between TBARS and AOPP (p < 0.001) and between carbonyl residues and AOPP (p < 0.0001) were
observed. Interestingly, Fpg sites and AGEs, were inversely associated with eGFR (p < 0.05 and
p < 0.0001, respectively). Fpg sites were also correlated with the duration of diabetes and AGEs with
the age of the patients (Table 2).
Table 2. Correlations between changes in oxidative stress-related biomarkers, duration of diabetes,
eGRF and the age of the patients.





Age 0.4243 * −0.5970 ***
AOPP −0.2149 0.0421 0.2980
AGEs 0.6587 **** −0.6825 **** 0.5500 ** −0.1214
TBARS −0.3783 * 0.0814 0.1575 0.6358 *** −0.2406
FRAP −0.0172 0.2041 0.0182 0.0411 0.0405 0.0592
ROS −0.1504 0.1554 −0.0942 −0.2483 −0.1995 −0.0253 −0.1191
Carbonyl
Residues −0.2661 0.1154 0.2785 0.6948 **** 0.0514 0.5342 ** 0.3504 * −0.2148
Fpg Sites 0.5659 *** −0.4055 * 0.3473 −0.1654 0.3887 * −0.2485 0.2160 0.0257 0.0206
**** p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.05. eGRF: estimated glomerular filtration rate; AOPP: Advanced
oxidation protein products; AGEs: advanced glycation end products; TBARS: thiobarbituric acid reactive substances;
FRAP: ferric reducing ability of plasma; Fpg sites: formamidopyrimidine DNA glycosylase sites.
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Figure 1. Scatter dot plot of reactive oxygen species (ROS) (panel A), ferric reducing ability of plasma
(FRAP) (panel B) Fpg sites (panel C) thiobarbituric acid reactive substances (TBARS, panel D), advanced
glycation end products (AGEs) (panel E), carbonyl residues (panel F), and advanced oxidation protein
products (AOPP) levels (panel G) in type 2 diabetes mellitus (T2DM) patients with and without
treatment with dipeptidyl peptidase-4 inhibitors (DPP4i). Comparison of continuous variables between
matched pairs were performed using the paired t-test (when data were normally distributed) or
Wilcoxon test (when data were non-normally distributed).
4. Discussion
The present data do not suggest any major effect of DPP4i on oxidative stress, as explored through
the measurement of several circulating biomarkers. This result is at variance with those of several
experimental studies, in vitro and in vivo on animal models of diabetes, showing a protective effect of
DPP4i [16–20]. Differences from animal studies could be attributed either to diversities across species
or to differences in circulating drug concentrations.
Some previous studies explored the effects of DPP4i on oxidative stress markers. In randomized,
active-comparator-controlled trials, sitagliptin and vildagliptin failed to produce any effect on lipid
peroxidation markers, in line with our results on TBARS [22,23]. Consistent with our findings,
circulating levels of AGEs were not modified by alogliptin [24] and sitagliptin did not reduce ROS
levels [25]. Conversely, a single-arm trial with linagliptin, revealed a beneficial effect of the treatment,
when compared to baseline, on malondialdehyde-modified LDL; however, there was a concomitant
reduction of mean glucose and HbA1c, which could explain the improvement of oxidative status [26].
Similarly, in the study by Rizzo and collaborators, the beneficial effects of sitagliptin and vildagliptin
on nitrotyrosine plasma levels were associated to a significant decline in HbA1c and glucose levels
and to a better control of daily glucose excursions [27]. Sakata et al. [24] demonstrated that alogliptin
reduced AGE levels only in patients with higher values of AGEs at baseline and this decrease was
positively correlated with that of HbA1c; however, when all patients were analyzed, no significant
effect was observed.
In our study, the difference in glycemic control between cases and controls was very small,
since both groups were extracted from a cohort receiving accurate treatment for T2DM. Therefore,
the present study could underestimate the global effect of treatment with DPP4i, since the possible
benefits of blood glucose reduction are blunted because of study design. The enrolled cohorts showed,
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on average, a satisfactory glycemic control, with a low dispersion of HbA1c values. This prevents any
analysis on possible effects of hyperglycemia on oxidative stress. It is also important to highlight that
the levels of oxidative stress biomarkers in the entire cohort of T2DM patients did not significantly
differ from those measured in the serum of healthy controls [35]. We demonstrated previously that
significant differences in FRAP levels were seen between heathy controls and poorly controlled T2DM
patients but not between heathy controls and T2DM patients with good glycemic control [36]; similarly,
Morsi et al. [37] did not find significant differences in malondialdehyde (MDA) levels between controls
and well controlled T2DM patients. However, in heathy volunteers, Fpg sites, marker of oxidative
damage, were reduced compared to well controlled T2DM patients [36]. Indeed, Fpg sites levels
were the sole biomarker showing a borderline difference between patients taking DPP4i and those
not treated.
Another limitation of this study, is represented by the fact that propensity score matching did
not prevent a significant difference in estimated glomerular filtration rate between cases and controls.
Renal failure is associated with oxidative stress [38]; this is consistent with the inverse correlation
of estimated glomerular filtration rate with AGEs and Fpg sites observed in the present study. As a
consequence, there could be a bias in favor of controls with respect to biomarkers of oxidative stress.
It is also worth to highlight that although intriguing, the borderline increase in the levels of Fpg sites
observed in patients taking DPP4i, is strongly linked to the presence of a single patient with particularly
high levels of Fpg sites.
On the other hand, some strengths of this study should also be recognized. Propensity score
matching warrants a greater reliability of results than traditional observational data. In addition,
the selection of patients from a larger clinical cohort accounts for a greater representativeness of
samples in comparison with randomized trials. Study procedures on patients were kept to a minimum
(only one venipuncture with a blood sample), in order to remain close to routine clinical practice.
A further strength is represented by the fact that several biomarkers of oxidative damage were assessed,
with concordant results across different markers. Conversely, studies focused on the evaluation of a
single oxidative damage marker may give incomplete information on the overall redox status. Notably,
we measured various biomarkers reflecting oxidative damage to the main macromolecules such as
lipids (TBARS), proteins (carbonyl residues and AOPPs) and DNA (Fpg sites) and found positive
correlations among almost all of them, in line with our previous results [35].
All these biomarkers share some advantages including relatively easy detection and possibility
to be used in large scale; carbonyl residues are highly stable products and AOPP are also considered
inflammatory markers. However, some limitations should be also accounted: TBARS has been
employed for MDA determination but thiobarbituric acid TBA may also react with other aldehydes;
the FRAP assay is reliable for detecting uric acid, α-tocopherol, ascorbic acid and bilirubin, but may
underestimate albumin and glutathione GSH content [39]. Another important issue also highlighted
in our previous work [15], is the lack of standardization among methods employed for determining
oxidative stress biomarkers, the different biological fluids used, the absence of reference range intervals
and validation in prospective studies.
However, several data suggest that oxidative damage is associated to cardiovascular diseases:
increased carbonyl residues, AGEs and AOPPs were found in T2DM patients with cardiovascular
complications compared to those without [40,41]. Increased AOPP plasma levels were considered
a risk factor for endothelial dysfunction in T2DM patients without albuminuria [42]. AOPP levels
were also higher in hypertensive patients and in particular, in those with renal complications [43].
In a prospective study, oxidative DNA damage, measured as 8-hydroxy-2-deoxyguanosine (8-OHdG),
predicted micro and macrovascular complications in T2DM patients [44]. Experimental studies also
highlighted the pathological role of some of these markers: by binding to their common receptor
RAGE, AOPP and AGEs activate inflammatory and apoptotic pathways leading to oxidative stress,
inflammation and cell death both on cardiomyocytes and renal cells [45–47].
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The results of the present study are consistent with those of available cardiovascular outcome
trials, which failed to show either beneficial or detrimental effects of DPP4i on major cardiovascular
events [6–8]. Considering that oxidative stress is a well-established risk factor for atherogenesis
and cardiovascular diseases, pharmacological strategies able to limit oxidative stress in humans
should theoretically produce a reduction of cardiovascular risk. Results from the Cardiovascular
and Renal Microvascular Outcome Study with Linagliptin in Patients with Type 2 Diabetes Mellitus
(CARMELINA) study [10], performed in patients at high renal risk, suggested a protective effect of
linagliptin on microalbuminuria; this result was not confirmed by other large-scale trials enrolling
patients at lower risk of renal disease [48]. Oxidative stress is thought to play a role in the pathogenesis
of microvascular complications of diabetes [12,49]; however, our results suggest that the hypothetical
protective effect of DPP4i on microalbuminuria does not appear to be mediated by a reduction of
substrate oxidation.
In conclusion, this observational study assessing several biomarkers of oxidative damage in
propensity score-matched cohorts does not suggest any major effect of DPP4i on oxidative stress
in humans.
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Abstract: Metabolic homeostasis is differently regulated in males and females. Little is known about
the mitochondrial Sirtuin 3 (Sirt3) protein in the context of sex-related differences in the development
of metabolic dysregulation. To test our hypothesis that the role of Sirt3 in response to a high-fat diet
(HFD) is sex-related, we measured metabolic, antioxidative, and mitochondrial parameters in the
liver of Sirt3 wild-type (WT) and knockout (KO) mice of both sexes fed with a standard or HFD for
ten weeks. We found that the combined effect of Sirt3 and an HFD was evident in more parameters in
males (lipid content, glucose uptake, pparγ, cyp2e1, cyp4a14, Nrf2, MnSOD activity) than in females
(protein damage and mitochondrial respiration), pointing towards a higher reliance of males on
the effect of Sirt3 against HFD-induced metabolic dysregulation. The male-specific effects of an
HFD also include reduced Sirt3 expression in WT and alleviated lipid accumulation and reduced
glucose uptake in KO mice. In females, with a generally higher expression of genes involved in lipid
homeostasis, either the HFD or Sirt3 depletion compromised mitochondrial respiration and increased
protein oxidative damage. This work presents new insights into sex-related differences in the various
physiological parameters with respect to nutritive excess and Sirt3.
Keywords: sirtuin 3; high fat diet; sex differences; mice; oxidative stress; metabolic stress
1. Introduction
The metabolic syndrome is metabolic derangement involving a cluster of risk factors primarily
associated with obesity, type two diabetes, and a high risk of cardiovascular events, but also
with the development of inflammation, atherosclerosis, renal, liver and respiratory disease, cancer,
and premature aging [1,2]. The prevalence of metabolic syndrome is dramatically on the rise in low-
and mid-income countries and is one of the leading risks for global deaths representing serious threat
to public health. The increase in caloric food intake or consumption of diets high in both fat and
carbohydrates (also known as a “western diet”) along with physical inactivity leads to increased obesity,
a key factor in the development of metabolic syndrome. Human metabolic syndrome can be effectively
mimicked in rodent models using dietary intervention, such as high-fat diets (HFDs) [3]. The nutrient
overload generated by an HFD in mice leads to a chronic increase in reactive oxygen species (ROS)
production, which leads to oxidative stress (rev. in [1]). Oxidative stress is associated with the metabolic
syndrome, but whether it is the cause or the consequence is a matter of debate. Nevertheless, an HFD is
capable of functioning as a metabolic stressor causing mitochondrial dysfunction and other metabolic
changes that contribute to pathological state and may mimic age-related pathology [4].
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In most mammals, including humans, life expectancy differs between sexes. Females show lower
incidence of some age-related pathologies linked with oxidative stress conditions and this sex-difference
disappears after menopause, which led to the conclusion that this protection is attributed to the effect
of sex hormones (rev in [5]). The important approach to study ageing and age-linked pathologies is
to investigate sex dimorphism in defense to metabolic stressors. Historically, the impact of sex on
metabolic status in mouse models has been neglected [6]. Indeed, most in vivo studies are focused
on male mice. One of the reasons for a strong male sex bias is the belief that female mammals are
intrinsically more variable than males due to the estrogen cycle. However, this has been disproven
and without foundation [7]. While numerous papers examined the metabolic profiles of inbred mouse
strain 129 [8–10], little attention has been paid to the impact of sex on the development of metabolic
syndrome caused by HFD.
Sirtuin 3 (Sirt3) is the only member of sirtuin family that has been linked to longevity in humans [11].
In addition, Sirt3 integrates cellular energy metabolism and various mitochondrial processes including
ROS generation. The excessive production of ROS leads to oxidative stress, a crucial event that
contributes to mitochondrial dysfunction and age-related pathologies [12]. Sirt3 plays a role in
preventing metabolic syndrome [10], and is found to be upregulated in response to caloric restriction
and exercise [13], while being downregulated with age, upon an HFD, and in diabetes [14]. Sirt3 is
dispensable at a young age under homeostatic conditions but is essential under stress conditions or
at an old age, making it a potential regulator of aging process. Although Sirt3 mediates oxidative
stress suppression during caloric restriction [15], it remains to be elucidated whether Sirt3 may
alleviate chronic oxidative stress initiated by excessive caloric intake in the form of an HFD. Many
mitochondrial proteins are targets for deacetylation and activation by Sirt3, including proteins of
oxidative phosphorylation, fatty acid oxidation, and the citric acid (TCA) cycle [16]. These data suggest
that fatty acid metabolism and the TCA cycle are among the pathways that are tightly regulated by Sirt3.
Moreover, Sirt3 is found to be regulated by a redox-sensitive, Keap1/Nrf2/ARE signaling axis, which
facilitates transcription of Sirt3 and other antioxidant-response genes under stress conditions [17].
Little is currently known about Sirt3 expression in the context of sex-related differences in the
development of metabolic syndrome. The understanding of sex differences in physiology and disease
is of fundamental importance with regard to preventing metabolic disease. Therefore, our aim was to
determine the role of Sirt3 in sex-related responses to a high-fat diet in 129S mice. In this study, we found
that an HFD reduces hepatic Sirt3 expression only in wild-type (WT) males, while HFD-induced lipid
accumulation is alleviated in Sirt3 knockout (KO) males, with impaired glucose uptake and increased
reliance on fatty acids. Moreover, females had more efficient lipid metabolism but also displayed higher
oxidative stress following an HFD in both genotypes with compromised mitochondrial respiration and
increased protein oxidative damage. These data present new insights into sex-related differences in the
metabolic parameters with respect to nutritive excess and Sirt3.
2. Materials and Methods
2.1. Animal Model and Experimental Design
Sirt3 WT (hereafter WT) and Sirt3 KO (hereafter KO) mice on a 129/SV background (stock no. 027975)
were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). WT and KO mice of both sexes
at of 8 weeks of age, were fed with either a standard fat diet (SFD, 11.4% fat, 62.8% carbohydrates,
25.8% proteins; Mucedola, Settimo Milanese, Italy) or a high fat diet (HFD, 58% fat, 24% carbohydrates,
18% proteins; Mucedola, Settimo Milanese, Italy) during 10 weeks. The mice were age-matched and
housed in standard conditions (3 mice per cage, 22 ◦C, 50–70% humidity, and a cycle of 12 h light
and 12 h darkness). The animals were divided into 8 groups (6 mice per group): SFD-fed WT males,
HFD-fed WT males, SFD-fed KO males, HFD-fed KO males, SFD-fed WT females, HFD-fed WT
females, SFD-fed KO females, and HFD-fed KO females. Body weight was measured once a week,
as well as glucose level, which was measured by glucometer (StatStrip Xpress-I, Nova Biomedical,
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GmbH, Mörfelden-Walldorf, Germany) in a blood drop taken from the tail vain. Before glucose
measurements, mice were fasted for 6 h. After 10 weeks, mice were anesthetized by intraperitoneal
injection of ketamine/xylazine (Ketamidor 10%, Richter pharma Ag, Wels, Austria; Xylazine 2%,
Alfasan International, Woerden, Netherlands) and organs of interest were obtained and stored in liquid
nitrogen until analysis. Animal experiments were done within the project funded by Croatian Science
Foundation, project ID: IP-014-09-4533, approved on 01/09/2015. All procedures were approved by the
Ministry of Agriculture of Croatia, (No: UP/I-322-01/15-01/25 525-10/0255-15-2 from 20 July 2015) and
carried out in accordance with the associated guidelines EU Directive 2010/63/EU.
2.2. Histology and Oil Red O Staining
A histological analysis of the liver sections from all experimental groups was performed in order
to determine lipid accumulation caused by HFD. At the end of the feeding period, the anesthetized
animals were perfused via the left ventricle of the heart with ice-cold phosphate-buffered saline (PBS;
137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, and 2 mM K2PO4, pH 7.4) for 2–3 min (to remove blood
via the incised abdominal vena cava). Liver tissue was fixed by immersion in 4% paraformaldehyde in
0.1 M PBS (pH 7.4), left overnight at 4 ◦C, and was then washed with 1× PBS and cryoprotected in 30%
sucrose in PBS until the sectioning on cryomicrotome at 8 μm. Fat vacuoles in hepatocytes of frozen
sections were visualized by Oil Red O dye (Sigma Aldrich, St. Louis, MO, USA) prepared in propylene
glycol (0.5% Oil Red O solution) according to the following protocol. The slides were dried for 60 min at
room temperature (RT) and then fixed in ice-cold 10% formalin for 10 min followed by another 60 min
of drying. The slides were then incubated for 5 min in absolute propylene glycol followed by staining
in pre-warmed (60 ◦C) Oil Red O solution for 10 min and incubation for 5 min in 85% propylene
glycol. Before staining with hematoxylin for 30 s, the slides were rinsed 2× in distilled water. After
hematoxylin, the stained slides were thoroughly washed in running tap water followed by distilled
water and mounted in mounting medium. An analysis of the stained liver sections was done using
an Olympus BX51 microscope (Tokyo, Japan) with associated software analysis. The quantification
of the lipid accumulation signal was done using ImageJ software (U.S. National Institutes of Health,
Bethesda, MD, USA).
2.3. Total Lipid Extraction
Total lipids were extracted from liver tissue according to a modified Folch procedure [18]. Briefly,
0.1 g of liver tissue was homogenized in MeOH, followed by the addition of 2 mL of CHCl3 and vigorous
shaking. The mixture was filtered, and the remaining mixture was resuspended in CHCl3-MeOH (2:1).
The mixture was filtered and washed again with fresh solvent, followed by washing the solution with
1.5 mL of 0.88% KCl and drawing off the aqueous layer using a Pasteur pipette. The washing step was
repeated with 1.5 mL of KCl/MeOH (4:1, v/v), and the organic layer containing lipids was carefully
transferred to a glass tube. A rotary evaporator (IKA Rotary evaporator RV 10 digital, Staufen, Germany)
was used to remove the solvent, and the total lipids were determined by gravimetric analysis.
2.4. RNA Isolation and Quantitative Real-Time PCR Analysis
The TRIzol reagent (Invitrogen, Waltham, MA, USA) was used for total RNA extraction from a
mouse liver (5% extract). The isolated RNA was treated with DNAse (TURBO DNA-free Kit, Thermo
Fisher Scientific, Waltham, MA, USA) followed by reverse transcription using a High-Capacity cDNA
Reverse Transcription Kit (Thermo Fisher Scientific) according to the manufacturer’s recommendations.
For real-time PCR analysis, an ABI 7300 sequence detection system was used. To quantify the
relative mRNA expression of cyp2a4, cyp2e1, cyp4a14, hnf4α, pparα, and pparγ in the livers of mice,
the comparative CT (ΔΔCT) method according to the Taqman® Gene Expression Assays Protocol
(Applied Biosystems, Foster City, CA, USA) was used. The assays’ ID used for the analyses are shown
in Supplementary Table S1. The data on the graphs are shown as the fold-change in gene expression,
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which is normalized to the endogenous reference gene (β-actin) and relative to the Sirt3 WT males fed
with a SFD.
2.5. Protein Carbonylation
Protein carbonylation experiments were performed with an ELISA-based assay. Liver homogenates
(5%) were prepared in PBS with protease inhibitors (Roche, Basel, Switzerland) and incubated for
1 h at RT with a lipid removal agent (13360-U, Sigma Aldrich, St. Louis, MO, USA), followed by
centrifugation for 20 min at 16,000× g. A Pierce™ BCA Protein Assay Kit (Thermo Fischer Scientific)
was used to determine the protein concentration, and 100 μL of 1 μg/μL lysate was incubated overnight
at 4 ◦C using Maxisorb wells (Sigma Aldrich). 2,4-dinitrophenylhydrazine (DNPH; 12 μg/mL)
was used for derivatization of adsorbed proteins, and rabbit anti-DNP primary (D9656, Sigma
Aldrich) followed by goat anti-rabbit secondary antibody conjugated to HRP (NA934, GE Healthcare,
Chicago, IL, USA) were used to detect the derivatized dinitrophenol (DNP)-carbonyl. Enzyme substrate
3,3′,5,5′-tetramethylbenzidine (Sigma Aldrich) was added into samples and incubated until color
developed, followed by stopping the reaction using 0.3 M H2SO4. The absorbance was measured at
450 nm on a microplate reader (Bio-Tek Instruments, Winooski, VT, USA).
2.6. Analysis of Antioxidative Enzyme Activities
Antioxidative enzyme activities were analyzed in liver tissue lysates homogenized in
PBS supplemented with protease inhibitors (Roche, Basel, Switzerland) using an ice-jacketed
Potter-Elvehjem homogenizer (Thomas Scientific, Swedesboro, NJ, USA), at 1300 rpm. Superoxide
dismutase (SOD) activities were determined measuring inhibition of the xanthine/xanthine
oxidase-mediated reduction of 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride
(I.N.T.) using a Ransod kit (Randox Laboratories, Crumlin, UK) according to the manufacturer’s
recommendations. This reaction is inhibited by the conversion of the superoxide radical to hydrogen
peroxide and oxygen as a consequence of SOD activity. A total of 4 mM of KCN for 30 min was used to
selectively inhibit CuZnSOD activity and obtain the MnSOD activity. CuZnSOD activity was obtained
by subtracting the MnSOD activity from the total SOD activity. The Catalase (Cat) activity was done, as
previously described [19], by measuring the change in absorbance (at 240 nm) in the reaction mixture
during the interval of 30 s following sample addition. The final concentrations of 10 mM H2O2 and
50 mM PBS (pH 7.0) were used. Glutathione peroxidase (Gpx) activity was measured at 340 nm, as
previously described [20], using a RANSEL kit (Randox Laboratories). In kit, a decrease in absorbance
at 340 nm is accompanied by NADPH oxidation to NADP+ as an indirect measure of Gpx activity.
2.7. Protein Isolation and Western Blot Analysis
Liver samples were homogenized in an ice-cold lysis buffer (RIPA buffer supplemented with
protease inhibitors (Roche)) using an ice-jacketed Potter-Elvehjem homogenizer (1300 rpm). Liver
homogenates (5%) were centrifuged at 2000× g for 15 min at 4 ◦C, and the supernatant was sonicated
(3 × 30 s) and centrifuged at 16,000× g for 20 min at 4 ◦C. The resulting lysate was transferred to a
new tube and the protein concentration was estimated by the Pierce™ BCA Protein Assay Kit (Thermo
Fischer Scientific). Proteins (40 μg/μL) were resolved by SDS-PAGE and were electrotransferred onto a
PVDF membrane (Roche, Basel, Switzerland). Membranes were blocked in a I-Block™ Protein-Based
Blocking Reagent (Invitrogen, Waltham, MA, USA) for 1 h at RT and were incubated with primary
polyclonal or monoclonal antibodies overnight at 4 ◦C. For chemiluminiscence detection, an appropriate
horseradish peroxidase (HRP)-conjugated secondary antibody was used. The list of primary and
secondary antibodies is in Supplementary Table S2. AmidoBlack (Sigma Aldrich) was used for total
protein normalization. The Alliance 4.7 Imaging System (UVITEC, Cambridge, UK) was used for the
detection of immunoblots using an enhanced chemiluminscence kit Kit (Thermo Fischer Scientific).
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2.8. Mitochondria Isolation and Oxygen Consumption
Mice liver mitochondria were isolated by differential centrifugation as described previously [21],
with the following modification: liver was homogenized at a ratio of 100 mg tissue/mL of isolation
buffer (10% liver homogenate). Isolated mitochondria were kept in the isolation buffer (250 mM
sucrose, 2 mM EGTA, 0.5% fatty acid-free BSA, 20 mM Tris-HCl, pH 7.4) until the experiment on
the Clark-type electrode (Oxygraph, Hansatech Instruments Ltd., Pentney, UK) in an airtight 1.5 mL
chamber at 35◦C. The protein concentration was determined with a Pierce™ BCA Protein Assay Kit.
For the determination of oxygen consumption, mitochondria (800 μg protein) were resuspended in a
500 μL respiration buffer (200 mM sucrose, 20 mM TrisHCl, 50 mM KCl, 1 mM MgCl2·6H2O, 5 mM
KH2PO4, pH 7,0). Complex I assessment samples were incubated with 2.5 mM glutamate and 1.25 mM
malate. Mitochondrial respiration was accelerated by the addition of 2 mM ADP for state 3 respiration
measurements. Then, ATP synthesis was terminated by adding 5 μg/mL of oligomycin to achieve
state 4 rate. To inhibit the mitochondrial respiration, 2 μM antimycin A was used. Oxygen uptake is
calculated in nmol/min/mg protein.
2.9. PET Analysis
For 18FDG-microPET imaging, animals have been anesthetized in induction chamber with
4% isoflurane (Forane, Abbott Laboratories, Chicago, IL, USA) and intraperitoneally injected
with 100–200 μL of solution containing 25 MBq of radiotracer [18F] fluoro-2-deoxy-2-d-glucose
(18FDG). To avoid the influence of warming on 18FDG biodistribution in mice injected intravenously,
in our experiments we used the model of intraperitoneal FDG administration described in [22].
18FDG-microPET imaging, along with 18FDG liver uptake data analysis, was performed according to
our previous model [23]. The co-registration of PET images was made in PMOD FUSION software
mode (PMOD Technologies LLC, Zürich, Switzerland). The final result is given in standardized uptake
value units (SUV).
2.10. Statistical Analysis
For the statistical analysis of data, SPSS for Windows (17.0, IBM, Armonk, NY, USA) was used.
A Shapiro–Wilk test was used before all analyses to test the samples for normality of distribution. Since
all data followed normal distribution, parametric tests for multiple comparisons were performed: a
student’s t-test for comparisons between males and females, and a two-way ANOVA for the interaction
effect of Sirt3 × diet within each sex. If a significant interaction was observed, all pairwise comparisons
were made between groups, using Tukey’s post-hoc test with Bonferroni’s correction. Significance was
set at p < 0.05. On graphical displays, the indicator of the differences between males and females was
marked as x; the indicator of differences between SFD and HFD (the effect of diet) was marked as a
letter (a, b, etc.); the indicator of differences between WT and KO (the effect of Sirt3) was marked as *.
3. Results
3.1. HFD Reduces Hepatic Sirt3 Protein Expression in Males Only
To investigate if the hepatic expression of Sirt3 was altered in a sex- or diet-dependent manner,
we first detected Sirt3 protein expression in all groups. Expectedly, in KO mice, Sirt3 protein level
was undetectable. In WT mice, HFD partially (24%) reduced Sirt3 protein expression in males but
did not affect Sirt3 in females. Therefore, HFD-fed males had lower Sirt3 expression than females
(Figure 1A,B). These data suggest that ten weeks of HFD feeding reduces Sirt3 protein expression in a
male-specific manner.
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Figure 1. Hepatic Sirtuin 3 (Sirt3) protein expression in Sirt3 wild-type (WT) and knockout (KO)
mice fed with a standard fat diet (SFD) or a high fat diet (HFD) for 10 weeks. (A) A representative
immunoblot of the hepatic Sirt3 protein expression level. (B) A graphical display of the averaged
densitometry values of immunoblots in (A). Males: HFD-fed vs. SFD-fed WT mice (a p < 0.001);
Females: no changes. Males vs. females: HFD-fed WT mice (xxx p < 0.001). The data are shown as
mean ± SD. n = 6. Amidoblack was used as a loading control.
3.2. HFD Has no Infuence on Body Weight and Glucose Level
It has been shown that the decreased level of Sirt3 contributes to impaired glucose metabolism [24],
and since we noticed reduced Sirt3 expression upon HFD in WT males, we next tested whether
differential Sirt3 expression and HFD would affect body weight and fasting glucose levels. After 10
weeks of feeding, treatment with an HFD did not affect whole body weight or glucose level in either
sex, irrespective of Sirt3 (Figure 2A,B, Figure S1A,B). However, at the end of the 10th week, males had
a higher body weight and glucose level compared to female mice (Figure 2A,B).
Figure 2. Body weight and fasting glucose level in Sirt3 wild-type (WT) and knockout (KO) mice fed
with a standard fat diet (SFD) or a high fat diet (HFD) for 10 weeks. (A) A graphical display of body
weight. Males: no changes. Females: no changes. Males vs. females: SFD-fed mice (xx p < 0.01);
HFD-fed mice (xxx p < 0.001). (B) A graphical display of fasting glucose levels. Males: no changes.
Females: no changes. Males vs. females: xx p < 0.01. The data are shown as mean ± SD. n = 6 per group.
3.3. Differential Hepatic Fat Accumulation in Males Upon HFD Depends on Sirt3
While glucose levels showed a male-specific pattern, the interesting fact was that the HFD
failed to cause weight gain compared to SFD in both sexes. To investigate whether HFD-fed mice
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developed a fatty liver, we determined the hepatic accumulation of lipids. Expectedly, fat vacuoles
were predominately present in the livers of HFD-fed mice of both genotypes, confirming that HFD
treatment caused lipid accumulation in mice livers (Figure 3A–H, Supplementary Figure S2). Folch
extraction was performed to measure lipid content in larger parts of liver tissue. In males, an HFD
caused significant lipid accumulation in both WT and KO mice. In SFD conditions, WT males had less,
and, in HFD conditions, WT males had more hepatic lipids than KO males. In females, an HFD also
induced significant lipid accumulation regardless of Sirt3. While in WT mice there were no differences
in lipid content between males and females, more lipids were observed in SFD-fed, and less in HFD-fed
KO males compared to KO females (Figure 3I). These results suggest that, in males, the hepatic lipid
accumulation was partially influenced by Sirt3.
Figure 3. Sex-related differences in hepatic lipid accumulation and glucose (18FDG) uptake in Sirt3
wild-type (WT) and knockout (KO) mice of both sexes fed with a standard fat diet (SFD) or a high fat
diet (HFD) for 10 weeks. (A–H) Liver cryo-sections stained with Oil Red O. Representative images
show lower fat content in mice fed with a SFD (A, C, E, G), and promoted lipid accumulation in
HFD-fed mice of both sexes and genotypes (B,D,F,H). (I) A graphical display of total lipid content in
liver samples. Males: HFD-fed vs. SFD-fed mice (a p < 0.001); SFD-fed WT vs. KO mice (** p < 0.01);
HFD-fed WT vs. KO mice (*** p < 0.001). Females: HFD-fed vs. SFD-fed mice (b p < 0.001). Males vs.
females: SFD-fed KO mice (x p < 0.05); HFD-fed KO mice (x p < 0.05). (J) A graphical display of hepatic
glucose uptake expressed as standardized uptake value (SUV). Males: SFD-fed vs. HFD-fed KO mice
(a p < 0.001); HFD-fed WT vs. KO mice (** p < 0.01). Females: no changes. Males vs. females: HFD-fed
KO mice (xxx p < 0.001). Data are shown as mean ± SD. n = 3–4 per group. scale bar = 20 μm.
3.4. HFD Reduces Hepatic Glucose Uptake in Sirt3 KO Males
Because the presence of non-alcoholic fatty liver disease (NAFLD) is closely associated with
decreased glucose metabolism, we determined hepatic glucose uptake using 18F-FDG PET. In KO
males, an HFD significantly reduced glucose uptake. Also, HFD-fed KO males had lower glucose
uptake than WT mice. On the contrary, in females, an HFD had no effect on glucose uptake across
groups. Reduced hepatic glucose uptake in HFD-fed KO males resulted in significantly lower values
275
Antioxidants 2020, 9, 174
compared to HFD-fed KO females. These data indicate the importance of Sirt3 in the maintenance of
hepatic glucose uptake following HFD, but only in males (Figure 3J).
3.5. HFD Further Suppresses the Male-Specific Reduction of Hepatic hnf4α, pparα, pparγ, and cyp2a4
mRNA Level
Since it was observed that an HFD causes lipid accumulation in liver, we wanted to investigate
several important genes involved in the lipid metabolism that are known to be expressed in sex-related
manner and may be responsible for the observed phenotype, such as hnf4α, pparα, pparγ, cyp2a4, cyp2e1,
and cyp4a14.
Hepatocyte nuclear factor 4α (hnf4α) is a master regulator of many genes involved in lipid,
glucose, and drug metabolism. In our study, no change in hnf4a transcript level was found either
within the male or female group of mice. The only differences were found between WT males and
females, where males had less hnf4α transcript compared to females (Figure 4A,C).
The peroxisome proliferator-activated receptor α (pparα) is shown to be upregulated during HFD
as it serves as a ligand for free fatty acids [25]. In males, we observed no change in the transcription
level of pparα, while in females, pparα was reduced in the absence of Sirt3. Interestingly, HFD had no
effect on the pparα in any sex. WT females had higher pparα than males. These data indicate sex-related
differences in pparα gene expression that are lost in the absence of Sirt3 (Figure 4A,D).
Hepatic pparγ gene expression is upregulated in animal models of severe obesity and
lipoatrophy [26]. Since in our study HFD-fed mice did not have increased weight gain compared to
SFD, we checked whether this was associated with the altered expression of pparγ in liver. In WT males,
an HFD strongly reduced pparγ, which was maintained in KO males as well. On the contrary, females
exhibited no change in pparγ. Overall, HFD-fed WT males had reduced pparγ compared to females.
These data indicate that both HFD and Sirt3 depletion reduce pparγ only in males (Figure 4A,E).
Cyp2a4 (steroid 15α-hydroxylase) is the enzyme that is constitutively expressed in the livers of
female mice while in males its expression is hormonally regulated [27]. Considering its sex-related
expression and regulation, we wanted to check whether lack of Sirt3 or change in diet affects the
expression of this gene. In WT males, an HFD reduced cyp2a4, whereas in KO mice, an HFD rescued
the reduced cyp2a4 observed in SFD-fed mice. In SFD conditions, WT males had more cyp2a4, and in
HFD conditions less than KO males. In females, HFD induced cyp2a4. Additionally, higher cyp2a4
was observed in SFD-fed KO females compared to WT. Overall, males had lower cyp2a4 than females
across all groups (Figure 4A,F).
Cyp2e1 expression and activity in the liver are increased in humans and in animal models of
NAFLD [7,10,11]. Similar to cyp2a4, in WT males, an HFD reduced cyp2e1, whereas in KO mice an
HFD rescued reduced cyp2e1 observed in SFD-fed mice. SFD-fed KO males displayed lower cyp2e1
than WT mice. In females, HFD induced cyp2e1. The differences in cyp2e1 between males and females
were observed only in SFD-fed KO mice, with lower cyp2e1 expression in males (Figure 4A,G).
Figure 4. Cont.
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Figure 4. Gene expression of hnf4α, pparα, pparγ, cyp2a4, cyp2e1, and cyp4a14 in the livers of Sirt3
wild-type (WT) and knockout (KO) mice fed with a standard fat diet (SFD) or a high fat diet (HFD) for
10 weeks. (A) A heatmap of the mRNA levels of hnf4α, pparα, pparγ, cyp2a4, cyp2e1, and (B) cyp4a14
genes. The color of the squares on the heat map corresponds to the mean value of the log fold change
from three biological and three technical replicates. (C) A graphical display of hnf4a mRNA level.
Males: no changes. Females: no changes. Males vs. females: SFD-fed (x p < 0.05) and HFD-fed
(xx p < 0.01). (D) A graphical display of pparαmRNA levels. Males: no changes. Females: KO vs. WT
mice (** p < 0.01). Males vs. females: WT mice (xxx p < 0.001). (E) A graphical display of pparγmRNA
levels. Males: HFD-fed vs. SFD-fed WT mice (a p < 0.001); SFD-fed WT vs. KO mice (*** p < 0.001).
Females: no changes. Males vs. females: HFD-fed WT mice (xxx p < 0.001). (F) A graphical display of
cyp2a4 mRNA levels. Males: HFD-fed vs. SFD-fed WT mice (a p < 0.001); HFD-fed vs. SFD-fed KO
mice (b p < 0.01); SFD-fed WT vs. KO mice (** p < 0.01) and HFD-fed WT vs. KO mice (*** p < 0.001);
Females: HFD-fed vs. SFD-fed WT (c p < 0.001) and KO mice (d p < 0.01); SFD-fed KO vs. WT mice
(** p < 0.01); Males vs. females: xxx p < 0.001. (G) A graphical display of cyp2e1 mRNA levels. Males:
HFD-fed vs. SFD-fed WT mice (a p < 0.05); HFD-fed vs. SFD-fed KO mice (b p < 0.001); SFD-fed KO vs.
WT mice (*** p < 0.001). Females: HFD-fed vs. SFD-fed mice (c p < 0.01). Males vs. females: SFD-fed
KO mice (xx p < 0.01). (H) A graphical display of cyp4a14 mRNA levels. Males: HFD-fed vs. SFD-fed
mice (a p < 0.001). Females: HFD-fed vs. SFD-fed KO mice (b p < 0.01). Males vs. females: WT mice
and SFD-fed KO mice (xxx p < 0.001). β-actin was used for normalization. The data are shown as mean
± SD. n = 3 per group in technical triplicates.
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Mouse Cyp4a14 catalyzes the omega-hydroxylation of saturated and unsaturated fatty acids in
mice and shows female-predominant expression in liver, where it is induced by pparα [28]. In WT
males, HFD strongly increased otherwise very low cyp4a14 by 51-fold, and in KO males by almost
400-fold. In females, HFD upregulated cyp4a14 by 2.5-fold in KO mice. Overall, females displayed
higher cyp4a14 expression than males, except in HFD-fed KO mice (Figure 4B,H).
3.6. Sirt3 KO Mice Exhibit Increased Protein Oxidative Damage and Upregulated Keap1-Nrf2-Ho1 Axis
in Liver
Following the observed differences between males and females in lipid accumulation and the
genes involved in lipid homeostasis, along with the fact that sensitivity towards the oxidative stress is
sex-related as well [29,30], we next examined sensitivity to oxidative stress with respect to Sirt3 or diet
by measuring protein carbonylation (PC), a marker of protein oxidative damage. In males, higher PC
levels were observed in the absence of Sirt3. Contrary to that, in WT females, an HFD increased PC,
resulting in levels similar to KO females in both diets. Moreover, SFD-fed KO females had higher PC
than WT mice. Overall, the sex-specific differences evident in HFD-fed WT mice were abrogated in
the KO mice, where similar PC levels were observed in both sexes (Figure 5A). These data indicate
that, besides protein oxidative damage caused by the absence of Sirt3 in both sexes, females are also
susceptible to protein damage caused by an HFD only.
We next aimed to investigate whether major proteins involved in antioxidative response pathway,
such as Keap1/Nrf2/Ho1, were altered. Nrf2 is a transcription factor that induces the gene expression
of antioxidant enzymes and many other cytoprotective enzymes. Upon oxidative stress, the interaction
between Keap1 and Nrf2 is disrupted, which induces Nrf2-dependent gene expression [31]. WT males
had higher Keap1 compared to KO mice and HFD partially rescued Keap1 in KO mice. Likewise,
in females, Keap1 was also reduced in KO mice. There were no differences in Keap1 between males
and females (Figure 5C). In WT males, HFD reduced Nrf2. Moreover, Nrf2 was higher in KO mice
compared to WT mice of both sexes, which is in accordance with reduced Keap1. Differences between
males and females were evident only in SFD-fed WT mice, where males had higher Nrf2 (Figure 5D).
In males, an HFD had the opposite effect on Ho1 expression, where it decreased the expression of the
Ho1 protein in WT and increased it in KO males. In WT females, an HFD increased Ho-1 protein level,
which remained higher in KO mice, irrespective of diet. Differences in Ho1 between males and females
were only observable in WT mice, with higher Ho1 in SFD-fed and lower in HFD-fed males (Figure 5E).
This finding indicates the presence of the adaptive stress response in conditions of nutritional excess
only in the absence of Sirt3.
Figure 5. Cont.
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Figure 5. Protein oxidative damage and antioxidant response in the livers of Sirt3 wild-type (WT)
and knockout (KO) mice fed with a standard fat diet (SFD) or a high fat diet (HFD) for 10 weeks.
(A) The total amount of protein carbonyls (PC) measured with an ELISA-based assay at 450 nm. Males:
KO vs. WT mice (** p < 0.01). Females: HFD-fed vs. SFD-fed WT mice (a p < 0.01); SFD-fed KO vs. WT
mice (*** p < 0.001). Males vs. females: no changes. The data are shown as mean ± SD. n = 6 per group.
(B) The representative immunoblots of hepatic Keap1, Nrf2, and Ho1 protein expression. Amidoblack
was used as a loading control. (C) A graphical display of the averaged densitometry values for Keap-1
protein expression. Males: HFD-fed vs. SFD-fed KO mice (a p < 0.05); WT vs. KO mice (* p < 0.05).
Females: WT vs. KO mice (* p < 0.05). Males vs. females: no changes. (D) A graphical display of the
averaged densitometry values for Nrf-2 protein expression. Males: HFD-fed vs. SFD-fed WT mice
(a p < 0.001); KO vs. WT mice (*** p < 0.001). Females: KO vs. WT mice (*** p < 0.001). Males vs.
females: SFD-fed WT mice (x p < 0.05). (E) A graphical display of averaged densitometry values of
Ho-1 protein expression. Males: HFD-fed vs. SFD-fed WT mice (a p < 0.05); HFD-fed vs. SFD-fed KO
mice (b p < 0.01); HFD-fed KO vs. WT mice (*** p < 0.001). Females: HFD-fed vs. SFD-fed WT mice
(c p = 0.002); SFD-fed KO vs. WT mice (** p < 0.01). Males vs. females: WT mice (xx p < 0.05). The data
are shown as mean ± SD. n = 6.
3.7. HFD-Induced Reduction in Sirt3/MnSOD Axis is Male-Specific
Sirt3 mediates the reduction of oxidative and metabolic damage, while exposure to HFD leads to
reduced Sirt3 expression, consequent hyper acetylation of manganese superoxide dismutase (AcSOD2),
and the reduction of SOD2 activity (hereafter MnSOD) [32]. Since we found that an HFD reduced Sirt3
protein level only in males, we further examined whether this pattern affects AcSOD2 protein and
MnSOD activity in the same way. HFD-fed WT males displayed increased AcSOD2 protein levels along
with decreased MnSOD activity. SFD-fed WT males had reduced AcSOD2 protein and higher MnSOD
activity than KO mice. HFD-fed WT females also displayed increased AcSOD2 protein, but without
change in MnSOD activity. SFD-fed WT females had reduced AcSOD2 protein but higher MnSOD
activity on both diets compared to KO mice (Figure 6A–D). This suggests that the acetylation status of
MnSOD acetyl-K68 that regulates MnSOD activity in males under HFD conditions, does not contribute
to alteration of MnSOD activity in females. Both KO males and females had similar AcSOD2 levels,
with reduced MnSOD activity, thus confirming the importance of Sirt3 in regulation of MnSOD activity.
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Figure 6. Sirt3/MnSOD axis in liver of Sirt3 wild-type (WT) and knockout (KO) mice fed with a standard
fat diet (SFD) or a high fat diet (HFD) for 10 weeks. (A) A representative immunoblot of hepatic Sirt3
and AcSOD2 protein expression. Amidoblack was used as a loading control. (B) A graphical display of
averaged densitometry values for AcSOD2 protein expression. Males: HFD-fed vs. SFD-fed WT mice
(a p < 0.01); SFD-fed WT vs. KO mice (** p < 0.01). Females: HFD-fed vs. SFD-fed WT mice (b p < 0.01);
SFD-fed WT vs. KO mice (** p < 0.01). Males vs. females: no change. (C) MnSOD activity. Males:
HFD-fed vs. SFD-fed WT mice (a p < 0.01); SFD-fed WT vs. KO mice (* p < 0.05). Females: WT vs. KO
mice (* p < 0.05). Males vs. females: no change. The data are shown as mean ± SD. n = 6 per group.
3.8. HFD Affects Antioxidant Enzyme Activities Differently in Males and Females
Beside major mitochondrial antioxidant enzyme MnSOD, we also determined other antioxidant
enzymes, such as copper zinc superoxide dismutase (CuZnSOD, SOD1), catalase (Cat), and glutathione
peroxidase (Gpx1) at protein level (Supplementary Figure S3) and their activities (Figure 7A–C).
We observed a discrepancy between protein expression and antioxidant enzyme activity, indicating the
complex regulatory mechanisms of enzyme activities. Therefore, the results of enzyme activities are
more informative and are shown here. In males, an HFD reduced very mildly CuZnSOD activity in both
WT (14%) and KO (10%) mice. Additionally, SFD-fed WT mice had marginally higher CuZnSOD activity
compared to KO mice (14.2%). On the contrary, females displayed no changes in CuZnSOD activity
(Figure 7A). Cat activity was increased following an HFD in both sexes and genotypes (Figure 7B).
The inducing effect of HFD on Cat activity in both genotypes and sexes suggests that increased Cat
activity is needed to effectively degrade excess of H2O2 produced by increased lipid metabolism,
irrespective of sex or Sirt3. Gpx is a cytosolic enzyme that also functions in the detoxification of H2O2,
specifically by catalyzing the reduction of hydrogen peroxide to water. In WT males, HFD increased
Gpx activity to levels of KO mice. SFD-fed WT males also displayed lower Gpx activity compared to
KO mice. In females, Gpx activity was lower in WT mice compared to KO mice. The differences in
Gpx activity between males and females were evident only in HFD-fed WT mice, where males had
higher Gpx activity (Figure 7C). These results point toward differential sex-related effect of HFD on
antioxidant enzyme activities.
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3.9. HFD and Sirt3 Depletion Affect Mitochondrial Respiration Differently in Males and Females
Sirt3 is an important regulator of mitochondrial respiration, and its targets include subunits of the
respiratory chain complexes. Studies showed that KO mice display decreased oxygen consumption
in liver [33] and reduced glucose tolerance when placed on an HFD [10]. To examine whether the
loss of Sirt3 would impair respiration in a sex- and diet-dependent manner, we measured oxygen
consumption in mitochondria from liver using a Clark type electrode.
WT males had higher malate/glutamate (MG) + ADP respiration than KO males, suggesting
defective CI-driven respiration in the absence of Sirt3. Interestingly, an HFD partially restored
low CI-driven respiration in KO males. In WT females, an HFD significantly decreased CI-driven
respiration, which remained low in the absence of Sirt3. Finally, we observed that females had higher
CI-driven respiration compared to males, except in HFD-fed WT mice, where this difference was
reversed in favor of males (Figure 8A).
The respiratory control ratio (RCR) is defined as the ratio of the state 4 respiratory rate (termination
of ATP synthesis by addition of oligomycin) to the state 3 (ADP-stimulated respiration) respiratory
rate and indicates how well the electron transport system is coupled to ATP synthesis. WT males had
higher RCR than KO males on a SFD, while an HFD partially restored low the RCR observed in the
absence of Sirt3. In WT females, an HFD decreased RCR, which remained low in the absence of Sirt3.
Females had higher RCR than males in SFD-fed conditions, while the opposite was found in HFD-fed
WT mice. These results collectively indicate that the effective CI respiration in both sexes depends
on Sirt3. Moreover, both CI-driven respiration and RCR display a sex-specific effect of HFD and Sirt3,
with an inducing effect of HFD in KO males and a suppressive effect in WT females.
Figure 7. Analysis of CuZnSOD, Cat, and Gpx1 activities in the livers of Sirt3 wild-type (WT) and
knockout (KO) mice of both sexes fed with a standard fat diet (SFD) or a high fat diet (HFD) for 10 weeks.
(A) CuZnSOD activity. Males: HFD-fed vs. SFD-fed mice (a p < 0.05); SFD-fed WT vs. KO mice
(* p < 0.05); Females: no changes. Males vs. females: no changes. (B) Cat activity. Males: HFD-fed
vs. SFD-fed mice (a p < 0.05). Females: HFD-fed vs. SFD-fed mice (b p < 0.01). Males vs. females:
no changes. (C) Gpx1 activity. Males: HFD-fed vs. SFD-fed WT mice (a p < 0.05); SFD-fed WT vs.
KO mice (* p < 0.05). Females: WT vs. KO mice (* p < 0.05). Males vs. females: HFD-fed WT mice
(x p < 0.05). The data are shown as mean ± SD. n = 6 per group.
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Figure 8. Complex I (CI)-driven respiration and the respiratory control ratio (RCR) of liver mitochondria
of Sirt3 wild-type (WT) and knockout (KO) mice of both sexes fed with a standard fat diet (SFD) or a
high fat diet (HFD) for 10 weeks. (A) CI-driven respiration. Males: HFD-fed vs. SFD-fed KO mice
(a p < 0.05); WT vs. KO mice (*** p < 0.001). Females: HFD-fed vs. SFD-fed WT mice (b p < 0.001);
SFD-fed WT vs. KO mice (*** p < 0.001). Males vs. females: SFD-fed WT mice (xxx p < 0.001); HFD-fed
WT mice (xx p < 0.01); KO mice (xx p < 0.01). (B) The respiratory control ratio (RCR). Males: HFD-fed vs.
SFD-fed KO mice (a p < 0.001); SFD-fed WT vs. KO mice (*** p < 0.001). Females: HFD-fed vs. SFD-fed
WT mice (b p < 0.001); SFD-fed WT vs. KO mice (*** p < 0.001). Males vs. females: SFD-fed WT mice
(xxx p < 0.001); HFD-fed WT mice (xxp < 0.01); SFD-fed KO mice (x p < 0.05). The data are shown as
mean ± SD. n = 4 per group.
4. Discussion
Sexual dimorphism exists in various physiological processes, with males and females differing
with respect to their regulation of energy homeostasis, metabolic rate, or body weight gain [34].
For example, HFD feeding leads to larger body weight gain in male rats/mice than in females [35].
In this study, we report the following novel observations in conditions of HFD feeding and Sirt3
depletion in liver of 129S mice: (a) HFD reduces hepatic Sirt3 expression solely in males, but only
partially; (b) HFD-induced lipid accumulation is alleviated in the absence of Sirt3 only in males, which
may be attributed to impaired glucose uptake and an increased reliance on fatty acids; (c) in females,
either an HFD or the absence of Sirt3 compromised mitochondrial respiration and increased protein
oxidative damage, which could be associated with more efficient lipid metabolism.
Sirt3 plays an important role in regulating lipid homeostasis by ameliorating HFD-induced
inflammation, liver fibrosis, and steatosis. Reports show that HFD feeding in WT male mice results
in a reduction of Sirt3 expression in the liver [36] and that deleterious effects of HFD feeding are
exacerbated in male mice lacking Sirt3 [10]. Accordingly, we found that Sirt3 was reduced upon HFD
feeding in male mice, however, without any change in females (Figure 1A,B). This result suggests that
the regulation of Sirt3 in a sexually dimorphic manner following HFD in males may contribute to the
observed sex-related differences in the development of metabolic dysregulation.
It has been shown that a decreased level of Sirt3 contributes to impaired glucose metabolism [24].
However, in our study, we did not observe the effect of Sirt3 on differences in glucose levels, only the
effect of sex, where females had lower fasting glucose levels compared to males (Figure 2B), suggesting
a possible role of female sex hormones in maintaining low glucose in females [37]. The interesting
fact is that we did not observe gained weight in mice fed with an HFD (Figure 2A). The observed
phenotype upon HFD feeding comes from the specific characteristics of this particular strain of mice
(129S), which are not prone to the development of obesity when fed with an HFD [38]. However,
despite the fact that mice did not gain weight following HFD feeding, both sexes displayed excessive
hepatic lipid accumulation (Figure 3), indicating a fatty liver phenotype after ten weeks of an HFD.
Sirt3 deficiency reduces fatty acid oxidation and results in the accumulation of hepatic lipids in
SFD-fed male mice [39], which is confirmed in our study. On the contrary, this effect was not evident
in Sirt3-depleted females, which showed less accumulation of lipids than males in SFD conditions
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(Figure 3I). Thus, disturbances in fatty acid oxidation in standard conditions and upon the depletion
of Sirt3 may result in elevated lipids and impaired metabolism, thus supporting the critical role of
Sirt3 in the maintenance of metabolic homeostasis in males. Studies have shown that an HFD acts as a
metabolic stressor causing mitochondrial dysfunction and other metabolic changes that contribute to
pathological conditions [4]. In HFD conditions, Sirt3-depleted males displayed the lowest total lipid
content in liver along with the lowest hepatic glucose uptake (Figure 3I,J). These results indicate that
in the absence of Sirt3 in males, HFD may cause impairments in hepatic glucose uptake, creating an
increased reliance on fatty acids. This was previously also shown in the skeletal muscles of Sirt3 KO
male mice [33]. Again, the observed differences in males were not evident in Sirt3-depleted females.
The absence of these effects in WT mice indicates that sex-related differences in lipid accumulation and
glucose uptake are present only in Sirt3-depleted mice.
In tissues that have a high fatty acid uptake, such as adipocytes and liver tissue, the capacity
for the β oxidation of fatty acids, the major lipid catabolic pathways, is regulated at the level of
gene expression in response to various physiologic stimuli [28]. Moreover, the maintenance of lipid
homeostasis relies on cytochrome P450 (P450) enzymes, the majority of which are regulated in a
sex-dependent manner [40]. To test if hepatic P450 enzymes are involved in sex-related differences in
lipid accumulation in the absence of Sirt3, we measured the expression of several genes involved in fatty
acid oxidation and lipid homeostasis (Figure 4). One important factor is pparγ, which is predominantly
expressed in adipose tissue but also in the liver and muscle, and promotes the storage of lipids [41].
Since in our study HFD-fed mice did not have increased weight compared to SFD-fed mice, we tested
whether this was due to the altered expression of pparγ, which is essential for adipogenesis [42].
Indeed, both sexes displayed downregulated levels of pparγ (Figure 4E), allowing us to hypothesize
that the downregulation of hepatic pparγmay be related to the fact that mice did not gain weight after
feeding with HFD. Furthermore, we observed sex-related differences in cyp2e1, cyp2a4, and cyp4a14
transcripts of P450 genes involved in the maintenance of lipid homeostasis (Figure 4A,F–H). Females
generally responded to an HFD with an upregulated expression of these involved genes, while males
had a different response to an HFD with respect to Sirt3. Considering their role in lipid metabolism,
the downregulation of cyp2a4 and cyp2e1 in male KO mice fed with SFD may be associated with their
tendency towards accumulating more hepatic fat than females. In HFD conditions, these genes tend to
be upregulated in KO males, therefore suggesting more effective lipid metabolism in association with
lower accumulation of total lipids in liver.
Since we found sex-related differences in several parameters involved in lipid homeostasis upon
different types of diet, we next investigated whether they reflected sex-related sensitivity to oxidative
stress under the same conditions. Protein carbonylation (PC) is considered to be an important marker of
oxidative stress resulting from HFD-induced oxidative damage to proteins [43,44]. Here, we show that
an HFD induced a female-specific increase in the PC of WT mice (Figure 5A) as a possible consequence
of the upregulated expression of genes involved in fatty acid oxidation, that is associated with the
generation of hydrogen peroxide [45] involved in protein oxidative damage. Unlike WT males, HFD-fed
WT females also displayed increased Ho1 protein expression (Figure 5B,E), which is an indicator of
the presence of oxidative stress [46]. However, they failed to counteract oxidative damage by the
activation of an antioxidative response, since no induction of the Keap1/Nrf2 axis (Figure 5C,D) and
major antioxidative enzyme activities (MnSOD, CuZnSOD, Gpx1) was observed (Figures 6C and 7A,C),
resulting in greater protein oxidative damage (Figure 5A). On the other hand, higher PC levels in
KO mice of both sexes were associated with upregulated Keap1/Nrf2 axis, but with no response in
antioxidant enzyme activities. This shows that in WT mice, an HFD induces oxidative stress only in
females, pointing at their increased susceptibility towards the oxidative stress in conditions of nutritive
stress. Furthermore, Sirt3 deficiency increases susceptibility to protein oxidative damage equally in
both sexes, indicating that Sirt3 is important for protection against the oxidative damage of proteins.
Several studies demonstrated that lipid metabolism has a potential to generate ROS [47,48].
For example, both peroxisomal and mitochondrial β-oxidation produce H2O2 and O2- as byproducts
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of fatty acid degradation. During nutritional excess, the imbalance in lipid metabolism along with
upregulated key genes involved in fatty acid β-oxidation, such as pparα, contributes to increased
ROS and oxidative stress [45]. Catalase (Cat), a peroxisomal enzyme, has also been found in cardiac
mitochondria with significantly increased activity during HFD feeding [48]. We observed the inducing
effect of HFD on Cat activity in both genotypes and sexes (Figure 7B), suggesting that increased Cat
activity is needed to effectively degrade excess of H2O2 produced by increased fat metabolism in
HFD-fed mice.
Mitochondrial function is tightly associated with the activity of the respiratory chain complexes,
and depends on the degree of coupling of oxidative phosphorylation [49]. Fatty acids are metabolic
fuels and β-oxidation represents their main degradation pathway in mitochondria [50]. Sirt3 WT
females had significantly higher CI-driven respiration and RCR than Sirt3 WT males in standard
conditions, suggesting a more efficient function of Complex I in the electron transport chain of hepatic
mitochondria in females. Contrary to males, in WT females, HFD feeding dramatically decreased
MG-ADP state respiration, indicating female-specific impairment in CI-driven respiration and RCR
following an HFD (Figure 8A,B). The observed defective CI-driven respiration in HFD-fed females
could be due to their higher fatty acid oxidation, in synchronization with upregulated genes involved
in the lipid oxidation process (pparα, cyp2a4, cyp2e1, cyp4a14), resulting in increased oxidative damage
of mitochondrial proteins, thereby affecting mitochondrial respiration. Indeed, fatty acids can act as
inhibitors of mitochondrial respiration, either by the partial inhibition of electron transport within
CI or III, or by a decrease in proton motive force [51,52]. Based on this result, we hypothesize that
in conditions of nutritive excess, more efficient lipid metabolism in WT females may cause higher
oxidative stress in association with reduced mitochondrial function.
Sirt3 KO male mice display decreased CI-driven oxygen consumption [33], which is in agreement
with our results. In addition, we show for the first time that, despite reduced respiration in Sirt3-depleted
mice, females have higher respiration than males. However, since in KO males an HFD increased
respiration, we hypothesize that they compensate impaired glucose uptake by increasing their reliance
on fatty acids to provide substrates for the respiratory chain. This is in accordance to [53,54], where
HFD-fed male rodents exhibited increased mitochondrial capacity and respiration [55]. Our results
collectively indicate that the CI-driven respiration displays a sex-specific effect with respect to both
HFD and Sirt3, with an inducing effect of HFD on respiration in KO males and a suppressive effect in
WT females.
Sexual dimorphism exists in various physiological processes, which also includes sex-related
prevalence towards metabolic dysregulation. In this study, we found significant sex differences at
the level of metabolic, oxidant/antioxidant, and mitochondrial parameters. In addition, this study
points towards a different role of Sirt3 in males and females under the conditions of nutritive stress.
This is an important step that adds to previous knowledge that can be studied to prevent metabolic
dysfunction, improve preclinical research, and allow for the development of sex-related therapeutic
agents for obesity and diabetes.
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